Using next-generation sequencing to understand the aetiology of dystonia and other neurological diseases by Charlesworth, G
	   1	  
	   Using	  Next-­‐Generation	  Sequencing	  To	  Understand	  the	  Aetiology	  of	  Dystonia	  and	  Other	  Neurological	  Diseases	  	  A	  thesis	  submitted	  to	  the	  University	  College	  London	  for	  the	  degree	  of	  Doctor	  of	  Philosophy	  August	  2015	  By	  	  Dr	  Gavin	  Charlesworth	  
  
	   2	  
Declaration of Authorship 
 
I, Gavin Charlesworth, confirm that the work presented in this thesis is my own.  
Where information has been derived from other sources, I confirm that this has been 
indicated in the thesis. 
  
	   3	  
Abstract 
 
This thesis presents my work using both next-generation and traditional genetic 
techniques aimed at further clarifying the aetiology of hereditary neurological disorders, 
with a particular focus on dystonia.  A large part of this was focused on the 
identification, clinical phenotyping, and genetic analysis of kindreds with neurological 
disease inherited in a Mendelian fashion but for which no causal mutation had yet 
been identified.  My work led directly to the discovery of two new dystonia genes, 
ANO3 and HPCA, and the identification of two novel phenotypes for the known 
disease-associated genes, ATM and NUBPL.  Mutations in a third novel gene, 
SLC25A46, was identified as the most likely cause of disease in a kindred with a 
complex neurological disorder consisting of optic atrophy, severe action myoclonus and 
peripheral neuropathy, but could not be confirmed due to lack of a second segregating 
kindred – it was published, a year and a half after we had first identified it, by another 
group, just as I was in the process of submitting thesis.  Taken together, these results 
confirm that whole exome sequencing in combination with linkage analysis or 
homozygosity mapping represents a powerful means of dissecting out the genetic 
aetiology of Mendelian disease. 
 
In addition, this thesis summarises my foray in the world of association analyses, a 
technique which underpins the recent explosion in knowledge regarding the genetic 
architecture of so-called ‘complex’ disease.  I use this technique to show that the 
association signal over MAPT in Parkinson’s disease survives when affectation status is 
defined neuropathologically.  Finally, I present my work using traditional Sanger 
sequencing to better understand the prevalence of already published Mendelian disease 
genes for both dystonia and Parkinson’s disease.  
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1. Introduct ion 
 
1.1 Genetics  and Neurological  Disease 
As the control centre of the body, the human nervous system represents one of the 
most complex biological structures known.  It mediates not only our ability to interact 
with the environment via sensation and movement, but is also the seat of those higher 
faculties – cognition, memory, speech, thought and emotion – that combine to give 
each human being their particular individual nature.  The correct development and 
maintenance of this exquisitely intricate structure require the co-ordinated action of a 
large number of genes, often with precise spatial and temporal patterns of expression.  
Moreover, although the nervous system exhibits considerable plasticity – a prerequisite 
to environmental adaptation and learning – this is evident predominantly at the 
synaptic level.  In contrast, on a cellular level, nervous tissue is characterised by a 
relatively limited capacity for regeneration once damaged.  Thus, when considered in 
the context of the relatively long life span of a human being, genetic variation that 
results merely in ‘inefficiencies’ or moderate dysfunction of the pathways involved in 
cellular maintenance may alone be sufficient to cause progressive neuronal dysfunction 
and, ultimately, cellular death, manifesting clinically as neurodegenerative disease.  
Taken together, these facts go some way towards explaining the vulnerability of the 
nervous system to genetic disease.  Even considering monogenic forms of genetic 
disease alone, it has been estimated that at least 60 - 70% involve the nervous system 1.  
Many such Mendelian disorders – motor neuron disease, Alzheimer’s disease, 
Parkinson’s disease and dystonia to name but a few – have so-called ‘sporadic’ 
counterparts that affect a much larger number of individuals and thus represent a 
substantial burden on patients and carers, as well as a major challenge in terms of 
healthcare provision and its associated costs for society as a whole.  A significant 
proportion of these disorders show increasing prevalence with age, such that the 
problem is becoming increasingly acute as life expectancy climbs, the elderly population 
grows in size worldwide, and the cost of caring for affected individuals threatens rise to 
unsustainable levels.  In 2010, in an attempt to tackle this challenge, 22 EU countries 
launched the first Joint Programming Initiative to combat neurodegenerative disease, 
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based on a shared vision to speed up the progress towards new treatment options, to 
identify preventative strategies, and to improve the care of those already affected.  
 
A prerequisite step in attempting to treat or even prevent any neurological disorder is 
gaining an understanding of what exactly has gone wrong.  An understanding of the 
pathogenesis of human disease is thus a key goal for researchers working within the 
health sciences.  Armed with knowledge of the cellular and molecular events that 
underpin a particular condition, clinicians and scientists can begin to develop truly 
targeted therapies, designed either to interrupt the underlying biological cascade at 
some key nodal point or, alternatively, to modulate critical cellular pathways that are 
dysfunctional.  However, deciding which molecules and pathways are of aetiogenetic 
importance for a particular disease, from amidst the myriad that make up the 
exquisitely complex machinery of the cell, is an almost Herculean task.  What is needed 
is a ‘way in’ – a protein, robustly connected to the disease, that can serve as a starting 
point for the further exploration of the wider molecular biology of the condition.  At 
present, one of the best available means of identifying such a protein in relation to any 
particular disease remains the discovery of causal genes linked to monogenic forms of 
the disorder.  Knowledge of a gene causal for a Mendelian disorder provides the 
identity of a protein whose dysfunction is alone sufficient to cause disease. If the 
function of this protein is known or can be experimentally established, then it can be 
placed within a cellular pathway that is presumably important for pathogenesis.  From 
there, cellular and animal models can be created that permit the testing of therapies 
designed to prevent, to slow, or – at the very least – to compensate to some degree for 
the disease process, with the hope that some may show sufficient promise to make it to 
human trials and, possibly, beyond.  Furthermore, it has long been recognised that 
disease-modifying agents aimed at neurodegenerative disorders are most likely to be 
effective if they are implemented at an early point in the course of the disease, ideally at 
a preclinical stage.  At present, identification of presymptomatic individuals carrying 
high-risk Mendelian mutations represents one of the most promising means of 
assembling such cohorts for future clinical trials, thus further reinforcing the 
importance of genetics throughout the process of developing successful treatment 
strategies for disease.   
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Mendelian forms of neurological diseases represent, however, only a tiny proportion of 
the clinical disease burden.  Why expend so much time and effort elucidating the 
genetic cause of such rare forms of disease?  In fact, it has long been hypothesised that 
the insights gained from genetic analysis of Mendelian disorders will be relevant – to 
some degree at least – to the more common, sporadic forms of these disorders.  In 
sporadic forms of disease, it is envisioned that disease may result from mild to 
moderate ‘ineffeciencies’ in at least some of the same cellular pathways responsible for 
Mendelian disease, acting in combination with other individual genetic and 
environmental factors.  Recently, the results of genome wide association studies (see 
section 1.7 below) – undertaken in relatively common sporadic neurodegenerative 
disorders, such as Alzheimer’s or Parkinson’s disease – have provided the first solid 
evidence to support this belief: common variants in some of the same genes that are 
known to cause Mendelian forms of a disorder also modulate the risk of developing 
sporadic disease 2-5. 
 
1.2 Genetics  and Mendel ian Disease 
Three decades or so prior to my own work in this area, the process of genetic analysis of 
Mendelian disease began in earnest.  Using the genetic techniques available to them at 
the time – linkage analysis, positional cloning and, subsequently, candidate gene studies 
– and often only after painstaking years of work, researchers were able to gradually flesh 
out the list of known causal genes for Mendelian forms of many hereditary conditions.  
Neurology has been one of the leaders in applying the developing tools of genetics to 
understand the aetiology of disease.  Extending as far back as the early 1980s, these new 
methods were used to identify first the location of the Huntington disease gene, 
Alzheimer disease genes, and the first Parkinson disease gene.  Extremely rare, highly 
penetrant mutations in these genes were subsequently shown to be causative for 
disease.  These discoveries redirected entire fields of study and greatly improved our 
understanding of the underlying pathophysiology of these conditions. 
 
The identification of the genes responsible for Mendelian disease was critically 
dependent on the identification of large, well-characterised pedigrees, groups of 
pedigrees with a presumed identical genetic aetiology, or consanguineous families with 
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disease most likely resulting from homozygous mutations.  This was not always a simple 
matter given the relative rarity of Mendelian disease as well as the tendency for smaller 
family sizes and falling rates of consanguinity in much of the world today (particularly 
that part of the world where the technology existed to study such families).  The critical 
importance of phenotypic characterisation to the success of linkage analysis also meant 
that issues such as phenotypic heterogeneity, reduced penetrance or late-onset disease 
(where the affectation status of the youngest generation cannot be determined) made 
some diseases inherently difficult to tackle.  Beyond the relative scarcity of suitable 
pedigrees, other practical factors severely limited progress, in particular the huge cost 
and physical time commitments required to sequence the large number of candidate 
genes that were covered by linkage peaks.  As a result – and though nonetheless an 
impressive feat – it is estimated that the genetic basis of less than 50% of all Mendelian 
disorders had been determined by 2010 6, when I started my research.  Experience from 
the specialised neurogenetics clinics of the National Hospital for Neurology and 
Neurosurgery echoes this estimation – there remained numerous kindreds exhibiting 
ostensibly Mendelian disease, but for which no causal gene could be identified.  A 
significant part of this thesis focuses on my attempts to solve the puzzle of the cause of 
disease in these kindreds by application of the most recently developed genetic 
sequencing technologies, in combination with more traditional linkage and 
homozygosity mapping strategies.  In the following sections, I describe the early impact 
and potential of this new genetic technology, whilst discussion of its technical aspects 
and associated methodologies can be found in chapter 2 and 3. 
 
1.3 Next -Generation Sequencing and Its  Impact 
DNA sequencing was first developed in 1975 by Sanger and Coulson 7.  Over the next 
three and a half decades, gradual improvements in technology and reagents led to a 
streamlining of the process, but the underlying chemistry – which remained 
fundamentally unchanged – imposed an upper limit on the speed and scale of the 
process.  The arrival of next-generation sequencing (NGS) technologies in the late 
2000s allowed researchers to break through this glass ceiling.  Unlike Sanger 
sequencing, which is based on the electrophoretic separation of chain-termination 
products generated by individual sequencing reactions, next-generation sequencing 
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(NGS) involves the massively parallel sequencing of clonally-amplified or single-DNA 
molecules that are spatially separated on a flow cell.  Sequencing is performed by 
repeated cycles of polymerase-mediated nucleotide extensions.  As a massively parallel 
process, NGS generates hundreds of gigabases of nucleotide-sequence output in a single 
instrument run and has the capacity to sequence the whole genome in days to weeks. 
 
Despite the fact that an individual laboratory could now feasibly sequence an 
individual’s whole genome, this remained – particularly in the early years after the 
advent of NGS – a relatively costly endeavour.  Moreover, from the point of view of the 
identification of causal mutations in genetic disease, ascertaining the likely functional 
consequences of variants in non-coding parts of the genome is extremely difficult, given 
the relatively poor understanding of what these regions (which were, until recently, 
branded as ‘junk’) actually do.  Therefore, more commonly, an adaptation of the same 
basic technique is used to sequence selected regions from across the genome that are 
presumed to be of higher importance.  As around 85% of all disease-causing mutations 
identified (prior to the advent of next-generation sequencing) were exonic 8, 9, 
sequencing strategies that targeted only the protein-coding regions of the genome (the 
‘exome’) represented an attractive compromise.  Accounting for only ~1% of the 
genome, the exome can be sequenced at a much lower cost and in a much quicker 
time, whilst still generating sequence data for those regions in which a causal mutation 
is most likely to be found.  This strategy, known as whole exome sequencing (WES), is 
that which is most commonly employed in current attempts to identify causal genes for 
unexplained Mendelian disease and is also that which I used in my own efforts. 
 
1.4 The Challenge of  Human Genetic  Variabi l i ty  
The advent of NGS technologies permitted large scale projects aimed at sequencing the 
exomes of numerous individuals, including large cohorts of ostensibly healthy people of 
various ethnicities.  Such sequencing projects have revealed that human beings tolerate 
a surprisingly high degree of genetic variation. 
 
With reference to disease in particular, two important insights have been gained.  
Firstly, there is a relative excess of low frequency variants most likely resulting from the 
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recent demographic explosion in the human population 10-14.  This event has allowed 
the accumulation in the human genome of an excess of new mutations and rare alleles, 
skewing the pattern of genetic variation.  Furthermore, such low frequency variants are 
enriched for nucleotide changes that affect protein function, particularly those that are 
predicted to be deleterious, and are therefore more likely to be related to disease 10-15.  
Given their recent origin, the persistence of such variants may be explained to some 
extent by the lack of sufficient evolutionary time for their removal by natural selection.  
Nonetheless, some degree of purifying selection has taken place as evidenced by the 
observation that nonsynonymous variants are significantly under-represented compared 
with synonymous variants 15-17.  Secondly, most rare variants are restricted to particular 
populations and show very little mixing between the continents 13, 14, 18, 19.   
 
In fact, it is now known that ostensibly healthy individuals can – and indeed do – carry 
many apparently disadvantageous variants without exhibiting any obvious ill effects.  
This situation can arise for a number of reasons – healthy individuals may: 1) carry only 
a single disease allele for a recessive disorder; 2) carry a disease-causing variant for a 
disorder that has its onset late in life and may not reach the required age to manifest; 3) 
carry a disease-causing variant for a disorder that requires additional environmental or 
genetic factors to manifest (i.e. reduced penetrance); or 4) carry a variant resulting in a 
clinical phenotype that is mild enough be classified with the range of normal healthy 
variation (i.e. reduced potential intelligence).      
 
Experience to date suggests that analysis of an average exome would be expected to 
reveal between approximately 20,000 to 24,000 single nucleotide variants, depending 
on the population from which the DNA sample originates (see table 1 overleaf) 20.  The 
vast majority of these variants will have been recorded in publically available databases 
of genetic variation and thus will most likely (but not necessarily) be non-disease 
causing polymorphisms.  However, between 300 to 500 per exome variants are ‘novel’, 
i.e. never previously recorded in such databases.  Of these, around two thirds will alter 
coding and about 1 – 2% will either produce a premature stop codon or affect a splice 
site.  Novel missense, nonsense and splice site variants are associated with a greater a 
priori probability of being deleterious and thus, even considering these categories of 
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variants alone, the average exome will contain approximately 200 – 300 variants that 
could potentially cause disease 20.  A more recent study examined sequencing data from 
individuals and classified variants as damaging (on the basis of a Condel score of 
>0.99) or disease-causing (on the basis of a known causal association with a Mendelian 
disease).  On the basis of their study, the authors estimate that the average individual 
will carry  >400 damaging variants and approximately 5 disease-causing mutations 21. 
 
These facts present obvious challenges for the use of WES data in experiments designed 
to dissect out the genetic architecture of both sporadic and Mendelian disease.  As this 
is not the main focus of my thesis, the difficulties such revelations pose in relation to 
dissecting out the genetic architecture of sporadic disease are touched on only briefly in 
section 1.9.  In terms of Mendelian disease, however, the main problem centres around 
how to recognise a true, disease-causing variant from amongst a dense background of 
genetic variation that includes not merely polymorphisms but also hundreds of 
potentially damaging alleles.  To date, researchers have employed a number of different 
strategies to overcome this difficulty, with choice depending on a number of factors, 
including the nature of the phenotype under consideration, the mode of inheritance, 
pedigree structure and likelihood of genetic heterogeneity.  As these have direct 
relevance to the work presented in this thesis, the sections that follow provide an 
overview of how some of these approaches work as well as some of their possible pitfalls 









	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  Condel is a method to assess the outcome of non-synonymous SNVs using a CONsensus 
DELeteriousness score that combines various tools (MutationAssessor and Functional Analysis 
through Hidden Markov Models).  	  
 Generally dbSNP135 or below, as more recent versions are flooded with variants from NGS 
projects involving individuals with disease phenotypes or projects assessing somatic variation. 
	  The work presented in this chapter was peer-reviewed and published with adaptations in 
Charlesworth et al., 2013 108. 
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Table 1 - Typical number and distribution of variants observed by exome sequencing in two 
different populations.  This table was originally published in Bamshad et al., 2011 20. 
Variant Type Mean Number of Variants  
(±  sd) in African Americans 
Mean Number of Variants   
(±  sd) in European Americans 
Novel Variants 
Missense 303 (± 32) 192 (± 19) 
Nonsense 5 (± 2) 5 (± 2) 
Synonymous 209 (± 26) 109 (± 16) 
Splice 2 (± 1) 2 (± 1) 
Total 520 (± 53) 307 (± 33) 
Non-novel variants 
Missense 10,828 (± 342) 9,319 (± 233) 
Nonsense 98 (± 8) 86 (± 6) 
Synonymous 12,567 (± 416) 10,536 (± 280) 
Splice 36 (± 4) 32 (± 3) 
Total 23,529 (± 751) 19,976 (± 505) 
Total Variants 
Missense 11,131 (± 364) 9,511 (± 244) 
Nonsense 103 (± 8) 93 (± 6) 
Synonymous 12,776 (± 434) 10,645 (± 286) 
Splice 38 (± 5) 34 (± 4) 








	   35	  
1.5 Outl ine of  the Strategies  Used for  Identi fy ing Causal Variants 
in Mendel ian Disease 
Strategies for honing in on the true causal variant for a Mendelian disorder from 
amongst the numerous variants in a typical exome sequencing dataset can be broadly 
divided in two:  restricting the genomic search space and variant prioritisation.  In 
order to narrow down the areas of the genome where the causal variant must lie (or, at 
the very least, is more likely to lie), either linkage analysis or homozygosity mapping can 
be employed.   A fuller explanation of these methods can be found in sections 2.9 and 
2.10, respectively.  However, it is worth pointing out here that these techniques, 
particularly linkage analysis, are entirely reliant on accurate designation of affectation 
status within the pedigree.  In particular, erroneous assignment of unaffected status to 
individuals that that are not thought to exhibit the disease phenotype but do, in fact, 
carry the causative mutation (either because the are non-manifesting carriers of a 
mutation that is not fully penetrant or because there is variable expressivity and the 
phenotype they manifest is not recognised as a possible manifestation of the same 
disease) has the potential to significantly reduce or even abolish linkage over the critical 
area.  This is especially likely to happen if linkage analysis is performed under a model 
that assumes a too high a penetrance or if the pedigree is small.  The scientific literature 
is littered with examples of published linkage loci in which no causal variant could be 
identified.  Some of these have subsequently been shown to be incorrect when the 
kindred is eventually sequenced for a newly-identified disease gene and is found to carry 
a mutation in that gene; re-examination of the family in the light of the sequencing 
data often reveals sample handling errors, critical non-manifesting carriers or 
phenocopies (see, for example, Wider et al. [2008] 22 or Weber et al. [2011] 23).       
 
Even with the benefit of accurate linkage or homozygoisty data to narrow down the 
genomic areas under consideration, there would usually still be far too many 
undifferentiated variants to ever allow a researcher to easily identify the true causal 
variant within a particular kindred.  In order to overcome this problem, additional data 
for each variant, drawn from publically available databases, must be sought and 
associated with the variant in a process called annotation.  The lowest level of 
annotation, which is, to a large extent, completed automatically by freely available 
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scripts such as Annovar, involves the collation of a basic ‘character profile’ of each 
variant.  Such a character profile typically includes: 1) the variant’s consequence in 
terms of transcription and translation (e.g. coding, non-coding or spice site, 
synonymous or non-synonymous, frameshift or non-frameshift, ect.); 2) its previously 
reported frequency in disease free controls; 3) the level of pre-computed evolutionary 
conservation at and immediately surrounding its genomic position; and 3) its predicted 
pathogenicity according to various commonly used in silico softwares.  Of these 
characteristics, the observed frequency of the variant in databases of normal human 
sequence variation and its effect on protein transcription are the two most commonly 
used means to rapidly reduce the number of variants under consideration.  However, 
even here, there are potential pitfalls, as detailed below.  
 
1.5.1 Rarity as a Means of Variant Fi l tration  
Mendelian disease is rare and the genetic mutations that underlie it are generally highly 
penetrant.  As such, one would not, as a rule, expect to find a variant that is truely 
causal for a Mendelian disorder in publically-available databases of normal human 
sequence variation.  The most common databases used for this purpose are earlier 
version of dbSNP, the 1000 Genomes project, the NHLBI Exome Sequencing Project, 
and the Complete Genomics 69 databases.  In-house databases of exome sequenced in 
individuals without the phenotype under question can also be used for this purpose.  
Unfortunately, experience teaches that some of the variants that are contained within 
these databases of normal sequence variation will subsequently be shown to be causal 
for Mendelian disease.  For example, the common p.G2019S mutation in LRRK2, 
which is causal for a autosomal dominant form of Parkinson’s disease, was initially 
present in dbSNP.  The most common reasons for the appearance of Mendelian 
variants in such databases are much the same as those enumerated previously in the 
discussion of why healthy individuals may habour deleterious variants:  reduced 
penetrance or age-related penetrance, meaning that non-manifesting carriers or 
individuals who will develop disease only at a later date may be sequenced and labelled 
as healthy; or, alternatively, heterozygosity for a highly penetrant recessive allele.  This 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 Generally dbSNP135 or below, as more recent versions are flooded with variants from NGS 
projects involving individuals with disease phenotypes or projects assessing somatic variation. 
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potential for ‘contamination’ means that filtering variants against these databases 
independently of their minor allele frequency entails a risk of accidentally eliminating a 
true causal variant.  Instead, it is standard and accepted practice to eliminate variants 
from consideration if they are reported in such databases at a particular frequency or 
greater (usually determined by the presumed inheritance pattern and frequency of the 
phenotype under consideration).  In general, for the genetic analysis of rare dominant 
and recessive Mendelian disorders, filtering variants on a maximum minor allele 
frequency of 0.1% and 1%, respectively is considered to be effective at reducing the 
number of variants under consideration without significantly reducing the power of the 
study to detect the causal variant 20. 
 
Another consideration arises from the fact that many rare variants are private to 
particular populations (see section 1.3 above) 13, 14, 18, 19.  Therefore, some neutral rare 
variants that appear completely novel  with respect to databases of sequence variation in 
one population (and would thus be considered more likely to be disease-causing) may, 
in fact, be seen in healthy individuals in another population.  This emphasises the need 
for population-specific databases of sequence variation.  Unfortunately, such databases 
simply do not exist for all populations. For various reasons, this is principally true of 
populations that tend to have higher levels of consanguinity and is thus a particular 
concern for studies of autosomal recessive disease thought to result from biallelic 
mutations inherited as a consequence of autozygosity. 
 
1.5.2 Using Kindred Structure as a Means of Variant Fi l tration  
When there is some idea of the likely mode of inheritance of a disease, kindred 
information is also frequently used to reduce the number of variants under 
consideration.   As already mentioned, disease-causing variants in Mendelian disease 
are usually rare.  For very rare alleles, the probability of identity-by-descent given 
identity-by-state is high even among distantly related individuals.  For example, two first 
cousins share a rare allele that is identical-by-descent in approximately one-eighth of the 
genome.  For dominant kindreds, sequencing the two most distantly related individuals 
with the phenotype of interest and then considering only those variants that are shared 
between both individuals can substantially restrict the genomic search space 20.  The 
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main difficulty lies in identifying kindreds with affected individuals who are sufficiently 
separated genetically, notwithstanding with the small, but non-negligible risk that one 
of the individuals chosen for sequencing may turn out to be a phenocopy and has 
therefore been deemed to be affected incorrectly. 
 
In kindreds with likely autosomal recessive inheritance but without evidence of 
consanguinity, filtering for homozygous or compound heterozygous mutations, 
especially when combined with linkage data, can be a powerful method for honing in 
on the causal variant(s) 24.  Where there is evidence of consanguinity, on the other 
hand, the search can usually be restricted (initially at least) purely to homozygous 
variants lying in regions of autozygoisty, as determined by homozygoisty mapping based 
on genome-wide genotyping data, that are shared exclusively by all affected individuals,.  
In these cases, usually only the DNA of a single affected individual need be exome 
sequenced – essentially, the data is merely being used as a cost-effective, time-saving 
replacement for Sanger sequencing of all the genes in a pre-defined, crucial interval.  
Nonetheless, at least three caveats need to be borne in mind when tackling kindreds 
with ostensibly autosomal recessive disease.  Firstly, an affectation pattern suggestive of 
an autosomal recessive mode of inheritance can occasionally be produced by dominant 
mutations when neither parent is affected, most often as a result of germline mosaicism 
or reduced penetrance.  Secondly, in a small, but not insignificant number of 
consanguineous kindreds with autosomal recessive inheritance of disease, the causative 
mutations will, in fact, turn out to be compound heterozygous rather than homozygous 
mutations 25.  Thirdly, and of particular relevance if the disease phenotype is not 
uncommon in a particular population, locus heterogeneity and/or allelic heterogeneity 
existing within the same family can confound attempts to delineate a shared haplotype 
or region of shared autozygosity, as has been demonstrated in several studies 26-29.   
 
Although not of direct relevance to the work presented in this thesis, disease secondary 
to de novo mutations can be tackled by exome sequencing of multiple parent–child trios.  
As multiple de novo events occurring within a specific gene (or within a gene family or 
pathway) can reasonably be considered an extremely unlikely event, genes showing 
recurrent variants that are present only in multiple affected children but not in any of 
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their parents can be rapidly selected for further assessment 30.  This study design may be 
particularly applicable to gene discovery in disorders for which most cases are appear 
sporadic (that is, the parents are unaffected) but a dominant mode of inheritance is 
suspected or when substantial locus heterogeneity is expected (as is found in intellectual 
disability 31, schizophrenia 32 or autism 33, for example).  However, it should be noted 
that, in around 70% of cases where a variant is called in a an affected child that is not 
present in either parent, this inconsistency is eventually found to be artefactual, related 
either to a failure to call the variant in one or both parents or, alternatively, to a false-
positive sequencing error in the affected child 20.   
 
1.5.3 Effect on Protein Structure as a Means of Variant Fi l tration 
As mentioned in section 1.2, around 85% of all disease-causing mutations identified 
(prior to the advent of next-generation sequencing) were exonic and thus altered 
protein sequence.   Many of the remaining intronic variants altered canonical splice 
sites.  Therefore, it is common practice to filter out synonymous exonic variants and 
intronic variants, provided they do not affect canonical splice sites.  However, one must 
always bear in mind that splice site prediction methods are imperfect and it is possible 
that disease-causing synonymous variants may be inadvertently discarded because they 
affect a splice site (or, indeed, a transcription start site for an alternative transcript or 
even a promotor region for a downstream gene) that is not currently recognised as such. 
 
Candidate variants remaining after synonymous variants can then be further stratified 
on the basis of their predicted deleteriousness to protein structure.  In general, greater 
weight is given to variants that cause a frameshift, introduce a stop codon or disrupt a 
canonical spice site since such variants tend to result in either a more radical alteration 
in protein structure than simple missense SNVs or, alternatively, lead to a reduction in 
quantity or even complete loss of the protein product from the mutated allele, due to 
nonsense-mediated decay and other such factors.  Nonetheless, the assumption 
underlying this approach should be recognised as an oversimplification.  Redundancy 
in the molecular machinery of the cell means that complete loss of many proteins can 
be tolerated, even when bialleleic, and may not result in any perceptible impact on 
health.  Indeed, based on a sample of 185 individuals, the 1000 Genomes project 
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recently reported the average healthy person carries an average of 14.3 to 15.9 biallelic 
frameshift or stopgain mutations, depending on the population studied 34.  On the 
other, even a single amino acid substitution might be sufficient to cause disease if it is 
located in some critical functional domain of the protein or radically alters the proteins 
final structural conformation.  
  
Occasionally, when decent linkage of homozygosity data are lacking and most of the 
genome is remains under consideration, investigators may resort to eliminating non-
frameshift indels or retaining only truly novel variants in a bid to see if anything ‘stands 
out’.  However, since non-frameshift deletions are sometimes pathogenic (i.e. the 
ΔGAG mutation in TOR1A) and variants with reduced penetrance may make their way 
into databases of normal sequence variation at low frequencies, this strategy entails a 
significant risk of accidentally eliminating the true causal variant whilst simultaneously 
increasing the chance of the erroneous assignment of pathogenicity to some other 
novel, but ultimately harmless, variant.  As such, claims of putatively causal variants 
identified by this manner would be unlikely to be accepted for publication, unless it 
were supported by evidence of segregation in one or more independent families. 
 
1.5.4 Other Variant Data Used in Supporting Capacity  
Of the other data usually assembled automatically on each variant, conservation scores 
and in silico predictions of pathogenicity are often considered the most useful in helping 
to prioritise variants and to support the argument for any proposed role in the 
causation of disease.  It should be noted, however, that it is not considered good 
practice – no matter how tempting at times – to formally eliminate variants on the basis 
of conservation scores or in silico predictions of pathogenicity, for the reasons set out 
below. 
 
Evidence that a genetic site has experienced purifying selection suggests that it is of 
functional importance to the organism.  By extension, measurements of evolutionary 
conservation can serve as a relatively reliable proxy marker for sites at which an 
alteration could potentially have deleterious affects on the organism’s health.  Variants 
affecting such sites can thus be considered as having a higher a priori probability of 
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being disease-causing, whereas those affecting sites with neutral or higher than expected 
rates of evolutionary change are much less likely to be so.  In fact, approximately 90% 
of known pathogenic variants affect evolutionarily conserved bases or regions.  At the 
same time, the fact that at least 10% of reported pathogenic mutations must therefore 
lie in apparently non-conserved regions means these scores can never be used to exclude 
a variant absolutely.  In addition, there is a significant difference in the utility of 
conservation scores as a guide to pathogenicity when considering dominant versus 
recessive disease mutations 35.  Bases where disease-causing variants for dominant 
disease are generally found to be more conserved than those that are affected by 
variants causing recessive disease.  In the latter case, the variant can effectively ‘evade’ 
purifying selection while in the heterozygous state. 
 
Evolutionary conservation scores for most sites across the genome are available pre-
computed and are typically calculated by one of three programmes – GERP, PhyloP and 
PhastCons – each of which employs a slightly different algorithm.  More information 
about these programs can be found in sections 2.7.1 – 2.7.3.   
 
Another means of assessing the likelihood that a variant is deleterious involves the use 
of in silico predictions of pathogenicity.  The number of published algorithms designed 
to generate such predictions is constantly expanding, but, at the time that this work was 
completed, the programmes most commonly used were SIFT/PROVEAN, PolyPhen2 
and MutationTaster.  Each employs different strategies in its attempt to identify 
functional sites at which variation is most likely to affect phenotype and these strategies 
are briefly explained in sections 2.7.4 – 2.7.7.  Overall, however, estimates for the 
sensitivities of such software tools, based on studies using them to distinguish between 
well-established pathogenic mutations and known polymorphisms, range from 
approximately 70 to 90%; more worryingly, estimates of their specificities are much 
wider, ranging from approximately 15% to 80% 36-39.  It is clear, therefore, that these 
predictions should only ever be considered as ‘an educated guessimate’ at the true 
pathogenicity of a variant.  
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One consequence of the different approaches adopted by all these algorithms is that 
there exists significant discordance between the predictions generated by different 
methods.  A recent study of five of the most common prediction methods in use 
(PolyPhen2, SIFT, LTR, MutationTaster, PhyloP) demonstrated that the correlations 
between scores for identical mutations at the same site from the various prediction 
methods were mostly weak to moderate 35.  The authors hypothesised that two factors 
were predominantly responsible for this.  Firstly, the set of species used by one method 
in deriving evolutionary conservation differ considerably from those used by another.  
Secondly, the set of perfectly conserved sites used for training by one method may also 
differ from those used by others, due to a disparity in sequence alignments adopted by 
each method.  Thus, in summary, in silico predictions of pathogenicty, whilst not 
without a role in the assessment of the candidate variants, are best regarded as a source 
of supplementary information alone and, in an ideal world, they should not be used as 
the basis for variant filtration 
 
Finally, once the number of variants under consideration has been whittled down to at 
most 20 or less, it is often necessary to curate more detailed information on each of the 
variants in order both to help eliminate some and highlight others as priority 
candidates.  At this stage the information has to be manually curated and the process 
can be quite time consuming.  Useful data might include expression profiles, protein 
function, protein structure (particularly location of the variant with regard to predicted 
functional domains), biological pathway annotations, known gene-disease associations, 
and previously published papers making mention of the gene.  At times, there is an 
abundance of data on a particular gene; at others, there is none.  In truth, only rarely 
does this second level of data allow complete exclusion of a gene (usually by revealing 
absence of expression in the tissue of interest).  It can, nonetheless, be helpful in 
prioritising variants for PCR screening in cohorts of other affected individuals based on 
the strength of the case for each. 
 
1.6 Early Impact and Promise of  NGS in Clinical  Genetics  
The introduction of NGS technologies has ushered in a new age of promise in clinical 
genetics.  Though it remains in its relative infancy and developments continue at a 
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significant pace, the early impact of these new techniques might nonetheless be said to 
have constituted somewhat of a revolution for the field.  The main areas of impact, as 
relevant to the work presented herein, are summarised in the sections below. 
 
1.6.1 Identif ication of Novel  Disease Genes  
The rate of identification of novel genetic causes for Mendelian phenotypes has 
accelerated rapidly since the introduction of NGS.  A literature search conducted as 
part of a recent review paper published in 2012 revealed that more than 100 causative 
genes in various Mendelian disorders have been identified by means of exome 
sequencing 40 and this number continues to rise.  Genetic analysis of autosomal 
recessive disease is particular well suited to the application of these new techniques, 
which explains the greater success rates in kindreds exhibiting this mode of inheritance.  
In all, 61 out of the 108 newly-identified genes exhibited autosomal recessive 
inheritance (56.5%), 40 of them were transmitted as an autosomal dominant trait 
(37%), whilst only one X-linked recessive and one X-linked dominant disorder had 
yielded 40. 
 
Considering the known ‘facts’ in medical genetics around the time of the NGS 
technologies came into existence, it is not surprising that whole exome sequencing 
generated such excitement.  As previously stated, around 85% of disease-causing 
mutations identified at that time were located in protein-coding regions of the genome 
8, 9.  Furthermore, most (91.8%) of the variants that alter protein coding are either 
nonsense/missense (~56%), small insertion/deletions (~24%), splicing (~10%) or 
regulatory (~1.8%) mutations, all of which are notionally detectable with standard 
NGS.  It followed, therefore, that – in theory at least – whole exome sequencing alone 
should be able to identify at least 78% of causal variants. 
 
As regards whole genome sequencing, there have, to date, only been a handful of 
studies that have successfully employed this technique data to identify a novel disease-
causing mutation.  This is in part due to the relative expense involved in obtaining this 
increased breadth of coverage.  At the same time, and perhaps more importantly, there 
remain no rigorous solutions to the problems arising from the current dearth of 
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information about the extent of normal variation in non-protein-coding regions and the 
relative difficulty in predicting the potential pathogenicity of the observed variants in 
these regions.  However, as the cost of sequencing continues to fall and databases of 
whole genome data increase in size, it seems likely that whole-genome sequencing will 
become increasingly common and perhaps even standard in the near future. 
 
1.6.2 Expanding the Phenotype: Genetic Pleiotropy and Disease.  
Pleiotropy is a well-defined concept in genetics:  it refers to the idea of a single locus 
that exerts an influence on two or more, sometimes seemingly unrelated, phenotypes 41.   
When disease-causing variants occur in such genes only a subsection of the phenotypes 
may be altered, depending on the position of the mutation within the protein or other 
genetic or environment factors, leading to variable presentation in the disease state.  It 
has long been recognised that mutations in the same gene can lead to quite different 
presentations of the same disease or, indeed, even presentations that are normally 
considered as entirely different diseases.  Nonetheless, the increasing use of exome 
sequencing has led to a growing awareness of the true extent of such phenotypic 
pleiotropy and evidence is rapidly accumulating that this may be much more common 
than was previously thought.  For instance, de novo mutations in ATP1A3, a gene 
normally associated with rapid-onset dystonia parkinsonism (RPD), were recently 
shown to be the cause of alternating hemiplegia of childhood, a paediatric neurological 
condition normally considered quite unrelated to RPD 42-44.  Similarly, a homozygous 
mutation in ATP13A2, a gene usually associated with a form of atypical parkinsonism 
known as Kufor-Rakeb, was recently found to be segregating with disease is a kindred 
exhibiting neuronal ceroid lipofuscinosis with typical histopathology, suggesting that 
lysosomal dysfunction may be a common aetiological factor in these two clinically 
distinct, neurological disorders 45.  Perhaps the most stunning example of such 
pleiotropy in disease, however, comes from the recent identification by exome 
sequencing of mutations in PRRT2 as the cause of paroxysmal kinesogenic dyskinesia 
(PKD) 46, 47.  It has subsequently been shown that, in addition to typical PKD, 
mutations in PRRT2 may also manifest as infantile convulsions with choreoathetosis, 
benign familial infantile seizures, episodic ataxia, hemiplegic migraine and/or benign 
paroxysmal torticollis of infancy 48-51.  Moreover, in the case of PRRT2 mutations, the 
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resultant phenotype may differ not merely between kindreds carrying different 
mutations (as might be expected), but also between kindreds carrying the same 
mutation and even between affected individuals within the same family 52. 
 
1.6.3 Screening for Known Causes of  Genetic Disease.  
Currently genetic diagnosis in individuals with hereditary disease can be a time-
consuming and costly procedure both for the referring clinician and for the laboratory 
staff at the receiving institution.  The first step in the process of genetic diagnosis is to 
match the patient’s clinical phenotype to one of the reported phenotypes associated 
with a known disease gene for the condition.  If the disease phenotype in question is 
associated with mutations in a single gene alone, the choice of which gene to sequence 
is straight-forward.  However, this is not the case for many disease phenotypes:  many, if 
not most genetic diseases, exhibit considerable locus heterogeneity, meaning that a 
particular phenotype may be associated with a long list of possible genetic causes, 
which, after mode of inheritance has been taken into account, can only, at best, be 
ordered in terms of their relative frequency of occurrence when deciding what to 
screen.  The genetics of Charcot-Marie-Tooth (CMT) disease exemplify this situation 
perfectly.  Over 70 disease genes have been described for CMT and related disorders 
and, to a large extent, the presentations associated with these various genes are 
potentially clinically indistinguishable 53.  Testing instead relies on sequential Sanger 
sequencing of each possible causative gene, which, because of the cost and effort 
involved, must be done serially rather than in parallel, until either a disease-causing 
mutation is found or no further possible genes remain to test (taking into account the 
fact that, for many rarer genes, testing is only available on a research basis). 
 
The application of NGS technology, in an adapted form, to genetic screening promises 
to significantly speed up this process and, moreover, to reduce costs in the process.  Just 
as the same basic science can be used to sequence either the entire genome or only the 
protein-coding part thereof, so the protocol for NGS can also be adapted to sequence 
any user-defined fraction of the genome by the addition of some initial, simple PCR 
amplification and library preparation steps.  So-called ‘disease-targeted sequencing’ 
takes advantage of this fact 54.  In this paradigm, primers are designed to amplify all 
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protein coding regions of all known genes associated with a particular disease 
phenotype, thus allowing them to be interrogated in parallel (rather than in series) for 
potential disease causing variants (see section 2.8 for more details).    Moreover, with 
the addition of special indexing primers, samples from different individuals can be 
multiplexed and sequenced together in a single run.  Several NGS platforms, 
specifically designed for this purpose and complete with integrated on-board 
bioinformatics, are now on the market, promising low cost, rapid sample-to-sequence 
turn-around times.  These advances hold out the possibility of speedy testing of whole 
panels of disease genes simultaneously, which may considerably hasten the process of 
genetic diagnosis while also reducing the workload for staff at the diagnostic laboratory. 
 
Although NGS platforms have a higher sequencing error rate (approximately 1 error 
per 10,000 bases sequenced at 20x read depth) compared to Sanger sequencing, this is 
largely offset by the extremely high read depth achieved as a result of the PCR 
amplification step (usually >100x).  Data from our own diagnostics laboratory as well as 
that of others suggests that that targeted NGS is just as reliable as Sanger sequencing in 
detecting pathogenic SNVs and small indels.  For instance, in a recent study of DNA 
samples from 84 patients with hereditary cardiomyopathy, all of the 168 variants 
identified using an NGS-based approach targeted to all 48 known cardiomyopathy 
genes were subsequently confirmed with Sanger Sequencing 55.  These variants included 
deletions up to 18 bp and insertions up to 8 bp.  No false-negative or false-positive 
results were obtained for variants selected for confirmation.  These results suggest that, 
at a read depth of at least 30x per nucleotide, there is no bar to the use of disease-
targeted NGS in place of Sanger sequencing in a diagnostic setting. 
 
The methodologies employed in targeted NGS also have research applications and 
these are of direct relevance to the work presented in this thesis.  In presenting 
evidence for a putative novel disease gene, one of the most compelling arguments for its 
pathogenicity is the demonstration of one or more independent kindreds who carry 
mutations in the same gene and in which the mutations segregate with the disease in 
question.  To do this, the putative gene must be screened in a large number of 
genetically undiagnosed individuals exhibiting a similar phenotype.  However, 
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Mendelian diseases are rare to start with and most exhibit considerable genetic 
heterogeneity, meaning the number of cases due to any particular disease gene can be 
very low.  Thus, the number of individuals that must be screened in order to stand any 
chance of identifying independent kindreds with segregating mutations in the same 
gene is often in the hundreds.  When the putative gene has just a few exons, the most 
efficient way of doing this is by Sanger sequencing; however, when a gene is large, 
Sanger sequencing becomes a costly and extremely time-consuming process.  Instead, 
the same methodology that underlies disease-targeted NGS can be employed to amplify 
and sequence only the gene in question.  Given the ability to multiplex samples in the 
same experiment, this can dramatically reduce the time taken to sequence a set number 
of cases in genes with a sizeable number of exons.  This technique has direct relevance 
to the work presented in this thesis and further explanation of its technical aspects can 
be found in section 2.8. 
 
1.7 Modern Genetic  Techniques for  Examining Complex Disease  
Up to this point, the discussion in this chapter has been largely centred around 
Mendelian disease and it is certainly the case that most of the work presented herein is 
directed towards elucidating the genetic cause of disease that is inherited in that 
fashion.  However, as part of my work, I also examined the genetic contribution to 
complex disease (in this case, Parkinson’s disease).  It is to the genetic architecture of 
complex disease and the development of the genetic techniques used to dissect it that I 
will now turn to in the sections below. 
 
As previously noted, Mendelian inheritance underlies only a tiny fraction of the 
number of individuals affected by many diseases;  in most cases, the disease appears at 
least to occur sporadically.  However, it is common knowledge that some families show 
a ‘predilection’ for certain sporadic diseases, albeit without clear Mendelian 
inheritance.  This everyday observation has been borne out by twin studies, which have 
demonstrated that most conditions – ranging from hypertension and obesity through 
to Parkinson’s disease and multiple sclerosis – show some degree of heritability.  This 
heritability, which might most profitably be thought of as an in-built susceptibility or 
risk, is conferred by the individual’s genetic make-up, which acts in concert with 
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environmental factors to determine whether he or she will develop a particular 
phenotype or disease.   
 
Different hypotheses have been proposed to explain how such in-built risk might be 
encoded in the human genome.  Under the ‘common disease, common variant’ 
hypothesis, it is postulated that, for common, sporadic disease, multiple variants with a 
high minor allele frequency (that is, variants that are found commonly in the general 
population) will be found to modulate the risk of developing the disease.  Individually, 
each variant would impart only a small additional risk but, collectively, they might act 
additively or synergistically to produce a more significant effect.  Testing such a 
hypothesis does not, theoretically at least, involve a particularly complicated or even 
novel experimental design:  by examining the genetic make-up of a large number of 
individuals with a particular common disease and comparing it to that of a similarly 
large number of individuals without the disease, it should be possible to identify those 
genetic elements mediating risk since they would be expected to occur at a significantly 
higher frequency in affected cases when statistically compared to unaffected controls.  
Practically, however, the technology to obtain genome-wide genotyping information on 
a large number of individuals was initially lacking and association studies of the time 
were limited to considering a handful of candidate genes at most and utilised only 
relatively modest sample sizes.  From around 2005 onwards, there was a radical change 
in the state of play: advances in the understanding of human genetic variability ushered 
in by completion of the Human Genome Project coalesced with concomitant 
improvements in genotyping technology to permit, for the first time, the rapid, 
relatively inexpensive and unbiased examination of the whole-genome for disease-
associated elements in enormous case-control cohorts.  The genome-wide association 
study (GWAS) was born.  In the sections below, the scientific advances that paved the 
way for this revolution in the genetics of complex disease are briefly detailed. 
 
1.8 SNPs, Chips and Haplotype Blocks  
Single nucleotide variants (SNVs) represent genetic differences between individuals that 
have been introduced into the human population by random mistakes in the DNA 
replication process over the evolutionary time frame.  The error rate for DNA 
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replication is very low – estimated at around 1.1 to 3 x 10-8 mistakes per base per 
generation.  Nonetheless, in view of the vast size of the genome, errors are inevitable 
and studies suggest that each individual will carry around 70 novel SNVs with respect 
to their parents 56.  The frequency of such genetic variants in the population is in part 
determined by their age, as transmission to subsequent generations would be expected 
to result in a higher and higher frequency over time.  However, some variants may be 
subject to natural selection or random genetic drift, leading to a lower frequency in the 
human population than might otherwise be anticipated based on their age alone.  In 
general, SNVs with a minor allele frequency of greater than 5% are considered 
common and are often also referred to as single nucleotide polymorphisms or SNPs for 
short.  SNVs with a minor allele frequency of less than 0.5% are considered rare, whilst 
those with a minor allele frequency of greater than 0.5% but less than 5% are said to be 
of intermediate or moderate frequency. 
 
The initial draft of the Human Genome Project in 2000 identified around 1.4 million 
SNVs.  As present, over 50 million SNVs are known and this number is expected to 
increase further as more genomes are sequenced.  These variants represent a pool of 
genetic variability that could potentially underlie an individual’s in-built risk for 
sporadic disease.  However, genotyping every single one of these SNVs was (at least 
until the event of NGS) impossible in any statistically meaningful number of people 
and, even with NGS technologies, the cost is still prohibitive.  However, it has long 
been known that the alleles of different SNVs lying in physical proximity on the same 
chromosome show non-random combinations – that is, the observation of one allele of 
an SNVs at one position makes it more likely that you will observe a particular allele of 
a second SNV nearby.  This results from the fact that SNVs in close proximity tend not 
to be separated by chromosomal recombination during meiosis and thus tend to travel 
together between generations.  This phenomenon is called linkage disequilibrium and 
the blocks of SNVs between recombination hotspots, which tend to travel together 
from generation to generation, are termed haplotype blocks.  From a genomic 
perspective, linkage disequilibrium operates only over relatively short ranges and 
haplotype blocks typically do not extend beyond 200 – 300kb. 
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The international HapMap project, proposed in 2002, set about creating a map of 
typical human haplotype blocks 57.  Armed with such a map, the number of SNVs that 
needed to be genotyped to cover the entire genome was drastically reduced.  Instead, 
‘tagging’ SNPs could be selected that served as a marker for a particular haplotype block 
and the genotype of the remaining SNVs constituting the same block derived 
probabilistically.  Subsequent development of such ‘imputation’ algorithms made it 
possible to predict the genotype of millions of SNVs based only on the physical 
genotyping information of a limited set of approximately 500,000 tagging SNPs.  At the 
same time, advances in genetic technology based on immobilised nucleic acid sequences 
and labelled allele specific oligonucleotide probes made it possible to miniaturise the 
genotyping process so that it could be performed on the back of a chip and analysed 
automatically by a computer.  The advent of these so-called ‘SNP chips’ paved the way 
for rapid, inexpensive and accurate genotyping of large numbers of individuals across 
their entire genomes and opened the door to the first truly genome-wide association 
studies (GWAS), which began to appear in the literature with increasing frequency 
from 2005 onwards.   
 
1.9 Insights  f rom GWAS of Complex Disease  
The GWAS approach has provided important information regarding the pathogenesis 
of complex disease.  Firstly, it has delivered evidence to support the hypothesis that at 
least a subset of the same pathways involved in Mendelian disease is involved in the 
more common sporadic forms of disease as well.  In the case of Parkinson’s disease, 
GWAS have repeatedly demonstrated strong association signals overlying the genes 
SNCA (α-synuclein), LRRK2 (leucine repeat rich kinase 2), and MAPT (tau microtubule 
associated protein), all three of which are known causes of Mendelian forms of 
parkinsonism 3, 4, 58.  These findings lend credence to the argument that therapeutics 
that are developed based on a knowledge of pathways involved in Mendelian disease 
may prove more widely beneficial to individuals suffering from sporadic forms of the 
same disease.  It this respect, the development of LRRK2 kinase inhibitors represents a 
promising therapeutic avenue for Parkinson’s disease 59.  
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Secondly, large-scale international GWAS and subsequent metanalyses of their results 
have demonstrated that numerous genetic loci modulate risk for sporadic disease, even 
for disorders that were previously considered to have little genetic component, as was 
the case for Parkinson’s disease 60.  Some of these loci overlie genes that might 
reasonably have been expected to be associated with the particular condition under 
examination based on the prior understanding of its pathogenesis (examples include 
the association signal overlying apolipoprotein E in Alzheimer’s disease or those 
overlying genes involved in the immune response in multiple sclerosis 61, 62).  Many 
association signals, however, overlie genes involved in pathways that might not 
otherwise have been connected with that condition.  Such unexpected associations may 
provide new clues to the underlying pathogenesis of the disease in question.  Examples 
of such findings include a role for autophagy in Crohn’s disease 63, for the complement 
pathways in age-related macular degeneration 64, and for the central nervous system in 
obesity 65.  Yet, despite the exciting opportunity provided by the signposting of such 
novel avenues for exploration, care must be taken to keep in mind that the exact same 
phenomenon that makes microarray-based GWAS possible – that is, linkage 
disequilibrium – also means that the SNPs identified as ‘top hits’ is such studies do not, 
in all probability, represent the causal SNVs themselves.  Instead, it is altogether more 
likely that these top hits represent markers that are in linkage disequilibrium with the 
true causal variant.  Indeed, the true causal variant may be located at a considerable 
distance from the implicated risk SNP, especially if that causal variant is itself rare 66.  
For this reason, GWAS hits – particularly those where the underlying gene’s function 
cannot immediately be connected to the pathophysiological mechanisms thought to be 
relevant to that disease – require further exploration using cellular biological 
techniques.  A good example of this kind of follow-through work can be found by 
considering GWAS findings in Parkinson’s disease.  An association signal for this 
condition was identified in multiple GWAS overlying the gene GAK (cyclin G 
associated kinase) 3, 5, 67.  The protein product of this gene acts as a key mediator of 
endocytic vesicle trafficking by regulating interactions with adaptor proteins and later 
driving disassembly of the vesicle clathrin coat 68.  Following on from this, it has now 
been demonstrated experimentally that GAK knockdown accentuates protein load and 
toxicity in cell culture when α-synuclein is overexpressed and decreases cell viability in 
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rat primary neuron cultures expressing α-synuclein with the Parkinson’s disease-
associated p.A53T mutation 69.  This new information suggests that targeting endocytic 
pathways may be a viable approach to combat Parkinson’s disease.   
 
Finally, another important finding to arise from GWAS is that the ‘common disease, 
common variant’ hypothesis does not explain all of the heritability of a condition.  
Most GWAS-implicated common SNPs display only modest individual effects on 
disease risk and, even when considered together, fail to account for all of the estimated 
genetic risk 70.  For example, although approximately 60 to 80% of AD risk is estimated 
to derive from genetic factors 71, known genetic risk loci (including the uniquely large 
effect of apolipoprotein E) account for just half of this variance in genetic susceptibility  
72.  In many other conditions, the figure appears to be closer to 20% 73, 74.  It is likely 
that at least a portion of this missing heritability may be accounted for by an alternative 
hypothesis, which states that predisposition to common disease may be determined by 
multiple rare to moderately-rare variants of higher penetrance.  The basis for a good 
example of a genetic risk factor such as this comes not from any particularly exciting or 
novel advancement in genetic technology, but instead from good, old-fashioned, astute 
clinical observation.  It was noted some time ago by clinicians caring for individuals 
suffering from Gaucher’s disease – an autosomal recessive lysosomal storage disorder 
caused by biallelic mutations in the gene GBA – that individuals with clinically mild 
disease, as well as their otherwise neurologically-normal parents, appeared to exhibit a 
higher incidence of Parkinson’s disease than would be expected by chance alone 75.  It 
has now been conclusively demonstrated that rare heterozygous variants in GBA act to 
moderately increase the risk of developing Parkinson’s disease.   
 
‘Moderately rare, moderately penetrant’ variants, such as those found in GBA, are 
poorly represented in GWAS that are based on microarray genotyping of tagging SNPs.  
Imputation can only provide probabilistic information on genotypes for known low-
frequency SNPs that are not directly genotyped and, furthermore, this can only be 
obtained for populations in which accurate haplotype information is already available.  
In an attempt to overcome this problem, association studies are already underway that 
use sequencing data generated by NGS platforms.  Such studies represent somewhat of 
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an intersection between the genetic techniques relevant to Mendelian and complex 
disease that have already been explored in this introductory chapter.  However, whilst 
the use of NGS to directly genotype all variants allows – theoretically at least – for an 
assessment of the contribution of rare variants to complex disease, it brings with it its 
own set of challenges.  Particular concerns include the increased sample size required to 
detect association when so many more variants are under consideration and the added 
risk of false positives arising from population stratification, which, as mentioned in 
section 1.3, appears to be the rule where rare variants are concerned.  Since the work 
presented herein is concerned only with association of common polymorphisms, an full 
exploration of the above-mentioned and other challenges related to rare variant 
association analyses is beyond the scope of this chapter; interested readers are, however, 
referred to the recent review article by Lee et al., which covers this subject in depth 76 
and also to the final discussion chapter of this thesis, which touches on future 
directions in genetic research. 
 
1.10 Summary  
In this chapter, I have aimed to give a broad overview of the recent scientific advances 
that have underpinned latest advances in our understanding of the genetic contribution 
to neurological disease.  Thus far, I hope, what has emerged is the idea of a tripartite 
model of the contribution of genetic variation to disease susceptibility.  This model is 
represented in figure 1 with reference to the common neurodegerative disorder, 
Parkinson’s disease.  NGS technologies have been developed and used to identify 
extremely rare variants of high penetrance that underlie rare Mendelian forms of a 
disease, whilst DNA microarrays and the statistical techniques inherent to association 
analyses have been used to examine common variants of low effect-size that underpin 
some of the hereditability associated with common forms of the same disease.  These 
techniques are directly relevant to most of the work presented herein.  More recently, a 
combination of the two techniques promises to allow the exploration of the 
contribution of variants of rare to moderate frequency and intermediate penetrance to 
complex disease, though many challenges remain to overcome.   
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Figure 1 - The tripartite approach to genetic variation as a risk factor for disease, using 
Parkinson's disease as an example.  Very rare Mendelian mutations conferring very high risk are 
shown on the left; moderately rare mutations of intermediate penetrance are shown in the 
centre; and some examples of common polymorphisms of small effect are shown on the far 
right.  This figure was originally published in Lesage et al. (2012) 77 
 
 
In chapter 2, I first provide some additional technical information that is required to 
fully understand NGS sequencing technologies and the work exome sequencing work 
presented herein.  This is followed, in chapter 3, by an overview of the current 
understanding of the genetics of the condition upon which most of my work was 
focussed – dystonia.  Chapter 4 gives details of the core methods used time and again 
in my research work.  Chapters 5 through 15 detail the bulk of my work – exome 
sequencing in genetically-unresolved kindreds with hereditary neurological disease, a 
small association analysis of neuropathologically-proven Parkinson’s disease and various 
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PCR-based sequencing experiments aimed at determining the relevance or frequency of 
proposed Mendelian disease genes.  Chapter 16 offers a discussion of the work 
presented herein and addresses the question of the direction of genetic research is likely 
to take in the future. 
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Technical Aspects of Sequencing 
and Ancillary Genetic Techniques 
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In the sections that follow, I discuss some of genetic techniques that I have employed in 
my attempts to tackle the kindreds detailed in the chapters that follow.  The aim here is 
not to explain the use of these techniques in relation to any particular family (this can 
be found in the individual chapters that are dedicated to each kindred) but instead to 
outline the scientific rational that underpins their use and the generic methodology 
that must be followed to produce accurate and useful data.  This repertoire of 
techniques represent a set of core tools from amongst which the modern geneticist 
must select the most appropriate combination to elucidate the genetic aetiology of a 
particular phenotype, based on the characteristics of the disease and the kindred in 
question.    
 
2.2 Dideoxynucleot ide Sequencing 
This common, enzymatically-based method of reading small fragments of DNA 
(≤700bp) was the mainstay of DNA sequencing for around 3 decades since it was first 
pioneered by Fred Sanger in the mid-70s 7 and is usually termed Sanger Sequencing for 
short.  It relies on the random inhibition of chain elongation by DNA polymerase, 
creating newly synthesised DNA strands of various lengths that can by separated by size.  
Random inhibition of chain elongation is achieved by including a small quantity of 
dideoxynucleotides (ddNTPs), which are similar to their deoxyribonucleotide (dNTP) 
counterparts but lack the hydroxyl group at the 2’ and 3’ carbon positions, in the 
reaction mix.   The lack of the hydroxyl group at the 3’ carbon in particular precludes 
the formation of a phosphodiester bond with the subsequent dNTP, preventing DNA 
polymerase extending the chain any further.  Since the input DNA sample is a 
population of identical molecules population produced by PCR amplification, each of 
the fragments in one reaction will have a common 5’ end (defined by the sequencing 
primer) but a variable 3’ end (defining by the essentially random insertion of the 
appropriate ddNTP into any one of the many positions that will accept that base).  By 
combining the ddNTPs with fluorescent dyes with different emission wavelengths, 
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automated DNA sequencing machines could be produced that used laser excitation 
during electrophoresis to construct the DNA sequence from the intensity profiles of 
four fluorophores. 
 
The main use of dideoxynucleotide sequencing within this work is to read small 
portions of DNA – usually no more than a single exon of a gene at a time – in order to 
confirm the potentially causal variants detected by exome sequencing or, alternatively, 
to screen the DNA of other individuals with a similar phenotype for mutations in the 
same exon or gene. 
  
2.3 Next Generation Sequencing 
Unlike Sanger sequencing, which is based on the electrophoretic separation of chain-
termination products produced in individual sequencing reactions, next-generation 
sequencing (NGS) involves the massively parallel sequencing of clonally amplified or 
single DNA molecules that are spatially separated in a flow cell.  Sequencing is 
performed by repeated cycles of polymerase-mediated nucleotide extensions.  As a 
massively parallel process, NGS generates hundreds of gigabases of nucleotide-sequence 
output in a single instrument run. 
 
Most NGS workflows share the general processing steps delineated in figure 2.  As the 
figure suggests, there is in fact little difference between protocols for whole exome and 
whole genome sequencing – the former simply includes an additional step involving the 
ligation of oligonucleotide probes defining the target sequence and the subsequence 
washing away of non-ligated DNA.  Significant differences do exist, however, in terms 
of the basic chemistry used by different manufacturers of NGS platforms, which has 
consequences for both library preparation and data generation.  In our own lab, we 
employed Illumina technology using the HiSeq 2000 and details of the chemistry 
underpinning this technology are given below.  For the purposes of comparison only, 
details of Roche’s alternative methodology are also provided, though this was not 
available within our institution and thus not used to the generate any of data presented 
in this thesis. 
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Figure 2 - Next generation sequencing process steps for platforms requiring clonally amplified 
templates (Roche 454, Illumina and Life Technologies). Input DNA is converted to a 
sequencing library by fragmentation, end repair, and ligation to platform specific 
oligonucleotide adapters. Individual library fragments are clonally amplified by either (1) 
water in oil bead–based emulsion PCR (Roche 454 and Life Technologies) or (2) solid surface 
bridge amplification (Illumina). Flow cell sequencing of clonal templates generates 
luminescent or fluorescent images that are algorithmically processed into sequence reads. 
Figure adapted from Voelkerding et al., (2009) 78 	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The first step is to prepare the ‘library’ comprising DNA fragments ligated to platform 
specific oligonucleotide adapters.  Template DNA is fragmented into lengths of several 
hundred base pairs and end-repaired to generate 5′-phosphorylated blunt ends.  The 
polymerase activity of Klenow fragment is used to add a single A base to the 3′ end of 
the blunt phosphorylated DNA fragments.  This addition prepares the DNA fragments 
for ligation to oligonucleotide adapters, which include an overhang of a single T base at 
their 3′ end to increase ligation efficiency.  The adapter oligonucleotides are 
complementary to anchors attached either directly to the flow-cell (Illumina) or, 
alternatively, to individual beads (Roche).   
 
The method of clonal amplification differs depending on the system used.  On 
Illumina platforms, the adapter-modified, single-stranded template DNA is added to 
the flow cell and immobilized by hybridization to the anchors under limiting-dilution 
conditions. DNA templates are then amplified in the flow cell by ‘bridge amplification’, 
which relies on captured DNA strands ‘arching over’ and hybridizing to an adjacent 
anchor oligonucleotide. Multiple amplification cycles convert the single-molecule DNA 
template to a clonally amplified arching cluster, with each cluster containing 
approximately 1000 clonal molecules. Approximately 50 × 106 separate clusters can be 
generated per flow cell.  On Roche platforms, one the other hand, the library is first 
diluted to single-molecule concentration, denatured, and then hybridized to individual 
beads containing sequences complementary to adapter oligonucleotides. The beads are 
compartmentalized into water-in-oil microvesicles, where clonal expansion of single 
DNA molecules bound to the beads occurs by means of emulsion PCR.  After 
amplification, the emulsion is disrupted and the beads containing clonally amplified 
template DNA are enriched. The beads are again separated by limiting dilution and 
deposited into individual picotiter-plate wells, which function as the flow cell. 
 
Sequencing – the final step in the process – differs again depending on the platform 
used.  On Illumina platforms, the clusters are denatured and a subsequent chemical 
cleavage reaction and wash leave only forward strands for single-end sequencing.  
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Sequencing the forward strand is initiated by hybridizing a primer complementary to 
the adapter sequences, followed by the addition of polymerase and a mixture of four 
differently coloured fluorescent reversible dye terminators.  The terminators are 
incorporated according to sequence complementarity in each strand in a clonal cluster.  
After incorporation, excess reagents are washed away, the clusters are optically 
interrogated, and the fluorescence pattern recorded.  With successive chemical steps, 
the reversible dye terminators are unblocked, the fluorescent labels are cleaved and 
washed away, and the next sequencing cycle is performed.  Roche systems, on the other 
hand, employ iterative pyrosequencing (successive flow addition of the 4 dNTPs).  A 
Figure 3 - Cluster strands created by bridge amplification are primed and all four fluorescently 
labeled, 3’-OH blocked nucleotides are added to the flow cell with DNA polymerase. The 
cluster strands are extended by one nucleotide. Following the incorporation step, the unused 
nucleotides and DNA polymerase molecules are washed away, a scan buffer is added to the 
flow cell, and the optics system scans each lane of the flow cell by imaging units called tiles. 
Once imaging is completed, chemicals that effect cleavage of the fluorescent labels and the 3’-
OH blocking groups are added to the flow cell, which prepares the cluster strands for another 
round of fluorescent nucleotide incorporation.  This figure was published in Mardis et al. 
(2008) 79 
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nucleotide-incorporation event in the picotiter plate well containing clonally amplified 
template produces pyrophosphate release and thus localized luminescence, which is 
transmitted through the fiber-optic plate and recorded on a charge-coupled device 
camera.  With the flow of each dNTP reagent, all wells are imaged simultaneously, 
analyzed for their signal-to-noise ratio, filtered according to quality criteria, and 
subsequently algorithmically translated into a linear sequence output.  Regardless of the 
chemistry used to generate the raw sequence read data, the output is stored in a 
standardised format as a FASTQ file. 
 
2.4 Post  Process ing of  Exome Data 
To generate the final variant calls for analysis, the FASTQ files are fed through an 
automated bioinformatics pipeline.  The data is passed sequentially through a series of 
freeware tools designed to accomplish the following steps: 
1. Verification of input integrity, quality checks, read trimming and primer 
contamination removal  
2. Gapped alignment to the reference genome  
3. BAM conversion, sorting and indexing 
4. Duplicate removal  
5. Local realignment around the position of known indels 
6. Quality score recalibration 
7. Variant calling  
8. Association of variants to annotations recorded in a number of publically 
available databases (dbSNP, 1000 genomes, Washington exome sequencing 
project, complete genomics) and to pre-computed in silico predictions of 
pathogenicity and conservation. 
9. Data post-processing and output as Excel-compatible, comma-separated files text 
files for manual inspection and filtration. 
 
Although alternative pipelines exist (utilising different software tools to perform 
particular tasks such as alignment and variant calling), the actual individual steps 
involved in the process remain much the same regardless.  It should be noted, however, 
that the selection of one pipeline over another is not without consequences in terms of 
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the final list of variants that are actually called, as is discussed in section 2.5.3 below.  
An expanded explanation of the bioinformatics pipeline employed in our own 
laboratory can be found in section 4.16 .  
 
2.5 Technical  Limitations of  Exome Sequencing 
As with any technology, it is important to be aware of some of the technical limitations 
of NGS in general and of exome sequencing in particular.  Essentially, exome 
sequencing can be thought of as a modular process, consisting of three core steps that 
are completed sequentially to produce the final output file.  These steps are: 1) library 
preparation; 2) sequencing; and 3) bioinformatic analysis.  For each of these steps, there 
are important technical considerations that may impact on the likelihood of success for 
a study aiming to identify a novel disease-causing mutation. 
 
2.5.1 Library Preparation: Defining the Exome 
One of the perceived strengths of exome sequencing over the candidate gene studies 
that it superceded is that there is supposedly no requirement for a priori hypotheses 
regarding the gene(s) likely to be responsible for the disease being tackled.  However, 
this is not quite true: exome sequencing is predicated on the hypothesis that the causal 
variant will be located within a protein-coding portion of the genome.  This is a 
certainly not an unreasonable hypothesis given that, as mentionned previously, 
approximately 85% of all causal mutations for Mendelian disease discovered so far have 
been found in such regions.  However, this figure is in all likelihood inflated as a result 
of detection and publication bias.  Firstly, the limitations of scale imposed by the 
genetic technology available when these disease-causing mutations were identified (i.e. 
linkage analysis and Sanger sequencing) effectively precluded any detailed examination 
of non-coding regions due to their size.  Secondly, there is a tendency to publish only 
successful studies, such that the true number of studies in which linkage was obtained 
but no causal mutation was found will never be known.  Thus, it is important to realise 
that one inherent limitation of exome sequencing is that it runs the risk of missing the 
causal variant if that variant is not located in a coding sequence and that, furthermore, 
the proportion of disease-causing variants located in what are traditionally considered 
non-coding regions may be much higher than anticipated for the reasons detailed 
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above.  Indeed, the recent identification by two independent groups of a 
hexanucleotide repeat expansion in the 5’ region of the gene C9orf72 as the cause of 
hereditary amyotrophic lateral sclerosis (ALS) and fronto-temporal lobar dementia 
(FTLD) serves to illustrates this point well 80, 81.  Not only is this expansion located in a 
non-coding portion of the genome and thus would not be captured by exome 
sequencing, but the expansion range is typically in the 100s to 1000s and would thus be 
too large for detection by Sanger sequencing.  Nonetheless, this mutation appears to be 
the single most common genetic cause of this spectrum of neurodegenerative disorders 
that has been identified to date, with pathological expansions having been observed at 
frequencies of up to 29%, 50%, and 88% in case series of FTLD, ALS, and FTLD-ALS, 
respectively 82. 
 
The situation is further complicated by the fact that the exome is, in practice at least, a 
somewhat arbitrary and changeable concept.  Theoretically, the exome is defined as the 
entire protein-coding portion of the human genome.  However, in spite of the rapid 
advances in our genetic understanding, there remains considerable uncertainty about 
which genomic sequences are actually protein-coding and which are not.  From an 
operational perspective, the exome is often defined by the content of the consensus 
coding sequence (CCDS) database, a consortium effort to delineate the human 
sequences for which there is strong evidence of transcription and translation.  This 
database currently contains 25,564 unique IDs, corresponding to 18,407 human genes.  
Even if this were the only database in existence, the exome would still remain 
necessarily fluid as knowledge of which sequences within the genome are transcribed 
and translated is constantly improving, leading to changes in the content of the CCDS 
database.  However, the waters are further muddied by the existence of other alternative 
databases of coding sequences.  Some, such as RefSeq, include sequences with a lower 
level of evidence for coding and are correspondingly larger, whilst others, such as 
GENCODE, are archival and thus contain numerous redundant sequence identifiers.  
It is likely that these non-consensus databases contain many more errors than the 
relatively conservative CCDS database, but it is equally likely that they contain a large 
number of sequences not yet included in the CCDS database that will, in fact, turn out 
to be protein coding.   
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This uncertainty regarding the exome is reflected in the variability of targeting between 
the various commercially available exome capture kits.  By way of example, table 2 
(taken from a recent paper by Coonrod et al. [2012] 83), shows comparative metrics for 
some of the most commonly used kits currently on the market. 
 
Table 2 - Comparative metrics for three commonly used exome capture kits used in library 
preparation for exome sequencing by 2012.  CCDS, RefSeq and GENCODE databases are 
described in the text above.  RefSeq plus = RefSeq exons + 5’ and 3’ UTRs + microRNA + 
noncoding RNA.  miRBase = database of microRNAs sequences.  Rfam = database of RNA 
families. 





Target Region Size 44.1Mb 50Mb 62Mb 
Number of Targets ~300,000 331,518 201,121 
Number of Probes 2.1 million 430,400 340,427 
Probe Type DNA RNA DNA 
Bases covered at 10x 81% >85% 85% 
On target reads 90% (±100bp) 77% (±200bp) ~83% (±150bp) 
















On the whole, over the three-year period that this research spanned, we observed a 
general tendency for the size of the targeted region to expand, as more databases were 
included in the probe design process, and for the depth of coverage obtained to 
progressively improve.  The exome capture kits used at the start of this research project 
targeted only ~30Mb and coverage was often suboptimum; by the end of the project, 
the Illumina TruSeq kit, which targets a genomic area twice that size and generally 
produces excellent coverage, had become the standard choice.  Clearly, kits with larger 
target areas stand a higher chance of including sequences where a causal variant could 
potentially lie and thus a study’s chance of success may be determined by the target 
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used for library preparation.  To date, at least one study has been reported in which the 
disease-causative variant was initially missed because it was located in a sequence not 
defined as protein coding by the CCDS; it was only later identified when the larger 
RefSeq definition of the exome was used as the basis for capture 84. 
 
2.5.2 Sequencing Failures:   Breadth and Depth of Coverage 
It is worth noting two important technical limitations of exome sequence that are 
evident from the table above, namely:  1) only a portion of the target will sequence 
successfully (breadth of coverage); and 2) that the number of reads covering any 
particular successfully-sequenced target is uneven and can be suboptimal (depth of 
coverage).  Each NGS platform has its own particular characteristics related to the 
underlying chemistry employed in sequencing that determines which regions are more 
likely to be poorly represented or more prone to sequencing errors.  In general, 
however, all have a tendency to perform poorly in regions of DNA with certain 
physiochemical properties, such as those with high GC content or those consisting of 
highly repetitive or low complexity sequences of nucleic acids.  Sequences such as these 
present difficulties in probe design, probe binding, PCR amplification and subsequent 
mapping of the resultant sequence to reference genome and can thus result in little or 
no coverage of areas that could nonetheless potentially habour a disease-causing 
mutation. 
 
Low coverage depth is a particular problem when the causal variant is likely to be 
heterozygous.  If only a few reads are obtained for a sequence that contains a 
heterozygous disease-causing variant, there is a significantly increased probability that all 
the reads obtained may come from the strand containing the normal allele and thus the 
variant would be missed even though the area had apparently been covered.  This 
problem compounded by the fact that all exome sequencing kits exhibit reference bias, 
as capture probes are designed to match the reference sequence and thus tend to 
preferentially enrich the reference allele at heterozygous sites 85.  If the variant is located 
on the anti-sense strand to the reference, it is much less likely to be detected at low read 
depths.  Moreover, NGS technologies rely on redundancy of coverage to compensate 
for a relatively high intrinsic error rate, which approaches 1% for most platforms.  
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When considered alone, a sequencing error is indistinguishable from a sequence 
variant.  However, even if all reads contain a 1% variant-error rate, the combination of 
eight identical reads that cover the location of the variant will produce a strongly 
supported variant call with an associated error rate of 10−16 86, 87.  Thus, when evaluating 
an exome sequencing study, it is necessary to consider not just the breadth of coverage, 
but also the depth of coverage.  At present, there is a general consensus that good 
quality exome data will cover around 80% of target region at a minimum depth of 10 
reads.  Studies with coverage metrics that fall significantly below these values have a far 
greater chance of false-negative and false-positive variant calls and any conclusions 
drawn from such data should be evaluated with caution. 
 
2.5.3 Limitations of  Sequencing Data Analysis  
Processing of raw exome sequencing data is a computational intensive process and the 
algorithms involved in these steps (delineated in sections 2.4 and 4.16) are subject to 
constant change and development.  The first step in this process involves alignment of 
the sequencing reads to the reference genome.  The choice of alignment algorithm will 
impact on the final coverage values, as different algorithms show varying false-positive 
and false-negative rates 88, 89.  Even the best mapping algorithms will fail to align all 
reads to the reference genome.  This may be due to sequencing errors, structural 
rearrangements or insertions in the query genome, or deletions in the reference.  
Furthermore, it is not possible to unambiguously assign reads to all genomic regions.  
The 'mappability' of a sequence within a genome has a major influence on the average 
final mapped read depth and is an important source of false-negative and false-positive 
single-nucleotide variant calls 90.   Since sequence reads that map to multiple sites in the 
genome are usually discarded, genomic regions with high sequence degeneracy or 
repetition show a lower mapped read coverage – inversely correlated to the size of the 
genomic repeats – than do unique regions, creating a form of systematic bias 91.  In 
addition, pseudogenes, which show high sequence homology to their expressed 
counterparts but are subject to greater genetic drift and thus more likely to contain 
variants, also pose a problem for read mapping.  As the surrounding sequence can be 
essentially identical, a sequencing read containing a variant that actually originated 
from the pseudogene may be incorrectly mapped to its expressed counterpart, 
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introducing false-positive errors.  Such false positive SNVs were observed in a recent 
study using exome sequencing in patients with Fanconi anaemia, a condition for which 
some of the known causative genes have closely-homologous pseudogenes, forcing the 
authors to resort to long-range PCR to prove the true their true origin 92. 
 
To some extent the problem of low mappability arises as a result of the short read 
lengths used by many NGS platforms, including the Illumina platform used in our own 
laboratory.  Longer read lengths increase the chance of a read encompassing a unique 
sequence that anchors all remaining sequences.  However, for read lengths greater than 
200bp, the gains in mappability fall off rapidly and a recent study has demonstrated 
that even a read length of 1000bp would still not permit the unique alignment of reads 
for many coding regions of human genes 93.  A second approach to this problem has 
been to generate paired-end libraries with longer insert sizes, which increases the chance 
of one read of the pair mapping to a unique region outside the repeat sequence.  This 
approach is employed by Illumina in its HiSeq 2000 platform, which utilises paired end 
reads of approximately 100bp in length. 
 
Regardless of the chemistry used in performing NGS, there still remains considerable 
discrepancy between the output of difference data analysis pipelines, even when used 
with near-default parameterization on the same raw sequencing data.  This was 
beautifully illustrated by a recent study, which passed the same raw sequencing data 
from 15 exomes generated on the Illumina HiSeq 2000, through five separate variant 
analysis pipelines (SOAP, BWA-GATK, BWA-SNVer, GNUMAP, and BWA-
SAMtools) 94.  In this study, SNV concordance between the five pipelines across all 15 
exomes was found to be only 57.4%, whilst between 0.5 to 5.1% of variants were called 
as unique to each pipeline.  More worryingly from a disease gene discovery point of 
view was the finding that for, novel SNVs (i.e. those not found in dbSNP135), the 
overall concordance rate was just 11.4%.  Indel calling showed even higher levels of 
discrepancy, with the overall concordance for known and novel indels being just 43.3% 
and 4.7%, respectively.  In a second phase of the research, the authors focused on two 
of the most commonly used pipelines, based around GATK and SOAP, in order to 
assess the validity of the variants detected.  A total of 1,140 SNVs found in a single 
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exome were selected for MiSeq validation; 760 of these SNVs were randomly selected 
from the set of SNVs that were unique to the GATK and SOAP pipelines (380 from 
each pipeline).  The MiSeq’s reliance on PCR amplification (as opposed to exon 
capture), its longer read lengths, and the much higher depth of coverage made its use a 
strong method of validation for SNVs and indels alike.  Of the 1,140 SNVs targeted for 
MiSeq validation, 919 (81.0%) were successfully amplified and sequenced, with an 
average read depth of 5,392.  Validation rates for unique-to-GATK SNVs were high, 
with 306 of 315 (97.1%,) being successfully validated. For unique-to-SOAP SNVs, 174 
of 289 SNVs (60.2%) were validated. Validation rates for indels were considerably 
lower:  only 180 of 336 (54.0%) unique-to-GATK and 148 of 332 (44.6%) unique-to-
SOAP indels could be validated.  In this study, the authors conclude that this 
discordance between pipelines is likely to be the result of many factors including 
differences in alignment methods, post-alignment data processing, parameterization 
efficacy of alignment and variant-calling algorithms, and the underlying models utilized 
by the variant-calling algorithm(s).  Indeed, it is clear from this data that each variant-
calling pipeline detects variants that others do not and, whilst the accuracy of these 
discordant variants is naturally reduced, between 60.2 – 97.1% of unique SNVs and 
44.6 – 54% of indels were nonetheless subsequently validated.  However, in the realm 
of biomedical research, missing even a single variant can mean the difference between 
discovering a disease-causing mutation or not 95. 
 
2.6 From Potential  Causal Variants to Disease -Causing Mutation:  
Confirmation, Segregation and Independent Kindreds  
As a result of the inherent limitations of NGS sequencing and its supporting 
bioinformatics, each variant is best viewed as a hypothesis to be tested.  As such, any 
suspected causal variants must first be confirmed by Sanger sequencing to ensure that 
they are not artefactual.  This is particularly important with indel calls, which are more 
prone to error, but is, in reality, a requirement for all variants before any further 
sequencing or experimental work can be undertaken.  Subsequently, segregation of the 
variant with the disease in the index family must be demonstrated by Sanger 
sequencing in all affected and unaffected individuals for whom DNA is available.  At 
this stage, it is necessary to keep the possibility mind that segregation may not be 
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perfect as a result of potential issues such as incomplete penetrance and, occasionally, 
phenocopies.  Finally, if segregation is demonstrated in the index family, one would 
normally then go on to sequence first the exon and, subsequently, if feasible, the entire 
protein-coding portion of the gene in which the variant lies in a large cohort of 
individuals with phenotypically similar disease.  Typically, the number of individuals 
that need to be sequenced to stand a reasonable chance of finding further potentially 
disease-causing variants in the same exon/gene for rare Mendelian diseases will be in 
the hundreds.  Should further individuals who carry the same or a different potentially-
causative variant be identified in this cohort, an attempt is made to contact these 
individuals and establish the pattern of disease in their own families and, provided 
consent is obtained, to collect DNA samples from other affected and unaffected 
members of their families in order to try and demonstrate segregation in one or more 
independent kindreds.  Only rarely is experimental work undertaken without having 
demonstrated segregation in at least one other independent kindred.  
 
2.7 A Basic Guide to Common Variant Annotations 
In the sections below, I give a brief overview of some of the annotations of evolutionary 
conservation and predicted pathogenicity to which frequent reference is made in this 
work.  The programs that produce these annotations often rely on different algorithms, 
which each take into account a slightly different set of factors in producing their final 
‘score’.  My aim here is in no way to provide a comprehensive account of the internal 
workings of these algorithms (which is beyond my own understanding), but simply to 
allow the reader to familiarise themselves with their purpose and the meaning of their 
individual score systems. 
 
2.7.1 Evolutionary Conservation 
Three main programmes are used to assess the evolutionary conservation of a variant:  
GERP 96, 97, PhyloP 98 and PhastCons 99.  In general, evolutionary conservation scores 
appear to be one of the most reliable markers of potential pathogenicity of a variant.  
Approximately 90% of known pathogenic variants affect evolutionarily conserved bases 
or regions.  However, the fact that at least 10% must therefore lie in apparently 
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unconserved regions means these scores can never be used to exclude a variant 
absolutely. 
 
2.7.2 GERP (Genomic Evolutionary Rate Profi l ing)  
For each aligned site, GERP defines a ‘rejected substitution’ (RS) score by estimating 
the actual number of substitutions at that site and subtracting it from the number 
expected assuming neutrality (~5.82 substitutions per site).  Selectively constrained sites 
tolerate fewer substitutions than neutral sites and have positive RS scores.  This concept 
was first described in Cooper et al. (2005) 96.  GERP++, as described in Davydov et al. 
(2010) 97, is a development of the same methodology, which uses a more rigorous set of 
algorithms to calculate site-specific RS scores and to thus detect evolutionarily 
constrained elements. 
 
Each site is scored independently.  Positive scores represent a substitution deficit (i.e. 
fewer substitutions than the average neutral site) and thus indicate that a site may be 
under evolutionary constraint.  Negative scores indicate that a site is probably evolving 
neutrally; negative scores should not be interpreted as evidence of accelerated rates of 
evolution because of too many strong confounders, such as alignment uncertainty or 
rate variance.  Positive scores scale with the level of constraint, such that the greater the 
score, the greater the level of evolutionary constraint inferred to be acting on that site.  
Pre-computed scores for 35 mammals are available on the UCSC browsers, ranging 
from a maximum of 6.18 down to -12.36.  In general, variants with a GERP score of >2 
are felt to have a much greater chance of being pathogenic. 
 
2.7.3 PhastCons and PhyloP 
PhastCons utilises a hidden Markov model-based method that estimates the probability 
that each nucleotide belongs to a conserved element, based on the multiple alignment. 
PhastCons values may thus vary between 0 and 1 (the closer the value is to 1, the more 
probable the nucleotide is conserved).  It considers not just each individual alignment 
column, but also its flanking columns. 
 
By contrast, PhyloP separately measures conservation at individual columns, ignoring 
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the effects of their neighbours.  Its score range is similar to GERP (-14 to 6), with 
positive scores indicating conservation. 
 
The two methods have different strengths and weaknesses. PhastCons is sensitive to 
‘runs’ of conserved sites, and is therefore effective for picking out conserved elements. 
PhyloP, on the other hand, is more appropriate for evaluating signatures of selection at 
particular nucleotides. 
 
2.7.4 In Si l ico Predict ions of  Pathogenicity 
To date, several variant prioritization tools have been developed that aim to identify 
damaging alleles.  The most commonly used and most robustly tested are SIFT (Sorting 
Intolerant From Tolerant) and PolyPhen (Polymorphism Phenotyping).  Experiments 
using these tools to try to correctly predict known pathogenic and benign variants have 
demonstrated that the sensitivity of SIFT and PolyPhen is reasonably high (~70% in 
both cases), but that their specificity may be as low as 13% and 16%, respectively 36, 38, 39. 
Both algorithms proved to be significantly better at predicting loss-of-function 
mutations than gain-of-function mutations.  For the purpose of this thesis, I have used 
these tried-and-tested favourites, alongside newer programs, such as MutationTaster, 
which aims to improve upon their basic approach by integrating more information into 
the calculation, and PROVEAN, which is similar to SIFT but can additionally make 
predictions for indels.   
 
2.7.5 SIFT and PROVEAN 
SIFT 100 employs multiple sequence alignments to assay conservation levels of novel 
amino acid changing variants with the underlying assumption that sequence variants 
that alter highly conserved positions in protein sequences are a priori more likely to be 
damaging.  SIFT scores range from 1 to 0, with scores less than 0.05 corresponding to a 
prediction that the substitution will be damaging.  The authors suggest the tool has a 
sensitivity of 85.03% and a specificity of 68.95%, leading to an overall accuracy of 
74.77%, though, as mentioned above, others studies using this algorithm to predict 
known pathogenic or benign variants suggest that these figures – particularly the 
specificity – are overinflated. 
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PROVEAN (Protein Variant Effect Analyser) 101 uses a similar approach to SIFT, based 
on sequence conservation, but can also handle small indels.  The procedure used to 
generate a score in PROVEAN is complicated and for the purposes of this work, it 
suffices only to know that if the score is equal to or below a predefined threshold of -
2.5, the protein variant is predicted to have a ‘deleterious’ effect. If the PROVEAN 
score is above this threshold, then the variant is predicted to have a ‘neutral’ effect.  
The authors suggest that PROVEAN has a slightly lower sensitivity of 79.76%, but an 
improved specificity of 78.63%, leading to an overall accuracy of 79.19%. 
 
2.7.6 PolyPhen-2 
PolyPhen-2 102 uses eight sequence-based and three structure-based predictive features 
that were selected automatically by an iterative greedy algorithm.  The majority of these 
features involve comparison of a property of the wild-type (ancestral, normal) allele and 
the corresponding property of the mutant (derived, disease-causing) allele, which 
together define an amino acid replacement.  The most informative features characterize 
how well the two human alleles fit into the pattern of amino acid replacements within 
the multiple sequence alignment of homologous proteins, how distant the protein 
harbouring the deviation is from the wide-type protein, and whether the mutant allele 
originated at a hypermutable site.  The alignment pipeline selects the set of homologous 
sequences for the analysis using a clustering algorithm and then constructs and refines 
their multiple alignment.  The functional significance of an allele replacement is 
predicted from its individual features by a Bayes classifier.   
 
PolyPhen-2 assigns a qualitative label to the variation – either ‘benign’, ‘possibly 
damaging’ and ‘probably damaging’ – and calculates the Bayesian posterior probability 
that this mutation is damaging.  Thus, scores closer to 1 indicate a greater likelihood 
that the variation is damaging.  The authors suggest the tool has a sensitivity of 88.68% 
and a specificity of 62.45%, leading to an overall accuracy of 75.56%.  Again, as for 
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2.7.7 MutationTaster 
MutationTaster 103 also employs a Bayes classifier to predict the potential pathogenicity 
of a genetic alteration, but its strength lies in the breadth of the inputs that the 
classifier receives.  Examples of such inputs include evolutionary conservation scores 
(PhyloP and PhastCons), interspecies nucleotide and amino acid conservation, splice 
site predictions (NNSplice), annotated protein domain disruption, and likelihoods of 
an alteration resulting in protein truncation or non-sense mediated decay, amongst 
others. 
 
The Bayes classifier is fed with the outcome of all tests and the features of the 
alterations and calculates probabilities for the alteration to be either ‘disease-causing’ or 
a harmless ‘polymorphism’. The prediction is accompanied by a ‘probability value’, 
which indicates the security of the prediction, i.e. a value close to 1 indicates a high 
'security' of the prediction.  The authors suggest the tool has a sensitivity of 87.9% and 
a specificity of 89.3%, leading to an overall accuracy of 88.6%. 
 
2.8 Targeted Next -Generation Sequencing 
Targeted high-throughput sequencing brings the power of NGS techniques to bear on 
the problem of sequencing small areas of interest within the genome to a high degree of 
accuracy with a rapid turnaround time.  The platform used in our own laboratory for 
this purpose – and the current market leader in this field – is the Illumina MiSeq and 
this machine thus forms the basis of the discussion below. 
 
As with Sanger sequencing, the individual areas for sequencing (known as amplicons) 
in targeted NGS are small, typically around the size of an average human exon (150 - 
250bp).  However, up to 1,536 amplicons can by sequenced simultaneously from a 
single DNA sample and, by multiplexing samples using special indexing primers, up to 
198 DNA samples can be included in a single experiment, resulting in an enormous 
saving in the time and hands-on lab work required to generate the same amount of data 
when compared with traditional Sanger sequencing.  The turnaround time – regardless 
of the number of amplicons or samples included – is an invariable 3 days from DNA to 
data.  For the purpose of comparison, taking into account constraints of equipment 
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availability within a typical laboratory such as our own, a researcher using Sanger 
sequencing might be able to produce, on average, data for two exons in 198 samples per 
day.  The total time taken to sequence even a single 30-exon gene in 198 individuals 
would thus be 15 working days (probably closer to 20 when primer optimisation and 
inevitable repeats due to primer or reaction failures are taken into account).  Even this 
simple scenario demonstrates the huge savings in time that the new technology allows.  
Moreover, these savings only increase the greater the number of amplicons that are 
included per MiSeq experiment.  For example, it would take an experimenter, using 
traditional methodologies and working at the same pace as above, two years (including 
weekends) to produce the same amount of data as could be obtained from a single 3-
day MiSeq experiment when running at full capacity. 
 
Moreover, this enormous saving in labour and time is achieved without any significant 
reduction in accuracy.  As mentioned in section 1.5.3, studies comparing the accuracy 
of targeted high-throughput sequencing with traditional deoxynuxleotide sequencing 
for the purpose of diagnostic genetic testing have shown no significant difference in 
their rates of mutation detection or generation of false positives, leading to the 
conclusion that targeted high-throughput sequencing of panels of disease genes will 
soon become the standard methodology used in diagnostic genetic laboratories. 
 
As regards cost, targeted high-throughput sequencing is slightly cheaper than 
deoxynucleotide sequencing, but still represents a considerable outlay, especially in 
terms of research work.  At the time of writing, an experiment generating data for 30 
amplicons in 198 individuals currently costs around £3,500.  Within the context of this 
thesis, the main use of this new technique has thus been to screen large numbers of 
DNA samples quickly for mutations in sizable genes of interest, where traditional 
sequencing would be extremely time consuming and costly.  In addition, in our own 
laboratory at least, it was felt that at least one other confirmatory mutation in an 
independent pedigree should have been observed before NGS sequencing of the 
remaining portions of the gene might be considered a financially sound investment. 
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In terms of the actual underlying chemistry, the Miseq platform relies on the same 
techniques of cluster generation, bridge amplification and optic interegation of 
incorporated flurophores in order to generate the sequencing data, but the initial 
library preparation requires a few additional steps (see figure 4 overleaf).  Firstly, small 
areas of interest (amplicons) are targeted by hybridisation of custom oligonucleotide 
probes to unfragmented genomic DNA.  After the removal of unbound 
oligonucleotides, the intervening sequence between probes is synthesised by a DNA 
polymerase, which begins extension from the upstream oligonucleotide probe; 
subsequently a DNA ligase contects the extended sequence to the downstream 
oligonucleotide probe, resulting in the formation of products containing the area of the 
targeted regions of interest, flanked by sequences required for amplification.  Next, 
PCR amplification is used to drive the incorporation of indexed sequencing primers 
(which identify the individual DNA samples using a simple grid referencing technique 
and also include common adaptors required for cluster generation).  These first steps 
take about a day to complete.  
 
Ampure XP beads are then used to separate the PCR products from other reaction 
components and the samples are normalised to ensure an equal sample representation 
in the final library.  Once purified and normalised, the earlier inclusion of indexing 
sequences means the samples can be pooled into a single tube without risk of sample 
cross-contamination.  After a brief heat denaturation step, the pooled library is ready 
for loading into the MiSeq flow cell.  This second part of the process also takes about a 
day to complete.   
 
Finally, generation of clusters by bridge amplification, sequential incorporation of 
flurophores, optic interrogation and data generation is completed automatically on the 
MiSeq over a period of around 18 hours, meaning that the data is ready for subsequent 
analysis by the end of the third working day. 
 
As the sample preparation for the MiSeq includes a PCR amplification step, coverage 
in number of reads per base tends to be much higher (often > 100x) than for whole 
exome sequencing (~20 – 50x), without any lost of accuracy.   
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Figure 4 – A schematic representation of the initial library preparation steps in targeted NGS 
using Illumina’s MiSeq.  The target sequences are first targeted by hybridisation of custom 
oligonucleotide probes created with aid of Illumina’s DesignStudio software. Extension by 
DNA polymerase adds the sequences required for amplification.  During PCR amplification, 
special indexing primers are incorporated onto the ends of the products that permit the 
multiplexing of samples during later stages of the process without risk of sample cross-
contamination. 
 
2.9 Linkage Analys is  
Until around 5 years ago, genetic linkage analysis combined with positional cloning was 
the primary tool used in trying to establish the causal genetic variant underlying familial 
diseases.  Even today, in the age of NGS, it remains of paramount importance in 
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helping to narrow down the number of potential variants under consideration by ‘sign-
posting’ areas of the genome where the causal variant is likely to lie. 
 
In essence, genetic linkage analysis is a statistical method that is used to associate 
functionality or phenotype of a gene or variant with their location on chromosomes.  It 
relies on the phenomenon of recombination during meiosis and knowledge of the 
position of genetic markers spread throughout the genome.  Since recombination is a 
monotone, but non-linear function of the distance between two any two genetic loci, 
the position of a disease gene can be inferred by finding markers that tend not to 
recombine in all affected individuals.  
 
The probability that an odd-number of crossovers will occur between two loci during 
meiosis (and that the loci will thus be physically separated by recombination) is termed 
termed the recombination fraction and represented by the Greek letter θ.  This value is 
defined by the Haldane map function and ranges from 0 (complete linkage) to 0.5 (no 
linkage whatsoever).  On average, about one recombination event occurs every 108 bases 
and this distance is defined as 1 Morgan.  For closely linked loci (where θ < 0.1), the 
recombination fraction approximates the genetic map distance, such that two loci 
showing recombination in 1% of meiosis are approximately 1cM apart.  These basic 
concepts underpin the complex mathematics of linkage analysis.  
 
In practice, the result of linkage analysis is a table of LOD scores that can be used to 
identify one (or several) candidate regions, which may still contain many potentially 
causative genes.  The LOD score is derived by a maximum likelihood analysis, which 
calculates the probability that two loci are linked, expressed as a logarithmic function of 
the odds ratio favouring linkage 104.  Conventionally, a LOD score of >3, which 
indicates a probability of 1000 to 1 that the loci are linked, is taken to be statistically 
sound evidence of linkage.  Conversely, a LOD score of -2, which indicates a probability 
of 100 to 1 that the loci are not linked, is considered sufficient to rule out linkage 
between two loci.  The mathematics of linkage analysis is computationally intensive, 
especially when pedigree is large or when information is incomplete and inferences 
must be made regarding missing genotypes and phase.  Several pieces of software exist 
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to perform the analysis with one of the most common being MERLIN (Multipoint 
Engine for Rapid Likelihood Inference), described in Abecasis et al., 2002 105. 
 
2.10 Autozygosi ty  Mapping 
Mapping of autosomal recessive disorders is more problematical than for autosomal 
dominant or X linked disorders.  Many autosomal recessive disorders are individually 
rare, making it difficult to collect a sufficient number of cases unless this is done on an 
international collaborative basis.  In addition, in most parts of the world family sizes are 
limited, with it being uncommon for families to have more than three to four children 
and therefore making it unusual for there to be more than one or two affected 
individuals within a sibship. 
 
In 1953, Smith observed that offspring of consanguineous matings would be 
homozygous for genetic markers near the disease gene 106.  Over 30 years later, Lander 
and Botstein subsequently realised that a recessive trait could thus be mapped using the 
offspring of such consanguineous matings, an approach they termed 'homozygosity 
mapping', but which is probably more correctly termed autozygosity mapping 107.  The 
principle behind autozygosity mapping is that a fraction of the genome of any particular 
offspring of a consanguineous mating is expected to be homozygous by virtue of 
identity by descent.  On average, one-sixteenth of the genome of offspring of first-
cousin matings would be expected to be homozygous.  Furthermore, one might 
anticipate that the regions of homozygosity should be randomly distributed throughout 
genome in the different offspring of these matings, except at a common disease locus 
shared by all affected offspring.  Thus, with the use of the genotyping data from the 
offspring of several first-cousin matings, markers can be identified that are linked to a 
recessive disorder by virtue of the fact that they are homozygous for the same allele in 
all affected individuals.   
 
This method works best when several small families from the same population are used 
together to define the regions of interest, provided there is not significant genetic 
heterogeneity in the cause of the disease under investigation.  However, the approach 
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In this chapter, I have tried to provide an overview of the technical aspects of the 
genetic techniques commonly applied in attempting to eluciadate the cause of genetic 
disease in a kindred.  In addition, I have highlighted some of the limitations of these 
techniques, which both the reader and researcher must be aware of when interpreting  
data generated by these means.  When considered collectively with the information 
provided in chapter 1, there emerges, I hope, the concept of a general workflow –  
incorporating numerous pieces of supporting information – that the researcher follows 
in order to try and move from the raw exome data to the disease causing mutation.  
This workflow, which underpins all of my work on exome sequencing, is summarised 
graphically in figure 5 overleaf. 
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Figure 5 - A schematic representation of the typical workflow that is followed when trying to 
identify a disease-causing mutation in a kindred with hereditary neurological disease of 
unknown cause by use of exome sequencing and genetic mapping techniques (linkage 
analysis/autozygosity mapping).  The process involves the drawing together of numerous 
strands of information used to whittle down the list of potentially causal variants.  In addition, 
the process does not stop once a candidate disease-causing mutation has been identified.  
Further sequencing in the index family and phenotypically similar case cohorts as well as, where 
possible, functional studies to assess the biological effect of the variant are prerequisites if the 
findings are to merit publication.  This figure was adapted from Sims et al., 2014 86. 
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3. Clinical ,  Genet ic  and Molecular Aspects  of  Dystonia  
 
3.1 Introduction 
In the sections of my thesis dealing with the use of exome sequencing, the majority of 
the patients that I worked with had a form of hereditary dystonia.  In this chapter, 
therefore, I present an overview of the state of knowledge with regard to the genetics 
and molecular pathophysiology of dystonia as it stood during the time of my PhD.  It 
should be noted that a number of the genes discussed in this chapter were only 
identified as a cause of hereditary dystonia during the active period of my research and 
this discussion does not therefore represent a thus not represent an accurate picture of 
the understanding in this field when I originally took up my post.  Moreover, 
discussion of the genes that I identified within my PhD is not included here, but can be 
found in chapters 5 and 7.  They are, nonetheless, included in tables and figures. 
 
The dystonias are a heterogenous group of hyperkinetic movement disorders, 
characterized by involuntary sustained muscle contractions affecting one or more sites 
of the body that lead to twisting and repetitive movements or abnormal postures of the 
affected body part.  It is the third most common movement disorder worldwide 109-112.  
Approximately 70,000 people are affected by dystonia in the UK alone, including some 
8,000 children and adolescents 113.  Affected individuals can suffer considerable 
physical and psychosocial distress, which has been demonstrated to have a significant 
impact on their quality of life 114-116.  The pathophysiology of the disorder is poorly 
understood at present. In all probability, it is heterogeneous and arises from a 
dysfunction of the various central neural circuits that control and coordinate voluntary 
movements, such as those found in the basal ganglia, the cerebellum, the sensorimotor 
cortex, and the interactions between these three regions of the brain 117-120.  
 
3.2 Class i f ication of  Dystonia 
The classification of the dystonia is complex and not entirely satisfactory.  Several 
approaches or systems operate in parallel.  Clinically, the dystonias are usually classified 
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  The work presented in this chapter was peer-reviewed and published with adaptations in 
Charlesworth et al., 2013 108. 
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according to one of 4 major variables:  1) age of onset (early onset vs. adult onset); 2) 
distribution of affected body parts (focal, multifocal, segmental or generalised);  3) the 
underlying cause (primary, secondary or heredodegenerative); or 4) special clinical 
features (paroxysmal, exercise-induced, task-specific or dopa-responsive) 121.  The current 
European Federation of Neurological Societies classification scheme is a two-axis 
approach that incorporates many of these factors (see table 3) 121. 
 
From a genetic point of view, hereditary dystonia can be classified either by the gene 
causing the condition, where it is known, or by reference to one of the ever expanding 
list of dystonia loci, of which there are currently 23 (see table 4).  The system of DYT 
loci is particularly unsatisfactory.  The system was designed to indicate genomic regions 
that had been linked to a specific hereditary disorder, but where the actual causative 
gene was not yet known 122.  DYT loci were assigned in chronological order based on 
the appearance of reports in the medical literature.  In theory, once the underlying 
genetic cause was known, the locus was supposed to be withdrawn and the disorder 
merged into the entry for the cloned gene.  However, in practice, this has not happened 
and both clinicians and researchers alike tend to use dystonia loci and genes names 
interchangeably, e.g. DYT1/TOR1A or DYT6/THAP1.  With time, several other 
problems have arisen.  The designation of some loci has never been replicated and is of 
questionable significance (e.g. DYT7 or DYT13), whilst others are known to be the 
result of incorrect assignations due to erroneous linkage (e.g. DYT9, DYT14 and 
DYT19) 22, 23.  Some DYT loci did not even designate any chromosomal location, but 
were (prior to this work, at least) based solely on the observation of a few families with a 
similar phenotype or mode of inheritance (e.g. DYT2) 123, 124. More importantly, not all 
pathogenic mutations causing dystonia have been assigned to a DYT locus (e.g 
mutations in SPR, CIZ1 or GNAL), whilst some syndromes with prominent dystonic 
components have been assigned to loci belonging to other movement disorders (e.g. 
PARK13 and PARK14) or vice versa (DYT3 and DYT12). 
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Table 3 - Classification of dystonia, based on the European Federation of Neurological Societies 
current 2013 scheme. 
Axis I – Clinical Characteristics 
Age at Onset 
• Infancy Birth to 2 years 
• Childhood 3 years to 12 years 
• Adolescence 13 to 20 years 
• Early adulthood 21 to 40 years 
• Late adulthood > 40 years 
Distribution of Affected Body Parts 
• Focal Single body region (e.g. writer’s cramp, blepharospasm)  
• Segmental Contiguous body regions (e.g. cranial and cervical, cervical and 
upper limb) 
• Multifocal Noncontiguous body regions (e.g. upper and lower limb, cranial 
and upper limb)  
• Generalised Both legs and at least one other body region (usually one or both 
arms) 
• Hemidystonia Half of the body  
Temporal Pattern  
• Disease Course Static vs progressive 
• Variability Persistent, action-specific, diurnal or paroxysmal 
Associated Features  
• Evidence of another movement 
disorder 
Isolated if dystonia +/- tremor only (previously termed ‘pure’); or 
combined if dystonia and another movement disorder present 
• Evidence of other neurological or 
systemic manifestations 
List of co-occurring neurological manifestations 
Axis II – Etiology  
Nervous System Pathology  
• Evidence of Degeneration Previously termed heredodegenerative dystonia 
• Evidence of Structural Lesion Stroke, tumour, demyelination ect 
• No Evidence of Above Previously and often still termed ‘primary’ dystonia 
Inherited or Acquired  
• Inherited Autosomal dominant/recessive, X-linked, or mitochondrial 
• Acquired Perinatal brain injury, infection, drug-induced, toxic, vascular, 
neoplastic, brain injury or psychogenic 
• Idiopathic Sporadic or familial 
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Table 4 - The current DYT loci with brief description of associated phenotype, gene of linkage interval (where known), mode of inheritance and OMIM 
reference numbers.  Note:  DYT9, DYT14, DYT19 are not included in the table as they are now known to be synonymous with DYT18, DYT5a, and DYT19 
respectively.  Inaddition, there is great confusion over what the symbol DYT23 actually refers to and it has thus been omitted. 
Locus Symbol Phenotype 





DYT1 Early-onset primary torsion dystonia TOR1A AD 605204 
DYT2 
Early-onset primary dystonia with prominent cranio-cervical 
involvement 
See chapter 7 AR 224500 
DYT3 
Adult onset dystonia-parkinsonism, prevalent in the 
Philippines. 
TAF1 X-Linked 31420 
DYT4 
Whispering dystonia (adult onset spasmodic dysphonia) with 
generalisation and ‘hobby horse’ gait 
TUBB4A AD 128101 
DYT5a Progressive dopa-responsive dystonia with diurnal variation GCH1 AD 128230 
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DYT5b 
Akinetic rigid syndrome with dopa-responsive dystonia or 
complex encephalopathy 
TH AR 191290 
DYT6 
Adult-onset torsion dystonia with prominent cranio-cervical 
and laryngeal involvement 
THAP1 AD 602629 
DYT7 Adult-onset primary cervical dystonia 18p AD 602124 
DYT8 Paroxysmal non-kinesigenic dyskinesia MR1 AD 118800 
DYT10 Paroxysmal kinesigenic dyskinesia PRRT2 AD 128200 
DYT11 Myoclonic dystonia (often with alcohol responsiveness) SGCE AD 159900 
DYT12 




(often de novo) 
128235 
DYT13 Early onset torsion dystonia in one Italian family 1p36.32-p36.13 AD 607671 
DYT15 
Myoclonic dystonia with alcohol responsiveness in one 
Canadian kindred 
18p11 AD 607488 
DYT16 Early-onset dystonia-parkinsonism PRKRA AR 612067 
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DYT17 
Primary focal dystonia with progression in one Lebanese 
family 
20p11.2-q13.12 AR 612406 
DYT18 Paroxysmal exercise-induced dyskinesia +/- epilepsy SLC2A1 AD 612126 
DYT20 
Paroxysmal nonkinesiogenic dyskinesia 2, in one large 
Canadian family 
2q31 AD 611147 
DYT21 
Adult-onset mixed dystonia with generalisation in one Swedish 
family 
2q14.3-q21.3 AD 614588 
DYT22 Reserved, but not published ? ? ? 
DYT24 
Tremulous cranio-cervical dystonia +/- upper limb tremor 
without generalisation  
See chapter 5 AD 610110 
DYT25 
Craniocervical predominant primary dystonia with 
generalisation +/- hyposmia 
GNAL AD 615073 
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3.3 Invest igation of  Dystonia 
The diagnosis of dystonia is, fundamentally, clinical.  It relies on the presence of 
repetitive or sustained abnormal postures (with or without tremor) and the recognition 
of specific features, such as a geste antagoniste or overflow and mirror movements.  Geste 
antagonist refers to a voluntary manoeuvre (such as touching the face or an affected 
body part) that temporarily reduces the severity of dystonic posture or movements.  An 
overflow movement is an unintentional muscle contraction which accompanies, but is 
anatomically distinct, from the primary dystonic movement, i.e. posturing of a hand 
normally unaffected by dystonia when performing tasks with the affected hand.  
Conversely, mirror movements are dystonic postures of a body part normally affected 
by dystonia when performing a motor task with a body part that is not affected by 
dystonia. 
 
In general, for primary dystonia, few, if any, tests are required.  The main exception to 
this rule is early-onset (<30 years of age) dystonia of unknown aetiology, which should 
always prompt consideration of a diagnosis of dopa-responisve dystonia or Wilson’s 
disease, as accurate identification of these diseases at an early stage will permit the 
introduction potentially life-changing treatments.  Therefore, many would advocate, at 
the very least, a metabolic analysis that includes measurement of serum copper and 
caeruloplasmin and, possibly, a trial of L-dopa in this group.  In practice, an MRI and 
genetic testing for TOR1A and THAP1 mutations are often also performed.  Finally, 
given the recent identification of a new form of treatable dystonia caused by brain 
manganese deposition secondary to mutations in SLC30A10 125, 126, serum manganese 
measurement should at least be considered. 
 
The features listed in table 5 are those that might raise suspicion that the dystonia is 
not primary and trigger further investigation.  The purpose of such investigations is to 
identify a secondary cause for the dystonia or to further elucidate the cause of dystonia 
presenting as part of a heredodegenerative condition.  In practice, a combination of 
blood tests, structural imaging and selected secondary investigations are usually 
required to secure the diagnosis and table 6 gives an indication of some of the 
investigations that may be appropriate given the aetiology under consideration.  As 
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regards neuroimaging, MRI is generally the modality of choice, although secondary CT 
may be required to accurately distinguish calcium from iron deposition in the basal 
ganglia.  A dopamine transporter (DaT) scan may be useful to distinguish dopa-
responsive dystonia or rapid-onet dystonia-parkinsonism (where it will be normal) from 
other causes of parkinsonism with secondary dystonia 127, 128.   
 
Table 5 - Some features that should raise suspicion that dystonia is secondary or 
heredodegenerative and trigger further investigation.  It should be noted that some of these 
features are found in some types of primary dystonia, but their presence should nonetheless 
trigger careful consideration of a secondary dystonia or heredodegenerative disorder. 
Features suggestive of non-primary dystonia 
Abnormal birth or perinatal history 
Dysmorphia 
Delayed developmental milestones 
Seizures 
Hemidystonia 
Sudden onset or rapidly progressive dystonia 
Prominent oro-bulbar dystonia 
The presence of another movement disorder (except tremor) 
Neurological signs suggesting involvement of other neurological systems (pyramidal signs, 
cerebellar signs, neuropathy, cognitive decline) 
Signs suggesting disease outside of the nervous system (hepatomegaly, splenomegaly) 
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Table 6 - Some investigations used in the diagnosis of secondary and heredodegenerative 
dystonia with example indication.  Please note: this list is not exhaustive. 
 
Investigation Example indications 
Blood 
Acanthocytes Neuroacanthocytosis, neuronal brain iron accumulation 
Alpha fetoprotein Ataxia telangiectasia 
Creatinine Kinase Neuroacanthocytosis 
Copper and caeruloplasmin Wilson’s disease, neuronal brain iron accumulation 
Lactate and pyruvate Mitochondrial disorders 
Serum manganese Dystonia with brain manganese deposition due to 
SLC30A10 mutation 
Serum ferritin Neuroferritinopathy 
White cell enzymes Lysosomal storage disorders 
Urine 
Urinary aminoacids Aminoacidaemias 
24h urinary copper Wilson’s disease 
Neuroimaging 
MRI Most secondary causes, looking for structural lesions, 
iron/calcium deposition, caudate atropy, white matter 
abnormalities, etc. 
Dopamine Transporter (DaT) Scan  Parkinsonism 
Other 
Nerve condition tests Spinocerebellar ataxia, neuroacanthocytosis, 
metachromatic leukodystrophy 
Trial of L-dopa Early onset dystonia (<30 years of age) of unknown 
aetiology 
Autonomic function tests Multiple system atrophy 
Slit-lamp examination Wilson’s disease 
Liver biopsy Wilson’s disease 
Muscle biopsy Mitochondrial disorders 
Electro-retinography Neuronal brain iron accumulation 
Genetic tests See table 9 for the genetic causes of heredodegenerative 
dystonias 
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3.4 Genetic  Burden in Dystonia and Genetic  Test ing 
Current evidence suggests that there is a significant genetic contribution to many forms 
of dystonia.  Monogenic inheritance is most often seen in early-onset cases, where a 
family history can often be elicited.  However, the reduced penetrance of some 
monogenic forms of dystonia, such as those due to mutations in TOR1A and THAP1, 
means that many apparently sporadic cases may also fall into this category.  
Furthermore, it is likely that a number of genes responsible for familial dystonia remain 
to be discovered, such that negative genetic testing for all currently known dystonia 
genes does not imply that the disorder is not genetic. 
 
Late-onset dystonia, which represents by far the greatest number of cases, also appears 
to have a strong genetic basis.  Studies based on the clinical examination of first-degree 
relatives of patients with focal dystonia have reported a risk of developing the same or 
another form of dystonia in the range of 23 to 36% 129, 130.  Epidemiological studies 
have suggested that, although often apparently sporadic, adult onset dystonia may 
sometimes be inherited in an autosomal dominant manner, but with a markedly 
penetrance of 12 to 15% 129, 131, 132. Unfortunately, this presents significant challenges 
for gene discovery and, at present, the genetic architecture of late onset dystonia 
remains largely unknown.  It is possible that the use of endophenotypes, based on 
imaging or neurophysiological testing, to identify non-penetrant mutation carriers will 
help by permitting accurate linkage and segregation analyses in some of the larger 
kindreds 110, 133.  However, multigenic inheritance, resulting from the combination of 
two or more genetic changes, each imparting a low to moderately increased risk of 
developing dystonia and acting in combination with environmental factors, may also 
underlie a significant proportion of the apparent heritability of late-onset dystonia.  
Large-scale genome wide association studies will be helpful in dissecting out the genetic 
contribution in these cases.    
  
At the present time, genetic testing is most profitably employed in familial or early-
onset cases, where it is likely to have the highest yield.  Despite the fact that the 
establishment of a molecular diagnosis rarely alters management radically, it can be 
helpful for patients to understand the cause of their dystonia and also bring a halt to 
	   97	  
unnecessary continued investigation, as well as allowing the physician to impart 
accurate information regarding the risk of recurrence in subsequent generations.  A 
scheme for deciding which genes may be appropriate to test in which patients is 




Figure 6 - A workable strategy for identifying the likely genetic basis for some major forms of 
dystonia.  Mutational screening for some genes is currently only available on a research basis 
 
3.5 Monogenic Forms of  Dystonia 
In the sections below, we present an overview of the major forms of dystonia exhibiting 
Mendelian inheritance for which an underlying genetic cause has been identified.  
Table 7 offers an overview of some of the key features of each of the various subtypes of 
primary dystonia where the causative gene is known. 
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Table 7 - Summary of the key clinical features of some of the major forms of primary dystonia by causative gene.  Features described relate to typical cases and it 
must be borne in mind that there is often wide phenotypic variation between cases.  † = clinical description restricted to rapid-onset dystonia-parkinsonism only 
(for alternating hemiplegia of childhood, see main text) 	  
 Gene 
Typical age 
range for onset 




dystonia (at onset) 
Generalisation 
or progression? 
Clinical clues or 
















Childhood - Legs >> arms Often 
Generalises 
Jewish ancestry; dystonia progressing to 
fixed deformity; laryngeal or cranial 
sparing 
DYT2 
See chapter 7 
Childhood to 
adolescence 










Laryngeal or brachial onset with 
progression. 
CIZ1 Adult - Cervical No 
generalisation 
Only reported in pure focal cervical 
dystonia 
DYT24 
See chapter 5 
Adolescence to 
early adulthood 













Ataxic, hobbyhorse gait; extrusional 





- Craniocervical Generalisation 
observed 
- 























Limbs and face No Long (mins to hours) attacks, triggered by 






(see clinical clues also) 
Legs Progression to 
static dystonia 
can occur 
Exercise or hunger induced.  May be 
associated with other complex neurology – 









the limb affected 
is the limb that is 
moving) 
No Frequent, brief (secs to mins) attacks 
triggered by movement.  Family history of 



















Childhood Parkinsonism in some Legs Progressive, but 
often becomes 
static later.  
Diurnal variation; dramatic response to L-







encephalopathy in some; 
‘lethargy-irritability’ crises. 
Generalised but 
often with axial 




L-dopa response related to phenotype:  
response tends to be less good in those 
with complex encephalopathy. 





oculogyric crises  
Generalised but 
often with axial 




L-dopa response related to phenotype:  
response tends to be less good in those 
with complex encephalopathy.  5-HTP may 
be a useful adjunct. 
SGCE 
(DYT11) 
Childhood Myoclonus.  
Neuropsychiatric 
manifestations 
Cervical Dystonia usually 
remains 
segmental 
Myoclonus usually more prominent than 









Onset in context of febrile illness or other 
stressor.  No response to L-dopa. 
PRKRA 
(DYT16) 
Childhood Variable parkinsonism Any body part Generalisation No response to L-dopa 
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3.6 The Primary Iso lated Dystonias 
Primary isolated dystonia is usually defined as a syndrome in which dystonia is the only 
clinical feature (except for tremor of the arms or head and neck) without any evidence 
of neurodegeneration or any obvious secondary cause (e.g. trauma, autoimmune, post-
infectious, ect.).   
 
3.6.1 TOR1A Mutations (DYT1/Oppenheim’s Disease)  
In 1911, Oppenheim proposed the term ‘dystonia musculorum deformans’ to describe 
a syndrome in children with twisting or jerking movements, muscular spasm, gait 
abnormalities that often progressed to a fixed postural deformity.  The hereditary 
nature of the condition was subsequently recognised and, in 1990, the disease was 
linked to chromosome 9q32-34 and designated with the first dystonia locus (DYT1) 122.  
It was quickly realised that this locus was associated with a significant proportion of all 
childhood-onset dystonia, particularly in Ashkenazi Jews 134, 135.  Seven years later the 
gene responsible for the condition was identified and named TOR1A 136.  The TOR1A 
gene comprises 5 exons and is widely expressed.  In almost all cases of DTY1-related 
dystonia, the underlying genetic mutation is an inframe GAG deletion located in exon 
5 of the gene, resulting in the loss of a single glutamic acid in the final protein product 
(TorsinA).  This mutation has been shown to be responsible for around 80% of all 
primary, early-onset dystonia in Ashkenazi Jewish populations and up to 50% of 
primary, early-onset dystonia in non-Jewish populations 137, 138.  Only two other missense 
variants (p.A288G and p.F205I) and one frameshift, 4-base-pair deletion 
(c.934_937delAGAG) in this gene have since been reported to cause dystonia, though 
their pathogenicity is by no means certain 139-141.  
 
The penetrance of the GAG deletion is notably low, with current estimates somewhere 
within the region of 30% - 40% 134, 137.  Moreover, even when the condition does 
manifest, the spectrum of severity of the symptoms is wide, ranging from mild focal 
dystonia to severe and disabling generalised dystonia.  The exact mechanism underlying 
this variability remains unclear, but is presumed that other genetic or environmental 
modifiers must exist that influence the penetrance and presentation of the disease.  To 
date, only one coding polymorphism in exon 4 of TOR1A (rs1801968), which encodes 
	   101	  
either aspartic acid (D) or histidine (H), has convincingly been shown to modify the risk 
of developing symptoms of dystonia.  It appears that carrying the H allele in trans (that 
is, on the opposite allele from that harbouring the GAG deletion) may reduce the risk 
of developing symptoms of dystonia by ten-fold, to as little as 3%  142, 143.  Interestingly, 
in cellular models, the overexpression of TOR1A containing the H allele in cis was 
sufficient by itself to induce formation of inclusions of torsinA in a manner similar to 
expression of GAG-deleted TOR1A, though at a much lower level 144.   It is thought 
that this may be the result of a disruption of protein interactions induced by the 
presence of the exposed histidine residue.  However, expression of GAG-deleted 
TOR1A containing the H allele actually reduced the formation of inclusions, implying 
that these two changes act to cancel each other out to some degree 144.  It has even been 
suggested that the GAG-deletion may need to be carried in conjunction with a D allele 
in cis to be penetrant 143, though this has not yet been proven.  Yet, although the effect 
of the 216H coding polymorphism appears to be robust (in trans, at least), its relatively 
low population frequency (approximately 12% in Europeans and less in other 
populations) means it cannot fully explain the reduced penetrance or variable 
expressivity seen in this condition; other factors clearly remain to be identified.   
 
In terms of nongenetic factors that might affect the penetrance of TOR1A mutations, 
one small study has assessed exposure to perinatal adversity, childhood infections, 
general anaesthesia and trauma in manifesting and non-manifesting carriers as well as 
non-carriers from a series of 28 families with DYT1-related dystonia by means of a 
retrospective questionnaire 145.  Only self-reported perinatal adversity, in particular 
complications of vaginal delivery, showed a statistically significant (p=0.02) positive 
correlation with manifestation of the disease.  
 
Clinically, DYT1-related dystonia typically presents in childhood with dystonic 
posturing of the foot or leg, though it may begin in any part of the body, and evolves to 
generalised dystonia with fixed deformities.  As mentioned above, however, late-onset 
or much milder forms of the disorder are recognised 138.  There is generally a family 
history consistent with autosomal dominant inheritance, albeit with reduced 
penetrance, but apparently sporadic early and late onset cases are also seen 146. 
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The TOR1A gene encodes a protein TorsinA, which is a member of the AAA+ family of 
ATPases and is believed to be involved in maintenance of both structural integrity 
and/or normal function of protein processing and trafficking.  TorsinA is expressed 
throughout the central nervous system in humans, but is found at particularly high 
levels in the dopaminergic neurones of substantia nigra pars compacta, locus coeruleus, 
Purkinje cells, cerebellar dentate nucleus, basis pontis, thalamus, hippocampal 
formation, oculomotor nuclei and frontal cortex 147-149.  The exact mechanisms by which 
torsinA causes dystonia are still unclear, but there is accumulating data to suggest that 
torsinA is important for cellular compartments and pathways, including the 
cytoskeleton, the nuclear envelope, the secretory pathway and the synaptic vesicle 
machinery 150-155. 
 
3.6.2 THAP1 Mutations (DYT6) 
After the discovery of TOR1A and the subsequent uptake of genetic testing for 
mutations in this gene, it became clear that a second, distinct form of pure primary 
dystonia existed.  Affected individuals, who were negative for TOR1A mutations, 
tended to have an older age at onset - in their adolescence or adulthood - and presented 
predominantly with cranio-cervical or focal dystonia affecting the upper limbs.   In 
1997, the DYT6 locus was assigned to chromosome 8p21-q22 by linkage analysis in two 
Mennonite families, but it was not until 2009 that the gene responsible for the 
condition was finally identified as THAP1 (thanatos-associated protein domain-
containing apoptosis-associated protein 1) 156, 157. Missense, nonsense and frameshift 
mutations, spread throughout most of the coding portion of the gene, have all been 
associated with disease.  Mutations in this gene have been detected in genetically 
diverse populations throughout the world and, unlike TOR1A, do not seem to be 
especially prevalent in any one particular population.  Inheritance is autosomal 
dominant with a reduced penetrance.  To date, penetrance has only been measured in 
Amish-Mennonite families, where it appears to be around 60%, but this may not be 
true of all populations or mutations 158.  Most mutations are found in the heterozygous 
state, but homozygotes are described 157, 159.  
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The clinical spectrum of THAP1 mutations is wide.  Presentation with oromandibular, 
cranio-cervical or laryngeal dystonia is common, but presentations with focal dystonia 
of the limbs, segmental or generalised dystonia are all described in the literature.   In a 
recent analysis by Xiromerisiou et al. of 100 patients reported to carry THAP1 
mutations, the mean age at onset of dystonia was 24 years, 60% of patients were 
females and the distribution was generalised in 37%, segmental in 30%, multifocal in 
6% and focal in 27% 160.   
 
The THAP1 protein is an atypical zinc finger protein characterized by an N-terminal 
THAP domain, a proline rich region and a c-terminal nuclear localization domain 161.  
The THAP domain is conserved in both vertebrates and invertebrates 162.  It has DNA 
binding properties and is thought to be involved in the regulation of transcription, 
either on its own or in concert with other proteins.  Thus, one possible mechanism by 
which mutations in THAP1 might cause dystonia is by dysregulated transcription of key 
genes.  THAP1 protein is also known to interact with the prostate apoptosis response 
protein 4 (PAR-4), which is a transcription regulator involved in apoptosis 161.  Under 
conditions of cellular stress or toxicity, this protein is rapidly upregulated and it has 
been linked to neurodegeneration in a number of disease models 163-165.  One intriguing 
finding has been that THAP1 may regulate transcription of TOR1A by binding to one 
of two sites in its promotor region 166, 167.  Mutations in THAP1 have been shown to 
disrupt binding to the TOR1A promotor and decrease TOR1A-driven luciferase 
expression, thus suggesting that under some conditions TOR1A is negatively regulated 
by THAP1 protein and that mutations in THAP1 may lead to abnormally high levels of 
torsinA 168.  Although these data come from experimental cell lines and thus are of 
uncertain physiological significance, this does at least raise the possibility that the 
disease mechanisms in DYT1 and DYT6 dystonia may be linked.  However, if this is 
the case, the question arises as to how to square this mechanistically with the prevailing 
idea that the GAG-deletion in TOR1A leads to a loss of function of the protein 153.  
One possibility is that TOR1A expression must be maintained within a set range in 
relation to its binding partners and that dysfunction may result from either increased 
expression or loss of function 169.  Indeed, transgenic mice overexpressing wildtype 
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TOR1A have been shown to display evidence of neurohistological, neurochemical and 
behavioural abnormalities, which may provide some support for this hypothesis 170. 
 
3.6.3 GNAL Mutations (DYT25) 
During the period of this research, mutations in the gene, GNAL, were identified as 
further cause of familial primary cervical dystonia 171.  Using whole exome sequencing 
and linkage in two unrelated families, two mutations in GNAL were initially identified, 
a nonsense mutation (p.Ser293*) resulting in a premature stop codon in one family and 
a missense mutation (p.Val137Met) in the other.  Screening of 39 additional families 
identified 6 further novel mutations, with segregation confirmed in all families for 
which DNA from additional affected individuals was available. 
 
Clinically, of the 28 individuals with dystonia resulting from a mutation in GNAL, 
82% had onset in the region of the neck and 93% had cervical involvement when 
examined for the study.  However, progression to other sites had occurred in at least 
half of those affected and generalised dystonia was seen in about 10% of cases.  Thus, 
the clinical phenotype in GNAL-related dystonia appears to be not dissimilar to that 
caused by mutations in THAP1.  Though the authors noted that onset in GNAL 
mutations was never brachial, this may just be a chance finding given the small number 
of cases known so far, rather than a true distinguishing factor. 
 
GNAL encodes Gαolf, the alpha subunit of triheteromeric G protein Golf, which is 
involved in dopamine (D1) signaling.  Experimental evidence exists to show that Gαolf 
is mostly responsible for the coupling of D1 receptors to adenylyl cyclase in striatal 
neurons and that Gαolf is required for D1-mediated behavior and biochemical effects 
172-174.  Since D1 dopamine receptors have a known role in mediating locomotor 
activity, the link between GNAL and dystonia is biologically plausible.  The gene is 
located on the short arm of chromosome 18 in a region that has been linked not only 
to DYT7 dystonia (though the original DYT7 family do not appear to carry a mutation 
in GNAL), but also to bipolar disorder, schizophrenia and attention deficit 
hyperactivity disorder 175-179.  Interestingly, homozygous knockout mice for this gene are 
hyposmic and display hyperactive behaviours 180. 
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3.6.4 CIZ1 Mutations 
In early 2012, Xiao et al. reported that they had used a combination of linkage analysis 
and whole exome sequencing to identify a mutation in CIZ1 (p.Ser264Gly) as the likely 
causal variant in a large Caucasian kindred with primary cervical dystonia inherited as 
an autosomal dominant trait 181.  Those affected in the family exhibited focal cervical 
dystonia, occasionally with mild tremor, having its onset in early adulthood to late 
midlife (18 – 66 years of age).  However, affectation status was not always clear cut:  5 
family members were said to have ‘definite’ cervical dystonia, whilst 5 family members 
were said to have ‘possible’ cervical dystonia, making linkage analysis difficult 182. 
 
CIZ1 encodes Cip1-inderacting zinc finger protein 1, a p21Cip1/Waf1-interacting zinc 
finger protein expressed in the brain and involved in DNA synthesis and cell-cycle 
control.  Functional work suggests that the p.Ser264Gly mutation may alter splicing of 
the gene and normal subnuclear localization of CIZ1 protein 181.  Screening in a cohort 
of patients with adult-onset dystonia identified 2 additional missense mutations in 3 
individuals (p.Pro47Ser and p.Arg672Met), all with focal cervical dystonia developing 
in mid-to-late life. 
 
Some researchers feel it may be too early to place full confidence in the association of 
mutations in CIZ1 and focal cervical dystonia.  Firstly, databases of normal sequence 
variation reveal that the CIZ1 gene contains a large number of missense variants in 
supposedly healthy individuals (a third of which are predicted to be pathogenic) and, in 
the study by Xiao et al. an equal number of novel missense variants were found in 
controls as were found in patients.  Secondly, and more importantly, segregation was 
not demonstrated in a second independent family for any of the purported mutations.  
Thirdly, there is some question regarding the quality of the exome data used in this 
study:  coverage was only greater than twenty reads for around 60% of the exome and 
the number of false-positive variants appears unusually high 183.  Screening of this gene 
in further cohorts of cervical dystonia cases from various populations will be required 
to decide if these reservations are warranted or not. 
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3.6.5 TUBB4A Mutations (DYT 4) 
DYT4 was first described in 1985 by forensic psychiatrist Neville Parker in a large 
family with third decade onset of autosomal dominantly inherited ‘whispering 
dysphonia’ and generalized dystonia 184.  Over twenty-five affected individuals have been 
reported, typically presenting with a laryngeal dysphonia progressing to a generalized 
dystonia and a peculiar ‘hobby horse’ gait 185.  Alcohol responsiveness was not 
uncommon, leading to severe alcohol abuse in some DYT4 patients 185.  The family is 
descended from an affected male who was born in 1801 in the small rural coastal town 
of Heacham in Norfolk and, to date, no other kindred has so far been described 
worldwide with a similar phenotype. 
 
Using a combination of linkage analysis and exome sequencing, a mutation in the gene 
TUBB4A (p.Arg2Gly) has recently been identified as causal in the DYT4 kindred by 
two groups independently  186, 187.  TUBB4A encodes β-tubulin-4a, a constituent of 
microtubules, and the mutation results in an arginine to glycine amino-acid 
substitution in the key, highly conserved autoregulatory MREI (Methionine–Arginine–
Glutamic acid–Isoleucine) domain of the protein.  The gene is expressed throughout 
the brain, but at the highest levels in the cerebellum, which has been linked to the 
pathogenesis of dystonia 186.  The MREI tetrapeptide sequence at the start of the N-
terminal domain is known to be necessary for the autoregulation of the β-tubulin 
mRNA transcript and separate in vitro studies using site directed mutagenesis have 
previously demonstrated that the p.Arg2Gly mutation abrogates this autoregulatory 
ability 188, 189.  One further possibly pathogenic variant (p.Ala271Thr) was detected 
during the screening of a cohort of 394 unrelated dystonia patients:  the individual 
concerned exhibited spasmodic dysphonia with oromandibular dystonia and dyskinesia 
with an age at onset of 60.  Her mother had been similarly affected, but was now 
deceased so that segregation analysis was not possible, meaning the pathogenicity of the 
variant is uncertain 187. 
 
3.7 The Paroxysmal Dystonias 
The paroxysmal dystonias are characterized, in theory at least, by episodes of dystonia 
or other dyskinesia separated periods of neurological normality.  In practice, there may 
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be other associated neurological features besides the movement disorder and, especially 
in the case of SLC2A1-related disease, both the movement disorder and the other 
associated neurological symptoms may become relatively fixed with time. 
 
3.7.1 MR1 Mutations (DYT8) 
Symptoms of paroxysmal non-kinesigenic dyskinesia (PNKD) typically begin in 
childhood or adolescence and include dystonic and choreatic dyskinesias or ballistic 
movements, lasting from minutes to hours.  There are often premonitory symptoms of 
an impending attack (paraesthesia or tension in the affected area) and sleep can prevent 
or abort attacks.  The frequency of attacks varies between individuals, ranging from 
daily attacks to only a few in a lifetime.  Typically, they are precipitated by alcohol, 
caffeine or stress, but less often by exercise, fatigue or cold 190.  Neurological 
examination is normal between attacks.  Treatment is with carbamazepine or 
benezodiazepines, particularly clonazepam. 
 
The condition results from mutations in the myofribillogenesis regulator (MR1) gene 
and is inherited as an autosomal dominant trait.  Only three mutations have been 
described to date, all clustered in the N-terminus of the protein:  p.Ala7Val, p.Ala9Val 
and p.Ala33Pro 191-196.  Despite this, haplotype analysis has failed to reveal a common 
founder, suggesting that these represent independent mutational events 194.  It is 
currently believed that this region of the protein may represent a mitochondrial 
targeting sequence 196.  Mutations may act by disrupting protein processing in vivo, a 
hypothesis that is supported by evidence from transgenic mice 197. The function of the 
MR1 protein is not fully understood, but it shows close homology to glyoxalase 
hydroxyacylglutathione hydrolase, with is known to detoxify methylglyoxal, a 
compound found in coffee and alcohol and a by-product of glycolosis, thus providing a 
link to the standard triggers 191. 
 
3.7.2 PRRT2 Mutations (DYT10) 
Mutations in PRRT2 cause paroxysmal kinesigenic dyskinesia (PKD), which has an 
estimated prevalence 1 in 150,000 individuals 198. Affected individuals have short 
(seconds to minutes) and frequent (up to 100 times per day) attacks of dystonic or 
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choreiform movements, precipitated by sudden movements or startle.  As with PKND, 
there is often warning of an impending attack – a so-called ‘aura’ – consisting of 
numbness or paraesthesia in the affected body part.  The attacks usually begin in 
childhood and are highly responsive to anticonvulsant therapy, such as carbamazepine 
52.  Reports of what was, in reterospect, probably this disorder have appeared in the 
literature from as early as 1892 and the condition was designated dystonia 10 in 1998 
199, 200.  However, the discovery of the gene underlying the condition, PRRT2, would 
wait until exome sequencing approaches could be brought to bear on the problem in 
2011 46, 47. 
 
Most mutations are truncating and by far the most common of these is the c.649dupC 
mutation, but missense variants (possibly with reduced penetrance) have also been 
described 201-204.  The PRRT2 protein is highly expressed in the central nervous system 
and is probably localized to the synapse 48.  Using yeast 2-hybrid screening, it has been 
shown to interact with synaptosomal protein 25 (SNAP25), suggesting a role in the 
fusion of the synaptic vesicles to the plasma membrane 205.  Both PRRT2 and SNAP25 
are highly expressed in the basal ganglia and disrupted neurotransmitter release has 
been suggested as a possible pathogenic mechanism in PRRT2 mutations.  Truncating 
mutations produce a protein lacking the transmembrane domain, and are thought to 
result in altered subcellular localization 47.  Missense mutations may cause loss of 
function or act in a dominant-negative manner 46, 206. 
 
PRRT2-related disease is notable for its varied presentation, differing not merely 
between individuals carrying different mutations, but also between individuals carrying 
the same mutation and even between affected members within the same family 52.  As 
well as the classical PKD phenotype described above, infantile convulsions with 
choreoathetosis (ICCA) with or without PKD, benign familial infantile seizures, 
episodic ataxia, hemiplegic migraine and even benign paroxysmal torticollis of infancy 
all appear to be possible manifestations of mutations in this gene 48-51.  The common 
thread would appear to be the paroxysmal nature of all PRRT2-related disorders. 
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Finally, it would appear that the family used to define DYT19 also carry the common 
c.649dup mutation in PRRT2, suggesting that the initial linkage was incorrect 50. 
 
3.7.3 SLC2A1 Mutations (DYT18) 
Dominantly inherited mutations in the SLC2A1 gene are now known to be the cause of 
paroxysmal exercise induced dyskinesia (PED) 207, 208.  In fact, SLC2A1 mutations cause 
a wide spectrum of disease, resulting from a deficiency of the encoded glucose 
transporter, GLUT1.  GLUT1 is the principal glucose transporter in the brain and it 
has generally been assumed that neuronal dysfunction arises from energy failure.  
Under this assumption, the prevalence of movement disorders was thought to reflect 
the heightened sensitivity of the basal ganglia to energy deficits 209.  However, recent 
studies in a mouse model of GLUT1-deficiency, which recaptures many of the features 
of the disease, demonstrated the preservation of aerobic metabolism, such that 
mechanisms other than impaired aerobic glycolysis must be responsible for the 
manifestations of the disorder 210.  Possible culprits include reduced transfer of lactate 
generated via anaerobic glycolysis from the astrocyte into the neuron and reduced 
anaerobic ATP formation in the astrocyte having a negative impact on glutamate-
glutamine recycling, which, if proven, would place the emphasis on glial dysfunction in 
the pathogenesis of GLUT1-deficiency 210, 211.  
 
At its most severe, GLUT1 deficiency can present with early onset psychomotor delay, 
drug resistant epilepsy, acquired microcepahly and other signs of widespread 
neurological dysfunction, such as spasticity, ataxia, tremor, dystonia, choreoathetosis 
and ballism, which may all be paroxysmal, static or static with paroxysmal worsening.  
From this extreme, there exists an entire spectrum of decreasing disease severity, 
ranging through developmental delay and movement disorders without epilepsy, right 
down to the mildest cases, in which only minimal phenotypic abnormalities are 
detectable 212, 213.  There can be considerable heterogeneity of clinical presentation even 
within the same family 212.   
 
PED is, therefore, probably best regarded as one just possible manifestation of the 
complex and variable disorder that is GLUT1 deficiency.  It is characterized by attacks 
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of combined chorea, athetosis, and dystonia precipitated by exercise – particularly brisk 
walking or running – that usually begin in childhood 207, 208.  The legs and feet are by far 
the most commonly affected body parts during attacks, which generally last from a few 
minutes to an hour 198.  Unlike PKD or PNKD, affected individuals do not report aura-
like symptoms prior to an attack.  The symptoms tend to improve with intravenously 
administered glucose and with permanent ketogenic diet, though they can become 
static with time 208.  Since PED is simply a manifestation of GLUT1 deficiency, it may 
occur alone in minimally affected patients or may be accompanied by various other 
manifestations of the disease, such as epilepsy, ataxia, haemolytic anaemia or spastic 
paraplegia.  No doubt this wide variation in clinical presentation contributed to the 
erroneous assignation of DYT9 (paroxysmal choreoathetosis with spasticity) and 
DYT18 (PED with or without epilepsy) as two separate conditions; it is now known that 
the causative gene in both cases was, in fact, SLC2A1 23. 
 
Given the variable expressivity of SLC2A1 mutations, researchers have sought 
correlations between genotype and phenotype.  It has been suggested that multiple 
exon deletion is associated with the early-onset, more severe form of the disorder, whilst 
missense mutations are associated with less severe cognitive deficits and a lower rate of 
movement disorders 212. 
 
3.8 The Combined Dystonia Syndromes 
The combined dystonia (previously ‘dystonia plus’) syndromes represent a 
heterogeneous group of diseases, where dystonia is accompanied by other neurological 
features but is not part of a complex neurodegenerative disorder.   
 
3.8.1 SGCE Mutations (DYT11) 
Mutations in SGCE cause myoclonus-dystonia, the commonest of the combined 
dystonia syndromes with a prevalence of about 2 per million in Europe 214.  The 
condition is inherited in an autosomal dominant fashion but with a significant role 
played by imprinting (see below).  It usually begins in childhood, with a mean age of 
onset of ~6 years, and is characterized by brief lightning-like myoclonic jerks, most 
often affecting the neck, trunk and upper limbs, in combination with focal or 
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segmental dystonia in around two thirds of patients 215.  Myoclonus usually dominants 
the clinical picture and can be reliably provoked by complex motor activities, such as 
writing or copying a picture.  There is often a dramatic improvement after alcohol, but 
this feature is not specific to the condition and is not present in all cases 216. 
 
The SGCE gene encodes the 438-aminoacid protein ε-sarcoglycan, which contains a 
single transmembrane domain.  Despite its ubiquitous expression pattern and close 
homology to α-sarcoglycan  (68%), mutations in SGCE do not to lead to any detectable 
deficits in peripheral nerve or muscle function.  Over 50 different mutations have been 
reported as causing myoclonus-dystonia, most of them located within the portion of the 
gene encoding the extracellular domain of the protein 217.  It is thought that mutations 
lead to mislocalisation of the protein from the plasma membrane to the endoplasmic 
reticulum and to the promotion of its degradation by the proteasome 218.  Interestingly, 
in humans, transcription occurs almost exclusively from the paternal allele, whilst 
transcription from the maternal allele is silenced by promotor methylation 219.  Because 
of this fact, 95% of those inheriting an SGCE mutation from their mother will not 
manifest any symptoms of the disease. 
 
In patients exhibiting alcohol responsiveness, GABAergic drugs such as clonazepam or 
gamma-hydroxybutyrate often produce a pronounced but temporary improvement in 
the condition.  However, their short duration of action can lead to overuse and 
addiction and this danger is compounded by apparently higher rates of psychiatric 
comorbidity – particularly OCD, anxiety and alcohol dependency – in SGCE mutation 
carries 220, 221.  The myoclonus seen in this condition is subcortical and does not 
respond to agents used to treat cortical myoclonus, such as valproate, levetiractem or 
piracetam 222.  Levodopa responsivemess (of both the myoclonic and dystonic elements 
of the condition) has been reported in two cases and some have suggested a trial of 
levodopa is warranted 223. 
 
3.8.2 ATP1A3 Mutations (DYT12) 
Mutations in ATP1A3 are primarily associated with rapid onset dystonia-parkinsonism.  
Familial cases show autosomal dominant inheritence with reduced penetrance (~90%), 
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but de novo mutations are common so that the absence of a family history should not 
preclude consideration of the condition 224. Most mutations are missense, affecting 
highly conserved transmembrane or N-terminus domains.  The mechanism by which 
such mutations actually cause rapid onset dystonia parkinsonism is not fully 
understood.  ATP1A3 encodes the catalytic unit of a sodium pump that uses ATP 
hydrolysis to exchange Na+ and K+ across the cell membrane, thus maintaining the 
ionic gradients important for electrical excitability, neurotransmitter transport, volume 
regulation and other key cellular functions.  Studies using cells transfected with mutant 
ATP1A3 have suggested mutations may reduce affinity for Na+ and that the resultant 
dysfunction in ion transport may impair cell viability, but the relative importance of 
these mechanisms to the actual pathophysiology of rapid onset dystonia-parkinsonism 
remains uncertain 225, 226. 
 
Clinically, the condition is characterized by the onset, over minutes to days, of dystonia 
and parkinsonism, usually in the context of specific physical or psychological stressors, 
particularly febrile illness.  After this period of rapid development of symptoms, the 
condition usually stabilizes and continued progression has only been reported once 227.  
There is often a rostrocaudal gradient of symptoms.  Despite clinical parkinsonism, 
dopamine transporter PET and SPECT studies reveal normal dopamine uptake 127, 228 
and, unfortunately, patients with rapid-onset dystonia parkinsonism do not respond to 
levodopa or pallidal DBS 229, 230. 
 
Interestingly, de novo heterozygous mutations in ATP1A3 also appear to underlie a rare 
neuropaediatric condition termed alternating hemiplegia of childhood (AHC) 44, 231.  
AHC is characterized by the onset before the age of 18 months of paroxysmal 
neurological events, such as hemiplegia alternating in laterality, quadriplegia, dystonic 
spells, oculomotor abnormalities and autonomic dysfunction, all of which abate during 
sleep.  Non-paroxysmal manifestations develop after a few months or years of the 
disease, comprising developmental delay, intellectual disability of variable degree, 
ataxia, dysarthria, choreoathetosis, and, in some patients, pyramidal tract signs.  In one 
study, a mutation in ATP1A3 was demonstrated in all 24 patients with AHC 44.  A 
second study found ATP1A3 mutations is just under three quarters of their cases 231.  
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One mutation, p.Asp801Asn, was found 30-40% of all cases, suggesting it is a 
mutational hotspot.  
 
3.8.3 PRKRA Mutations (DYT16) 
Mutations in the gene PRKRA appear to be a rare cause of autosomal recessive dystonia-
parkinsonism.  Camargos et al. identified two apparently unrelated consanguineous 
Brazilian families with a total of 6 individuals exhibiting young-onset, generalised 
dystonia or dystonia-parkinsonism 232.  Autozygosity mapping revealed a shared segment 
of homozygosity segregating with the disease and subsequent mutational screening of 
the region identified a homozygous missense mutation (p.Pro222Lys) in all six 
individuals 232.  PRKRA encodes protein kinase, interferon-inducible double-stranded 
RNA-dependent activator, which, in response to extracellular stress activates latent 
protein kinase PKR, a protein involved in signal transduction, cell differentiation, cell 
proliferation, antiviral response and apoptosis 233.   The Pro222Lys mutation alters a 
conserved amino acid between the second and third RNA-binding motifs, but the 
manner by which it causes disease is remains elusive.  As with patients carrying 
mutations in ATP1A3, response to standard medical therapy was minimal or absent. 
 
3.9 Dopa-Responsive Dystonia 
Clinically, the dopa-responsive dystonias often present as combined or complicated 
dystonia syndromes, but they have been separated out in this discussion because they 
are bound together aetiologically by their connection to the endogenous pathway for 
the synthesis of dopamine, which accounts for their shared clinic characteristic of an 
improvement in symptoms in response to treatment with oral L-dopa.  To date, three 
genes have been convincingly shown to cause dopa-responsive dystonia:  GCH1 (GTP 
Cyclohydrolase 1), TH (Tyrosine Hydroxylase) and SPR (Sepiapterin Reductase) 234-236.  
All three genes encode enzymes required for the biosynthesis of dopamine (see figure 
7).   
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Figure 7 - Schematic illustration of the pathways for the synthesis of catecholamines and 
serotonin.  Breakdown products are indicated by broken arrows.  Enzymes in which defects 
cause DOPA-responsive dystonia are shown in red with the gene symbol in brackets.  
Tetrahydrobiopterin is a key cofactor in some enzymatic reactions. 
 
 
Table 8 - CSF neurotransmitter metabolite profiles in dopa-responisve dystonia secondary to 
GCH1, TH and SPR mutations.  5-HIAA = 5-hydroxyindoleactetic acid; MHPG = 3-methoxy-4-
hydroxy-phenylethylene gycol. 
CSF metabolite GCH1 TH SPR 
Biopterin Decreased Normal 
Normal to slightly 
raised 
Neopterin Decreased Normal Increased 
Homovanillic acid 
Normal to mildly 
decreased 
Decreased Very low 
5-HIAA 
Normal to mildly 
decreased 
Normal Very low 
MHPG 
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3.9.1 GCH1 Mutations (DYT5a/Segawa’s Disease)  
Mutations in this gene account for around 60-80% of autosomal dominant dopa-
responsive dystonia 237.  Penetrance is incomplete and lower for males (≈40-50%) than 
females (≈80%) 22.  GCH1 encodes the enzyme GTP cyclohydrolase 1, which catalyzes 
the ﬁrst step in the reaction of tetrahydrobiopterin neo-synthesis from GTP.   
Tetrahydrobiopterin is an essential cofactor for tyrosine hydroxylase, the rate-limiting 
enzyme for catecholamine synthesis, as well as for tryptophan hydroxylase and 
phenylalanine hydroxylase, which are involved in the production of serotonin.  GCH1 
mutations act in a dominant negative manner, with measurable enzyme activity usually 
being less than 20% of normal, resulting in a relative deficiency of dopamine and 
serotonin 238, 239.  Diagnosis can be confirmed on the basis of reduced CSF levels of total 
biopterin (of which tetrahydrobiopterin is the main component) and neopterin (a 
product of the reaction involving GCH1) (see table 8) or an abnormal phenylalanine 
loading test 240, 241. 
 
Clinical presentation is typically with lower limb dystonia and gait disturbance in the 
first decade of life, which occasionally leads to misdiagnosis as cerebral palsy or spastic 
paraparesis 242.  Diurnal fluctuation in the severity of the dystonia is common, though 
this may abate with age.  With time there is usually gradual generalization, and 
parkinsonism and dystonic tremor are possible complications of the condition 243, 244.  
In a subgroup of patients, the dystonia is mild, progresses only very slowly and may 
require no treatment 245.  Infrequently, patients may present later in life with a dystonic 
tremor, akinetic-rigid parkinsonism or even myoclonus dystonia 245-247.  There is some 
evidence that subtle neuropsychiatric features may be associated with mutations in this 
gene.  In one recent study of 18 patients, major depressive and sleep disorders occurred 
in about half of those over 20 year of age, whereas obsessive–compulsive disorder was 
found in 25% of cases 248.  In terms of treatment, the response even to low doses of L-
dopa is generally excellent (70-100% improvement in clinical symptoms), sustained and 
is not generally associated with the late-onset dyskinesias that often accompany 
prolonged use of L-dopa in other conditions, such as Parkinson’s disease 249 
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It should be noted that a previously-proposed novel form of dopa-responsive dystonia, 
DYT14, is now known to be synonymous with DYT5a.  Misclassification of one patient 
from the ‘DYT14’ family had led to incorrect locus assignment on the basis of 
erroneous linkage.  After removal of this patient, the linkage peak now included 
the GCH1 gene, which was found to habour a causative deletion 22. 
 
Finally, autosomal recessive mutations in GCH1 have also been reported, resulting in 
no detectable enzyme activity in the liver.  As might be expected the phenotype is 
generally distinct and much more severe, with complex neurological dysfunction, 
including developmental delay, spasticity, seizures and physiological 
hyperphenylalaninaemia, which is generally picked up on routine screening of newborn 
infants 250.  However, atypical presentations have been described with dopa-responsive 
dystonia 251, with a neonatal dopa-responsive extrapyramidal syndrome 252 or without 
hyperphenylaninaemia 253, 254. 
 
3.9.2 TH Mutations (DYT5b) 
Rarely, dopa-responsive dystonia can also be inherited as an autosomal recessive 
disorder associated with mutations in the gene encoding tyrosine hydroxylase itself 255.  
It is sometimes referred to as DYT5b.  Only about 40 cases have been reported 
worldwide but with over 30 different pathogenic mutations, scattered throughout the 
length of the gene, including its promotor regions 256. 
 
As shown in figure 7, tyrosine hydroxylase is involved in the conversion of 
phenylalanine to dopamine, but it is also the the rate-limiting enzyme in the synthesis 
of other catecholamines, such as norepinephrine and epinephrine.  The enzyme thus 
plays a key role in normal functioning of both dopaminergic and noradrenergic 
neuronal populations and, indeed, complete loss of tyrosine hydroxylase activity 
appears to be lethal in knock-out mice 257.  Patients with biallelic mutations in this gene 
tend to present with a more severe disease than is seen in those carrying heterozygous 
GCH1 mutations, which reflect the more profound deficiency of dopamine and 
norephinephrine.  Two major phenotypes can be discerned:  1) a progressive 
hypokinetic-rigid syndrome with dystonia beginning in the first year of life, with 
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significant improvement in response to L-dopa; and 2) a more complex 
encephalopathy, associated with variable degrees of hypokinesia, bradykinesia, 
hypotonia, dystonia, myoclonus, ptosis and eye movement abnormalities that has its 
onset in the first few months of life, is often poorly responsive to L-dopa and carries a 
far worse long term prognosis 249, 256.  In this latter type, autonomic functions are often 
disturbed leading to so-called ‘lethargy-irritability crises’, consisting of excessive 
drooling, sweating, body temperature instability and marked periods of ‘pyrexia of 
unknown origin’ 256. 
 
In keeping with the underlying biochemical defects, CSF levels of homovanillic acid 
and 3-methoxy-4-hydroxyphenylethylene glycol (MHPG), the breakdown products of 
dopamine and norepinephrine respectively, are found to be low.  CSF levels of 
biopterin and 5-hydroxyindoleacetic acid are normal, however, reflecting the fact that 
the synthesis of tetrahydrobiopterin and serotonin is unaffected by mutations in the 
tyrosine hydroxylase gene (see table 8 and figure 7).   
 
3.9.3 SPR Mutations 
Mutations in the gene SPR result in a second form of autosomal recessive dopa-
responsive dystonia.  Deficiency of the encoded enzyme, sepiapterin reductase, results 
in neurologic deterioration due to severe catecholamine and serotonin deficiencies in 
the central nervous system, caused by the resultant defect in tetrahydrobiopterin 
synthesis.  As well as being a cofactor for tyrosine hydroxylase, tetrahydrobiopterin is 
also a required cofactor for phenylalanine hydroxylase, but patients with sepiapterin 
reductase deficiency do not exhibit overt hyperphenylalaninaemia as is seen in other 
autosomal recessive disorders of tetrahydrobiopterin synthesis as alternative enzymes 
are able to replace sepiaterin reductase in peripheral tissues and can thus compensate to 
some degree.  In the brain, however, the low activity of dihydrofolate reductase means 
that an alternate pathway for tetrahydrobiopterin synthesis cannot complete and an 
intermediate, dihydrobiopterin, accumulates instead 258.  The accumulation of 
dihydrobiopterin is probably of pathological significance since it is a competitive 
inhibitor of both tyrosine and tryptophan hydroxylase, thus further compounding the 
deficits in catecholamine and serotonin production caused by the subnormal 
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tetrahydrobiopterin concentrations.  Furthemore, by displacing prebound 
tetrahydrobiopterin, it has been suggested that dihydrobiopterin may uncouple nitric 
oxide synthase and cause the release of potentially apoptotic levels of superoxide and 
peroxynitrite, resulting in neuronal cell death 258, 259.  
 
The complex biochemical abnormalities described above are reflected in CSF 
metabolite measurements which show severe decreases in homovanillic acid and 5-
hydroxyindoleacetic acid in the context of a normal neopterin and a normal or slightly 
raised total biopterin (see table 8).  The neurologic phenotype of SPR deficiency is quite 
variable, with milder cases being particularly susceptible to misdiagnosis as cerebral 
palsy 260.  Most affected individuals will display motor and speech delay, axial 
hypotonia, dystonia, weakness and oculogyric crises with diurnal variation and sleep 
benefit, whilst dysarthria, parkinsonian features, hyperreflexia, behavioural 
abnormalities, mental retardation, and autonomic signs are not uncommon 
accompaniments 260, 261.  Many patients will show considerable benefit from treatment 
with low-dose L-dopa, with most improvement being observed in motor and sleep 
symptoms.  Significant cognitive problems may remain, however, and some patients 
have shown further benefit from the addition of 5-HTP, a serotonin precursor, leading 
to the suggestion that it should be trialled in all patients without complete symptom 
resolution on L-dopa alone 260.    
 
3.10 Mechanist ic  Insights  f rom the Monogenic Primary Dystonias 
As with other disorders, it is believed an understanding of the genetic architecture of 
dystonia offers that best starting point for the complex task of unravelling the 
molecular pathophysiology of the disorder.  Identification of genes involved in rarer, 
Mendelian forms of dystonia, along with a knowledge of their cellular function, allows 
us to identify key molecular pathways, which, when compromised, might contribute to 
the onset of dystonia.  Since primary dystonia seems to result from a chronic cellular 
dysfunction, rather than a degenerative process, there are greater grounds for the belief 
that it may eventually be possible to ameliorate the disease by correcting the underlying 
dysfunction in these pathways. With this in mind, what do the functions of the 
causative genes identified so far tell us about the pathophysiology of primary dystonia? 
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One inescapable observation, evident from even a cursory look at the genes mentioned 
in the preceding sections above, is the apparent range of cellular pathways implicated in 
the pathogenesis of dystonia.  This suggests that the phenotypic heterogeneity of the 
dystonias is matched by a similar heterogeneity of pathological mechanism and that 
dysfunction in distinct pathways or cellular components is capable of resulting in the 
common clinical manifestations of the disease.  Nonetheless, several themes can be 
discerned on closer examination.  Firstly, and perhaps unsurprisingly, dopamine 
signalling problems are clearly an important pathogenic mechanism in dystonia.  All 
three of the genes involved in dopa-responsive dystonia (GCH1, TH, and SPR) are 
directly involved in the dopamine synthesis pathway (see figure 7); GNAL encodes the 
alpha subunit of G protein that directly couples to D1 receptors; and knock-in mouse 
models of the GAG deletion in TOR1A have been shown to exhibit neurochemical and 
structural changes in the dopamine pathways of the brain 262.  Regulation of gene 
expression and cell cycle dynamics also appear to be important:  the protein products of 
THAP1 and TAF3 are both transcription factors, whilst that of CIZ1 is a DNA 
replication factor that acts to transform nuclei poised to begin DNA synthesis into 
nuclei actively synthesising DNA 263.  With the recent identification of TUBB4A as the 
cause of whispering dysphonia, the function of several genes now point to cell structure 
as playing an important role in dystonia.  TUBB4A encodes tubulin, the major 
component of the cytoskeleton; TorsinA appears to important for the structure of the 
nuclear envelope where it may form a bridge complex between it and the cytoskeleton 
264 and also interacts with vimentin, a type III intermediate filament important for 
motility, chemotaxis, adhesion, intracellular signalling and neurite outgrowth 155; and 
SGCE, a gene linked to myoclonus-dystonia, encodes a member of the dystrophin-
glycoprotein complex that connects the cytoskeleton to the extracellular matrix in 
muscle and may have a role in synaptic organisation in the CNS 265.  Synaptic 
dysfunction is also highlighted by the recent identification of PRRT2, the protein 
product of which interacts with the SNARE protein, SNAP25 48, in addition to 
evidence suggesting TorsinA may regulate vesicular traffic and, by extension, 
neurotransmitter turnover 266.   ATP1A3, the cause of rapid onset dystonia-
parkinsonism and alternating hemiplegia of childhood, encodes the catalytic subunit of 
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a Na+/K+ pump that is expressed in neurons and cardiac cells and that is involved in 
maintaining ionic gradients 224. 
 
3.11 The Heredodegenerative Dystonias 
This category comprises a large number of complex neurological disorders of which 
dystonia can sometimes be a significant feature.  However, it is important to recognise 
that dystonia may not be present in all cases or, more often still, may not be the 
dominant neurological sign within the clinical picture.  Many of the conditions have a 
known genetic cause, but a full exposition of their clinical features and molecular basis 
is beyond the scope of this review.  Instead, they are summarised in the table 9 by mode 
of inheritance. 
 
Notably, DYT3-related dystonia belongs to this category of disease and is perhaps worth 
a more detailed consideration.  It is primarily found in Filipino males, due to a founder 
mutation, and is inherited in an X-linked recessive fashion.  It is due to a 2.6kb 
retrotransposon insertion in intron 32 of the TAF1 (TATA box-binding protein-
associated factor 1) gene 267.  The insertion appears to reduce neuron-specific expression 
of TAF1 and the dopamine receptor D2 gene in the caudate nucleus 267, 268.  Symptoms 
start as focal dystonia and progress to multifocal/generalized dystonia, sometimes with 
parkinsonism.  Neuronal degeneration on postmortem analysis has been described in 
association with mutations in this gene 269, 270. 
 
3.12 The Genetics  of  Sporadic Dystonia 
To date, no genome-wide association study has been reported for sporadic dystonia.  
Previous experience in allied diseases, such as Parkinson’s disease or Alzheimer’s, 
suggests that to be successful such a study would need to be a large-scale, international 
effort that included thousands of case and control subjects.  Such research is, of course, 
expensive and would require a considerable funding commitment.  A second problem 
that a potential association study would face is defining its case cohort.  Sporadic 
dystonia is an umbrella term, comprising multiple phenotypic subtypes that may well 
have distinct genetic architectures.  In this respect, it is not unlike epilepsy, a condition  
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Table 9 - The major forms of heredodegenerative dystonia where a genetic cause has been identified, arranged by mode of inheritance.  Major clinical features 
besides dystonia are indicated. 
Disease Gene Major Features Besides Dystonia 
Autosomal Dominant 
Dentatorubral-pallidoluysian atrophy ATN1 Ataxia, chorea and cognitive decline. 
Huntington’s disease IT-15 Chorea, depression and cognitive decline. 
Huntington’s disease-like 2  JPH3 Chorea, parkinsonism, ataxia and cognitive decline 
Neuroferritinopathy FTL Chorea and parkinsonism. 
SCA 2 ATXN2 Ataxia, ocular movement disorders, spasticity and parkinsonism 
SCA 3 ATXN3 Ataxia, spasticity, parkinsonism and ocular movement disorders. 
SCA 7 ATXN7 Ataxia, pigmentary macular degeneration, brisk reflexes 
SCA 17 TBP Chorea, parkinsonism, ataxia and cognitive decline 
Autosomal Recessive    
Ataxia-telangectasia ATM Ataxia, oculomotor apraxia, telangiectasia, susceptibility to malignancy. 
Choreoacanthocytosis VPS13A Chorea, orofacial dyskinesias, cognitive decline, axonal neuropathy 
Ceroid-lipofuscinosis Multiple genes Visual failure, cerebral atrophy and seizures 
Dystonia with brain manganese deposition SLC30A10 Hepatic cirrhosis, polycythemia and hypermanganesaemia. 
Fucosidosis FUCA1 Mental retardation, growth retardation, dysostosis multiplex, angiokeratoma 
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FBOX07-associated neurodegeneration FBX07 Parkinsonism 
Glutaric acidaemia type 1 GCDH Macrocepahaly, encephalopathic crises, axial hypotonia, parkinsonism. 
Hereditary dopamine deficiency syndrome SLC6A3 Pyramidal tract signs, eye movement disoreder, hyper and hypokinetic movement 
disorders 
Kufor-Rakeb syndrome ATP13A2 Parkinsonism 
Infantile striatonigral degeneration NUP62 Choreoathetosis, spasticity, nystagmus, developmental regression 
Metachromatic leukodystrophy ARSA Mental retardation, spasticity and bulbar palsy 
Mitochondrial membrane protein-associated 
neurodegeneration (MPAN) 
C19orf12 Cognitive decline, prominent neuropsychiatric abnormalities, motor 
neuronopathy 
Neimann Pick Type C and D NPC1/NPC2 Ataxia, ocular motor abnormalities (vertical gaze palsy), seizures 
Neurodegeneration with brain iron accumulation 
type 1  
PANK2 Parkinsonism, behavioural changes, pigmentary retinopathy in about 50% 
Neurodegeneration with brain iron accumulation 
type 2 
PLA2G6 Parkinsonism, pyramidal signs, cognitive decline, cerebellar ataxia 
Parkin-related parkinsonism PRKN Parkinsonism 
Tay-Sach’s disease HEXA Psychomotor regression, dementia, blindness. 
Wilson’s disease ATP7B Tremor, parkinsonism 
X-Linked 
Dystonia-deafness syndrome TIMM8A Progressive hearing loss, spasticity, cortical blindness 
Lesch-Nyhan syndrome HPRT Choreoathetosis, ballismus, cognitive/attentional deficits, self-injurious 
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behaviours 
Lubag disease (DYT3) TAF1 Parkinsonism 
Pelizaeus-Merzbacher disease PLP1 Pyramidal dysfunction, cerebellar ataxia, head tremor 
Retts syndrome MECP2 Mental retardation, motor regression, autistic behaviours, seizures 
Static encephalopathy of childhood with 
neurodegeneration in adulthood 
WDR45 De novo inheritance pattern, global developemental delay, parkinsonism and 
dementia 
Mitochondrial   
Leber’s Optic Neuropathy ND1, ND4, ND6 Bilateral or sequential visual failure 
Leigh’s syndrome Multiple genes Optic atrophy, ophthalmoplegia, ataxia, spasticity and developmental 
delay/regression.  May also be AR inheritance. 





Epilepsy, short stature, hearing loss 
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for which large association studies have so far been somewhat disappointing 271.  
Difficult decisions will have to be made regarding whether to lump all sporadic dystonia 
together and risk ‘diluting’ individual signals associated with particular subtypes or 
whether to spilt them apart and risk compromising the power of the studies to detect 
an association. 
 
In the case of sporadic primary dystonia, only candidate gene association studies have 
yet been published.  Six of these studies have examined common single nucleotide 
polymorphisms (SNPs) in and around the TOR1A gene. Two showed strong 
associations between individual SNPs and susceptibility for primary dystonia in 
populations from Iceland, southern Germany and Austria, and the United States 272-274. 
However, others have shown only modest associations in Indian, Italian and northern 
German populations 275-277 and yet other similar studies have been able to replicate 
these associations 278, 279.  In contrast to TOR1A, no strong associations have been 
reported with polymorphisms in the THAP1 gene 280, 281.  One recent study employed a 
haplotype tagging strategy to cover the majority of common variability in TOR1A, 
TAF1, GCH1, THAP1, MR1, SGCE, ATP1A3 and PRKRA 282.  No association survived 
correction for multiple testing in this study, though 3 variants in GCH1 did show 




In recent years, advances in sequencing technology has accelerated the pace of gene 
discovery in neurology and the field of dystonia has been no exception with several new 
genes appearing on the scene.  Indeed, there is every reason to believe that the pace of 
discovery will continue to accelerate as sequencing costs fall and exome sequencing 
gives way to affordable whole-genome sequencing, allowing examination for the first 
time of non-coding and regulatory regions of DNA and their potential contributions to 
disease. 
 
By pointing researchers in the direction of cellular pathways that are dysfunctional in 
familial dystonia, the discovery of new causative genes is the first step in unravelling the 
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complex molecular pathophysiology that underlies not just familial but also, one would 
hope, sporadic forms of dystonia.  Current data suggest that dystonia can result from 
dysfunction is a wide variety of cellular pathways, which probably reflects and in part 
explains the wide phenotypic variety seen in the disorder.  Further functional work, 
particularly on those new genes that have only recently been published and will require 
independent confirmation, may hep us identify a core set of pathogenic mechanisms in 
dystonia that might form the target for novel treatments.  In this respect, induced 
pluripotent stem cell-derived neurons would offer the advantage of a more accurate 
model system, as well as an initial means of assessing the effect of any proposed 
treatments.  Finally, it remains important to examine the genetics of sporadic dystonia 
independently by means of a large scale, genome-wide association study but, in order 
for this to be successful, international co-operation and a considerable funding 
commitment will be required. 
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4. Mater ials  and Methods 
 
4.1 Case Select ion,  Extended Phenotyping and Samples 
The kindreds that I worked during my period in research were predominantly 
identified by Prof. Kailash Bhatia and Prof. Nicholas Wood through their extended 
clinical practice.  In many cases, only an index case was under their direct care and the 
first step accomplishing the work presented in many of the following chapters was 
establishing contact with the rest of the family and visiting them in order to take a 
history, perform a neurological examination and obtain a sample for DNA extraction. 
Where families had become more geographically scattered and key individuals lived 
abroad, interviews were conducted by phone or with the aid of Skype and DNA was 
obtained by saliva samples traveling by post. 
 
Samples for mutational screening of candidate variants were selected from a library of 
samples held at our institution with research consent.  Selection criteria are given in the 
relevant chapters.  It must be said that the selection process was somewhat of an inexact 
science.  Unfortunately, clinical details were not recorded in a standardised fashion 
and, on the whole, tended to be sparse – sometimes containing no more than a single 
word description of the individual’s clinical condition, i.e. simply “dystonia” or “PD”.  
This meant that many samples originating from individuals that may well have 
exhibited a phenotype that was a good match for the index family’s disease phenotype 
were probably overlooked as there was insufficient information recorded to determine 
this.  Although regrettable, it is entirely understandable and perhaps inevitable given 
the constraints on clinicians’ time. 
 
4.2 Ethics  
The ethics for all work on biological samples obtained from individuals with any form 
of parkinsonism were written by me and approved by the relevant ethics committees.  
My work, which ended up focusing predominantly on dystonia, utilised previously 
existing ethics that had been written by Dr Mark Edwards and approved by the relevant 
ethics committees at that time..  
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4.3 Core Genetic  Methods 
The following sections give details of the materials, general protocols and software used 
to generate the genetic data including in this work.  Any significant deviations from 
these general protocols are indicated in the relevant chapter. 
 
4.4 DNA Extract ion 
DNA was extracted preferentially from whole blood samples where possible.  Where 
this was not possible due to difficulties in arranging to visit the individual providing the 
sample or because of a reluctance on the individual’s part to provide a blood sample, 
DNA could instead be extracted from saliva.  Using this later method, a DNA sample 
kit and consent form could be sent via the post and returned at the individual’s 
convenience. 
 
4.4.1 DNA Extraction from Whole Blood 
Fresh blood samples were obtained by clinical researchers, such as myself, using 
standard venepuncture.  Samples were transported in EDTA-coated bottles to the 
Diagnostic Genetics Laboratory at the UCL Institute of Neurology for extraction.  
DNA extraction was accomplished using the FlexiGene Kit (Quiagen) according to the 
manufacturer’s instructions as briefly summarised below. 
 
Initially, 300ul of whole blood is mixed with 750ul of FG1 lysis buffer to liberate the 
cell contents.  The sample is then centrifuged for 20 seconds at 10,000xg and the 
supernatant carefully discarded to leave only the pelleted cell cellular material.  
Subsequently, 150ul of FG2 buffer, which contains a protease, is added to the tube 
containing the pellet, before vortexing the tube to homogenise its content.  After a brief 
5 second centrifuge step, the tube is then placed in a heating block at 65oC for 5 
minutes to allow the protease to work.  Once this time has elapsed, 150ul of 
isopropanolol is added to the tube and the tube inverted several times to cause 
precipitation of the DNA.  The precipitated DNA is then pelleted by centrifuging for 3 
minutes at 10,000xg and the resultant supernatant discarded.  The pellet is then 
washed of impurities by the addition 150ul of 70% ethanol, vortexing briefly and then 
centrifugation for a further 3 minutes at 10,000xg.  The resultant supernatant is once 
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again discarded and the pellet allowed to air dry.  Finally, the extracted and purified 
DNA is resuspended in 200ul of FG3 buffer by vortexing for 5 seconds and heating to 
65oC.  The resultant suspension is assessed for quality and concentration as detailed in 
section 4.5 below. 	  
4.4.2 DNA Extraction from Saliva Samples 
Genomic DNA was extracted from saliva samples using the Oragene DNA kit 
according to the manufacturers instructions as briefly summarised below. 
 
Firstly, the saliva sample is incubated at 50oC in an air incubator for a minimum of two 
hours.  Subsequently, 500ul of the solution is pipetted into a clean 1.5mL 
microcentrifuge tube, to which 20ul of Oragene DNA purifier added.  The constituents 
are then vortexed briefly to ensure they are fully mixed, before the tube is placed in an 
ice bath to incubate for a further 10 minutes.  After this time had elapsed, the sample is 
transferred to the centrifuge and spun at 13,000 rpm for 15 minutes to pellet the 
cellular debris.  The resultant supernatant, containing the DNA in suspension, is 
transferred to a clean microcentrifuge tube and the pellet discarded.  In order to 
precipitate the DNA from suspension, 500ul of 100% ethanol is added to the 
supernatant, the tube inverted 10 times and then left at room temperature for 10 
minutes.  The precipitated DNA is then pelleted by centrifuging at 13,000 rpm for 2 
minutes and the resultant supernatant removed and discarded.  The pellet is then 
washed of impurities by adding 250ul of 70% ethanolol, allowing the sample to stand 
for 1 minute and then removing the ethanol, taking care not to disturb the pellet.  
Finally, the DNA is resuspended in 100ul of DNA buffer by vortexing and incubation 
at to 60oC for one hour.  The resultant suspension is assessed for quality and 
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4.4.3 DNA Extraction from Brain Tissue 
Genomic DNA was extracted from flash frozen samples of brain tissue using the Gentra 
Puregene Tissue DNA extraction kit (Quiagen, Hilden, Germany).  Briefly, 50mg of 
tissue is dissected from chips of flash frozen cerebellum whilst still frozen on a sterile 
plate in direct contact with dry ice.  The tissue is then homogenised in 3ml of cell lysis 
solution that had been previously dispensed into a 15ml tube.  15µl of proteinase K is 
added to the tube and the mixture inverted 25 times, prior to be being incubated at 
55oC overnight.  The following morning 15µl of RNase A solution is added to the tube 
before inverting the sample 25 times and incubating at 37oC for 1 hour.  Subsequently, 
rapid cooling of the sample is achieved by placing it in ice for 3 minutes.  100µl of 
protein precipitation solution is then added to the mixture and the tube vortexed 
vigorously 20 seconds at high speed.  The sample is then centrifuged for 10 minutes at 
2000xg.  Meanwhile, 3ml of isopropanolol is pippeted into a clean 15ml tube, to which 
will be added the supernatant from the previous step, taking care not to dislodge the 
pellet, which is subsequently discarded.  The mixture of isopropanolol and supernatant 
mixed by inverting the tube 50 times and then centrifuged for 3 minutes at 2000xg.  
The resulting supernatant is carefully discarded, taking care that the pelleted DNA 
remains undisturbed.  The DNA pellet is then washed by adding 3ml of 70% ethanol 
and inverting the tube several times and repelleting of the DNA was assured by a 
further period of centrifugation at 2000xg for 1 minute.  The resultant supernatant is 
then carefully removed to leave only the DNA pellet in situ, which is allowed to air dry 
for 5 minutes.   Once all of the ethanol has evaporated, 400µl of DNA hydration 
solution is added to the tube containing the dried pellet and the sample included at 65 
oC to dissolve the DNA.  The resultant suspension was then assessed for quality and 
concentration as detailed in section 4.5 below. 
 
4.5 DNA Quantif ication 
DNA quality, and for the purpose of PCR-based work, concentration was quantified by 
means of UV absorbance using the NanoDrop spectrophotometer.  Where greater 
accuracy in the initial starting concentration was required, such as for next generation 
sequencing (NGS), DNA was quantified by means of fluorescence intensity using the 
Qubit 2.0 fluorometer 
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4.5.1 DNA Quantif ication by Spectrophotometry 
Measurement of the concentration of DNA in a solution by spectrophotometry relies 
on the fact that DNA will absorb UV light at a wavelength of 260nm.  By measuring 
the absorbance of light at this wavelength when loaded with 1ul of solution, the 
Nanodrop is able to calculate the concentration of DNA in the solution and the result 
is displayed in ng/ul.  In addition, for quality control purposes, the ratios of absorbance 
at 260/280nm and 260/230nm are also derived.  Ratios of approximately 1.8 and 2.0 – 
2.2, respectively, indicate that the DNA in solution is of good quality and free of 
significant impurities.  DNA solutions that demonstrate absorbance ratios that 
significantly deviate from these norms may contain impurities that interfere with 
downstream reactions in PCR and thus were avoided where possible.   	  
4.5.2 DNA Quantif ication by Fluorescence 
Measurement of the concentration of DNA in a solution by fluorescence relies on the 
addition of a dye, Picogreen, which binds selectively to double stranded DNA.  When 
bound to DNA, the dye can then be excited by light at 485nm, causing it to emit 
fluorescence at 530nm, which is measured by the sample reader.  This allows for a more 
accurate determination of the amount of DNA in a solution, particularly in the 
presence of contaminants that would otherwise influence the UV absorbance at 
wavelength 260, such as RNA or salt and guanidine contamination.  The method is, 
however, more time consuming, as it requires the calibration of the fluorometer by use 
of standard dilutions before use, and more expensive, as it requires the use of reagents. 
 
To prepare samples for a analysis, a mix of the reagents is made by including 199ul of 
Qubit buffer with 1ul of Qubit reagent (dye) for every sample that is to be analyses.  
199ul of this mix is then added to a tube containing 1ul of DNA solution, vortexed, 
left to stand for 1 minute and then loaded on the sample reader, which completes the 
analysis as described above. 
 
4.6 Primer Design and Optimisation of  PCR Condit ions 
Primers were designed for the target DNA sequence using the free web-based software, 
Primer3, and subsequently checked for potential problems related to SNP-in-primer 
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using the latest build of the genome via Ensemble.  The oligonucleotide primers, 
synthesised on demand by Eurofins DNA, were then hydrated with PCR-grade water to 
a concentration 100ng/ul for long-term storage at -80oC.  Prior to use, a 500ul working 
stock of the primers was created at a concentration of 10ng/ul to minimise 
contamination and degeneration with repeated freeze-thaw cycles and use. 
 
Primers were tested using a stock of reference genomic DNA on a variety of PCR 
settings to obtain optimal PCR amplification of the desired DNA sequence alone, 
verified by direct visualisation after gel electrophoresis (see section 4.4 below).  
Generally, 10ul of Roche FastStart was combined with 1ul of each primer working 
stock and 1ul of a stock of the desired genomic DNA at a concentration of 25ng/ul.  
Once the optimal conditions had been identified, they were used for amplification of 
all participants’ DNA. 
 
4.7 Agarose Gel Electrophores is  
Agarose gel electrophoresis was performed to verify amplification of the desired target 
sequence alone and to enable a qualitative visual assessment of the amount of amplified 
product.  A stock solution of 10x tris-borate-EDTA (TBE) solution was prepared by 
dissolving 121.1g of Trizma base, 7.4g of ethylenediaminetetraacetic acid and 61.8g of 
boric acid in 1 litre of distilled water.  A working solution of 1x TBE was then prepared 
from this stock, heated, combined with 1.5% Ultrapure Agarose (Invitrogen) and 20ul 
of Gel Red (Cambridge Biosciences) and allowed to set in an tray overset with combs to 
create wells for sample insertion.  Samples were prepared by combining 3ul of PCR 
product with 3ul of Orange DNA loading dye (Thermo Scientific), before being 
pipetted into each well.  The last well of each row was filled with 6ul of midrange DNA 
ladder (Quiagen) to permit subsequent sizing of the amplified PCR products.  A 
current of 100mA was then applied across the gel for a period of 30 minutes.  The 
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4.8 Clean-up of  PCR Product for  Sequencing 
Prior to sequencing amplified PCR product must be purified to remove unbound 
primers and left-over dNTPs.  Two methods were used at different stages of this work to 
achieve this goal:  filtration and enzymatic digestion. 
 
4.8.1 PCR Clean-up by Fi ltration 
Using this method, 80ul of purified PCR grade water was added to the PCR product 
from each reaction in a 96 well plate and the entire mix transferred to an ultrafiltration 
plate (Millipore).  The filtration plate was then placed on a vacuum under moderate 
negative pressure for approximately 5 minutes or until the membrane was dry.  
Subsequently, the PCR product trapped on the membrane was resuspended in 50ul of 
purified PCR-grade water by means of gentle agitation on a unheated thermo-shaker for 
approximately 30 minutes. 
 
4.8.2 PCR Clean-up by Enzymatic Digest ion 
Using this method, 5ul of the PCR product is combined with 2ul of a prepared 
enzymatic clean-up solution in a fresh 96 well plate.  The enzymatic clean-up solution 
consists of a mix of 50ul of exonuclease I (which removes single stranded DNA such as 
unincorporated primers) and 200ul of fast alkaline phosphatase (which eliminates 
unused dNTPs), diluted to 1ml by addition of 750ul of purified PCR grade water.  The 
plate containing the mix of PCR product and enzymatic clean-up solution is then 
placed on a thermal cycler and run at temperature of 37oC for 30 minutes to drive 
enzymatic activity and then at 80oC for 15 minutes to deactivate the enzymes.  
 
4.9 Sequencing Using BigDye Terminator v3.1 
Sequencing of PCR products was performed using BigFye Terminator v3.1 chemistry 
(Applied Biosciences) with some adaptations made to reduce reagent cost without 
reducing sequencing quality.  Each reaction was constituted so as to contain 0.6ul of 
BigDye Terminator v3.1, 2ul of 5x sequencing buffer, 0.6ul of forward or reverse 
primer diluted to a concentration of 10pmol/ul, purified PCR product (3.8ul if 
purified by filtration and 3ul if purified by enzymatic digestion) and enough PCR-grade 
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water to make a final reaction volume of 10ul.  The reactions were placed in a 96 well 
plate in a thermal cycler set to run the invariable program shown in table 10. 
 
Table 10 - Thermal cycler settings for sequencing using BigDye Terminator v3.1 
Set-up of Thermal Cycler For Sequencing Using BigDye Terminator v3.1 
Denaturation 1.   Rapid thermal ramp to 96oC 
2.   Hold at 96oC for 1 minute 
Core Sequencing Cycle 
 
 
3.   Rapid thermal ramp to 96oC 
4.   Hold at 96oC for 10 seconds 
5.   Rapid thermal ramp to 50oC                          REPEAT 
6.   Hold at 50oC for 5 seconds                     CYCLE 25 TIMES 
7.   Rapid thermal ramp to 60oC 
8.   Hold at 60oC for 4 minutes 
Reaction End 9.   Rapid thermal ramp to 4oC 
10. Hold at 4oC until removal for purification 
 
4.10 Puri f ication of  Sequencing Reactions 
Unincorporated dye terminators must be completely removed prior to electrophoresis. 
Excess dye terminators in sequencing reactions obscure data in the early part of the 
sequence and can interfere with base calling.  During the period of this work, two 
different methods were used to achieve this goal:  either, passage of the reactions 
through an ultrafiltration plate or, alternatively, through Sephadex columns. 
 
4.10.1 Sequencing Reaction Purif ication by Fi l tration Plate 
Using this method, 80ul of purified PCR grade water was first added to the product of 
the sequencing reaction in each well of the plate.  The content of the plate is then 
transferred over to a fresh, 96-well ultrafiltration plate (Millipore).  The filtration plate 
was then placed on a vacuum under moderate negative pressure for approximately 5 
minutes or until the membrane was dry.  Subsequently, the PCR product trapped on 
the membrane was resuspended in 25ul of purified PCR-grade water by means of gentle 
agitation of the light-shielded ultrafiltration plate on a unheated thermo-shaker for 
approximately 30 minutes. 
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4.10.2 Sequencing Reaction Purif ication by Passage Through Sephadex 
Columns 
Using this method, a hydrated solution of Sephadex was prepared by mixing 2.9g of 
Sephadex G-50 powder (Sigma-Aldrich) with 40ml of autoclaved water and allowing the 
solution to stand for 30 minutes.  The solution is then briefly vortexed, before 350ul of 
the mixture is transferred to each well of a Corning FiltrEx 96-well plate.  The plate and 
its contents are then centrifuged for 3 minutes at 700xg.  A fresh, 96-well collection 
plate is then placed under the Corning FiltrEx plate and the entire volume of the 
sequencing reaction from each well pipetted onto the Sephadex column in the 
corresponding well of the Corning FiltrEx plate.  The plate containing the Sephadex 
columns along with the underlying collection plate is then centrifuged for 5 minutes at 
910xg.  The wells of the collection plate will now contain the purified sequencing 
reactions 
 
4.11 Electrophoret ic  Separation of  the Sequencing Reaction 
Products  and Sequence Analys is  
Electrophoretic separation of the sequencing reaction products and reconstruction of 
the underlying sequence was performed using the ABI Prism 3700 DNA analyser 
(Applied Biosystems).  The resultant electropherograms were visualised using 
Sequencher software (Gene Codes Corporation).  This software has some ability to 
automatically detect variations with respect to a reference sequence, but this function is 
imperfect and thus all sequences were, in addition, visually inspected for additional 
undetected variation. 
 
4.12 Genotyping by DNA Microarray 
Data from genome-wide genotyping of SNPs by DNA microarray was used for the 
purpose of linkage analysis, homozygosity mapping, copy number variant (CNV) 
detection and association analysis.  Human CytoSNP beadchips (Illumina), which 
genotype approximately 220,000 markers, were used to generate data for linkage 
analysis.  For homozygosity mapping and CNV detection, where denser genotyping is 
desirable, the Human OmniExpress beadchip was used instead, which provides 
genotypes for approximately 715,000 markers spread across the genome.  Finally, for 
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the association analysis, samples were genotyped using the custom-designed 
ImmunoChip.  Details of the design and intended purpose of this chip can be found in 
the review by Cortes et al. (2011) 283 or the initial paper announcing its conception by 
Lorenz et al. (2003) 284. 
 
Samples were processed, hybridised and scanned in accordance with manufacturers 
instructions at UCL Genomics, generating raw intensity files for further downstream 
use.  Clustering, normalisation and calling of the resultant data was performed in-house 
using Genome Studio 2010 (Illumina) 
 
4.13 Autozygosi ty  Mapping 
In order to perform autozygosity mapping, the raw intensity files for all affected and 
unaffected siblings available were first loaded in Genome Studio, along with the 
relevant manifest and cluster files for the Illumina Human OmniExpress DNA array 
chip.  The observed genotypes for all markers in all samples were then called.  The 
quality of the data was first verified using the appropriate metrics to ensure there had 
not been any chip sample failures.  Provided this was not the case, the genotype calls 
were exported from Genome studio in the form of PED and MAP files for use with 
PLINK.  Subsequently, PLINK was invoked and SNPs that had not genotyped in all 
samples were sought and removed by setting level for exclusion of a marker based on 
missingness to 0.1 using the ---geno command line option.  Using the newly generated 
clean files, PLINK was instructed to search for runs of homozygosity greater than 
0.5Mb in size in all samples by using the following command. 
 
> plink –file filename.ped filename.map –homozyg –homozyg-kb 500 
 
All other options were left in their default settings.  In order to detect runs of 
homozygosity, PLINK employs a windowing algorithm.  That is, PLINK effectively takes 
a window of x SNPs and slides this across the genome.  At each window position, the 
zygosity of the windowed SNPs is assessed and, after allowing for a small number of 
heterozygous calls, which could represent genotyping errors, a call is made as to whether 
the window is ‘homozygous’ or not.  Then, for each SNP the proportion of homozygous 
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windows that overlap its position is calculated.  This metric is used to call the segments 
based on a threshold for the average. 
 
The resultant files were transferred to Excel and the results sorted first by chromosome, 
then by segment start position and finally by sample ID.  The sorted results were then 
manually inspected for runs of homozygosity that were shared by all affected siblings 
but not present in any unaffected sibling. 
 
4.14 Linkage Analys is  
In order to perform linkage analysis, the raw intensity files for all affected and 
unaffected individuals available within the kindred were first loaded in Genome 
Studio, along with the relevant manifest and cluster files for the Illumina CytoSNP 
DNA array chip.  The observed genotypes for all markers in all samples were then 
called.  The quality of the data was first verified using the appropriate metrics to ensure 
there had not been any chip sample failures.  Provided this was not the case, the 
genotype calls were exported from Genome studio in the form of PED and MAP files 
for use with PLINK.  Subsequently, PLINK was invoked and SNPs that had not 
genotyped in most (>90%) samples or were too rare to be informative (minor allele 
frequency < 0.5%) were sought and removed by setting the level for exclusion of a 
marker based on missingness to 0.1 and that based on minor allele frequency to 0.05, 
using the ---geno and –maf command line options.  Inclusion of too many markers when 
performing linkage analysis can lead to inflation of LOD scores due to linkage 
disequilibrium.  Therefore, the density of the genotyping data was reduced by invoking 
PLINK with the command line option –thin, which eliminates a proportion of SNPs in 
a uniform but random fashion across the genome.  The proportion was set so as to 
leave approximately 5000 random markers spread across the genome. 
 
The cleaned and thinned genotypying files created by PLINK were then converted to 
the prerequisite format required by MERLIN, the freeware program used to perform 
the actual linkage analysis, as per the instructions on its website.  A .model file was 
created specifying the presumed disease model including mode of inheritance, 
estimated disease allele frequency and penetrance.  For the rare Mendelian disorders 
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dealt with in this work, the estimated disease allele frequency was set to a low value and 
penetrance was set, initially at least, to 0.8.  The files were first checked for formatting 
errors, pedigree consistency and genotyping problems by invoking PEDSTATS.  
Providing this did not reveal any significant problems, the files were fed to MERLIN in 
order to perform the linkage analysis.  This linkage analysis was repeated a further two 
times at least with newly generated random marker sets to ensure the results were 
consistent. 
 
In order to generate the genome-wide linkage plots used in this work, LOD scores were 
generated against chromosomal position rather than marker name and transferred 
directly to Excel for conversion in a line graph. 
 
4.15 Whole Exome Sequencing 
Most exome sequencing data used in this work was generated in house.  Library 
preparation and target enrichment was performed using the Illumina TruSeq 
Enrichment kit, as per the manufacturer’s instructions.  Details of this kit’s target 
design and its performance can be found in table 2.  After library preparation, 
sequencing of the samples was accomplished using the Illumina HiSeq 2000. 
 
Data for a few samples – those sequenced very early in the project prior to the 
acquisition of our own NGS platform – was generated offsite at either AROS Applied 
Biotechnology or the Beijing Genomics Institute.   
 
4.16 In -House Bioinformatics  Pipel ine For Exome Sequencing Data 
In order to move from raw sequencing data to variant calls, we employed a custom built 
in-house bioinformatics pipeline.  This pipeline was largely designed and maintained by 
Dr Vincent Plagnol and Dr Alan Pittman. A brief description of the rational behind 
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4.16.1 Removal of  Low Quality Reads 
The raw sequence data generated by the Illumina HiSeq is stored in the form of a 
FASTQ file.  This text-based file combines information on the observed sequences with 
the associated per base quality score, known as the Phred quality score or Q score.  The 
Q score indicates the probability that given base is called incorrectly by the sequencer.  
In order to generate the Q scoring scheme, parameters relevant to the particular 
sequencing chemistry must be analysed in a large empirical data set of known accuracy.  
The resultant quality score look-up tables are used in the calculation of quality scores 
for de novo sequencing data on board the NGS platform itself. 
 
For a mathematical point of view, Q scores are defined as a property that is 
logarithmically related to the base calling error probabilities (P), by means of the 
equation:  Q = 10 log10 P.  For example, if a Q score of 20 is assigned to a base, this is 
equivalent to incorrect base call probability of 1 in 100 or, stated differently, to a call 
accuracy for that base is 99% (see table 11).  In other words, roughly 1 base in every 
100bp of sequence read with a Q score of 20 will be called incorrectly.  If, on the other 
hand, a Q score of 30 is assigned to a base, this is equivalent to the probability of an 
incorrect base call 1 in 1000 times or, stated differently as previously, the call accuracy 
for that base is 99.9%.  In general, a Q score of 30 is considered a benchmark of quality 
in NGS.  Using Illumina chemistry on the HiSeq 2000, approximately 96% of base 
reads are expected to have a Q score of >30, with most falling within the range of 35 to 
45.  
 
Table 11 - Phred quality score translated into probability of incorrect base call and base call 
accuracy. 
Phred Quality Score Probability of 
Incorrect Base Call 
Base Call Accuracy 
10 1 in 10 90% 
20 1 in 100 99% 
30 1 in 1,000 99.9% 
40 1 in 10,000 99.99% 
50 1 in 100,000 99.999% 
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Initial quality control of the raw sequencing data is performed by a programme called 
FastQC.  FastQC provides a user-friendly graphical interface that allows, among other 
things, to check for over-represented sequences, deviation from the expected GC 
content, distribution of nucleotides per read position, thus allowing a fast identification 
of problems that can occur during sample preparation and sequencing. 
 
4.16.2 Alignment of Reads to the Reference Genome 
One of the most important and difficult steps in the processing of raw exome 
sequencing data is the alignment of the reads to the reference genome.  A single run on 
the HiSeq 2000 can produce up to 6 billion paired-end reads of approximately 100bp 
in length, equivalent to some 600Gb of raw data when stored in FASTQ format.  
Despite the rapid advancement in computer hardware, the vast size of the human 
genome means that mapping all of these sequences to their correct region of origin 
remains a computationally intensive process and a trade-off between speed and accuracy 
is to some extent unavoidable.  Although different alignment algorithms utilise 
different strategies to map reads with the highest level of accuracy in the quickest time 
possible, the core steps in involved in alignment of any particular sequence are broadly 
similar.  Initially, the algorithm rapidly narrows down the genomic search space by 
selecting out a small set of regions within the reference genome from where the 
observed sequence could potentially originate.  This subset of ‘loose matches’ is then 
fed into more accurate, but considerably slower sub-algorithms that decide which of the 
loose matches is the most likely region of origin.  The process is accelerated by the 
construction of an index of the reference genome.  From a computational point of 
view, aligning reads to a genome can be viewed as form of approximate string matching.  
The goal of this process is to find a pattern (the sequence read) that matches a target in 
a large text or corpus (the genome), allowing for some base changes and indels.  Whilst 
it is possible to scan the whole text for the pattern, this is inefficient; it might be 
considered somewhat akin to searching for a particular name in a phone book in which 
the names appeared in completely random order.  Indexing is a technique to pre-
process the search text (in our case, the reference genome) to make queries faster (in 
much the same way as listing the names in a phone book in alphabetical order makes 
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queries faster).  In addition, however, indexing that can also compress the size of the 
text. 
 
Within our own laboratory, Novoalign was the software tool utilised in alignment of 
the raw sequencing data.  Novoalign first constructs an index of the reference genome 
to speed up the mapping process, as described above.  Individual sequence reads are 
then mapped to the indexed reference genome by means of a full Needleman-Wunsch 
algorithm incorporating affine gap penalties and taking account of the Q scores for 
each base included in the FASTQ file.  This algorithm allows for mismatches of up to 8 
bases and small gaps of up to 7bp per single-ended read during mapping.  With paired-
end reads, such those generated by the Hiseq 2000, Novoalign first aligns the all those 
hits with the highest level of mappability to the reference genome (see section … for a 
definition of mappability and a discussion of its relevance to analysis of NGS 
sequencing data).  Once all the most easily mapped reads have been aligned, it scans 
through the remaining unmapped reads in an attempt to pair the two ends and thus 
assign the remaining reads, allowing for larger mismatches as it does so.  Importantly, 
for each read that is mapped to the reference, Novoalign generates a mapping quality 
score.  This score operates in a similar manner to the Phred quality score for single base 
read and reflects the probability of the correct alignment, based on the number of 
mismatches and gaps required to make the alignment as well as the uniqueness of the 
observed sequence with respect to the reference genome.  This metric is used in 
downstream analysis to aid decisions on which reads ought to be discarded due to low 
mappability. 
 
Once alignment of the raw sequencing data has been completed to the best of the 
algoritm’s ability, the resultant data is stored in the form of a Sequence 
Alignment/Map (SAM) file.  These text-based files stores information about each 
aligned read, in particular, the position on the reference contig, the orientation of the 
read, quality of the alignment and potential further alignment possibilities of the read.  
However, SAM files are large and in order to increase speed when manipulating these 
large files, they are often converted to BAM files by re-encoding the information in 
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binary format.  In addition, indexing of the BAM file to produce an accompanying BAI 
file can further speed up operations. 
 
4.16.3 Removal of  PCR Duplicates and Non-Unique Reads 
Library preparation involves a PCR step that is used for amplifying the library and 
adding adapters required for sequencing.  This step can introduce artifacts – reads or 
read pairs starting at exactly the same position and having the same insert length, 
respectively – which might otherwise overinflate the read depth and, by extension, 
perceived accuracy of the underlying base calls.  It is necessary therefore to identify such 
sequences and remove them.  This task is accomplished by Picard, a set of Java-based 
command-line utilities that manipulate SAM files.  Picard identifies read pairs with 
identical coordinates and removes all but the one with the highest sequence quality 
score.  Subsequently, all sequences with a non-unique alignment – that is, reads with 
more than one optimal alignment to the reference genome – are discarded since, in 
these cases, it cannot be determined from which site the read truly originates. 
 
4.16.4 Quality Score Recalibration 
Previous studies have demonstrated that the Phred quality scores issued by the 
sequencing platforms can sometimes deviate from the true error rate 285.  Accurate Q 
scores are, however, essential for variant calling algorithms, which utilise the scores 
assigned to each base call over lying a potential variant to help determine the likelihood 
that the variant is real and thus whether it should be called or not.  Q score 
recalibration is performed by GATK.  Bases are first grouped with respect to several 
characteristics (e.g., raw quality, dinucleotide content).  Subsequently, for each such 
category, the empirical mismatch rate is computed and used to correct the raw Q score.  
 
4.16.5 Variant Call ing  
The procedures involved in the calling of single nucleotide variants (SNVs) and indels 
are different and require the use of different software tools.  They are thus explained 
separately in the paragraphs below. 
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In our own pipeline, SNVs were called using the combination of SAMTools and 
BCFTools.  Early variant or SNV calling approaches relied entirely on counting the 
abundance of high-quality nucleotides at a singe site.  Modern algorithms, however, are 
capable of integrating several additional sources of information within a probabilistic 
framework.  One important source of information such as this is the prior probability 
of encountering a SNV at any given position.  These prior probabilities can be derived 
from databases of normal human sequence variation or by carrying out SNV calling in 
multiple individuals at the same time.  Moreover, by borrowing from the techniques 
used for imputation in genome-wide association studies, some algorithms are even able 
to take into account haplotype blocks when deriving the prior probabilities for nearby 
SNVs.  Information such as this facilitates SNV calls in medium to low coverage 
regions. 
 
The BAM file is first fed to SAMTools, which collects summary metrics in the input 
BAM (such as the number of reads showing a variant, the base Q scores, the alignment 
Q scores and PCR artefact information) and computes the overall likelihood of the 
data being correct given each possible genotype.  This information is then stored in a 
Variant Call Format (VCF) file.  Just as in the case of SAM files, the VCF file is then 
usually converted to binary format (BCF) for faster downstream manipulation.  The 
BCF file is then passed to BCFTools, which does the actual SNV calling based on these 
likelihoods and, once again, assigns the SNV call an overall Phred-like quality score. 
 
In order to call small indels, a software tool called Dindel was employed.  Dindel relies 
on the realignment of sequencing reads to candidate haplotypes in order to try and 
accurately detect the presence and extent of a potential indel.  According to its user 
instructions, its workflow consists of four basic steps.  Firstly, Dindel extracts all 
candidate indels from the read alignments stored in the BAM file and simultaneously 
calculates the library insert size distributions for paired-end reads.  Subsequently, the 
candidate indels are grouped into windows of approximately 120bp.  Then, for every 
window, Dindel generates candidate haplotypes from the candidate indels and SNPs it 
has detected in the BAM file and realigns the reads to these candidate haplotype.  In 
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the final step, Dindel calls the indels based on the realigned reads and stores these calls 
along with an associated quality score in a modified form of the VCF file (VCF4). 
 
It should be noted that, despite an enrichment step in library preparation designed to 
amplify the exome only, exome sequencing does in fact generate low level reads from 
non-exonic areas of the genome.  SNPs and indels from these regions are processed and 
called as described above, though low coverage makes them significantly more error 
prone and they are therefore stored in a separate file.  This ‘genomic’ file was consulted 
on occasion when exome sequencing failed to reveal any clear causal variant in certain 
kindreds.  However, due to the lack of any means of predicting the functional effect of 
the variants contained therein and the intrinsically high error rates due to low coverage 
depth, it never proved helpful in elucidating the genetic cause of disease in any 
kindred.  For the purposes of this research, therefore, it might suffice to say that, 
therefore, that off target reads were simply discarded.  
 
4.16.6 Variant Annotation  
Accurate annotation of SNVs and indels called from NGS data is critical as it forms the 
basis of the character profile for each variant against which the researcher filters the 
data to try and isolate the causal variant.  Its central role in gene-discovery by exome 
sequencing is explained in section 1.5 and an overview of some of the must commonly 
used annotations used in the filtering process is provided in sections 1.5.1 – 1.5.4 and 
2.7 – 2.7.7.  The software tool used to generate automatic annotations for the variant 
calls in the pipeline used in our laborartory was Annovar.  The level of annotation 
provided by Annovar can be customised by downloading the appropriate databases in a 
modular fashion.  In our laboratory, Annovar was asked to associate, where possible, 
the following annotations to each variant:  1) the name of the gene in which the variant 
resides; 2) the ensemble transcript number and codes for the amino acid and protein 
substitution; 3) its effect of protein coding (synonymous, nonsynonymous, frameshift 
indel, nonframeshift indel, stopgain or splicing); 4) zygosity; 5) read depth; 6) variant 
call quality score; 7) level of segmental duplication of the gene; 8) minor allele 
frequency of the variant in various builds of dbSNP, 1000 Genomes, NHLBI Exome 
Sequencing Project and Complete Genomics 69, if previously recorded therein; 8) 
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conservation scores from GERP++ and PhyloP; and 9) in silico predictions of 
pathogenicity from SIFT, PolyPhen-2, Mutation Taster and LRT. 
 
The resulting annotated variant list is stored in the form of a Comma-Separated Values 
(CSV) file with a separate column for each annotation.  This file can be loaded into 
Excel for easy viewing and filtering by the researcher.   
 
4.17 Targeted,  High -Throughput,  Next Generation Sequencing 
Targeted, high-throughput, next generation sequencing was performed in house using 
the Illumina MiSeq (Illumina, California).  Probes targeting the desired amplicons were 
designed using Illumina’s custom software, Design Studio, and shipped around 1 
month later.  The process of sample preparation takes about 2 days and was completed 
by following the manufacturer’s supplied protocol, without deviation.  The protocol is 
lengthy and is not therefore reproduced here.  A general overview of some of the key 
steps are provided in section 2.8 and the full protocol can be accessed via Illumina’s 
website. 
 
4.18 Association Analys is  
Although general methodologies for the completion of association studies using fresh 
data would best be included in the methods section of any thesis, the association 
analysis presented as part of this work was somewhat unusual at it involved the merging 
of multiple sets of genotyping data that had been generated using different DNA arrays.  
This involved particular challenges that can only really be understood within the 
context of that particular study and so, for this reason, a description of the methods 
used can be found instead in the chapter concerning this work. 
 
4.19 Generation of  Organism-Wide and Brain -Region Speci f ic  
Express ion Data 
For information on organism-wide expression of genes of interest, freely available 
datasets based on EST tags were obtained through UCSC Genome Browser. 
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For expression across various brain regions in humans, in-house datasets, originating 
from the work of Dr Mina Ryten and Dr Daniah Trabzuni, were used.  These datasets 
had been generated using Affymetrix Exon 1.0 ST Arrays and brain and CNS tissue 
originating from 137 control individuals, collected by the Medical Research Council 
(MRC) Sudden Death Brain and Tissue Bank, Edinburgh, UK 286, and the Sun Health 
Research Institute (SHRI) an affiliate of Sun Health Corporation, USA 287.  A full 
description of the samples used and the methods of RNA isolation and processing can 
be found in Trabzuni et al., 2011 288.   As described therein, all arrays were pre-
processed using Robust Multi-array Average (RMA) quantile normalisation with GC 
background correction and log2 transformation in Partek’s Genomics Suite v6.6 
(Partek Incorporated, USA) 289, 290.  Regional differences in gene-level expression were 
investigated using Partek's mixed-model ANOVA with gender and batch effects (date of 
hybridization and brain bank) included as co-factors. 
 
4.20 Cel lular Biological  Experiments 
Cellular biological experiments were performed as part of the necessary supporting 
evidence for the publication of two new disease genes as detailed in chapters 5 and 7.  
Although I participated as fully as my limited skills in the techniques of cellular biology 
allowed, the experiments were ultimately designed and interpreted by more expert 
minds than my own.  Moreover, the particular methods used to carry them out were 
peculiar to each gene.  For both these reasons, I have provided the specific methods 
only within the chapters where they are relevant.  I am indebted to colleagues in 
cellular biology – Prof Andrey Abramov, Dr Kira Holmström, Dr Plamena Angelova 
and Dr Fernando Bartolomé-Robledo – for their time, guidance and patience that was 
undoubtedly essential to the successful publication of these new dystonia genes.  
 









Exome Sequencing in Familial 
Tremulous Craniocervical Dystonia
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Cervical dystonia is the most common form of focal dystonia seen by neurologists 291. 
Previous epidemiological studies conducted in Europe and Northern England have 
suggested a prevalence of 5.7 - 6.1 per 100,000 persons 292, 293.  Although lifespan is not 
generally reduced, individuals affected by the condition can suffer considerable physical 
and psychosocial distress, which has been shown to have a significant impact on their 
quality of life 115.  Treatment remains symptomatic, with regular injections of 
botulinum toxin constituting the mainstay of current medical therapy. 
 
Genetic factors are believed to play an important role in the pathogenesis of cervical 
dystonia as around 10-20% of patients have one or more affected family members 294, 
295. Despite this fact, a later age at onset and characteristically reduced penetrance has 
made it difficult to identify kindreds of sufficient size to permit traditional linkage 
based approaches to gene identification.  At the time this work was completed, only two 
genes had been conclusively shown to cause autosomal dominant primary dystonia 
(TOR1A [MIM: 605204] and THAP1 [MIM: 609520]) 136, 157.  Even taken together, 
however, mutations in these genes could explain only a small fraction of familial 
dystonia, suggesting that there remained a number of genetic factors yet to be 
identified. 
 
In the chapter, I describe my work using whole-exome sequencing in combination with 
linkage analysis to identify the genetic cause of dystonia in a moderately-sized kindred 
from the United Kingdom.  This kindred appeared to exhibited autosomal dominant 
inheritance of primary cranio-cervical dystonia 296 and mutations in the genes TOR1A 
and THAP1 had previously been excluded.  Once, a candidate causal variant had been 
identified, sanger sequencing of the exon containing the mutation was undertaken in a 
large number of dystonia samples followed by next-generation targeted sequencing of 
the whole gene to provide a comprehensive genetic screening of phenotypically similar 
cases. 
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5.2 Subjects  and Methods 
5.2.1 Clinical Detai ls  of  the Index Family 
All samples were collected with the written consent of participants and formal ethical 
approval by the relevant research ethics committee.  All living individuals from the 
index family were re-examined and videoed as part of this study and the two now 
deceased individuals had been examined and videoed as part of a previous study 296.  
The family pedigree is shown in figure 9. 
 
All family members shown are over 25 years of age. All definitely affected family 
members exhibited tremulous cervical dystonia with a variable degree of associated 
upper limb dystonic tremor on examination.  In addition, family member II-7 and III-7 
had laryngeal involvement and family member II-4 had both laryngeal involvement and 
blephrospasm.  Age at onset ranged from 19 - 39, with most having onset in the last few 
years of their 4th decade.  One family member, II-1, had additional neurological signs 
on examination:  he exhibited mild truncal ataxia, dysarthria and mild cognitive 
impairment, all dating from an episode of Wernicke-Korsakoff’s encephalopathy 6 years 
previously.  His family confirmed that he had consumed alcohol excessively for much of 
his life prior to that episode. There was no evidence of dystonia or any other 
neurological signs in any definitely unaffected individual.  The affectation status of one 
individual, represented by a circle with a question mark in the centre (III-2 on the 
family pedigree), was uncertain.  She described neck pain with a tight, pulling sensation 
on the left-hand side.  Examination revealed a subtle left sided torticollis, but no 
tremor.  As onset for all but one member of the family affected by the disease had been 
in the late 30s and she was currently 46, it was felt possible that these symptoms and 
examination findings may represent an early stage or a forme fruste of the condition and 
so for the purpose of linkage analysis her affectation status was set to unknown. 
 
Genomic DNA extracted from whole blood was available for 15 individuals for analysis.  
DNA from individual III-8 and III-10 was only obtained at a late stage and was not 
available for linkage, but was used for segregation analysis. 
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Figure 9 - Pedigree showing structure of the index family.  Each generation in indicated on the left by means of a Roman numeral and each individual in that 
generation in indicated behind their genetic symbol in Arabic numerals.  Individuals marked with an asterisk were clinically examined, videoed and reviewed by 
a movement disorders specialist.	   	  Family members that were felt to be definitely affected are represented by filled symbols, whilst family members that were felt to 
be definitely unaffected are represented by empty symbols.  The affectation status of family member III-2, represented by a circle with a question mark in the 
centre, was uncertain.  DNA was available as marked. 	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5.2.2 Linkage Analysis  
Linkage anlaysis was performed in the standard manner as described in the section 
4.14.  For the parametric and non-parametric analysis, logarithm of odds (LOD) scores 
were calculated under the model of an autosomal dominant disease with a penetrance 
of 70, 80, 90 and 100%.  Maximum score were produced with a penetrance of 80%  
 
5.2.3 Exome Sequencing 
3ug of genomic DNA from the two most distantly-related, definitely affected family 
members (individuals II-1 and III-7) was used to perform exome sequencing as per 
section 4.15 
 
5.2.4 Targeted NGS Sequencing of the ANO3 Gene 
Targeted high-throughput sequencing of the ANO3 gene in 188 dystonia proband 
samples was performed as described in section 4.17 and 2.8.  Custom oligonucleotides 
were designed to target all 27 exons of ANO3 (including both untranslated regions).  At 
least 25 intronic bases were included either side of each exon. 
 
5.2.6 Expression Profi l ing of the ANO3 Gene 
Expression profiling data was collated for ANO3 as described in section 4.19 
 
5.2.7 Ca2+ Imaging in Patient Fibroblasts  
Fibroblasts were obtained from skin biopsy, after signed consent, from a patient 
carrying the (c.1470G>C; p.Trp490Cys) mutation in ANO3.  Age and passage-matched 
controls were selected from in-house cell lines.  The fibroblasts were cultured in 
Dulbecco’s Modified Eagle Medium Glutamax supplemented with 10% (v/v) heat–
inactivated fetal bovine serum and 1% Penicillin Strepomycin.  They were maintained 
at 37°C in a humidified atmosphere of 5% CO2 and 95% air. 
 
Cytoplasmic Ca2+ concentration ([Ca2+]c) was measured using fura-2 
297, following 
stimulation of cells with a variety of agonists to raise [Ca2+]c. Cells were loaded for 30 
min at room temperature with 5µM fura-2 AM and 0.005% Pluronic in a HEPES-
buffered salt solution (HBSS) composed (mM): 156 NaCl, 3 KCl, 2MgSO4, 1.25 
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KH2PO4, 2 CaCl2, 10 glucose and 10 HEPES, pH adjusted to 7.35 with NaOH. Ca
2+-
free medium contained 0.5mM EGTA. All analysed areas were chosen at random and 
three independent experiments were performed for each condition. The number of 
cells analysed for each set of experiments is indicated in the results section below. 
 
Fluorescence measurements were obtained on an epifluorescence inverted microscope 
equipped with a 20x fluorite objective. [Ca2+]c was monitored in single cells using 
excitation light provided by a Xenon arc lamp, the beam passing monochromator at 
340 and 380 nm (Cairn Research, Kent, UK).  Emitted fluorescence light was reflected 
through a 515 nm long-pass filter to a cooled CCD camera (Retiga, QImaging, Canada) 
and digitised to 12 bit resolution. All imaging data were collected and analysed using 
software from Andor (Belfast, UK). The fura-2 data have not been calibrated in terms 
of [Ca2+]c because of the uncertainty arising from the use of different calibration 
techniques.  
 
ATP (100µM) was used to stimulate [Ca2+]c  signals in fibroblasts via purinoceptors and 
release calcium from the endoplasmic reticulum via IP3 receptors.  50mM KCl was 
used induce depolarisation of the plasma membrane and open voltage gated calcium 
channels.  Thapsigargin (1µM) in Ca2+-free medium (plus 0.5 mM EGTA) was used to 
induce release of calcium from reticulum to cytosol and thus to estimate the size of the 
reticular Ca2+-pool. 	  
5.3 Results  
5.3.1 Linkage Analysis  
Setting the penetrance in the parametric model to 80% produced the highest linkage 
score.  With the penetrance set at this value, 5 linkage peaks were observed with an 
identical maximum LOD score of 2.01 on chromosome 4, 5, 6, 7 and 11, as shown in 
the plot overleaf (figure 10). 
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Figure 10 – Genome-wide linkage scan showing five peaks with an identical LOD score of 2.01 on chromosomes 4, 5, 6, 7 and 11.  The chromosome is 
indicated across the across the top of the plot; chromosomal distance in centiMorgans is indicated on the x-axis; and the LOD score is indicated on the y-axis.	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Details of the size and gene content was for each of these five peaks with the highest 
LOD score obtained from Ensemble BioMart using the hg19 build of the human 
genome and are summarised in table 12 below. 
 
Table 12 - Summary of position, size and genetic content of 5 regions with highest LOD score 
of 2.01.  The region size was calculated from the position of the first marker with a LOD score 
of greater than -2 to the position of the last marker to have a LOD score of greater than -2 for 
each peak in turn.  Chr. = chromosome; Mb = megabases 












4 41,749,265 101,131,209 59.4 514 238 30 
5 110,825,128 118,963,199 8.1 66 45 3 
6 9,275,355 14,322,665 5.0 42 28 6 
7 4,883,121 10,991,660 6.1 69 37 9 
11 24,192,528 42,730,635 18.5 110 76 14 
 
 
5.3.2 Exome Sequencing 
For the two exomes sequenced, 57,506,202 and 30,644,686 unique reads per exome 
were generated, translating to a total variant count of 20,935 and 17,024, respectively.  
Using the CCDS hg19 definition of the exome, coverage was 90% and 83% at least 2 
reads and the mean read depth across the exome was 46 and 45 reads, respectively. 
 
5.3.3 Init ial  Variant Fi l tration and Analysis  
Variant analysis for exome sequencing data was based on the assumption that the 
mutation causing this uncommon, heritable form of the disease in this family would 
not be present in the general population at an appreciable frequency.  In order to 
maximize the chances of isolating the causal variant and minimize the chances of error 
in assignment, two different strategies were employed to select candidate causal 
variants.  The first strategy involved selecting only those variants that were present in 
the exome data of both affected family members for analysis.  Homozygous variants, 
synonymous variants and variants recorded in dbSNP135 were initially removed.  We 
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then filtered out any variant present at a global minor allele frequency of ≥1% in a 
range of publically available databases of sequence variation (1000 Genomes, Complete 
Genomic 69 Database and NHLBI Exome Sequencing Project database) as well as those 
found in 2 or more our own in-house exomes from individuals with unrelated diseases 
(n=200).  Finally, variants within the regions under the linkage peaks with the highest 
LOD scores (on chromosomes 4, 5, 6, 7 and 11; see table 12 for definition of regions) 
were validated by Sanger sequencing in the forward and reverse directions using BigDye 
Terminator v3.1 chemistry and the Applied Biosystems 3130XL Genetic Analyser (Life 
Technologies, Carlsbad, CA) and checked for segregation.  This strategy revealed three 
potentially pathogenic variants in the genes TBC1D7, PPM1K, and ANO3. 
 
In order to compensate for any unequal coverage between the two exomes, a second 
strategy was employed in which all variants from the exome with the best coverage were 
first filtered as above to produce a list of every non-synonymous SNV or frameshift and 
non-frameshift indel that is not recorded in dbSNP135 or not recorded in public 
databases of sequence variation at a global minor allele frequency ≥ 1%.  We then 
discarded any variants that were not in areas covered by the linkage peaks with the 
highest LOD score (see table 12).  This strategy revealed variants in three further genes 
FAM13A, TMEM232, LMPK1. For each of these variants in turn, we then visually 
inspected the data for the other exome to ensure that it had been covered.  The region 
containing the variant in FAM13A had been covered at >50x read depth and was not 
present in the other exome and so was discarded.  However, the regions containing the 
other two variants had not been adequately covered in the other exome.  The exon of 
the gene containing the variant was there Sanger sequenced and, if the variant was 
found to present, it was checked for segregation in the rest of the family.   
 
The details of all the candidate variants revealed by both strategies, as well as the the 
results of the segregation analyses, are summarised in table 13 and discussed in the 
following sections in order of chromosomal location. 
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Table 13 - Summary of all previously unreported, potentially pathogenic variants within the regions of linkage detected within the exome with the best coverage.  
Only one variant in the gene ANO3 is seen to segregate with disease in the index family.  Chr = chromosome. 
Chr Gene Symbol 
(Transcript) 
Variant Present in 
other exome 





Yes Yes No Definitely unaffected individuals III-1 (age 42) and III-8 (age 


















Yes Yes No Definitely unaffected individual II-5 (age 61) and III-8 (age 










Yes Yes Yes Present in all definitely affected; not present in any 
definitely unaffected 
.
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5.3.4 Segregation Analysis  of  Candidate Variants in Index Family 
The first candidate variant, identified by the first strategy, affected the gene PPMK1 
(Protein Phosphatase, Mg2+/Mn2+ Dependent, 1K; MIM: 611065) on chromosome 4.  
The encoded protein, essential for cell survival and development, is targeted to the 
mitochondria where it plays a key role in regulation of the mitochondrial permeability 
transition pore.  Biallelic mutations in this gene are a cause of the childhood-onset 
metabolic disorder, maple syrup urine disease 298.  The heterozygous variant observed 
(c.77G>A) affected exon 2 of the gene, resulting in an arginine to histidine substitution 
at amino acid position 26.  It is not predicted to be damaging by MutationTaster, SIFT 
or PolyPhen2 and is found at a low frequency African American samples (2/4404) in 
the NHLBI exome data.  Most importantly, it did not segregate with disease in the 
index family, in that definitely unaffected individuals III-1, who is 42 years of age, and 
III-8, who is 32 years of age, both carry the variant. 
 
The second candidate variant affected the gene FAM13A (Family With Sequence 
Similarity 13, Member A; MIM: 613299), also on chromosome 4.  Little is known 
about the function of this gene, though it is believed to have GTPase activator activity 
299.  Polymorphisms in this gene have been associated with chronic obstructive airways 
disease and lung cancer 299, 300.  The heterozygous variant observed (c.1146_1149del) 
affected exon 2 of the gene, resulting in a frameshift at 383.  It was identified by the 
second strategy in the best covered exome, but was not present despite high read depth 
in the second exome (>50x; confirmed by Sanger Sequencing) and so was not 
considered further. 
 
The third variant, affecting the gene TMEM232 (Transmembrane Protein 232; OMIM: 
no entry) on chromosome 5, was also identified by the second strategy using the best 
covered exome only.  Inspection of the exome sequencing data for the second exome 
revealed that he region of the gene harbouring the variant had not been covered.  
Subsequent Sanger sequencing demonstrated the variant was indeed present in this 
exome too.  Nothing is known about the function of the protein.  The variant detected 
(c.1111-1112del) causes a frameshift in exon 10 of the protein at amino acid 371, 
predicted to lead to nonsense-mediated decay.  The affected amino acid is lies towards 
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the end of the second of two predicted transmembrane helices of 21 amino acids in 
length, according to Uniprot.  The variant did not segregate with disease in the index 
family in that definitely unaffected individual II-10 (age 54) carries the variant. 
 
The fourth candidate variant was a heterozygous frame-shift deletion in exon 2 (c.166-
167del; p.Trp56fs) of the gene TBC1D7 (TBC1 Domain Family, Member 7; MIM: 
612655) on chromosome 6.  The protein product of the gene appears to interact with 
the tuberous sclerosis TSC1-TSC2 complex to regulate of cellular growth and 
differentiation, probably through positive regulation of the mTOR-signaling pathway 
301.  Homozygous truncating mutations in this gene have been shown to cause 
macrocephaly and intellectual disability 302, 303.  No individual affected by this disorder 
or, more importantly, any of their heterozygous parents have been reported to 
demonstrate  dystonia, making the heterozygous frameshift mutation detected here an 
unlikely cause of cervical dystonia in our family.  Indeed, it failed to fully segregate in 
that individual II-5, who is unaffected at age 61, and individual III-8, who is unaffected 
at age 32, exhibit the deletion. 
 
The fifth candidate variant, a missense mutation (c.1827G>C; p.Met609Ile) in the gene 
LIMK1 (LIM domain kinase 1; MIM: 601329), located on chromosome 7, was also 
identified by the second strategy using the best covered exome only.  However, 
subsequent Sanger sequencing revealed that this change was a private mutation, which 
was not found in any other member of the index family, and so the variant was 
excluded from further consideration. 
 
The final candidate variant, a missense mutation in exon 15 (c.1480A>T; p.Arg494Trp) 
of the gene ANO3 (Anoctamin 3; MIM: 610110) on chromosome 11, segregated 
perfectly with the disease status in definitely affected and unaffected individuals (see 
figure 11).  In addition, the individual of uncertain affectation status was also seen to 
carry the variant.  The mutation occurred at a base that was highly conserved between 
species (see figure 12), resulting in a change from arginine to tryptophan at position 
494 of the protein, and was predicted to be damaging by MutationTaster, SIFT, and 
PolyPhen2. 
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Figure 11 – Pedigree showing structure of the index family with sequencing findings for the ANO3 c.1480A>T (p.Arg494Trp) mutation indicated above and to 
the left of each symbol:  wt = homozygous wildtype alleles; M = heterozygous mutation carrier.  Definitely affected family members are represented by filled 
symbols and definitely unaffected family members by empty symbols.  The affectation status of family member III-2, represented by a circle with a question mark 
in the centre, was uncertain.  DNA was available as marked. Individuals marked with an asterisk were clinically examined 
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Figure 12 - Diagram showing complete conservation of protein sequence and almost complete 
conservation of amino acid sequence across species in the region of exon 15 of ANO3 where 
the disease-segregating mutation (c.1480A>T; p.Arg494Trp) was found in the index family 
(affected base shown in bold and codon in red).  Below, aligned electropherograms showing 
normal and mutated sequences, with the mutation indicated by means of a red arrow. 
 
5.3.5 Sanger Sequencing of Exon 15 of ANO3 in a Cohort of  Phenotypical ly 
Similar Dystonia Cases 
Based on the data so far, I took our best candidate variant in exon 15 of ANO3 and 
Sanger sequenced the exon in a selection of phenotypically similar cases.  As an 
additional check, I also sequenced the exon containing the variant of the gene 
TMEM232, which had failed to segregate solely because of the presence of the variant 
in a single unaffected individual  in the same selection of cases.  This was done to 
account for the possibility of a reduced penetrance, which appears to be common in 
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dystonia.  DNA samples for sequencing were obtained from an in-house library of 
previously donated samples from individuals who had given research consent.  Samples 
were selected on the basis that the accompanying clinical description suggested cervical 
dystonia and/or dystonic upper limb tremor.  Both familial (n=137) and sporadic 
(n=247) cases were selected for inclusion.  Samples that were known to have previously 
tested positive for TOR1A or THAP1 were excluded.   We also included a small number 
of samples from individuals where the primary clinical impression had been of familial 
essential tremor or myoclonus dystonia (provided they tested negative for mutations in 
the only known connected to this disorder, SGCE [MIM: 604149]) as it was felt these 
clinical phenotypes might easily be confused with upper limb dystonic tremor and jerky 
cervical dystonia, respectively 304.  A total of 384 samples were screened. 
 
Analysis of the sequence traces for these 384 individuals revealed no potentially 
pathogenic variants in exon 10 of TMEM232.  In exon 15 of ANO3, however, we 
found a second heterozygous missense mutation (c.1470G>C; p.Trp490Cys) in the 
same highly conserved DNA sequence in which the mutation in the index family was 
located (see Figure 13).  This second mutation was also predicted to be universally 
damaging by SIFT, PolyPhen2 and MutationTaster.  It was not present in the data from 
NHLBI Sequencing Project (4090 ± 627 samples of European ancestry at a read depth 
of 80 ± 40), the 1000 Genomes Project or our own in-house exome data (n=200).  The 
phenotype of the individual (IV-2 in figure 14) in which the mutation was found was 
almost identical to that for the initial index family; she had tremulous, somewhat jerky 
craniocervical dystonia with laryngeal involvement and a dystonic tremor of the upper 
limbs.   Onset was in the early teens and her brother and father were also affected 
suggesting autosomal dominant inheritance.  DNA samples were obtained from all 
available members of the family, which confirmed that both the father (III-1) and 
brother (IV-1) carried the variant, whilst the father’s unaffected brother (III-3) did not.  
Interestingly, her paternal great-grandmother (I-1), but not her paternal grandmother 
(II-1), was also reported to be have been affected by head tremor.  Although both 
individuals were by that time deceased and could not be examined, this suggests the 
possibility that penetrance of this mutation may not be complete. 
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Figure 13 – Updated figure showing complete conservation of protein sequence and almost 
complete conservation of amino acid sequence across species in the region of exon 15 of ANO3 
in which disease-segregating mutations where found in both the index family (c.1480A>T; 
p.Arg494Trp) and in a second family with autosomal dominant tremulous cervical dystonia 
(c.1470G>C; p.Trp490Cys).  Affected bases are shown in bold and affected codons in red.  
Below, aligned electropherograms showing normal and mutated sequences, with mutations 
indicated by red arrows 






















5.3.6 Targeted NGS Sequencing of the Whole ANO3 Gene 
Based on the finding of a second mutation, we performed targeted high-throughput 
sequencing of the ANO3 gene in 188 samples as per section 4.17   A total of 110 
familial and 78 sporadic samples, selected as described in section 5.3.4, were screened. 
 
Targeted NGS sequencing identified 4 putative pathogenic variants:  3 missense 
variants in exons 2, 21 and 25 and a variant in the 5’ UTR (summarised in table 14 and 
shown on figure 18).  None of these variants were seen in the publically available 
datasets of the NHLBI Exome Sequencing Project, 1000 Genomes or within our own 
in-house exomes.  In-silico predictions of their pathogenicity using MutationTaster, 
SIFT and PolyPhen2 were, however, contradictory (see table 14 for individual results).  
Clinically, 2 of the four individuals had cervical dystonia and 3 of the 4 individuals had 
upper limb tremor.  The individual carrying a mutation in exon 21 of ANO3 
Figure 14 - Structure of the second phenotypically similar family, carrying a second, 
different mutation in the same exon of ANO3 (c.1470G>C; p.Trp490Cys).  DNA was 
available as marked.  Sequencing findings for the mutation are indicated above and to 
the left of each symbol:  wt = homozygous wildtype alleles; M = heterozygous mutation 
carrier.  Individuals marked with an asterisk were clinically examined 
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(c.2053A>G; p.Ser685Gly) had a clear autosomal dominant history of cervical, 
laryngeal and upper limb tremulous dystonia (see figure 15).  She (II-1), her mother (I-2) 
and her son (III-1) had all developed symptoms in their first decade of life.  I was able 
to obtain DNA samples from her mother and son: both individuals were heterozygous 
for the c.2053A>G mutation.  Her father was homozygous for the normal allele.  She 
also reported one unaffected sister and one sister who developed laryngeal dystonia in 
her late twenties.  These individuals currently reside outside of the UK and I was only 
able to obtain DNA from the affected sister, who was, however, heterozygous for the 
c.2053A>G mutation. 
 
Unfortunately, I was unable to obtain DNA for segregation for the variants in the 
UTR, exon 2 or exon 25, due either to social circumstances or because the affected 
relatives were deceased or did not wish to take part in the study.  
 
 
Figure 15 – Structure of the third family with phenotypically similar disease, carrying a third 
disease-segregating mutation in exon 21 of ANO3 (c.2052A>G; p.Ser685Gly).  DNA was 
available as marked.  Sequencing findings for the mutation are indicated above and to the left 
of each symbol:  wt = homozygous wildtype alleles; M = heterozygous mutation carrier.  
Individuals marked with asterisk were clinically examined  
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Table 14 - Additional variants in ANO3 identified by high-throughput targeted sequencing of all 27 exons of the ANO3 gene with in silico predictions of 
pathogenicity and brief clinical description of the cases.  None of these variants were in the publically available datasets of the NHLBI Exome Sequencing 














 Clinical phenotype of case 
Exon 2 c.161C>T p.Thr54Ile Polymorphism Tolerated Benign Diagnosed as 'familial essential tremor'; patient not 
contactable. 
Exon 21 c.2053A>G p.Ser685Gly Disease causing Tolerated Benign Early onset (first decade of life) autosomal dominant 
cervical dystonia, dystonic tremor of the upper limbs and 
laryngeal dystonia. Mother, one sister and son also affected.  
Sister affected later and by laryngeal dystonia only. 
Exon 25 c.2586G>T p.Lys862Asn Disease causing Tolerated Benign Cervical dystonia and oromandibular dystonia; deceased 
father was also affected 
5' UTR c.-190C>T - Disease causing No prediction No 
prediction 
Cervical dystonia and upper limb tremor since late teens; 
diagnosed as myoclonus dystonia but SGCE gene testing 
negative.  No family history on maternal side but father not 
seen since birth. 
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5.3.7 Regional Express ion Profi l ing of  ANO3 in the Human Brain  
We then investigated the expression of the ANO3 gene in brain and CNS tissues using 
publically available and in-house datasets, as described in section 4.19.  Figure 16A 
shows the distribution of ANO3 mRNA expression at the gene level for the following 
CNS regions:  putamen (PUTM, n=121), frontal cortex (FCTX, n=122), temporal 
cortex (TCTX, n=114), hippocampus (HIPP, n=114), cervical spinal cord (SPCO, 13), 
substantia nigra (SNIG, n=96), hypothalamus (HYPO, n=13), medulla (specifically 
inferior olivary nucleus , MEDU, n=109), intralobular white matter (WHMT, n=120), 
thalamus (THAL, n=107) and cerebellar cortex (CRBL, n=129).  This demonstrated 
significant regional differences in ANO3 mRNA expression with an 5.3-fold difference 
(p value <1.0 x 10-45) between the putamen, the highest ANO3 expressing region, and 
frontal cortex, the region with the second highest expression, whilst there is a 70 fold 
difference in expression between the putamen and the cerebellum, the region with the 
lowest expression (p value < 1.0 x 10-45).  These findings are consistent with those of 
Kang et al., 2011 and Johnson et al., 2009 305, 306, which demonstrate increasing 
expression of ANO3 mRNA during the course of human brain development from early 
mid-fetal development (13< Age <16 post-conception weeks) to adolescence (12< Age 
<20 years) particularly within the striatum, but also the neocortex, hippocampus and 
amygdala (figure 16B). 
 
5.3.8 Examination of the Effects  of  ANO3 Mutations on Cel l  Signal l ing by 
Use of  Patient Derived Fibroblasts   
ANO3 belongs to a family of genes that are thought to encode ion channels, more 
specifically Ca2+-activated Cl- channels 307.  Therefore, in order to investigate the 
influence of the ANO3 mutations on calcium homeostasis, cytoplasmic Ca2+ 
concentration ([Ca2+]c) was measured using fura-2, following treatment of cells with 
ATP, potassium chloride (KCl) and thapsigargin.  In the text below, n indicates the 
number of cells analysed for each set of experiments, which were universally carried out 
in triplicate. 
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Figure  16 -  A)  Box plot of mRNA expression levels for ANO3 in 12 CNS regions, based on exon array experiments and plotted on a log2 scale (y axis). This 
plot shows significant variation in ANO3 transcript expression across the 12 CNS regions analysed (see main text for list of regions and abbreviations used).  
ANO3 mRNA expression is significantly higher in PUTM as compared to all other brain regions. Whiskers extend from the box to 1.5 times the inter-quartile 
range.  B)  Graph to show mRNA expression levels for ANO3 in 6 brain regions during the course of human brain development, based on exon array 
experiments and plotted on a log2 scale 305, 306. The brain regions analysed are the striatum (STR), amygdala (AMY), neocortex (NCX), hippocampus (HIP), 
mediodorsal nucleus of the thalamus (MD) and cerebellar cortex (CBC). This plot shows increasing expression of ANO3 mRNA during human brain 
development from the early mid-fetal period to adolescence, particularly in the striatum.	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Initially, ATP (100µM) was used to stimulate [Ca2+]c  signals in fibroblasts via 
purinoceptors and release calcium from endoplasmic reticulum via IP3 receptors.  
50mM KCl was then applied to induce depolarisation of the plasma membrane and 
open voltage gated calcium channels.  Fibroblasts from the patient carrying the 
c.1470G>C; p.Trp490Cys mutation showed significantly reduced ATP-induced calcium 
signal (figure 17A-B; n=41; p<0.05) when compared to control cells.  Importantly in this 
respect, application of 50mM KCl induced a similar rise in [Ca2+]c in both control 
fibroblasts (Ctrl-1 and Ctrl-2; n=56 and 33, respectively) and in fibroblasts with the 
c.1470G>C; p.Trp490Cys mutation in ANO3 (figure 17B).  Thus, the mutation in 
ANO3 appeared to result in a reduced calcium signal in response to ATP that would 
most eloquently be explained by a smaller calcium pool within the endoplasmic 
reticulum. The lack of significant difference in response of control and mutation-
carrying cells to depolarisation of the plasma membrane by KCl suggests that the 
mutation does not modulate voltage-gated calcium channels or impair active Ca2+ 
transport (mechanism of calcium removal from cytosol).  
 
To confirm these findings, we performed further experiments using thapisgargin (1µM) 
in Ca2+-free medium (plus 0.5 mM EGTA).  Addition of thapsigargin, which is an 
inhibitor of the sarcoplasmic endoplasmic reticulum calcium ATPase (SERCA), induces 
a release of calcium from the reticulum to the cytosol and can be used to estimate the 
reticular Ca2+-pool. Adding Ca2+ at the end of the experiment stimulates elevation of 
[Ca2+]c in fibroblasts (figure 17C) due to the opening of store operated calcium 
channels. We found that the calcium signal in response to thapsigargin in fibroblasts 
carrying the c.1470G>C; p.Trp490Cys mutation was significantly smaller (n=26; 
p<0.001; Figure 17C and 17D) when compared to control fibroblasts Ctrl-1 (n=19) and 
Ctrl-2 (n=22).  This strongly suggests that the thapsigargin-sensitive Ca2+ pool in the 
endoplasmic reticulum of mutation-carrying fibroblasts cell is significantly smaller 
compared to control cells. Stimulation of the store-operated Ca2+ channels induced 
similar elevation of [Ca2+]c in control and mutated fibroblasts (figure 17C and 17D). 
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Figure 17 - Graphical Summary of Fibroblast Functional Studies.  A) Typical trace of cytoplasmic Ca2+ concentrations as measured by fura-2 ([Ca2+]c) in control (Ctrl 1 and Ctrl 2) and mutation-
bearing (ANO3, c.1470G>C; p.Trp490Cys) fibroblasts in response to application of 100 µM ATP.  B) Histogram showing a significantly decreased change in the cytoplasmic Ca2+ concentration in 
response to 100 µM ATP (black bars) in mutation-bearing fibroblasts, whilst the change in the cytoplasmic Ca2+ concentration in response to 50mM KCl was unchanged (blue bars).  Error bars 
represent standard error of the mean and the asterisk indicates p<0.05.  C) Mean trace of [Ca2+]c in response to thapsigargin (1 µM), and subsequent Ca2+ challenge (arrows; 2 mM).  Error bars 
represent standard error of the mean.  D) Histograms demonstrating a significant difference in ER calcium pool in ANO3 mutant cells in response to thapsigargin (black bars) but no changes in the 
activation of store operated calcium channels as a response to the subsequent calcium challenge (blue bars) compared to controls.  Error bars represent standard error of the mean and the double 
asterisks indicates p<0.001. 
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5.4 Discuss ion  
In a moderately-sized kindred from the UK with apparently autosomal dominant 
inheritance of cranio-cervical dystonia and dystonic tremor, I performed linkage 
analysis and exome sequencing to identify candidate causal variants.   Based on this 
approach, the top candidate was a missense variant in exon 15 of ANO3  (c.1480A>T; 
p.Arg494Trp).  Further sequencing of this exon of ANO3 revealed a second small 
family with an almost identical phenotype who haboured a second missense variant 10 
bases upstream (c.1470G>C; p.Trp490Cys) that segregated with the disease in the 
family members available for testing.  Neither variant in exon 15 was seen in the 
publically available datasets of the NHLBI Exome Sequencing Project, 1000 Genomes 
or within our own in-house exomes and both were predicted to be deleterious by SIFT, 
Polyphen2 and MutationTaster.  Subsequent targeted high-throughput sequencing of 
the entire gene in 188 individuals revealed 3 further coding variants and 1 variant in 
the 5’ UTR in individuals with tremulous cervical dystonia and/or upper limb tremor.  
Although these variants were also absent in the above databases, predictions of their 
pathogenicity were contradictory and further functional work or mutational screening 
will be required to firmly establish their link to dystonia.  However, at least one of these 
additional variants (c.2053A>G; p.Ser685Gly) appeared to segregate with disease in the 
family members available for testing, suggesting it may well be pathogenic. 
 
ANO3 encodes a protein called anoctamin 3, about which little is yet known.  It 
belongs to a family of genes (ANO1-10) that appear to be closely related in sequence 
and topology, but with distinct expression patterns 308, 309.  Members of the family are 
found throughout the eukaryotes, including mammals, flies, worms, plants, protozoa 
and yeast, but are best represented in higher vertebrates who possess the most members 
310.  Moreover, many of these genes have been linked to disease, suggesting that they 
play an important role within their specific tissue types.  For instance, ANO1 (MIM: 
610108) has been linked to cancer 311, mutations in ANO5 (MIM: 608662) are linked 
to several forms of muscular dystrophy 312, 313, mutations in ANO10 (MIM 613726) are 
linked to autosomal recessive spinocerebellar ataxia 314, and mutations in ANO6 (MIM: 
608663) are linked to Scott syndrome, a rare bleeding disorder 315. 
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ANO1 and ANO2 (MIM:610109), the best studied members of the family, encode 
proteins that function as Ca2+ activated chloride channels (CaCCs) 316.  It remains an 
open question as to whether anoctamin 3 functions in the same manner.  Hydropathy 
analysis suggests a similar topology, with eight hydrophobic helices that are likely to be 
transmembrane domains and cytosolic N- and C-termini (see figure 18), but more 
recent work has suggested that anoctamin 3 may in fact be targeted to the endoplasmic 
reticulum, rather than the cell surface, like anoctamins 1 and 2 307.  CaCCs are, 
nonetheless, known to have a role in the modulation of neuronal excitability 317, 318 and, 
in view of our data showing very high expression of ANO3 in the striatum, it is 
plausible to hypothesize that mutations in this gene might lead to abnormal excitability 
of striatal neurons, which then manifests itself clinically in unwanted dystonic 
movements.  In this regard, it is interesting to note that the two mutations that we 
found in exon 15 lead to amino acid changes within a predicted cytosolic loop of the 
protein that some have suggested may function as the Ca2+ sensor 308.  Indeed, 
mutations in the homologous loop of ANO3’s sister gene, ANO2, have recently been 
shown to alter the voltage dependence of channel activation 319.  Our own data from 
patient fibroblasts carrying a mutation in exon 15 of ANO3 confirm abnormalities in 
Ca2+ signaling.   The lack of a difference in Ca2+ response to KCl, which is expected to 
open ion channels in the plasmalemma, in the context of a significantly reduced 
response to two agents that are known to cause calcium release from the endoplasmic 
reticulum (ATP and, more specifically, thapsigargin), suggests a potential defect in 
endoplasmic reticulum related Ca2+ handling in these mutation-bearing fibroblasts. 
 
A third mutation (c.2053A>G, p.Ser685Gly) was found in the loop between the 5th and 
6th transmembrane domains of the protein (see figure 18).  In anoctamin 1, it is 
thought that this loop may form a critical component of the channel pore 320, though 
there remains debate about whether this loop is extracellular, re-entrant, or cytosolic 321.  
If anoctamin 3 were also proven to function as an ion channel, this work might suggest 
a possible mechanism by which an amino acid substitution in this loop could confer 
pathogenicity. 
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Figure 18 - Predicted topology of anoctamin 3, showing 8 hydrophobic transmembrame domains and cytosolic n- and c-termini.  The loop between domains II 
and III may function as a Ca2+ sensor.   The loop between domains V and VI may form a channel pore and there is debate over whether this loop may be re-
entrant or even internal 321.  Amino acids highlighted in red show the position and nature of mutations found in this study.  Key:  1 = c.161C>T, p.Thr54Ile; 2 = 
c.1470G>C, p.Trp490Cys; 3= c.1480A>T, p.Arg494Trp; 4 = c.2053A>G, p.Ser685Gly; and 5 = c.2586G>T, p.Lys862Asn. 
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Although further functional work will be required to establish the mechanism by which 
mutations in ANO3 might lead to dystonia, the implication of a transmembrane ion 
channel in the pathogenesis of this condition represents a completely fresh avenue of 
inquiry for future research in this field and, importantly, raises the possibility that 
pharmaceutical agents targeted at compensating for aberrant channel function could 
potentially be beneficial in the treatment of a subset of dystonia patients.  For instance, 
CaCCs can be blocked in vitro by nifulmic acid, by tamoxifen and, to a lesser extent 
and in a less specific manner, by fluoxetine 318.  Finally, it will be important to carry out 
further genetic screening of phenotypically similar cases in this and other populations 
in order to establish the prevalence of mutations in this gene as a cause of autosomal 
dominant cervical dystonia, dystonic head tremor and/or upper limb dystonic tremor. 









Exome Sequencing in Late-Onset 
Tremulous Cervical Dystonia
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As part of the work leading to the publication of ANO3, we sought to identify as many 
families as possible from our clinics and database records with tremulous cervical 
dystonia in the hope that they might also harbour a mutation in this gene.  In the 
process, we identified a family with a similar phenotype of tremulous cervical dystonia 
that appeared to be inherited with a high degree of penetrance.  Unlike individuals 
with ANO3 mutations, however, who mostly developed dystonia in their teens and 
always before the age of 40, individuals in this family developed the first signs of 
dystonia in late adulthood, typically in their 7th decade.  Targeted high-throughput 
sequencing failed to identify a mutation in ANO3 in the family, suggesting that it had a 
different genetic basis. 
 
The structure of the family (see figure 19) makes it at once attractive, whilst 
simultaneously presenting significant problems for the genetic researcher.  The family 
was particularly large by Western standards, with the oldest surviving generation 
consisting of a sibship of 15 individuals.  Of these, only 1 had passed away (reported to 
be unaffected), 1 lived elsewhere in the world (reported to be affected) and 1 could not 
be contacted (reported to be unaffected).  Of the remaining 12, 7 appeared to be 
affected by dystonia, suggesting an autosomal dominant inheritance pattern with 
almost complete age-dependent penetrance.  Most of these individuals had married and 
had children, but only 1 individual in the subsequent generation had so far developed 
very mild cervical dystonia.  However, the typical onset age of the condition in the 
members of oldest surviving generation meant that their children had not yet reached 
the age where they might be expected to manifest the condition if they were actually 
carrying the causative mutation.  As a result, an individual in the this generation with 
no clinical signs of dystonia when examined for this study could just as equally: 1) not 
have inherited the causative gene; or 2) have inherited the causative gene but not yet 
manifested the disease as they had yet to attain the typical age of onset.  By extension, 
for all but the single individual with signs of dystonia in this generation, it was not 
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possible to assign affectation status with any hope of accuracy, rendering informative 
linkage analysis an impossibility.  Thus, it was recognised from the outset that any 
attempt to ‘solve’ the family would be mired in diffiuculty because no variants could be 
excluded on the basis of genomic location in an area of negative linkage.    
 
Nonetheless, despite these challenges, the large size of the first generation and high 
number of affected individuals proved sufficiently tempting and the family was selected 
for further clinical review and exome sequencing. 
 
6.2 Subjects ,  Materials  and Methods 
6.2.1 Clinical Detai ls  of  the Index Family 
Participants were drawn a family of English ancestry.  The pedigree is shown in figure 
19.  The inheritance pattern was felt to be suggestive of a late-onset, autosomal 
dominant condition with high age related penetrancy.  Both males and females were 
affected, making sex linked inheritance unlikely.  The ratio of reportedly affected to 
unaffected individuals in the oldest surviving generation was 3:2, much more suggestive 
of a dominant rather than recessive trait, where the ratio would be expected to be 1:3.  
At least one example of vertical transmission was evident (between individuals II-4 and 
III-11) and the family also reported that individual I-2 may have been affected (which, if 
this was the case, would also rule out mitochondrial inheritance). 
The clinical characteristics of affected individuals were almost unvariable.  In summary, 
all individuals exhibited a tremulous cervical dystonia, often with associated hand and 
laryngeal tremor, leading to voice tremor.  Onset was generally in the 60s and was 
gradual.  Though the severity of the dystonia had worsened with time, generalisation 
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Figure 19 – Genetic pedigree of the index family.  Affected individuals are shown by solid black symbols.  Individual I:1 was reported to be affected but was now 
deceased and so this could not be confirmed.  It should be noted that, although one individual in the third generation (individual III:11) showed signs of 
dystonia, the affectation of all other members of this generation was uncertain as they were all below the average age of onset of symptoms in the second 
generation.  In the interests of space, the spouses of individuals in the second and third generations are not shown. 
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6.2.2 Exome Sequencing  
Given that linkage would be uninformative in this family, we decided to perform 
exome sequencing on the DNA of three affected individuals in order to provide the 
best chances of being left with a workable number of variants. DNA from individuals II-
5, II-8 and III-11 was thus used to perform whole exome sequencing as per section 4.14.  
Details of the filtering of exome sequencing data are given in the results section below.  	  
6.2.3 Express ion Data  
Expression data for all of the variants discussed below were collated as per section 4.19. 	  	  	  
6.3 Results  
6.3.1 Exome Sequencing  
Exome sequencing produced excellent breath and depth of coverage.  Key coverage 
statistics – percentage of the target definition covered a 2x, 10x and 20x; mean read 
depth; and total number of variants detected – are summarized in table 15 for each 
sample. 
 
Table 15 – Summary of exome coverage data from the three samples subjected to NGS. 





1 89.2% 84.3% 78.3% 45 20838 
2 92.7% 86.5% 81.4% 54 21266 
3 90.6% 86.3% 80.3% 52 20907 
 
 
6.3.2 Aggress ive Fi l tration to Identify Candidate Causal Variants  
The first step in the analysis of the data was to filter out all variants that were not 
shared between all the three affected individuals whose DNA had undergone next-
generation sequencing.  After sequential comparison and filtration, there remained 
12,417 shared variants.  Next, we removed any synonymous variants not affecting 
canonical spice sites, leaving 6,071 shared variants to carry over to the next stage.  In 
accordance with our assumed model of autosomal dominance, we then removed all 
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homozygous variants, leaving 2,724 shared, heterozygous variants that might be 
expected to have a consequence on protein transcription or translation.  In accordance 
with general conventions for variant filtration of exome data in kindreds exhibiting 
Mendelian diseases presumed to inherited in an autosomal dominant fashion, we then 
removed all variants that were present in the standard databases of natural human 
sequence variation (dbSNP, 1000 genomes, the NHLBI exome sequencing project, and 
complete genomics 69) at a minor allele frequency of greater than 0.1%.  This left 
variants under consideration. 
 
At this stage, it was clear that the number of variants left under consideration was too 
great.  Thus, in order to reduce the list to a number that could be realistically tackled by 
manual curation, a more aggressive filtering strategy was required than would have been 
ideal had it been possible to narrow the genomic search space further by use of linkage 
data.  We reasoned that, although cervical dystonia is not itself particularly rare, this 
particular form of cervical dystonia – highly-penetrant and dominantly-inherited – is 
only very rarely seen.  We chose, therefore, to continue working on the data under the 
assumption that the variant underlying in this highly-penetrant form of dystonia would 
not have been recorded in databases of sequence variation to date.  We recognize that 
this assumption is not unproblematic.  This is especially so given the late-onset of 
symptoms in this kindred:  carriers of a potentially causal mutation for such a condition 
could potentially have been included in projects designed to assess normal human 
genetic variation while asymptomatic, even though, at a later age, they might go on to 
manifest the disease.  However, in order to be able to reduce the candidates under 
consideration to a manageable level, there seemed little choice but to filter out all 
variants that were not truly ‘novel’ – that is to say, to carry forward only variants that 
were not recorded in the aforementioned, commonly-used databases of natural human 
sequence variation.  Finally, as an additional measure, we also removed any variants in 
regions of segmental duplication with greater than 95% sequence homology as 
experience has taught that these are almost always located in the non-transcribed 
pseudogene, which is naturally subject to greater genetic drift.  After these operations, 
there remained 18 variants left for consideration. 
	   184	  
6.3.3 Further Refinement of  the List  of  Candidate Variants by Manual 
Curation 
As obtaining primers for 18 exons, optimizing them and testing each of them for 
segregation in such a large family would be expensive, time consuming and, most 
importantly perhaps, a drain on patient DNA, an attempt was made to further refine 
the number of variants under consideration by gathering as much data as possible on 
each variant and the gene it was located in.  This information was then used as the basis 
to assign each variant to one of two categories:  either ‘possible’ candidate or ‘unlikely’ 
candidate.  Any variant for which no data could be found to favor assignment to either 
category was left as a ‘possible’ candidate.  It was understood that this process – being 
essentially qualitative – was necessarily imperfect (see discussion below) and would 
never be accepted as the basis of a publication on a new disease gene.  However, at the 
same time, it offered a pragmatic way forward that essentially aimed to build into the 
decision-making process two characteristics of proposed disease-causing mutations that 
tend be associated with eventual confirmation of pathogenicity.  Firstly, the proposed 
disease gene should be ‘biologically plausible’:  1) it should be expressed in the diseased 
tissue; 2) it should ideally have some link to the known molecular mechanism of that 
disease; and 3) it should not be associated with another disease, including recessive 
diseases where the heterozygous parents are reported to be neurologically normal; and 
4) on review of the databases of normal human sequence variation, it should not ideally 
be littered with other variants that are predicted to be damaging, particularly if the 
putatively-associated disease trait is dominantly inherited, in which case the occurrence 
of annotated variants predicted to result in significant protein truncation or non-sense 
mediated decay would raise suspicion that the disease-gene association is spurious 
(unless, of course, a purely dominant negative mechanism of action was postulated).  
Secondly, the proposed variant should: 1) affect a base and/or amino acid that is 
evolutionarily conserved; 2) it should not universally be predicted to be benign or 
tolerated by multiple in silico prediction programs; and 3) it would, ideally, affect a 
known functional protein domain.  Although it must be said upfront that, with the sole 
exception of an absence of gene expression in the diseased tissue, it is possible to find 
examples of a verified disease gene that breaks at least one of these rules, it remains the 
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case that most verified disease-causing genes and mutations do meet many if not all of 
these criteria. 
 
Information curated and considered when making this decision included: 1) the 
Grantham score (a measure of the dissimilarity of two amino acids involved in a 
substitution); 2) in silico predictions of pathogenicity from three different programs that 
use diverse methods to generate their predictions; 3) three complementary measures of 
evolutionary conservation; 4) organism wide expression data; 5) data regarding protein 
function; 6) data regarding location of the variant within the protein with reference to 
known or predicted functional domaines, 7) previous associations with other diseases; 
and 8) the presence of other mutations likely to be deleterious in databases of normal 
human sequence variation (particularly stopgain mutations given the presumed mode 
of inheritence, as genes tolerating stop gains in normal individuals are unlikely to cause 
disease by haploinsufficiency).  These data and the qualitative judgements made on the 
basis of it are summarized in table 16 and 17. 
 
Using this data, 9 variants were designated as unlikely candidates and excluded from 
further analysis. Manual inspection of the raw exome sequencing data demonstated 
that 3 variants (in the genes PKD1L2, HRC and ZNF677) were actually polymorphisms, 
already annotated in dbSNP or 1000 Genomes that had not been identified in the 
initial, automated annotation process as the offending indel was incorrectly from the 
raw data (this is not an uncommon occurrence with indels in detected by NGS, 
especially if the affected area is repetitive, which makes accurate mapping to the 
reference genome considerably harder).  The remaining rejected variants were either 
discarded as a result of one of a combination of the following factors (higlighed in red 
and emboldened in tables 16 and 17): 
1) inherent lack of plausibility (KRTAP1-3 and HHLA2) 
2) negative conservation scores (NELL2, FAM186A and MTPAP) 
3) universal predictions of toleration (NELL2 and FAM186A) 
4) definite association with another well characterized disease (SH3TC2) 
5) genetic considerations related to similar mutations seen in data of normal 
sequence variation (GALK2). 
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Table 16 - Characterisation of candidate causal variants based on the nature of the genetic variant detected.  Mutation code abbreviations are as follows:  NS=nonsynonymous; FS=frameshift; 
NFS=nonframeshift; SG=stopgain; SNV=single nucleotide variant; DEL=deletion; INS=insertion.  For in silico predictions of pathogenicity: D = deleterious (SIFT)/disease-causing (MutationTaster); 














ZDHHC18 NS SNV c.C461T:p.T154I  D - 0.02 Prob - 0.59 D - 0.999 5.27 3.584 1 
CACNA2D3 NS SNV c.A1814G:p.Y605C 194 D - 0.01 Prob - 0.947 D - 0.9999 6.16 6.99 1 
FAM107A NS SNV c.G308A:p.R103Q 43 D - 0 Prob - 0.992 D - 0.99999 5.05 5.06 1 
HHLA2 FS DEL  NMD 
NDUFA2 NS SNV  c.G50A:p.R17H 29 T - 0.06 B - 0.135 D - 0.9999999 4.93 2.27 1 
ARAP3 NS SNV c.G4001A:p.R1334Q 43 T - 0.11 Prob - 0.995 D - 0.999 5.66 7.24 1 
SH3TC2 NS SNV  c.A1150T:p.I384F 21 D - 0.02 B - 0.258 D - 0.999 4.64 1.35 1 
MTPAP NS SNV  c.A1651G:p.I551V 29 T - 0.3 B - 0.009 Poly - 0.9999 3.49 4.44 0.973 
NELL2 NS SNV  c.T83G:p.L28R 103  B - 0.55 Poly - 0.9999 -2.38 0.08 0 
FAM186A NS SNV  c.A4832T:p.Q1611L 113 T - 0.71 B - 0 Poly - 0.9999 -7.33 -8.35 0 
SLC4A8 NS SNV  c.A1283G:p.N428S 46 T - 1 B - 0.007 D - 0.67 5.42 0.27 0.78 
GALK2 SG SNV c.975delC:p.Y325X NMD 
NMD PKD1L2 FS DEL c.705_706del:p.235_236del 
NCOR1 NS SNV  c.T3331C:p.S1111P 74 D - 0.04 Prob - 0.937 D - 0.99999 6.07 7.13 1 
KRTAP1-3 NFS INS 
c.112_113insAGCTGCTGTGAGAC
C:p.S38delinsSCCETS 
Data not applicable to 
non-frameshift mutations 
HRC NFS DEL c.742_744del:p.248_248del 
ZNF677 FS INS c.523_524insAT:p.K175fs NMD 
EPB41L1 NS SNV  c.C1285T:p.R429C 180 D - 0 Prob - 0.976 D - 0.999999 5.48 3.76 1 
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Table 17 - Characterisation of variants based on gene function, biological plausibility, disease association and genetic factors. 
Gene Gene Function Plausibility Known Cause of Disease Genetic 
ZDHHC18 Palmitoyltransferase activity towards HRAS and LCK Possible No   
CACNA2D3 
Subunit of voltage-dependent Ca2+ channels; regulates Ca2+ current density and 
activation/inactivation kinetics of channel.  
High No (link to pain)   
FAM107A Suppresses cell growth when transfected into cells.  May play a role in tumour development Low No (link to cancer)   
HHLA2 Immunoglobulin Very low     
NDUFA2 Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase  Low No   
ARAP3 GTPase-activating protein that modulates actin cytoskeleton remodeling  Possible No   
SH3TC2 Involved in Schwann cell maintenance Low CMT4C (recessive), parent normal   
MTPAP Mitochondrial polymerase.  Creates UAA stop codons that are not encoded in mtDNA Low  No   
NELL2 Regulator of cell growth? Low No   
FAM186A Unknown Possible No   
SLC4A8 Plays a major role in pH regulation in neurons. Possible No   
GALK2 Carbohydrate transport and metabolism Low   
Multiple stop 
gains in dbSNP 
PKD1L2 May function as an ion-channel regulator. May function as a G-protein-coupled receptor. Possible No  (link to behavioural disorders) Annotated 
NCOR1 Mediates transcriptional repression by certain nuclear receptors. Possible No  (link to cancer)   
KRTAP1-3 Essential for formation of rigid and resistant hair Very low No   
HRC Regulation of calcium sequestration or release in the SR of skeletal and cardiac muscle Low No Annotated 
ZNF677 Transcription regulation Possible No Annotated 
EPB41L1 May function to confer stability and plasticity to neuronal membrane. High 
No (linked to AD mental 
retardation) 
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This left 8 variants for segregation analysis.  Primers were thus designed to amplify the 
exon of each gene in which the detected variant was located and mutational status was 
ascertained for all individuals in generation II (where affectation could be assigned with 
reasonable certainty) for whom DNA was available.  By definition, individuals II-9 and 
III-11 are affected.  The results of this analysis are shown in the table 18. 
 
Table 18 – Summary of segregation analysis of all members of the second generation for which 
DNA samples were available.  The number of phenotype-genotype mismatches are shown in the 
far right column, assuming a fully-penetrant autosomal dominant inheritance pattern.  M = 
mutation detected in the heterozygous state; wt = homozygous widetype alleles. 
 II-3 II-4 II-5 II-7 II-8 II-10 II-11 II-12 II-13 II-14 Mismatches 
Affected Yes Yes Yes Yes Yes Yes Yes No No No  
SLC4A8 M M M M M M wt M M wt 3 
FAM107A wt M M wt wt M M wt wt wt 2 
NCOR1 wt M M M M M wt wt wt M 3 
ARAP3 wt M M M wt M wt M M wt 4 
ZDHHC18 wt M wt wt M M wt wt wt wt 4 
EPB4IL1 wt M wt M wt M wt M wt wt 5 
NDUFA2 wt M M M wt M wt M M wt 5 
CACNA2D3 M M M M wt M M wt wt wt 1 
 
As can be seen for the table above, no candidate variant segregated perfectly with 
disease in this family.  The closest match was for CACNA2D3.  This candidate gene had 
been ranked highly on the basis of its biological plausibility and on the characteristics 
of the variant detected within the gene. 
 
6.3.4 An Overview of CACNA2D3 
A limited amount of information exists on the gene CACNA2D3.  This gene encodes a 
member of the α-2/δ subunit family, a protein involved in the voltage-dependent 
calcium channel complex.  Voltage-gated calcium channels (VGCCs) are thought to 
exist in the plasma membrane as heteromeric proteins, in which the α1 subunit is 
associated with two auxiliary subunits, the intracellular β subunit and the extracellular 
α2δ subunit.  These subunits influence the trafficking and properties of CaV1 and CaV2 
channels.  The first question therefore is whether the expression pattern of this gene 
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might be compatible with the development of a purely neurological disease.  Even here 
things become complicated.  According to Gong et al. (2001), CACNA2D3 is only 
expressed in the brain, in the mouse at least 322.  This would be an extremely favourable 
expression pattern.  According to Hanke et al. (2001), however, it is more widely 
expressed 323 and recent publications have suggested that methylation of CACNA2D3 
may be associated with a poorer prognosis in various cancers, such as that of the 
stomach, oesophagus, breast and brain 324-327.  Data from RNA sequencing experiments 
suggest a likely compromise:  it is probably expressed at some level throughout the 
organism, but appears to preferentially expressed in the brain and heart.  According to 
our own data (figure 20), it appears, within the brain, to be expressed at highest levels 




Figure 20 - Expression data for the gene CACNA2D3 in man.  The panel on the left shows the 
organism wide expression data based on publically available EST datasets.  The panel on the 
right shows regional differences in expression across the brain, across the 10 CNS regions 
analysed: putamen (PUTM, n=129), hippocampus (HIPP, n=122), temporal cortex (TCTX, 
n=119), frontal cortex (FCTX, n=127), occipital cortex (OCTX, n=129), thalamus (THAL, 
n=124), cerebellar cortex (CRBL, n=130), substantia nigra (SNIG, n=101), intralobular white 
matter (WHMT, n=131) and medulla (specifically inferior olivary nucleus, MEDU, n=109).  
Whiskers extend from the box to 1.5 times the inter-quartile range. 
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This expression pattern would be consistent with that of a gene capable of causing 
dystonia and is similar to the expression pattern of ANO3, which we found to be 
mutated in a family with autosomal dominant early onset tremulous cervical dystonia 
(covered in chapter 5), and also to that of HPCA, which we found to be mutated in a 
family with autosomal recessive generalised dystonia (covered in chapter 7) 
 
The second question is whether the gene’s function might fit in with currently accepted 
models of pathogeneisis for dystonia.  Experimental research suggests that α2δ proteins 
modulate the activity of the VGCCs, which in turn drive neurotransmitter release in 
neurons.  Specifically, α2δ subunits set synaptic abundance of VGCCs and α2δs 
configure synaptic VGCCs to drive exocytosis through an extracellular metal ion-
dependent adhesion site (MIDAS), a conserved set of amino acids within the α2δ 
protein’s predicted von Willebrand A (VWA) domain 328.  Expression of α2δ with an 
intact MIDAS motif leads to an 80% increase in release probability, while 
simultaneously protecting exocytosis from blockade by an intracellular Ca2+ chelator 328.  
Thus, mutation of this gene could potentially alter neuronal excitability or propensity 
to neurotransmitter release in an areas of the brain associated with movement 
disorders. 
 
The third question is whether the mutation we detected is located within an area of the 
protein known to have functional importance.  The α2δ subunits have been described 
as type I transmembrane proteins, because they have an N-terminal signal peptide and a 
C-terminal hydrophobic and potentially transmembrane region.  However, evidence has 
accumulated recently to suggest that α2δ proteins are probably associated with the 
plasma membrane through a glycosylphosphatidylinositol (GPI) anchor attached to δ 
part of the protein rather than the transmembrane domain 329.  The process of 
anchoring occurs within the endoplasmic reticulum, and it involves cleavage of the C-
terminal hydrophobic peptide at the ω-residue and attachment of a GPI group to this 
residue, which then attaches the protein to the membrane through its lipid side chains.  
The hypothesis was originally prompted by the results of prediction programs 
examining the α2δ3 proteins alone, but its validity is now supported by good 
experimental evidence for all α2δ proteins 329.  The mutation we detected occurs in the 
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α2 domain of the protein and so it unlikely to affect GPI-mediated membrane binding.  
The other key domain within the protein is the MIDAS domain (mentioned above), 
which binds divalent metal cations and its function is required for α2δ proteins to 
effectively modulate calcium currents.  The mutation that we detected is located 
approximately 400 amino acids upstream from this motif and, thus, altered binding of 
divalent cations cannot be invoked as a likely causal mechanism.  Overall, the mutation 
that we detected does not appear to disrupt area of the protein with previously 
described critical role in its function.  This, of course, does not preclude the idea that it 
may affect an area with as-of-yet unknown functional significance. 
 
The final question revolves around whether the gene has been associated with any 
particular function within the nervous system already.  There are only two papers that 
suggest a possible functional role for CACNA2D3 within the nervous system.  The first 
links the gene to nociceptive processing.  Using genome-wide neuronal-specific RNAi 
knock-down in Drosophila, Neely et al. (2010) set about identifying novel genes 
implicated in heat nociception in the fly 330.  One of the genes that they identified by 
this means was the calcium channel subunit straightjacket.  The mammalian ortholog of 
straightjacket is CACNA2D3 and its role in thermal nociception was confirmed in 
knock-out mice, which exhibit a significantly impaired basal heat pain sensitivity and 
delayed thermal hyperalgesia after inflammation 330. They went on to pinpoint single 
nucleotide polymorphisms in human CACNA2D3 that are associated with reduced 
acute heat pain sensitivity in healthy volunteers, as well as chronic postsurgical back 
pain 330.  This finding is intriguing since research conducted after the original 
publication of ANO3 as a dystonia gene has suggested that it too may be involved in 
nocioceptive processing.  Within the dorsal root ganglia, ANO3 is expressed mainly in 
the IB4 positive, non-peptidergic nociceptors, which also co-express the sodium-
activated potassium (KNa) channel Slack 331.  In rats, the expression of ano3 appears to 
promote KNa channel activity and thus dampen neuronal excitability.  Dorsal root 
ganglia neurons from ano3 knock-out rats have reduced Slack expression, broadened 
action potentials and increased excitability 331.  Moreover, the ano3 knock-out rats 
exhibit increased thermal and mechanical sensitivity 331.  The data thus suggests that 
both human ANO3 and CACNA2D3 may be involved in the processing of pain signals 
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and the two may therefore be envisaged as sharing a common function as modulators 
of neuronal excitability.  Continuing with the theme of modulation of signalling 
pathways, the second paper reporting on CACNA2D3 function suggests that the gene 
may also be important in modulating neuronal signals within the auditory pathway.  
CACNA2D3 knock-out mice display a reduced auditory startle response, most likely as a 
result of impaired synaptic transmission.  The authors further demonstrated that lack 
of CACNA2D3 resulted, on a cellular level, in a reduction of Cav2.1 expression in the 
somata of spiral ganglion neurons, but also in their synaptic terminals contacting bushy 
cells.  Given this data, it does not seem too implausible to speculate that mutations in 
CACNA2D3 might be envisioned to cause dystonia by ‘altering the gain’ in neuronal 
pathways controlling movement within the basal ganglia (where it is highly expressed) 
in a manner similar to that we hypothesised to underlie the effect of ANO3 mutations. 
 
6.4 Discuss ion 
We set out to identify the genetic cause of autosomal dominant, late-onset tremulous 
dystonia in an unusually-large, English kindred.  Despite the attractions offered by the 
unusually large size of the second generation and the seemingly near-complete age-
related penetrance of the disorder, the family was always going to be a challenge to 
solve.  The main reason for this is that the late-onset of the disorder means that the 
affectation status of the third generation could not be accurately be determined.  By 
extension, no linkage analysis is possible and thus the genomic search space is 
unmanageable. 
 
The first concession made to this imperfect situation was to only consider novel 
variants.  Although any discoveries based on such a concession would always have been 
unpublishable without further supporting evidence (in the form of several independent 
segregating kindreds), we felt that it was, nonetheless, worth pursuing this avenue in 
order to determine if an obvious candidate variant stood out.  As it happened, no 
candidate variant either immediately stood out as perfect or indeed survived a later 
segregation analysis.  All that can be said is that, of the candidate-causal, novel variants 
that had been selected for segregation analysis, that in which the pattern of inheritance 
matched most closely the pattern of disease in the family was also the same variant that 
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was deemed to have a higher a priori probability of being causal on the basis of the 
(necessarily somewhat subjective) character profile compiled for it – that is to say, the 
p.Y605C variant in the gene CACNA2D3.  However, since, even in the case of this 
variant, segregation analysis still showed one mismatch (and notwithstanding the fact 
that the gene is extremely large), a decision was made not to go on to sequence the gene 
in an independent dystonia cohort.  At the same, this family does show enormous 
potential from a genetic point of view.  If you will allow me the liberty of an everyday 
analogy:  like a good wine, it will mature with time.  In about 20 years or so, when the 
affectation status of the 3rd generation can be more easily ascertained, finding the gene 
should be relatively easy, given the number of the affected and unaffected individuals in 
the second and by then third generation.   
 
Could mutations in CACNA2D3 be the cause of dystonia in this family?  It is possible.  
The expression pattern is favourable and the genes function shows similarities to that of 
ANO3.  If one were to accept this hypothesis, however, then one would have to 
simultaneously accept the hypothesis that individual II-8 is a phenocopy.  There are 
three main reasons why such an individual may well turn out to be a phenocopy and 
both are particularly applicable to dystonia.  
 
The first reason revolves around the fact that some diseases are not so uncommon in 
the general population that it is always possible that an individual might suffer from 
that disease, but that it might not be the result of a genetic mutation that is causal in 
the rest of the family.  This exactly situation occurred during the analysis of the kindred 
in which the Parkinons’ gene SNCA was initially identified.  For reasons mentioned 
later, prevalence estimates for cervical dystonia are wide ranging.  The most robust 
studies suggest a prevalence of about 28 – 183 cases per million of population 332.  
Whilst unlikely, it is all the same within the realms of possibility that individual II-8 is 
affected by cervical dystonia, but not as a result of the mutation carried by the rest of 
her affected siblings. 
 
The second reason is linked to the difficulty in being certain that a clinical diagnosis is 
accurate in the case of certain disorders.  For disorders in which the clinical picture is 
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so strikingly obvious or, alternatively, where a diagnostic test exists that can accurately 
separate affected from unaffected individuals (for example, a DaT scan in Parkinson’s 
disease), there is usually little difficulty is determining whether an individual’s 
symptoms are due to the disorder being examined.  Dystonia, however, is a particularly 
difficult condition to deal with in this respect.  Not only does no robust diagnostic test 
exist, which might determine whether an individual is truly affected or not, but the 
clinical phenomenology of the condition is extremely variable, ranging from disabling, 
deforming and grossly abnormal movements of the head, trunk and limbs to subtle, 
relatively unintrusive, and easily overlooked movements or postures of a single or 
limited part of the body.  Enlisting movement disorders specialists – as we did here – to 
phenotype the family can help, but such individuals – highly attuned as they are to the 
tiniest suspicious movement – probably serve best to increase the positive predictive 
value of a clinical diagnosis, rather than reduce its false positive rate.  Nonetheless, it 
would only be fair to say that I have reviewed the examination video of individual II-8 
several times and clinical diagnosis of cervical dystonia was certainly not made on the 
basis of the subtle signs.  
 
The third and final reason for phenocopies is that an apparently affected individual’s 
clinical signs are a learned behaviour with a psychological basis.  On this vexed topic, I 
will go no further than to say three things:  1) that functional illness is a sufficiently 
common diagnosis that it probably enters most practicing neurologist’s heads at least 
once a week; 2) that movement disorders are particularly common and difficult 
manifestations of functional disease, as decisively diagnostic tests are often lacking; and 
3) that I was warned by one of my supervisor’s, on surveying the family tree, that the 
kindred looked ‘over-dominant’ (his words, not mine) and that he felt it was likely that 
there were phenocopies amongst the supposedly affected individuals. 
 
With all that said, given the concessions that I was forced to make in selecting my 
candidate variants, it is equally possible that: 1) I have filtered out a low frequency, but 
nonetheless causal variant; 2) I have discounted a novel, but seemingly implausible 
variant and therefore not subjected it to segregation analysis; 3) the causal variant is 
novel and exonic, but has not been covered in one or both exomes; or 4) the causal 
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variant is not exonic or is a large scale deletion/duplication or exonic copy number 
variant, all of which are impossible/difficult to detect by means of exome sequencing. 
 
In summary, therefore, work on this kindred must, ultimately, be declared a failure.  Its 
inclusion in this thesis, however, is – in my opinion at least – important, as it illustrates 
some of the key reasons for which exome sequencing studies often grind to a halt, a 
subject to which I will return in my concluding remarks.  Perhaps understandably, the 
majority of this thesis is taken up with describing my relative successes, but it is, at the 
same time, important to be honest and thus make the following confession:  for every 
family that I present herein, in which I either identify a by-now-already-published or an 
unpublished-but-altogether-plausible causal mutation, you can be assured that there was 
almost certainly one or more families in which work ground to a halt, either at this or 
at an even less advanced stage. 
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At the time of completion of this work, recent rapid advances in the field of dystonia 
genetics had pushed the total number of known causative genes for primary isolated 
dystonia to six (TOR1A 136, THAP1 157, CIZ1 181, ANO3 333 , GNAL 334 and TUBB4A 186, 
187).  In all cases, the dystonia resulting from mutations in these genes is transmitted in 
an autosomal dominant manner, often with reduced penetrance.  However, within the 
parallel DYT loci classification system, there remained somewhat of an anomaly:  
DYT2.  Unlike every other dystonia locus, DYT2 was never defined on the basis of a 
linkage interval, but merely on the observation of a phenotype: that is, primary, isolated 
dystonia that appeared – unusually with respect to this condition – to be inherited in 
an autosomal recessive fashion 335.  Perhaps regrettably, as further putatively-recessive, 
isolated dystonia kindreds were reported in the literature, there was a tendency to 
simply lump them together on the basis of their presumed mode of inheritance under 
the banner of DYT2 or ‘DYT2-like’ dystonia 124, 336, 337, even though there was no 
evidence to suggest that they all shared the same genetic aetiology.  The sole exception 
to this practice was the creation in 2008 of the locus DYT17 to designate a region on 
chromosome 20, defined by homozygosity mapping, in a consanguineous Lebanese 
kindred exhibiting apparently autosomal-recessive, isolated dystonia 338.  Yet, as with 
DYT2, the causal gene remains to be identified 338. 
 
The genetics of DYT2 and, more generally, autosomal recessive, isolated dystonia has 
thus remained a persistent mystery in the field of dystonia research.  In part at least, 
this is due to the fact that this form of dystonia appears to be relatively rare, as 
evidenced by the very limited reports in the literature 124, 335-338.  Some have even 
expressed doubt as to whether an autosomal recessively inherited form of isolated 
dystonia exists at all 123, 339.  In reality, if autosomal recessive isolated dystonia were 
proven to exist, it would be expected that it would show the greatest prevalence in 
populations characterised by a higher frequency of consanguineous marriages.  
Elsewhere, it would be expected to be relatively rare.  Even when it did arise, it might 
not be recognised as a recessive disorder, since the tendency towards small family size in 
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much of the Western world means that singleton cases could easily be mislabelled as a 
sporadic or assumed to be the result of cryptic inheritance of or de novo mutation in 
one of the known autosomal dominant dystonia genes (especially in view of the 
markedly reduced penetrance and wide clinical expressivity of the most common of 
these, TOR1A).  Thus, globally, autosomal recessive isolated dystonia may well be less 
rare than the scientific literature to date suggests.  In any case, identifying a genetic 
cause for ‘DYT2 dystonia’ remains important, as it would:  1) firmly establish the 
existence of an autosomal recessive form of primary isolated dystonia; 2) allow the 
anomalous DYT2 locus to be linked to a causative gene; 3) permit further genetic 
screening to determine whether other kindreds published under the banner of DYT2 
dystonia actually share a common genetic cause; and, most importantly of all, 4) further 
expand our knowledge of the molecular pathways involved in the pathogenesis of 
dystonia.  
 
With the advent of next generation sequencing technologies, we revisited a Sephardic 
Jewish kindred, previously reported as ‘DYT2-like’, exhibiting autosomal recessive, 
isolated dystonia 124.  The three affected siblings (now aged 61, 57 and 51, respectively) 
were the product of a consanguineous marriage between two first cousins.  Both 
parents were neurologically normal and there was no report of any dystonia within the 
wider kindred.  A combination of autozygoisty mapping and whole exome sequencing 
were employed to identify the likely causal variant in this family. 
 
7.2 Subjects ,  Materials  and Methods 
7.2.1 Clinical Detai ls  of  the Index Family 
The index family has previously been described extensively elsewhere and readers are 
referred to that description for full details of the clinical presentation and previous 
investigation 124.  A brief précis of this information is provided below for the purpose of 
this thesis. Figure 21 shows the genetic pedigree for the core family.  With the 
exception of the affected siblings, there was no report of dystonia within the extended 
family in the previous two generations (the extended family tree has previously been 
published in the paper by Khan et al. [2003]) 124. 
 




Figure 21 - Genetic pedigree of the index family showing a consanguineous marriage resuting in 
three siblings affected with young-onset, generalised dystonia.  Both parents and all members of 
the wider family were free of neurological disease. 
 
This Sephardic Jewish family originated from Tehran in Iran.  Intermarriage was 
relatively common in their small community and the unaffected parents (I:4 and I:5) 
are first cousins. Their three children (II:1 through II:3) were all affected, consistent 
with autosomal recessive inheritance. All affected individuals had normal birth and 
developmental milestones.  There was no history of drug use or psychiatric symptoms 
and no diurnal variation or worsening with intercurrent illness.  None had cerebellar, 
pyramidal, or extrapyramidal signs. 
 
Individual II:1 – Initial signs of a dystonic disorder were noted around one year after 
birth, when the patient was noted to walk ‘pidgeon-toed’. At age 7 she reported 
intermittent jerking of the head and unclear speech. Her symptoms progressed over the 
next 6 years, with the development of torticollis, facial grimacing, blepharospasm, 
intermittent dysphagia, and breathlessness. At age 40 years, she developed mandibular 
muscle spasms with teeth grinding.  On clinical examination, there was marked 
dystonic posturing and jerking of the upper limbs with blepharospasm and leftward 
torticollis.   
 
Individual II:2 – Initial symptoms consistent with dystonia where noted at the age of 8 
years of age, when the parents observed abnormal postures, including intermittent 
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inturning of the left foot and dragging of the left leg.  At age12, he reported abnormal 
postures of the arms, difficulty writing, and an intermittent intention tremor.  In his 
teenage years, he developed torticollis and dysarthria with no significant progression 
since then.  On clinical examination, there was evidence of an exaggerated lumbar 
lordosis, a dystonic gait with in-turning of the feet. There was dystonic posturing of 
hands with choreoathetoid movements of the right arm and retrocollis.  Speech was 
dysarthric. 
 
Individual II:3 – Initial symptoms were observed in this woman at the age of 5, when 
she exhibited mild gait abnormalities compatible with dystonia.  At 13 she developed 
painful jerky torticollis, intermittent shoulder movements, and tremor of both hands. 
At 16 she had marked grimacing, blepharospasm and lingual dystonia.  On clinical 
examination, speech was dysphonic with laryngeal adductor spasms and respiratory 
dyskinesia.  There was a “yes-yes” head tremor, right torticollis with retrocollic jerks, 
involuntary movements around the eyes and mouth, blepharospasm, and facial 
grimacing.  There was marked dystonic posturing of the limbs.  
 
In summary, all three affected siblings developed dystonia in their first decade of life, 
which gradually generalised over time, but remained most marked in upper limbs, 
cervical, and cranial regions. 
 
Initially, the siblings were reported to be suffering from an atypical form of 
metachromatic leukodystrophy (MLD) on the basis of markedly reduced levels of 
arylsulfatase A in fibroblasts and leucocytes, reduced nerve conduction velocities and 
detection of brown metachromatic granules in sural nerve biopsies.  Subsequent 
mutational screening by Sanger sequencing demonstrated that both the mother and the 
three siblings were homozygous and the father heterozygous for two variants in a cis 
configuration (NM000487.5: c.[1055A>G; *96A>G]) in the gene ARSA (MIM 607574), 
which are commonly referred to collectively as the ‘polyA mutation’.  The polyA 
mutation results in reduced levels of arylsulfatase A on biochemical assay without 
clinical symptoms (a state termed pseudodeficiency).  No other mutations were detected 
in the remainder of the gene at that time or in the current study.  In this context, the 
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detection of metachromatic granules in the sural nerve biopsy is unusual.  Nonetheless, 
despite prolonged follow up, no clinical or radiological features of progressive central or 
peripheral demyelination have developed, making MLD highly unlikely.  On current 
examination, there are no other neurological features besides the dystonia detectable 
on clinical examination and exhaustive radiological and biochemical investigations had 
failed to reveal any underlying cause.   Extensive genetic testing – including but not 
confined to TOR1A, THAP1, GNAL and ANO3 – has not revealed a causal mutation in 
these genes.   Although the severity of the dystonia had gradually increased over time, 
the clinical course appears relatively benign:  all three of the affected siblings continue 
to function well in daily life; there is no significant limitation of ambulation; and fixed 
deformities have not developed. 
 
7.2.2 Select ion of Cohorts for Mutational Screening 
Subsequent dystonia cases used to search for further confirmatory mutations in 
candidate genes were drawn from a bank DNA samples donated with research consent, 
which are held at our institution.  Despite the extensive nature of this clinical resource, 
the rarity of autosomal recessive, isolated dystonia meant that there were no other 
samples available from any other dystonia kindred where the inheritance pattern could 
definitively be said to be autosomal recessive.  We were therefore forced instead to 
select cases where the history was merely ‘not incompatible’ with autosomal recessive 
inheritance (i.e. with either no family history or a family history of affected siblings 
only).  Thus, for the initial cohort of 150 cases used to screen for mutations in the 
relevant exons of both candidate genes, we selected samples on the basis of an 
associated clinical history of the onset of isolated dystonia at 30 years of age or younger 
with no family history that might be taken to suggest autosomal dominant 
transmission, even with reduced penetrance.  We made a particular effort to include all 
research samples where the associated clinical details made mention of a possible family 
history involving only siblings, but in practice this only amounted to a handful of 
samples and most cases were thus singletons.  Because of the preponderance of 
singletons, it is, of course, inevitable that a proportion of the cases that we selected will 
have been either non-genetic or the result of cryptic autosomal dominant inheritance, 
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secondary to issues such as reduced penetrance, de novo mutations and germline 
mocaisism. 
 
For the second cohort of an additional 288 cases, used in the mutational screening of 
all coding exons of HPCA, we employed a slightly different approach.  As previously, we 
first identified those samples with an associated clinical description suggesting primary, 
isolated dystonia and no family history suggestive of autosomal dominant inheritance.  
From this pool, we then selected samples for actual sequencing on the basis of an 
associated clinical description of dystonia with a distribution similar to the that seen in 
the two families with recessive mutations in HPCA that we had by that time identified.  
That is to say, those with predominant upper limb, cervical or cranial involvement or 
those in whom the dystonia had generalised.  Regrettably, the clinical details associated 
with many of these samples did not always include a clear indication of the age at onset.  
However, we did make an effort to preferentially include samples from individuals with 
a younger age of onset (as might be expected in an autosomal recessive disorder) by 
selecting only those samples where the date of banking was within 5 decades of the 
sample donor’s date of birth (i.e. individuals aged 40 years or younger when the sample 
was donated). 
 
All research samples used in the study had previously undergone diagnostic testing for 
mutations in TOR1A and were negative.  As most of the cases had no family history, 
systematic testing for THAP1 mutations had not been carried out.  Finally, we also 
attempted to contact the authors of previous reports of autosomal recessive isolated 
dystonia in the literature in order to see if we could obtain DNA samples from affected 
members of these kindreds to include in our screening efforts.  In the end, however, we 
were only able to obtain DNA from an affected member of the DYT17 kindred, which 
was screened for mutations in both exon 7 of LAPTM5 and the whole coding region of 
HPCA, despite the fact that homozygosity mapping in this family had already suggested 
that the genetic cause was located elsewhere. 
 
The study was approved by the relevant local ethics committee at our institution and 
informed consent was provided by all participants in accordance with its guidelines. 
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7.2.3 Whole Exome Sequencing and Generation of Coverage Statist ics  
DNA was extracted from whole blood samples obtained from all three affected siblings 
and both parents.  DNA from one affected sibling was used to perform whole exome 
sequencing using Illumina’s TruSeq (62Mb) DNA sample preparation and exome 
enrichment kits as per section 4.15.  Reads were subsequently aligned and annotated 
using the standard approaches set out in sections 4.16. 
 
Coverage statistics for the exome as a whole were obtained using Picard.  Coverage 
across regions of shared homozygosity was calculated using BedTools against the CCDS 
definition of the exome and expressed as the percentage of bases target covered by at 
least one read.   
 
7.2.4 Genotyping and Subsequent Homozygosity Mapping 
Genome-wide genotyping data was obtained for all three affected siblings using the 
OmniExpress platform, which utilises approximately 500,000 markers, as per section 
4.12.  Autozygosity mapping was performed as per section 4.13.   
 
7.2.5 Filtration of Variants Detected by Exome Sequencing 
In view of the apparently recessive inheritance pattern and history of consanguinity, we 
initially selected all homozygous variants for consideration.  Subsequently, synonymous 
variants not likely to affect a canonical splice site (i.e. those not within 10 bases, in 
either direction, of the intron/exon boundary) were discarded.   Given the rarity of 
autosomal recessive dystonia, we further hypothesised that the causal variant was 
unlikely to be found in any database of normal sequence variation.  However, in order 
to minimize the possibility of incorrectly assigning causality, we filtered out those 
variants that were recorded in the 1000 Genomes, NHLBI or Complete Genomics 69 
datasets at a minor allele frequency of greater than 0.5%.  Given that a variant found at 
even this frequency would be expected to be occur naturally in the homozygous state in 
around 1 in every 160,000 births, it seemed distinctly unlikely that we would risk 
filtering out the causal variant with this cut-off.  Subsequently, variants that were 
located in a region of shared homozygosity were selected as potentially causal.  No 
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filtration was performed on the basis of in silico predictions of pathogenicity or 
conservation scores.   
 
7.2.6 Confirmation of Potential ly Causal Variants and Subsequent Sequencing 
of Candidate in Independent Dystonia Cohorts  
Primers were designed to amplify the relevant exons and exon/intron boundaries of 
both genes containing potentially causal variants, as defined above.  For both variants, 
mutational analysis by chain termination methodology was first performed in the 
remaining siblings and both parents in order to verify an appropriate pattern of 
inheritance.  Subsequently, the same primers were used to sequence the relevant exon 
of both genes in a cohort of 150 individuals with young-onset dystonia, selected as 
described in section 7.2.2.  After a second potentially causal mutation in HPCA was 
detected in one of these samples, primers were designed to amplify and sequence the 
remaining coding exons of that gene in these 150 samples and a further cohort of 288 
individuals with dystonia, selected as described in section 7.2.2.  Exon 1, which is 
entirely untranslated, was not sequenced.   
 
7.2.7 Generation of Nucleotide Multispecies Protein Alignments 
In order to assess conservation of amino acid sequence, Uniprot, FlyBase and 
WormBase were interrogated for orthologous protein sequences.  Actual alignment of 
the sequences obtained in this manner was performed using the freely available web-
based application ClustalΩ. 
 
7.2.8 Generation of Regional Gene Express ion Data 
Information on organism wide and brain region specific gene expression was collated as 
per section 4.19. 
 
7.2.9 Generation of Rat -Neuron Primary Culture and shRNA Knockdown Rat 
Primary Cortical  Cultures 
Animal husbandry and experimental procedures were performed in full compliance 
with the United Kingdom Animal (Scientific Procedures) Act of 1986.  For primary 
cortical cultures, Wistar wt rat pups were culled between postnatal days P1–3 and a 
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primary co-culture was prepared as described elsewhere 340.  Cerebral hemispheres were 
trypsinized and resuspended in 2 ml warm complete Neurobasal A medium and the cell 
suspension was plated on poly-L-lysine coated coverslips. The cultures were incubated in 
a humidified incubator at 37°C with 5% CO2 in air for 3–4 h, then 2 ml pre-warmed 
complete Neurobasal A medium was added. All live cell imaging experiments were 
performed between DIV 10-14. 
 
7.2.10 Rat hpca Knock-Down 
The hpca knock-down in rat cortical primary cultures was performed by Effectene 
transfection (Qiagen) after 9-10 days in culture with either one or a pool of 4 specific-
shRNAs targeting rat hpca (Thermo Fischer).  These four individual shRNAs as well as a 
pool thereof were used to knock-down hpca in rat cells.  The empty vector (pGIPZ) and 
the vector expressing a non-targeting RNA (SCR) were used as controls. Knock-down 
was confirmed by Western bot (please see results section for caveat regarding this and 
interpretation of results).  The transfection was made following the manufacturer 
instructions and the sequences from the mouse hpca shRNA were as shown in table 19.  
48 hours after transfection the cells were ready for subsequent experiments. 
 
Table 19 – shRNAs used for hpca knock-down are shown with corresponding genetic sequences 
shRNA label Genetic Sequence 
shRNA #1 AAAGAATACAGAACCTGAC 
shRNA #2 TTTCTAGCATCTCCTCCCG 
shRNA #3 CTTCTTGAACTCATCCACG 
shRNA #4 TGTTTGTGTCCATTTGGCG 
 
7.2.11 Functional Studies in Rat -Neuron Primary Culture 
Astrocytes and neurons from primary cortical co-culture were loaded for 30 min at 
room temperature with 5 µM fura-2 AM and 0.005% pluronic acid in a HEPES-
buffered salt solution composed of 156 mM NaCl, 3 mM KCl, 2 mM MgSO4, 1.25 mM 
KH2PO4, 2 mM CaCl2, 10 mM glucose, and 10 mM HEPES (pH was adjusted to 7.35 
with NaOH).  Fluorescence measurements were obtained on an epifluorescence 
inverted microscope equipped with a 20× fluorite objective. [Ca2+]c was monitored in 
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single cells with excitation light provided by a Xenon arc lamp, and the beam passed 
through a monochromator at 340 and 380 nm (Cairn Research, Kent, UK). Emitted 
fluorescence light was reflected through a 515 nm longpass filter to a charge-coupled-
device camera (Retiga, QImaging, Surrey, BC, Canada) and digitized to a 12 bit 
resolution. All imaging data were collected and analysed with software from Andor IQ 
(Belfast, UK). The fura-2 data were not calibrated in terms of [Ca2+]c because of the 
uncertainty arising from the use of different calibration techniques. Areas for the 
analysis were chosen depending on the GFP fluorescence intensity and four 
independent experiments were performed for each condition. The number of cells 
analysed for each set of experiments is indicated in the result section and in the legends 
of the figures. 
 
7.3 Results  
7.3.1 Exome Sequencing and Homozygosity Mapping  
Exome sequencing produced good coverage of the target.  Using the TruSeq exome 
definition as a reference, coverage was 96% at a read depth of 2, 87% at a read depth of 
10 and 74% at a read depth of 20.  Mean read depth across the exome was 58.  In total, 
22,097 variants were detected. 
 
The runs of homozygosity shared between all affected siblings are summarized in the 
Table 20, along with the number of Consensus Coding Database of Sequences (CCDS) 
genes in the region (obtained via Ensemble’s Biomart), their percentage coverage and 
the number of variants detected in that region prior to any filtering.  Overall, coverage 
of homozygous regions was well within the range expected for exome sequencing 
(≈85% of targeted bases).  Moreover, manual inspection of the uncovered bases within 
these regions revealed that the vast majority were in the untranslated regions of genes, 
were exome sequencing tends to perform more poorly.  Coverage of coding bases alone, 
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Table 20 - Regions of homozygoisty shared between all three siblings with genomic coordinates 
(hg19), length in megabases (Mb), the number of CCDS genes that lie in the region, the 
percentage of CCDS bases (including untranslated regions) covered by exome sequencing, the 
number of variants detected in that region and, finally, the number of potentially causal 
variants that remained after filtration as detailed in the methods. 











1 12880356 20476391 7.60 86 84.3% 166 0 
1 26909765 34686130 7.78 102 91.0% 43 2 
3 126380804 127502549 1.12 7 97.9% 5 0 
5 98552184 99968045 1.42 1 100% 0 0 
6 34502022 36226525 1.72 28 95.9% 16 0 
7 64926823 66464764 1.54 10 82.7% 3 0 
8 48639976 49656604 1.02 5 80.5% 3 0 
8 85802488 86990451 1.19 8 89.7% 4 0 
11 47976882 51591253 3.61 13 95.9% 32 0 
11 54794237 55943322 1.15 25 89.4% 52 0 
 
 
7.3.2 Filtration of the Data and the Identif ication of Two Potential ly Causal 
Variants  
Filtering of the variants, carried out as described in the section 7.2.5, left just 2 possible 
candidate causal variants for further consideration (Table 20 and 21).  Both were 
located in the largest stretch of shared homozygosity on chromosome 1.  The first was 
missense mutation (c.625G>A, p.V209M) in exon 7 of LAPTM5 (NM_006762), which 
encodes a lysosomal transmembrane protein.  The second, also a missense mutation 
(c.225C>A; p.N75K), was located in exon 2 of HPCA (NM_002143), a gene which 
encodes the neuronal calcium-sensor protein known as hippocalcin.   
 
According to Uniprot, the p.N75K variant in HPCA is located in the second EF-hand 
domain of the protein and affects an amino acid that is known to be critical to the 
domain’s calcium binding properties.  The variant detected in LAPTM5 does not lie in 
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any annotated functional domain of the protein, according to Uniprot.  Nonetheless, 
both variants are predicted to be highly damaging by all four in-silico prediction 
programs (SIFT, Provean, PolyPhen2 and MutationTaster) and the PhyloP and 
PhastCons scores suggest that both mutations affect a conserved base (see table 21 for 
scores).  With regard to the affected amino acids, multiple species alignment of 
orthologous protein sequences (see figure 22) demonstrated that the amino acid 
affected by the p.V209M mutation in LAPTM5 is conserved in most species for which 
an ortholog exists, with the exception of the tropical frog (X. tropicalis) which has an 
isoleucine at this position.  However, no orthologs are known for worm (C. elegans), fly 
(D. meganolaster), zebra fish (D. rerio) or pig (S. scrofula).  As might be expected given the 
affected amino acid’s critical role in calcium binding, multispecies alignment for the 
protein sequence surrounding the p.N75K mutation in HPCA showed absolute 
interspecies conservation of the affected amino acid down to fly and zebra fish.  Again, 
no orthologue is known to exist in the genome of C. elegans. 
 
7.3.3 Expression Data Supporting HPCA as a Higher -Priority Candidate for 
Dystonia  
Publically-available expression data based on experiments using EST tags demonstrated 
that both LAPTM5 and HPCA are expressed in a highly tissue-specific manner, though 
with quite distinct patterns of expression (Fig 23A and 23B).   Expression of LAPTM5 
was detected predominantly in the cells of the blood and associated haemopoietic 
organs.  This data is in line with the published murine tissue expression analysis 
performed at the time of the gene’s discovery, which showed it to be present at the 
highest levels in haematopoietic tissues (peripheral blood leucocytes, thymus and 
spleen) and the lung (possibly from contamination with alveolar macrophages), present 
in low levels in the placenta, liver and kidney, and absent or barely detectable in all 
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Table 21 – Summary of Candidate Causal Variants after Filtration 
Summary of both candidate causal variants with conservation scores (PhyloP and PhastCons), in silico predictions of pathogenicity (SIFT, Provean, PolyPhen2 
and MutationTaster) and the location of the variant with respect to predicted functional domains of the protein (from Uniprot).  Previously reported refers to 
the whether the variant can be found in the databases of dbSNP, NHLBI Exome Sequencing Project, the 1000 Genomes Project, and Complete Genomics 69.  
Both variants are conserved and predicted to be damaging by all four prediction programs.  Actual numerical scores provided by the in silico prediction programs 
are shown here in brackets for the sake of completeness and readers are referred to the programs websites for a detailed explanation of their meaning.  D = 
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other tissues (including, most importantly, the brain) 341.  HPCA, on the other hand, 
appears to be expressed almost exclusively in the brain.  This would be more in keeping 
with the expression pattern of a gene capable of causing a purely neurological disorder 
like isolated dystonia.  
	  
Figure 22 - Orthologous protein sequences for the relevant variant-containing regions HPCA 
and LAPTM5, obtained via Uniprot and Flybase for all species available and aligned using 
ClustalOmega.  No orthologous sequence was available for worm (C. Elegans) in either case.  
The affected amino acid in the p.N75K mutation in HPCA (left) shows absolute interspecies 
conservation.  Note also the high level of conservation in this region as a whole.  The amino 
acid affected by the p.V209M mutation in LAPTM5 (right) is not fully conserved, with the 
tropical frog possessing an isoleucine at this position, and no orthologue exists for pig, zebra 
fish or drosophila.  Symbols under each column indicate the degree of conservation (an asterisk 
= a single identical amino acid; a colon = strongly similar properties; a period = weakly similar 
properties; a blank = no conservation].  Colours indicate physiochemical properties of amino 
acids (red = small/hydrophobic; blue = acidic; magenta = basic; green = 
hydroxyl/sulfhydrl/amine/glycine). 
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Figure 23 - Publically-available expressed sequence tag data for a) LAPTM5 and b) HPCA, demonstrating that both genes show relatively tissue-specific expression patterns.  LAPTM5 is 
predominantly expressed in hemopoietic tissues, whilst HPCA is almost exclusively expressed in the brain.  c) Box plot of mRNA expression levels for HPCA in 12 CNS regions, based on exon array 
experiments and plotted on a log2 scale (y axis). This plot shows significant variation in HPCA transcript expression across the 10 CNS regions analysed: putamen (PUTM, n=129), hippocampus 
(HIPP, n=122), temporal cortex (TCTX, n=119), frontal cortex (FCTX, n=127), occipital cortex (OCTX, n=129), thalamus (THAL, n=124), cerebellar cortex (CRBL, n=130), substantia nigra 
(SNIG, n=101), intralobular white matter (WHMT, n=131) and medulla (specifically inferior olivary nucleus, MEDU, n=109).  HPCA mRNA expression is highest in the putamen, followed closely 
by the hippocampus.  Expression is also high in the cortex.  Whiskers extend from the box to 1.5 times the inter-quartile range. 
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Furthermore, our own in-house expression datasets based on exon array profiling of 
samples from multiple areas of ~130 control brains not only confirm that HPCA is well 
expressed in the brain as a whole, but also demonstrates significant regional differences 
in expression, with the highest levels of expression being detected in the striatum 
(represented by the putamen in our study), an area intimately connected with the 
pathophysiology of many movement disorders, including dystonia (Fig 23C).  Indeed, 
expression of HPCA was detected at levels 41 fold higher in the striatum than in the 
medulla (p=5.5x10-68), the region with the lowest levels of expression relatively-speaking, 
even though absolute levels of HPCA expression in the medulla are still quite high.  
Expression of HPCA is also high in the hippocampus and cortex.   
 
7.3.4 Mutational Screening of Both Candidate Variants in an Independent 
Cohort of  Young Onset Dystonia  
In an attempt to find a second novel mutation in either gene, we next sequenced the 
relevant exons of both genes in 150 cases of young onset dystonia, as well as a DNA 
sample from an affected member of the DYT17 kindred (see section 7.2.2 for full case 
selection criteria).  We did not detect any further novel variants in exon 7 of LAPTM5.  
In exon 2 of HPCA, however, we detected a second, heterozygous, novel, missense 
variant (c.212C>A) resulting in an amino acid substitution (p.T71N) at a position in 
the protein, just 4 amino acids before the location of original homozygous mutation 
found in the index family.  The affected nucleotide shows extremely high conservation 
scores (PhyloP=5.76 [max=6]; PhastCons=1 [max=1]).  Although the amino acid at 
position 71 is not itself recognized as an obligatory Ca2+-coordinator, it is still within 
the second EF-hand domain (amino acids 60 to 95, according to Uniprot) and does 
show the same absolute interspecies conservation as the amino acid affected by the 
N75K mutation.  In addition, it is predicted to be damaging by all 4 in silico prediction 
programs.  In view of this finding, we went on to sequence the remainder of the coding 
exons of HPCA in the same 151 samples.  We found only one additional variant of any 
kind and this was in the same sample that harboured the p.T71N mutation, meaning 
that individual was compound heterozygous for these two changes.  The additional 
variant was a novel missense mutation (c.568G>C; p.A190T) located towards the end 
of exon 4 of HPCA, which encodes the C-terminal of the protein.  The nucleotide 
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involved is conserved (PhyloP=2.015; PhastCons = 1), whilst the affected amino acid is 
conserved in most species, with the exception the fly (D. melanogaster) and the 
Tasmanian devil (S. harrisii).  However, only MutationTaster predicts it to be disease-
causing; SIFT, Provean and PolyPhen2 predict that the substitution will be tolerated. 
 
Having detected two potentially pathogenic mutations in HPCA in the same DNA 
sample of an individual with dystonia, we established contact with the patient, a 64 
year-old woman of Sri Lankan origin, to verify the medical and family history and 
perform a full neurological examination.  She reported the onset of dystonia in her 
early twenties, possibly even her late teens, which initially manifested with abnormal 
involuntary movements of her fingers that were most noticeable while trying to type.  
Over time, her dystonia has very gradually worsened, with the emergence of a 
tremulous component.  Nonetheless, it remains segmental, affecting only the hands, 
arms and muscles of the neck, and would be classified clinically as mild.  Despite being 
a member of sibship of seven, no other family member, including her parents, siblings, 
and her siblings’ children, reported any symptoms consistent with dystonia (figure 24).  
As both parents and two of her siblings were now deceased, we were only able to obtain 
DNA samples from the 4 surviving siblings, which we used to sequence the relevant 
exons of HPCA for segregation analysis.  The results of the segregation analysis in this 
family were consistent with the hypothesis that the compound heterozygous mutations 
we observed in HPCA in this individual are the cause of her dystonia, in that 1) one 
sibling was heterozygous for the p.A190T mutation alone, thus confirming that the two 
mutations had been inherited separately from each parent; and 2) the only affected 
individual was also the only individual in which we detected both the p.T71N and 
p.A190T mutations in the compound heterozygous state; and 3) the remaining 
unaffected siblings all possessed either one or both wild type alleles, incompatible with 
development of a recessive disease (figure 24). 
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Figure 24 – Genetic pedigree of the second family with compound heterozygous mutations in 
HPCA.  Individual II:1 developed young onset dystonia affecting the hands in her late teens or 
early twenties.  It has gradually extended to become segmental, involving the hands, arms and 
neck.  No other family member was affected.  Mutational status is shown under each 
individual:  w = wildtype allele; m1 = p.T71N mutation; m2 = p.A190T mutation. 
 
7.3.5 Further Mutational Screening in an Additional 288 Cervical/Upper 
Limb Onset Predominant Dystonia Cases  
We next attempted to find a third case by screening all 3 coding exons of HPCA in a 
second cohort of 288, non-autosomal-dominant cases of young-onset (<40 years of age), 
isolated dystonia in which the dystonia was either generalized or most prominent in the 
upper limbs, cervical or cranial region.  Unfortunately, no further variants of any kind 
– either novel or previously annotated – were detected in any sample. 
 
7.3.6 Low Level  of  Natural Human Sequence Variation in HPCA  
Given the failure to find even a single sequence variant of any sort in 438 individuals, 
we decided to examine the burden of natural human genetic variation in HPCA.  Using 
the pooled next-generation sequencing results of the NHLBI Exome Sequencing, 
ClinSeq, 1000 Genomes, and HapMap projects, which, contain collectively the exome 
sequencing data from 8,451 individuals of various ethnicities, we identified only 8 
separate missense variants (none of them homozygous) in this gene (Table 22).  By way 
	   217	  
of comparison, based on the same datasets, 31 missense (11 of which are predicted to 
be damaging by both SIFT and PolyPhen), 2 splice site and 1 frameshift variant have 
been detected in LAPTM5.  Although, due to a lack of data, we cannot be certain this 
low level of variation in HPCA extends to all populations, this observation does at least 
further increase the likelihood that the identification of compound heterozygous 
mutations in HPCA in a second dystonia kindred, segregating perfectly with disease, 
was very unlikely to have occurred by chance.  
 
7.3.7 Neuropsychological Test ing in an Affected Member of  the Index Family  
Given that the protein product of HPCA has been implicated in synaptic plasticity and 
that knock-out mice for this gene show defects in spatial and associative learning, we 
arranged for detailed neuropsychological testing of an affected member of the index 
family by a trained clinical psychologist who was blinded to the purpose of the 
assessment.  The results revealed a degree of cognitive under-functioning with respect to 
optimal premorbid estimates.  In particular, there was difficulty encoding visual and 
verbal information, difficulty with attention and processing speed, and mild problems 
with executive dysfunction.  Delayed visual and verbal recall memory, naming, visual 
constructional abilities and phonemic and category fluency were intact.   Although 
considerable anxiety was noted during testing, the clinical psychologist was of the 
opinion that this may have exacerbated but did not fully explain, the cognitive deficits 
evident on testing. 
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Table 22 – Publically annotated variants with protein-coding consequence in human HPCA.  In total, this represented a pool of 8,451 individuals (16,902 
chromosomes).  Only 8 separate missense variants were detected, none of which were common and none of which were homozygous.  Only two were predicted 
to be damaging by both SIFT and PolyPhen. 




Database of Origin Genotype Count 
(/8,451) 
SIFT Prediction PolyPhen Prediction 
rs11554958 c.63G>T p.Glu21Asp HapMap 
 
G/G = 8,450 
G/T = 1 
T/T = 0 
Benign Benign 
rs147332564 c.178G>C p.Asp60His NHLBI ESP G/G = 8,450 
G/C = 1 
C/C = 0 
Damaging Damaging 
rs182483890 c.196G>A p.Glu66Lys 1000 Genomes G/G = 8,450 
G/A = 1 
A/A = 0 
Benign Damaging 
rs201850746 c.286C>T p.Arg96Cys ClinSeq C/C = 8,450 
C/T = 1 
T/T = 0 
Damaging Benign 
rs138767632 c.373G>A p.Val125Met NHLBI ESP G/G = 8,449 
G/A = 2 
A/A = 0 
Damaging Damaging 
rs376349097 c.403G>T p.Val135Leu NHLBI ESP G/G = 8,450 
G/T = 1 
T/T = 0 
Benign Benign 
rs140440243 c.412A>C p.Met138Leu NHLBI ESP A/A = 8,450 
A/C = 1 
C/C = 0 
Benign Benign 
rs371851892 c.484G>A p.Gly162Ser NHLBI ESP G/G = 8,450 
G/A = 1 
A/A = 0 
Benign Benign 
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7.3.8 Functional Studies in Rat Neuron Primary Culture  
Hippocalcin, the protein product of HPCA, is a neuronal calcium sensor protein, 
believed to play an important role in intracellular calcium-dependent signalling.  The 
N75K mutation that we detected in the index family cause the substitution of a key, 
calcium-coordinating amino acid that forms part of the almost invariable, universal 
sequence motif that defines all functioning EF-hand domains (only asparagine or 
aspartic acid are found at this position; see also discussion below).  The loss of this 
motif and, in particular, the substitution of a positively charged lysine at an amino acid 
position directly involved in the binding of a positively charged Ca2+, would be expected 
to reduce the domain’s affinity for the ion or even block its binding completely.  Given 
that calcium-binding is known to be a prerequisite for the conformational change 
essential to the protein’s function, we hypothesized that the N75K mutation at least 
would be expected to result in significantly reduced or even complete loss of function 
of hippocalcin within the cell.  Therefore, we performed shRNA knockdown of hpca on 
rat primary neuronal and astrocytes and used the resultant cells to measure, by means 
of fura-2 florescence microscopy, the effect of hippocalcin deficiency on cellular calcium 
homeostasis after exposure to different neuropharmacological agents.  Specifically, cells 
were stimulated with:  glutamate (10 µM) to simulate a physiological calcium signal in 
neurons via activation of glutamate receptors; ATP (100µM) to stimulation of P2Y 
receptors in astrocytes; and potassium chloride (KCl, 50mM) to depolarize neuronal 
membrane and induce opening of voltage-gated calcium channels.  
 
Unfortunately, it is necessary to state at this point that the following results need to be 
interpreted with caution.  As is normal practice, hpca knock-down is transfected rodent 
neurons was confirmed by Western blot.  Regrettably, after publication of the data, the 
blots themselves have been misplaced and cannot therefore be included in this thesis as 
proof of successful knock down.  I have decided nonetheless to include the data as it is 
interesting, but thankfully is not required as part of the genetic proof for the causality 
of this gene.  
 
We found that application of glutamate to hpca-shRNA transfected neurons resulted in 
smaller, but non-significant neuronal response to glutamate (0.95±0.4, n=35; see figure 
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25A, lower panel), compared to the scrambled and empty vector transfected controls 
(1.35±0.4, n=35, p=0.48 and 1.45±0.3, n=21, p=0.38, respectively; see figure 25B, 
upper panel).   
 
Astrocytic signal to stimulation with ATP (100 µM) in HPCA knock-down cells was also 
smaller (figure 25C, D; 0.6±0.2, n=55) than those in scrambled and empty vector 
transfected control cells (1.4±0.35, n=45 (scr) and 0.9±0.5, n=28, respectively), but the 
reduction in signal only reached significance when compared to scrambled controls 
(p=0.04). 
 
Somewhat unexpectedly, the most significant difference between hpca-silenced and 
control neurons was observed after depolarization of the plasma membrane by 
application of 50 mM KCL.  As anticipated, in both scrambled and empty vector 
transfected control neurons, this resulted in a strong Ca2+-signal (1.65±0.45, n=35 and 
1.75±0.34, n=21, respectively).  In hpca-shRNA transfected neurons, however, 
application of KCL produced almost no observable calcium signal (0.1±0.02, n=35; 
p=0.001 vs scrambled and p˂0.0001 vs empty vector controls; Figure 25A and B). 
Importantly, all of these cells demonstrated a clear response to glutamate confirming 
their neuronal origin (figure 25B). 
 
Together, this pattern of severely altered neuronal responses to physiological stimuli 
suggests that HPCA deficiency may result in inhibition of potential-sensitive Ca2+ 
channels or, alternatively, modify the mechanism of maintaining the membrane 
potential, affecting cellular response to membrane depolarization.  As stated above, 
however, these results are included for interest’s sake only and, in the absence of the 
Western blot confirming successful knock-down, cannot form part of the argument for 
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Figure 25 – A and C) Representative traces of response of [Ca2+]c  to physiological stimuli as 
measured by changes in Fura-2 fluorescence intensity.  hpca knockdown neurons show no rise 
in [Ca2+]c in response to depolarisation of the plasma membrane with  50 mM KCl (A, dark 
grey trace; B, dark grey bars) in comparison to neurons from the scrambled or the empty 
control (A, black triangle trace). In addition, the amplitude of the response to physiological 
concentration of Glutamate (5µM) in the hpca knockdown neurons was decreased compared to 
the control (b, black bars), although not statistically significant.  hpca knockdown also 
diminished the amplitude of the [Ca2+]c response of astrocytes to an ATP stimulus (100µM) (C, 
D - light grey trace and bars). Error bars represent SEM; asterisks represents statistical 
significance (*** = p<0.0001, * = p<0.05). 
	   222	  
7.4 Discuss ion 
We set out to use homozygosity mapping and whole exome sequencing to help 
elucidate the genetic cause of the young-onset, isolated dystonia in a consanguineous 
kindred, suggesting autosomal recessive inheritance.  By appropriate filtration of the 
variants, we were able to narrow our list of candidates down to just two potentially 
causal mutations in the genes LAPTM5 and HPCA, respectively.  Given the 
neurological nature of the disease under consideration, expression data suggested 
HPCA to be the more probable candidate as it is brain-specific and is detected at the 
highest levels in the striatum, an area of the brain often implicated in movement 
disorders.  After sequencing the exon harboring the candidate variants for both genes 
in an independent cohort of young-onset dystonia, we identified a second kindred with 
isolated dystonia that segregated with novel, compound heterozygous mutations in 
HPCA, suggesting recessive mutations in this gene to be the cause of the isolated 
dystonia in both this and the original index family.  Despite further sequencing of the 
whole gene in both this cohort plus an additional case, we did not identify any cases 
with recessive mutations in HPCA.  In fact, we did not find any other coding or splice 
site variant in HPCA – either novel or previously annotated – in any of the other cases 
screened.  This low level of variation is confirmed by the results of the NHLBI exome 
sequencing project, which has detected only 6 missense variants (none of them 
homozygous) and 12 synonymous coding variants in HPCA in the 13,000 
chromosomes for which data has so far been made public (European and African 
American populations combined).  Although we cannot be certain this low level of 
variation extends to all populations because of a lack of data, this observation does at 
least further increase the likelihood that the identification of compound heterozygous 
mutations in HPCA in a second dystonia kindred, segregating perfectly with disease, 
was very unlikely to have occurred by chance. 
 
Notwithstanding the loss of the Western blot, functional studies in rodent neurons and 
astrocytes, knocked-down for HPCA gene, suggest that HPCA deficiency may modify 
the physiological calcium signal in both neurons and astrocytes.  Most importantly, we 
found that hippocalcin regulates the two most common pathways for calcium entry – 
glutamatergic receptors and potential-sensitive calcium channels.  This might suggest a 
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role of hippocalcin in maintenance of the plasmalemmal membrane potential either by 
affecting it indirectly or by direct influence on the voltage dependent calcium channels.  
Further experiemental work is required to confirm this, however.  
 
Hippocalcin is part of a subfamily of neuronal calcium sensor (NCS) proteins with high 
sequence homology, which includes vasinin-like proteins 1 and 2, hippocalcin-like 
protein 1 and neurocalcin δ (figure 26) 342.  All NCS proteins are characterized by four 
EF-hand domains that act as potential Ca2+ binding sites.  EF-hand domain 1, however, 
is invariably inactive, whilst EF-hand domain 4 is active in some, but not all NCS 
proteins.  Canonical calcium-binding EF-hand domains are characterized by the semi-
conserved sequence motif D-X-D/N-X-D/N-G-(X)5-E, where the obligate amino acids in 




Figure 26 - Sequence alignments for the subfamily of human NCS proteins of which 
hippocalcin is a member.  Protein sequences demonstrate a high degree of sequence homology, 
particularly between hippocalcin, neurocalcin delta and hippocalcin-like protein 1.  The area of 
shading at the N-terminal region of the protein indicates the myristoyl moiety, whilst the 
following three areas of shading indicate the potentially functional EF-hand domains 2, 3 and 
4.  EF hand domain 1 is non-functional in all members of the family and is not shaded in this 
figure.  Colours indicate physiochemical properties of amino acids (red = small/hydrophobic; 
blue = acidic; magenta = basic; green = hydroxyl/sulfhydrl/amine/glycine). 
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The binding of calcium to the EF hand domains of NCS proteins operates a myristoyl-
switch mechanism that controls the protein’s ability to translocate to target membranes 
and/or interact with downstream effectors (figure 27) 344-346.  This mechanism has been 
extensively studied in the related neuronal protein, recoverin 346.  In the native, Ca2+-
free state, recoverin and other such myristoyl-switch proteins assume a physical 
configuration that sequesters the myristoyl-side chain in an internal hydrophobic 
pocket.  After a rise in local Ca2+ concentrations, the functional EF-hand domains are 
believed to bind Ca2+ in sequential, semi-cooperative manner 347.  With the binding of 
the final Ca2+ ion, there is a conformational change that exposes the hydrophobic parts 
of the protein and causes the extrusion the N-terminal myristoyl side chain, freeing it 
for interaction with cellular membranes and/or target proteins.  In this way, Ca2+-
myristoyl switch proteins are able to act as reversible transducers of cellular Ca2+ signals, 
capable of integrating both temporal and spatial aspects of signaling over a tight 
dynamic range 344. 
 
	  
Figure 27 - A semi schematic diagram of the calcium-myristoyl switch mechanism using 
recoverin, a related neuronal calcium sensor protein as an example.  A) In the native, non-Ca2+ 
bound state, recoverin assumes a configuration in which the myristoyl moiety (just visible in 
magenta) is buried deep within a hydrophobic pocket within the protein.  B) Upon binding of 
Ca2+ first to EF-hand domain 3 and then to EF-hand domain 2, the protein undergoes a 
conformational change that causes the myristoyl moiety to be extruded, freeing it for 
interaction with target membranes and proteins.  (This figure has been modified from Figure 1 
as published by Ames et al., 1997) 
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From the point of view of the molecular mechanism mediating the pathogenicity of the 
mutations we detected, the p.N75K mutation in HPCA results in a substitution of the 
second Ca 2+-coordinating residue of the binding sequence within EF-hand domain 2.  
As detailed above, in functional EF-hand domains, usually only one of two amino acids 
will be found at this position:  a negatively charged aspartic acid or a neutral asparagine 
(as in hippocalcin).  The p.N75K mutation thus not only results in the loss of a 
canonical calcium-coordinating amino acid, but also results in the incorporation of a 
positively-charged lysine, which might reasonably be expected to present a particular 
impediment to the binding of the similarly-charged Ca2+ ion.  Thus, it is plausible to 
hypothesize that the homozygous p.N75K mutation, by impairing or even preventing 
calcium binding to EF-hand domain 2, might be expected to reduce the likelihood of 
the any conformational change of hippocalcin in response to Ca2+ signals.  Since 
conformation change is a prerequisite for its interaction with downstream effectors, the 
ultimate outcome would be a defect in cellular Ca2+ signal transduction.  In the case of 
the second family we identified, the p.T71N mutation is also located in EF-hand 
domain 2 and, despite not affecting an amino acid directly involved in coordinating 
Ca2+, could potentially adversely affect binding kinetics via alterations of local secondary 
or tertiary structure.  The p.A190T mutation, on the other hand, is not located in any 
EF-hand domain but, instead, in the C-terminal region of the protein.  The mechanism 
by which this mutation might impair protein function is less obvious.  Nonetheless, it 
has been suggested that the C-terminal regions of other NCS proteins may be involved 
in fine-tuning of their response or the determination of target specificity 348, 349.  Follow-
up studies involving direct mutagenesis will help definitively answer these mechanistic 
questions.  
 
Neuronal calcium sensor proteins, such as hippocalcin, possess no inherent enzymatic 
properties, but exert their calcium-dependent functions through interactions with other 
proteins.  Thus, the identiﬁcation of downstream interactors is a necessary first step in 
understanding their speciﬁc activities.  In the case of hippocalcin, the identity of these 
interactors remains incomplete.  There is, nonetheless, evidence to suggest that it may 
have a role in 1) the modulation of cyclic nucleotide signaling in the olfactory 
epithelium 350; 2) long-term depression in the hippocampus 351-353; 3) generation of the 
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slow afterhyperpolarization current, important is controlling neuronal excitability 354-356; 
4) regulation of gene transcription 357, 358; and 5) neurite outgrowth 359.  Whilst it is 
entirely possible that some other, currently unknown function of hippocalcin may 
underlie its involvement in dystonia, it notable that, in relation to the processes 
mentioned above, both the aberrant excitability of striatal neurons and altered synaptic 
plasticity due in part to decreased long-term depression are two mechanisms believed to 
be important in at least some forms of dystonia 360-363 
 
Hippocalcin has been most intensely studied in relation to its role in synaptic plasticity 
within the hippocampus where it has been hypothesized to play a role in memory 
formation.  Indeed, hippocalcin knock-out mice showed deficits in tests of spatial and 
associative memory, in the absence of any obvious structural abnormalities within the 
brain 357.  Difficulties with memory were not, however, reported by any of the 
individuals with hippocalcin mutations in our study.  Although the aim of this study 
was to identify the genetic cause of dystonia in the index family and not to clinically re-
phenotype them, we were able to arrange neuropsychological testing for one of the 
affected members of the index family who travels to our center frequently.  This did 
show evidence of cognitive underfunctioning, with particular difficulties in encoding 
verbal and visual information.  The affected individual in the second family – who also 
had a much milder dystonic phenotype – had only just recently retired as a teacher and 
had an MMSE of 30/30, arguing against any significant difficulties with memory or 
learning and limitations in the studies ethical approval precluded further testing.  
Whether memory deficits represent subtle and variable associated phenotype in 
humans with HPCA mutations (like hyposmia in GNAL mutations 364) or whether the 
neuropsychological deficits observed in the individual in this study were an incidental 
finding remains an open question that only the identification of further cases and a 
study dedicated to their neuropsychological profiling will answer. 
 
In summary, in this chapter I have presented evidence to support biallelic mutations in 
HPCA as the first identified cause of autosomal recessive, isolated dystonia.  This 
discovery permits the assignation of an actual causal gene to the anomalous DTY2 locus 
and demonstrates the existence of a recessive form of isolated dystonia.  Although we 
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were only able to identify one additional family with dystonia presumed secondary to 
mutations in HPCA, this is not inconsistent with the relative rarity of the disorder and 
it is unlikely that any European or American institution would have possesed a 
significantly higher number of cases.  However, screening of further suitable cases, 
particularly in geographical regions with higher rates of consanguinity, will be required 
to give a better idea of its actual prevalence.   
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8.  Exome Sequencing in Autosomal Recess ive ,  Cervical -
Onset  Dopa-Responisve Dystonia  
 
8.1 Introduction 
Dopa-responsive dystonia is an uncommon condition, with a prevalence of 0.5 – 1 
individual per million.  Nonetheless, it remains an important condition to recognise as 
it is, by definition, readily treatable by the oral administration of L-dopa.  Response to 
this treatment is often dramatic, sustained and is not usually associated with the 
development of motor fluctuations and dyskinesias, which tend to develop with 
prolonged treatment in other dopa-responsive disorders, most notably Parkinson’s 
disease.  To date, 3 genes have been convincingly shown to cause dopa-responsive 
dystonia:  GCH1 (GTP Cyclohydrolase 1), TH (Tyrosine Hydroxylase) and SPR 
(Sepiapterin Reductase) 234-236.  All three genes encode enzymes that are involved in the 
endogenous biosynthesis of dopamine. 
 
We identified a Muslim Indian kindred in which three out of five siblings presented 
with dopa-responsive, predominantly cervical dystonia.  Previous mutational screening 
had ruled out GCH1, TH or SPR as the cause of the disorder 365.  Using a combination 
of linkage analysis and exome sequencing, we sought to identify the cause of the dopa-
responsive dystonia in this family. 
 
8.2 Subjects ,  Materials  and Methods 
8.2.1 Clinical Detai ls  of  the Index Family 
Participants were drawn from a multi-generational Muslim Indian family.  The core 
pedigree of the family as initially provided to us is shown in figure 28.   No other 
member of the extended family was said to have suffered from any symptoms that 
might be compatible with dystonia. DNA was initially available from three affected 
individuals as well as both parents.  The pattern of inheritance was consistent with an 
autosomal recessive condition.  The parents reported no consanguinity. 
 
     
	   232	  
  
	  
Figure 28 – Pedigree as initially provided for the core index family.  DNA is marked as was 
available.  All affected siblings demonstrated dopa-responsive cervical dystonia.  No member of 
the extended pedigree reported or were reported to have symptoms consistent with dystonia. 
 
Individual II-1 developed jerky right-sided torticollis at the age of 15, which 
progressively worsened over the period of a year.  Subsequently, laryngeal dystonia, 
clawing of his fingers, hand tremor, and difficulty writing also developed. On 
examination at 18 years of age, he had right torticollis, left sternocleidomastoid 
hypertrophy, head and hand tremor, and tremulous writing.  Distal finger contractures, 
mild right scoliosis, and spasmodic dysphonia were noted.  Treatment with 
trihexyphenidyl and baclofen did not produce any benefit.  However, on initiation of 
treatment with levodopa-carbidopa (100:25mg three times daily), there was dramatic 
improvement in his cervical dystonia and he was able to resume work.  The postural 
hand tremor, however, remained unchanged.  
 
Individual II-2 and II-3 were similarly affected, developing cervical dystonia with 
associated side-to-side head tremor at ages 13 and 11 years respectively.  In addition, 
there was postural hand tremor that interfered with writing.  In the case of both 
additional siblings, treatment with levodopa-carbidopa at low doses produced 
significant improvement in the degree of cervical dystonia. 
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No progression of dystonia occurred on follow-up for 12, 6, and 5 years in the three 
siblings.  The excellent response of the dystonia to low doses of levodopa was sustained 
in all three cases.  Withdrawal of levodopa resulted in the return of symptoms within 4 
days and these resolved again after levodopa was readministered. 
 
8.2.2 Whole Exome Sequencing 
DNA was extracted from whole blood samples obtained from all five siblings and both 
parents.  Whole exome sequencing was performed as per section 4.15.  Reads were 
subsequently aligned and annotated using the standard approaches set out in section 
4.16.   
 
Initially DNA from individual II-1 only was used for exome sequencing.  However, this 
left a too large number of potential candidate variants for consideration aand so, 
subsequently, DNA from both other affected individuals were also exome sequenced.  
Variant filtration is described in the results section 8.3.4. 
 
8.2.3 Genotyping and Autozygosity Mapping 
The family did not report any consanguinity and we hypothesised that disease in this 
family was most likely secondary to compound heterozygous mutations.  However, we 
undertook autozygosity mapping, as per section 4.13, in any case to quantify the extent 
of any tracts of homozygosity and thus provide a estimation of the likelihood of 
unreported consanguinity.  Genome-wide SNP data was obtained for all three affected 
individuals using the OmniExpress, which analyses approximately 500,000 markers, as 
per section 4.12.  
 
8.2.4 CNV Analysis  
Genome-wide SNP data was also used to search for shared deletions and duplications 
that might be the cause of the dopa-responsive dystonia in this family.  Potential CNVs 
were detected using PennCNV for each sample individually.  Subsequently, CNVs that 
were common to all three affected individuals were identified. 
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8.2.5 Linkage Analysis  
Linkage analysis was performed using MERLIN as per section 4.14.  A parametric 
analysis under an autosomal recessive model of disease inheritance with penetrance of 
100% and a pathological allele frequency of 0.0001 produced the best scores. 
 
8.3 Results  
8.3.1 Autozygosity Mapping 
Autozygosity mapping demonstrated that shared areas of homozygosity in this family 
were both rare and small (see table 23 for a comparison of the size and distribution of 
homozygosity in a typical consanguineous kindred).  In assition, no potentially 
pathogenic, homozygous mutations were found in these regions.  Based on this 
information, we concluded that the report of no consanguinity in the core kindred was 
correct and that the dystonia was most likely the result of compound heterozygous 
mutations. 
 
Table 23 - Areas of extended (>1 megabase) homozygosity shared by all the affected siblings with 
genomic coordinates, length (in kilobases) and number of genes covered. 
Chr Start Position Stop Position Length (Kb) Genes 
Potential 
Pathogenic 
3 48636099 49860854 1224.76 49 0 
3 50368806 51887557 1518.75 27 0 
7 118356108 120086499 1730.39 3 0 
8 99413330 100993147 1579.82 6 0 
12 60601848 61732540 1130.69 3 0 
 
 
8.3.2 Linkage Analysis  
Linkage analysis in a kindred of this size was not expected to produce a truly significant 
LOD score, but was, instead, used to highlight areas with a greater likelihood of 
harboring a causal variant and identify others where potentially causal variants could be 
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excluded (i.e. areas with LOD score of less than -2).  The summary of the genome wide 
linkage data is shown in figure 29 and table 24.  The highest LOD score achieved was 
1.204 on chromosome 6, 11 and 12, which defined the primary areas of interest.  
These peaks were also the widest of the linkage peaks, suggesting a large common 
haplotype.  There were a further 5 peaks with a maximal LOD score of between 1 and 
1.203, which defined the secondary areas of interest. 
 
Table 24 - Regions of linkage with a LOD score of greater than 1.  Three peaks had an identical 
LOD score of 1.204 and are identified as the primary areas of interest.  For each region, the 
genomic coordinates, size, LOD score and number of known genes within the region are given 
(hg19 via Ensembl), 
Chr Start Position Stop Position Size (Mb) Max LOD 
Known 
Genes 
PRIMARY AREAS OF INTEREST 
6 506231 42044945 41.5 1.204 364 
11 76996593 114753038 37.8 1.204 407 
12 2456115 48272895 45.8 1.204 548 
SECONDARY AREAS OF INTEREST 
3 43797458 65180001 21.4 1.203 318 
3 172843082 187269748 14.4 1.181 149 
6 100785588 127726196 26.9 1.202 208 
7 49733584 77977855 28.2 1.116 423 
8 31159012 60237300 29.1 1.180 240 
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Figure 29 – Plot of genome-wide linkage data.  The chromosome numbers are shown across the top of the plot.  The central x-axis represents 
chromosomal distance in centiMorgans (CM).  The y axis indicates the LOD score.  The maximal LOD score was 1.204 and there are 8 peaks 
with a LOD score of greater than 1. 
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8.3.3 CNV Analysis  
CNV analysis revealed 8 small CNVs common to all three affected individuals (table 
25).  Most of these were within intergenic regions and contained no known genes, 
including the only homozygous deletion.  The three shared CNVs that did contain 
genes, on chromosomes 7, 9 and 16, were heterozygous duplications and thus unlikely 
to be the cause of this ostensibly autosomal recessive condition. 
 
Table 25 - Copy  number variants (CNVs) common to all three affected siblings.    2 is the 
normal copy number, such that 0 indicates a homozygous deletion, 1 a heterozygous deletion, 
and 3 a heterozygous duplication.  For each CNV, genomic coordinates, size (in kilobases), the 
number of SNPs the call is based upon and the number of genes in the region are given. 







5 117418263 117421055 2.7 4 1 0 
6 121775368 121858807 83.4 16 3 0 
7 27127364 27227300 99.9 23 3 14 
8 43689385 43793527 104.1 6 1 0 
9 107507950 107518947 10.9 4 3 1 
11 81181640 81194909 13.2 7 0 0 
13 22320753 22437563 116.8 14 3 0 
16 1247677 1315264 67.5 10 3 5 
 
 
8.3.4 Exome Sequencing and Variant Fi l tration 
Exome sequencing generated an average of 81270305 unique reads.  Based on the 
CCDS hg19 definition of the exome, average coverage at 2x, 10x and 20x read depth 
was 94.3%, 91.2% and 86.7%, respectively, with the mean coverage across the whole 
exome of 66 reads.  This translated to an average variant count of 22877 variants per 
exome. 
 
In order to isolate potentially pathogenic variants, we applied a systematic filtering 
procedure to the data (figure 30).  We began by selecting only those variants that were 
present in the exome data of all three affected family members for analysis. 
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Synonymous variants and variants recorded in dbSNP135 were initially removed.  We 
then filtered out any variant present at a global minor allele frequency of ≥1% in a 
range of publically available databases of sequence variation (1000 Genomes, Complete 
Genomic 69 Database and NHLBI Exome Sequencing Project database) as well as those 




Figure 30 – Graphic illustration of the filtering process applied to the exome datasets in order 
to select out likely candidate causal variants for this ostensibly autosomal recessive condition.  
Other databases = 1000 Genomes, NCHLBI Exome Sequencing Project and the Complete 
Genomic 69 database. 
 
8.3.5 Potential ly Causal Candidate Variants 
No shared, potentially pathogenic homozygous variants were identified by this method, 
suggesting that our hypothesis that compound heterozygous mutations were the likely 
cause of disease was correct.   
 
Two genes with shared compound heterozygous variants were identified:  LRRC16A, on 
chromosome 6, which haboured two missense mutations (c.293C>T [p.A98V] and 
c.437A>G [p.D146G]); and ATM, on chromosome 11, which haboured a 4 base-pair, 
frameshift deletion (c.7886_7890del) and a missense mutation (c.6154G>A [E2052K]). 
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LRRC16A has not been associated with any disease at present.  It encodes a 1,374 
amino acid protein that contains 11 leucine-rich repeats and a c-terminal actin capping 
protein (CAPZA2) binding domain.  This CAPZA2-binding domaine appears to be 
both necessary and sufficient for the protein to inhibit actin capping by CAPZA2 366.  
The gene is predominantly expressed in the kidney, though it is detected in many 
tissues at low levels, and it appears to be involved in lamellipodia protrusion 366.  
Knockout of this gene in mice does not result in any detectable phenotype 367.  Both of 
the mutations detected in this study are located near beginning of the protein, 99 
amino acids before the beginning of the first leucine rich repeat and over 800 amino 
acids before the beginning of the critical CAPZA2-binding domain.  The c.293C>T 
mutation is predicted to be benign by both SIFT (score=0.32) and PolyPhen 
(score=0.005), whilst the c.437A>G mutation is predicted to be deleterious by SIFT 
(score=0.03) and possibly damaging by PolyPhen (score=0.698).  Most importantly, 
segregation analysis by Sanger sequencing demonstrated that the variants in LRRC16A 
were present in the compound heterozygous form not just in the affected individuals 
but also in one unaffected sibling (II:3 in figure 28), thus making LRRC16A an unlikely 
cause for the DRD.  
 
The second gene in which we identified compound heterozygous mutations was ATM, 
ATM is a gene normally associated with ataxia telangiectasia, a condition in which 
dystonia can be seen.  Notably this was the only compound heterozygous mutation that 
sat within a linkage peak, occurring in a primary peak of interest on chromosome 11.  
One of the mutations, a frameshift deletion in exon 54 of the gene (c.7886_7890del), is 
predicted to lead to nonsense mediated decay of the truncated mRNA product and has 
been detected in our own patients with ataxia telangiectasia (AT).  The other, a point 
mutation in exon 43 (c.6154G>A), results in a substitution of a positively charged 
lysine in the place of a negatively charged glutamic acid at position 2052.  This position 
lies in a FAT domain of the protein, which is thought to interact with ATM’s kinase 
domain to stabilise the c-terminus.  It is predicted to be deleterious by SIFT 
(score=0.05) and possibly damaging by PolyPhen (score=0.74) and lie in a region of 
substantial interspecies conservation with a GERP score for 35 eutherian mammals of 
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3.81 (see figure 31).  Most notably, it has previously been detected in patients with AT 
















8.3.5 Clinical Rephenotyping and AFP Measurement 
Given the finding of two pathological mutations in ATM, we returned to the family to 
re-evaluate the pedigree and re-examine the index cases.  Re-evaluation of the pedigree 
revealed that one of the unaffected siblings had since had two daughters who are now 
affected by clinically typical AT.  DNA samples were obtained for this branch of the 
family and the relevant exons of ATM sequenced.  This revealed that the unaffected 
sibling and his wife (who may be related to him, though the family is unaware of this) 
both carry the 4 basepair, frameshift deletion (but not the missense mutation) in the 
heterozygous state.  One of his daughters, who suffers from clinically-typical AT, is 
homozygous for the same deletion.  We were unable to obtain blood from the other 
affected daughter.  Figure 32 shows the updated pedigree with mutational status. 
Figure 31 – Diagram demonstrating complete conservation at the base position c.6154 between 
18 amniota vertebrates.  This base is the first of a codon specifying glutamate (GAA).  Note 
that despite the 3rd base interspecies ‘wobble’ between an A and a G, the redundancy of the 
genetic code means there is nonetheless complete interspecies conservation of the amino acid 
at this position (p.2056).  The same is true of the three codons shown adjacent to this. 
	   241	  
 
	  
Figure 32 - Updated genetic pedigree in light of the initial exome sequencing results.  The 
individuals marked with a cross (III:6 and III:8) have clinically typical ataxia telangiectasia.  
Mutational status for ATM is marked below the relevant individuals as follows:  wt = wildtype 
allele; fs = frameshift mutation (c.7886_7890del); and m = missense mutation (c.6154G>A).  
DNA availability is marked as previously.  The marriage between individuals II:5 and II:6 is 
probably consanguineous. 
 
Re-examination of the three siblings affected by DRD revealed conjunctival 
telangiectasia (figure 33) but no ataxia or oculomotor signs.  They remained responsive 
to levodopa.  In addition, a fourth sibling now exhibited very mild cervical dystonia and 
dysarthria, but did not wish to participate in the genetic analysis and so his mutational 
status could not be ascertained. 




Figure 33 - Conjunctival telangectasia in a sibling affected by cervical dopa-responsive dystonia. 
 
Alpha fetoprotein is a generally elevated in AT.  Therefore, we obtained simultaneous 
blood samples from all individuals that were willing to donate blood for DNA analysis 
for estimation of serum alpha fetoprotein levels.  Testing revealed that alpha 
fetoprotein was raised in all three siblings with DRD as well as the daughter of the 
unaffected sibling who has clinically typical AT (table 26). 
 
Table 26 - Serum alpha fetoprotein measurements for key individuals in the family.  Individual 
labels relate to the genetic pedigree (figure 32).  Mutational status is coded as follows:  wt= 
wlidtype allele; fs = frameshift deletion (c.7886_7890del); m = missense mutation (c.6154G>A). 
Individual 
 
Alpha Fetoprotein measurement 
in IU/ml (normal = <7) 
Mutational status 
II:1 55.42 fs/m 
II:3 53.19 fs/m 
II:9 97.28 fs/m 
II:5 1.23 fs/wt 
II:6 1.93 fs/wt 
III:6 208 fs/fs 
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8.4 Discuss ion 
We performed whole exome sequencing and linkage analysis in 3 individuals affected 
by dopa-responsive dystonia from a Muslim, Indian kindred.  We did not find any 
evidence of significant autozygosity within the family to suggest inbreeding was a factor.  
Compound heterozygous mutations were identified in two genes – LRRC16A and 
ATM.  However, the mutations in LRRC16A did not lie within a linkage peak and as 
expected did not thus segregate with disease in the family. 
 
The compound heterozygous mutations in the gene ATM, on the other hand, did lie 
within a linkage peak of primary interest and were found to be shared by all 3 affected 
individuals.  Sanger sequencing subsequently confirmed that the two mutations were 
on separate alleles, with each parent carrying only one mutated allele.  One mutation, a 
frameshift deletion in exon 54 of the gene (c.7886_7890del), is predicted to lead to a 
nonsense mediated decay of the truncated mRNA product and has been observed in 
individuals with clinically typical AT in our own neurogentics diagnostic laboratory; the 
other, a point mutation in exon 43 (c.6154G>A), leads to the substitution of a 
conserved amino acid, is predicted to be deleterious by SIFT and possibly damaging by 
PolyPhen and has been observed in the homozygous state in patients with clinically 
typical AT by others 368. 
 
Biallelic mutations in ATM are generally associated with ataxia telangiectasia (AT), an 
autosomal recessive form of early-onset ataxia associated with oculomotor apraxia, 
ocular and cutaneous telangiectasia and variable immunodeficiency Patients with 
classical disease generally develop an ataxic gait in their early childhood and are 
wheelchair bound by early adolescence.  Death often occurs in the second or third 
decade of life due to malignancies or respiratory failure 369,370.  However, a variant form 
of the disease is recognised with either much a later and more slowly progressive course, 
or, occasionally, where the cardinal features of the disease – ataxia, telangiectasia, and 
immunodeficiency – are completely absent and the patient presents instead with a 
movement disorder or peripheral neuropathy 371.  Extrapyramidal disorders appear to 
dominate the clinical presentation of variant ataxia:  in the study by Verhagan et al., 
60% had rest tremor, 60% had dystonia and 70% had choreoathetosis.371. 
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Notably, a recent publication identified members of three Canadian Mennonite 
families who presented with early-onset, isolated, predominantly cervical dystonia 
without frank ataxia or oculomotor apraxia.  These individuals harboured a 
homozygous c.6200C>A missense mutation in exon 43 of ATM 372.  This is the same 
exon, in which we detected a missense mutation (c. 6154G>A) in our Indian Muslim 
kindred with dopa-responsive dystonia.  Since the frameshift mutation that they carried 
on the other allele would be expected to lead to nonsense mediated decay of the 
truncated mRNA product, the allele bearing the c.6154G>A mutation would be the 
only one expected to reach the point of translation into a protein product.  The exact 
mechanism by which some mutations lead to the variant presentation is not 
understood.  It was originally suggested that, unlike null mutations which leave no 
functional ATM protein, other mutations – particularly point mutations, which are 
seen in about 10% – may result only in ATM with a reduced or aberrant functionality.  
However, other studies have shown that the milder phenotype – including that of pure 
cervical dystonia mentioned above – can be associated with a very low or even complete 
lack of detectable ATM activity 372, 373.  It is, however, interesting to note that all 
individuals with dopa responsive dystonia exhibited a serum alpha-fetoprotein 
measurement in the intermediate range (approximately 50 -100IU), whereas the 
individual with clinically typical AT (who habored two frameshift mutations) had a 
serum alpha fetoprotein level that was four-to-two times this level (208IU). 
 
Furthermore, the relationship between ATM and extrapyramidal features of the 
disorder remains unclear.  Abnormalities of the basal ganglia have been noted on 
studies involving brain imaging (T2 putaminal hyperintesity on MRI 374; 
hyperechogenicity on transcranial ultrasound 372) or neuropathological examination 
(Lewy Body formation 375) carried out in a handful of cases of classical or variant AT.  
However, the numbers are too small and the changes described often too non-specific 
to draw any meaningful conclusions.  Nonetheless, ATM knockout mice have 
consistently been shown to exhibit late-onset degeneration of nigro-striatal neurons, 
suggesting a possible mechanism underlying the development of extrapyramidal 
features in AT 376. 
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The identification of dopa-responsive dystonia as a manifestation of AT has double 
significance.  Firstly, it suggests that at least a subset of the dystonic features seen in 
classical and variant AT may be ameliorated by treatment with L-dopa, possibly leading 
to an improvement in the patient’s functional ability.  Secondly, despite the milder 
phenotype, the rate of malignancy in variant AT appears, nonetheless, to be 
significantly elevated and patients remain at increased risk from exposure to radiation 
used diagnostically or as a treatment 371, 377.  Therefore, unexplained dopa-responsive 
dystonia – particularly cervically located and of young onset joins the list of conditions 
in which clinicians should consider, at the very least, routine assay to look for raised 
alpha fetoprotein.  In cases of high suspicion, in which unexplained dopa-responisve 
cervical dystonia is combined with other features of variant AT, such as clumsiness, a 
sensorimotor neuropathy or early malignancy, chromosomal fragility studies or genetic 
testing may be warranted. 	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9. Exome Sequencing in a Family with An Autosomal 
Recess ive Complex Neurological  Disorder  Including Visual  




Most of the families presented so far have been characterised by a relatively simple 
phenotype.  The clinical picture has generally been dominated by a single neurological 
sign – dystonia – suggesting dysfunction confined to particular neurological circuits, 
most likely within the basal ganglia.  In some respects, this can be helpful in trying to 
find new disease genes:  a candidate can be prioritised as having higher biological 
plausibility if its pattern of expression within the brain matches the pattern of regions 
or structures that are dysfunctional in the disease state.  The dystonia gene ANO3, 
detailed in chapter 5, serves as a convenient example here.  It is much more highly 
expressed in the striatum, a structure intimately linked to many movement disorders 
including dystonia, than in any other region of the brain, suggesting that its main 
biological function is related to this particular neuroanatomical region.  This lends 
biological plausibility to the disease-gene association and suggests a reason why 
mutations in this gene can cause dystonia with no evidence of more widespread 
neurological dysfunction.  
 
Many neurological disorders, however, present with a complex phenotype, indicating 
dysfunction of multiple systems within the brain or, alternatively, of disparate parts of 
the nervous system.  The list of genetic causes of such complex neurological disorders is 
long (see section 3.11 for a list of those in which dystonia is a feature) making accurate 
diagnosis challenging at times.  Thus, in order help them arrive at the correct diagnosis, 
clinicians often pick a particular key symptom or sign on which ‘to hang’ their list of 
differential diagnoses.  Progressive bilateral visual failure is one sign that can serve as a 
useful hook.  In the context of a patient suspected of having a genetic disorder, bilateral 
visual failure significantly reduces the list of possible diagnoses and even suggests a 
likely pathogenetic mechanism.  Whether the sole or predominant sign of the disorder, 
as in autosomal dominant optic atrophy or Leber’s hereditary optic atrophy, or whether 
simply one of numerous signs suggestive of more widespread neurological dysfunction, 
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progressive bilateral visual failure is highly suggestive of underlying mitochondrial 
dysfunction.  Although mitochondrial DNA is not routinely sequenced as part of 
current NGS approaches, many of the genes required for normal mitochondrial 
function are, in fact, autosomally encoded and can thus be examined by whole exome 
sequencing.  With respect to gene discovery, consanguineous kindreds exhibiting signs 
suggestive of mitochondrial dysfunction, in which the disease is most likely to have 
resulted from autosomal recessive inheritance, offer a particularly good prospect of 
success:  the power of homozygosity mapping and whole exome sequencing can be 
further boosted by reasonable a priori hypotheses regarding the likely cellular function 
of the disease gene. 
 
We identified a family in which two of three children were affected by an undiagnosed 
severe infantile-onset complex neurological phenotype that included bilateral visual 
failure.  The family reported consanguinity, suggesting a probable nuclear-encoded 
homozygous recessive variant as the underlying genetic cause.  We set about trying to 
identify this causal variant using a combination of whole exome sequencing and 
homozygosity mapping, based on the hypothesis that the disease gene would most likely 
be involved in mitochondrial function. 
 
9.2 Subjects ,  Materials  and Methods 
9.2.1 Clinical Detai ls  of  the Index Family 
Participants were drawn from a small Pakistani kindred under the care of the Prof.  
Kailash Bhatia at the National Hospital and Neurosurgery.  The pedigree of the family 
is shown in figure 34.  The parents of the affected individuals were first cousins. 
 
Individual II:1 is currently 16 years old.  He has been affected by his illness since his 
infancy and is currently confined to a wheelchair.  The most prominent finding on 
examination is severe action-induced myoclonus, resulting in constant and disabling 
jerks of all four limbs.  Neurophysiological testing has failed to demonstrate a cortical 
correlate to his myoclonic movements suggesting they are subcortical in origin.  On 
examination of the cranial nerves, eye movements are abnormal with difficulties in  
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Figure 34 – Core genetic pedigree of the index family.  Affected individuals are shown as filled 
symbols.  The marriage between individual I:1 and I:2 is consanguineous and the individuals 
concerned are first cousins. 
 
initiation of saccades, suggesting an incipient gaze palsy.  Vision is impaired bilaterally 
with evidence of rod-cone dystrophy on the electroretinogram.  On examination of the 
limbs, there is reduced power distally, with striking wasting of the calf muscles 
bilaterally and clawing of the hands, with accompanying sensory loss in a glove and 
stocking distribution.  On nerve conduction studies and electromyogram have 
confirmed the clinical impression of an axonal motor-sensory neuropathy.  Finally, 
MRI of the brain has shown cerebellopontine atrophy only. 
 
Individual II:3 also developed signs of neurological illness in his infancy.  With time 
this developed into the same cluster of symptoms, consisting of visual impairment, eye 
movement abnormalities, action myoclonus and peripheral neuropathy.  He is 
currently 13 years of age and is also wheelchair bound. 
 
Individual II:2 and both parents (individuals I:1 and I:2) are well with no signs of 
neurological illness.   
 
9.2.2 Whole Exome Sequencing and Generation of Coverage Statist ics 
DNA was extracted from whole blood samples obtained from all three affected siblings 
and both parents.  DNA from one affected sibling was used to perform whole exome 
sequencing using Illumina’s TruSeq (62Mb) DNA sample preparation and exome 
enrichment kits as per section 4.15.  Reads were subsequently aligned and annotated 
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using the standard approaches set out in sections 4.16.  Coverage statistics for the 
exome as a whole were obtained using Picard. 
 
Coverage across regions of shared homozygosity was calculated using BedTools against 
the CCDS definition of the exome and expressed as the percentage of bases target 
covered by at least one read.  Briefly, using Ensembl’s Biomart function, a list of every 
exon of every CCDS gene within each homozygous region was obtained, along with its 
start position, end position and strand.  This information was used to construct a 
simple BED file of the desired targets within the region.  Coverage of these target 
regions was then checked against the BAM file for the exome using BedTools 
‘coveragebed’ function. 
 
9.2.3 Genotyping and Autozygosity Mapping 
Genome-wide genotyping data was obtained for all three affected siblings using the 
OmniExpress platform, which utilises approximately 500,000 markers, as per section 
4.12.  Autozygosity mapping was performed as per section 4.13.   
 
9.2.4 Fi l tration of Variants Detected by Exome Sequencing 
In view of the apparently recessive inheritance pattern and history of consanguinity, we 
initially selected all homozygous variants for consideration.  Subsequently, synonymous 
variants not likely to affect a canonical splice site (i.e. those not within 10 bases, in 
either direction, of the intron/exon boundary) were discarded.   Given the rarity of 
autosomal recessive dystonia, we further hypothesised that the causal variant was 
unlikely to be found in any database of normal sequence variation.  However, in order 
to minimize the possibility of incorrectly assigning causality, we filtered out those 
variants that were recorded in the 1000 Genomes, NHLBI or Complete Genomics 69 
datasets at a minor allele frequency of greater than 0.5%.  Given that a variant found at 
even this frequency would be expected to be occur naturally in the homozygous state in 
around 1 in every 160,000 births, it seemed distinctly unlikely that we would risk 
filtering out the causal variant with this cut-off.  Subsequently, variants that were 
located in a region of shared homozygosity were selected as potentially causal.  No 
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filtration was performed on the basis of in silico predictions of pathogenicity or 
conservation scores.  
 
9.2.5 Generation of Nucleotide Multispecies Protein Alignments 
In order to assess conservation of amino acid sequence, Uniprot, FlyBase and 
WormBase were interrogated for orthologous protein sequences.  Actual alignment of 
the sequences obtained in this manner was performed using the freely available web-
based application ClustalΩ. 
 
9.2.6 Generation of Regional Gene Express ion Data 
Information on organism wide and brain region specific gene expression was collated as 
per section 4.19. 	  
9.3 Results  
9.3.1 Whole Exome Sequencing  
Exome sequencing produced excellent coverage against the target region.  94.6% of 
target bases were covered at a read depth of 2, 83.3% were covered at read depth of 10 
and 81.1% at a read depth of 20; the mean read depth across the exome was 46.  In 
total exome sequencing generated 94,291,782 reads, of which 62,819,270 were 
successfully aligned to the reference genome.  A total of 21,696 variants were detected 
in the exome of this individual. 
 
9.3.2 Autozygosity Mapping,  Coverage of Homozygous Regions and Variant 
Fi l tration 
Autozygosity mapping demonstrated that runs of homozygosity greater than 1Mb were 
relatively common in all three siblings, with the largest single run of autosomal 
homozygosity stretching for 64Mb. This suggested the possibility of extensive 
consanguinity within the family. Runs of homozygosity shared between both affected 
siblings but not present in the unaffected sibling are summarized in the table 27 below. 
 
Initially, coverage of the homozygous regions was checked as set out in section 9.2.2.  
Coverage was defined as the percentage of target bases covered by at least one read.  
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Coverage was generally excellent, with all regions of interest showing coverage of >80% 
and all but two showing coverage of >90%.  Nonetheless, it should be noted that 
manual inspection of the uncovered bases revealed that many of these fell within the 
UTRs of target genes meaning that coverage of coding bases is probably somewhat 
better than shown below. 
 
Subsequently, the number of variants of all types detected in each homozygous region 
was determined.  Finally, variant filtration was performed as per section 9.2.4 to 
generate a list of candidate homozygous variants.  Those that lay with a run of 
homozygosity were defined as potentially causal.  This information is also summarized 
as part of table 27. 
 
Table 27 - Genomic position and size of runs of shared homozygosity.  The number of CCDS 
genes in each region, along with percentage coverage on exome sequencing, total variants 
detected and potentially causal variants remaining after exome sequencing in also shown. 











1 208369825 214588645 6.22 38 90.0% 31 1 
2 95395757 98334450 2.94 33 92.7% 37 0 
2 226092297 226814991 0.72 1 96.4% 1 0 
3 79919894 81187867 1.27 0 - 0 0 
3 186961478 190330777 3.37 13 83.0% 12 0 
4 88882095 112909820 24.03 86 86.8% 62 0 
5 93798912 121463284 27.66 73 90.6% 62 1 
8 85802488 87003929 1.20 9 91.3% 4 0 
10 125602021 127251058 1.65 9 94.8% 4 0 
11 63691049 67526279 3.84 147 92.8% 116 3 
11 126303742 134934063 8.63 30 93.7% 15 0 
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9.3.3 Overview of Potential ly Causal Variants 
After appropriate data filtration, five homozygous variants were identified that met the 
criteria for being potentially causative, on chromosomes 1, 5, and 11.  These variants 
are summarized in the table 28 and discussed individually in the following sections. 
 
Table 28 – Details of potentially causal variants remaining after filtration of exome data, 
including chromosomal location, sequence change, amino acid substitution, zygosity, novelty, 
minor allele frequency (if previously observed) and number of reads covering the variant. 
 
NSL1: 
NSL1 encodes a protein that forms part of the MIS12 complex, which is required for 
normal chromosome alignment and segregation 378. 
 
The variant identified by exome sequencing in this family is a C to T substitution at 
position 725 of the cDNA (ENST00000366977) resulting in the incorporation of an 
isoleucine in place of an threonine at position 242 in the protein product.  The 
affected base is well conserved (PhyloP = 3.759; PhastCons = 0.99).  The variant is not 
located in a key domain of the protein according to Uniprot, but the affected threonine 
is a target for phosphorylation 379.  It is predicted to be tolerated by SIFT (0.111), 
deleterious by Provean (-3.362), probably damaging by PolyPhen2 (0.997), and disease-
causing by MutationTaster (0.999). 
Chr Position Gene Change Zygosity Novel? MAF 
Read 
depth 
1 212911871 NSL1 
c.725C>T 
p.T242I 
Hom Yes - 17 
5 110081998 SLC25A46 
c.413T>G 
p.L138R 
Hom Yes - 15 
11 64003467 VEGFB 
c.286C>G 
p.Q96E 
Hom No 0.0018 49 
11 65658601 CCDC85B 
c.347G>T 
p.C116F 
Hom Yes - 2 
11 66392434 RBM14 
c.1087T>G 
p.S363A 
Hom No 0.0009 68 
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As might be expected for a gene involved in chromosome alignment, publically 
available systemic expression data for NSL1 based on EST tags shows that it is widely 
expressed throughout the body, including the brain (figure 35, left side).  Our own in 
house region-specifc brain expression data demonstrate relatively good expression in all 




Figure 35 - Expression data for the gene NSL in man.  The panel on the left shows the organism 
wide expression data based on publically available EST datasets.  The panel on the right shows 
regional differences in expression across the brain, derived as described in section 9.2.6, across 
the 10 CNS regions analysed: putamen (PUTM, n=129), hippocampus (HIPP, n=122), 
temporal cortex (TCTX, n=119), frontal cortex (FCTX, n=127), occipital cortex (OCTX, 
n=129), thalamus (THAL, n=124), cerebellar cortex (CRBL, n=130), substantia nigra (SNIG, 
n=101), intralobular white matter (WHMT, n=131) and medulla (specifically inferior olivary 
nucleus, MEDU, n=109).  Whiskers extend from the box to 1.5 times the inter-quartile range. 
 
SLC25A46: 
SLC25A46 encodes a protein that belongs to the SLC25 family of mitochondrial carrier 
(MC) proteins.  These proteins are embedded in the inner mitochondrial membrane 
and catalyse the transportation of a variety of substances.  In doing so, they provide a 
vital link between that mitochrondria and cytosol.   
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Though MCs display a great diversity of transported solutes (i.e., a large variety of 
metabolites, nucleotides and coenzymes), all SLC25 members share common sequence 
features: a tripartite structure, a 3-fold repeated signature motif, and six transmembrane 




Figure 36 - Topological model of the mitochondrial carrier proteins.  Six helices traverse the 
inner mitochondrial membrane with the C- and N-termini facing the cytosol.  The whole 
sequence is divided into three domains, each with two transmembrane helices connected by a 
long hydrophobic matrix loop that is assumed to protrude into the membrane.  Reproduced 
from Palmieri (2004) 381. 
 
SLC25A46, along with SLC25A38 and SLCA25A44, is one of a small group of MCs 
that are quite different from other members of the family and as well as from each 
other 382.  Phylogenetically, it is most closely related to SLC25A1, which is also known 
as Citrate Transporter Protein on account of its own preferred substrate (see figure 37).  
However, identity between even these two members of the family is only 13%.   The 
substrate of SLC25A46 is unknown at present. 
 
The importance of this family of proteins to proper cell functioning is attested by the 
fact that mutation of many members of this gene family is associated with disease 
(summarised in table 29).  Moreover, as might be expected with mutations affecting a 
mitochondrial pathway, the resultant disease often affects that nervous system. 
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Table 29 - Current known disease associations for various members of the SLC25A family of 
mitochondrial carrier proteins.  Note that many diseases affect the nervous system. 
Gene Substrate Disease 
SLC25A3 Phosphate Mitochondrial phosphate carrier deficiency 383 
SLC25A4 ADP/ATP 
AAC1 deficiency 384 
Autosomal dominant  progressive external 
ophthalmoplegia. 384 
SLC25A12 Aspartate/glutamate 
AGC1 deficiency with associated global 
hypomyelination 385 
SLC25A13 Aspartate/glutamate 
AGC2 deficiency (neonatal intrahepatic 
cholestasis/type II citrullaemia) 386, 387 
SLC25A15 Ornithine/citrulline 
Hyperornithinaemia-hyperammonaemia-
homocitrullinuria syndrome 388 
SLC25A19 Thiamine pyrophosphate 
Congenital Amish microcephaly 389 
Neuropathy with striatal necrosis 390 
SLC25A20 Carnitine/acylcarnitine CAC deficiency 391 
SLC25A22 Glutamate Early epileptic encephalopathy III 392 
SLC25A38 ?Glycine/alanine 
Pyridoxine-refractory autosomal recessive 
sideroblastic anaemia 393 
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Figure 37 - Phylogenetic tree of human MCs.  The tree was originated from ClustalΩ multiple-
sequence alignments by using the neighbor-joining method implemented in MEGA5. All 53 
carriers of Homo sapiens are shown. Bootstrap values for 1000 replicates are reported on each 
node; gene names and aliases describing carrier function are reported on each leaf node. The 
clades of uncoupling proteins (UCP) and carriers transporting nucleotides, carboxylates and 
amino acids are highlighted.  This figure and figure legend are reproduced from Palmieri et al. 
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The variant identified by exome sequencing was situated in the largest stretch of 
homozygosity in this family.  It is a T to G substitution at position 413 of the cDNA 
(ENST00000366977) resulting in the incorporation of an arginine (large and strongly 
hydrophilic) in place of a leucine (small and hydrophobic) at position 138 in the 
protein product.  The substitution of a hydrophilic amino acid at this position is likely 
to be of function relevance since, according to Uniprot, the variant is located in the 
first of two key SOLCAR (solute carrier) domains of the protein, specifically in the 
hydrophobic matrix loop which is presumed to imbed in the mitochondrial membrane. 
 
The affected base is well conserved (PhyloP = 4.417; PhastCons = 1) and the affected 
amino acid is identical in all species down to C. elegans (figure 38).  It is predicted to be 
damaging by SIFT (0.001), deleterious by Provean (-4.314), probably damaging by 
PolyPhen2 (0.972), and a disease-causing by MutationTaster (0.999). 
 
	  
Figure 38 - Multiple sequence alignments for the region of SLC25A46 harbouring the 
potentially causative p.L138R variant detected by exome sequencing.  The affected base is 
conserved in all species down to C. elegans.  Colours indicate physiochemical properties of 
amino acids (red = small/hydrophobic; blue = acidic; magenta = basic; green = 
hydroxyl/sulfhydrl/amine/glycine). 
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Publically available organism-wide expression data for SLC25A46 based on EST tags 
shows that it is widely expressed throughout the body, including the brain (figure 39, 
left side).  Our own in house expression data based on Affymetrix Exon Array profiling 
of ~130 control brains across multiple areas demonstrates high levels of expression in 
all areas of the brain (figure 39, right side). 
 
	  
Figure 39 - Expression data for the gene SLC25A46 in man.  The panel on the left shows the 
organism wide gene expression based on publically available EST datasets.  The panel on the 
right shows regional differences in expression across the brain, derived as described in section 
9.2.6, for the 10 CNS regions analysed: putamen (PUTM, n=129), hippocampus (HIPP, 
n=122), temporal cortex (TCTX, n=119), frontal cortex (FCTX, n=127), occipital cortex 
(OCTX, n=129), thalamus (THAL, n=124), cerebellar cortex (CRBL, n=130), substantia nigra 
(SNIG, n=101), intralobular white matter (WHMT, n=131) and medulla (specifically inferior 
olivary nucleus, MEDU, n=109).  Whiskers extend from the box to 1.5 times the inter-quartile 
range. 	  
In addition, relative expression for this protein has been determined throughout the 
brain and body of the rat for its ortholog Slc25a46 382.  Theses data demonstrate that, 
although Scl25a46 is expressed in most tissues throughout the body of the rat, it 
expression level is much higher in the CNS (see figure 40).  Within the rat brain, it is 
expressed at particularly high levels in the hindbrain (cerebellum, pons and medulla; 
marked by a red arrow in figure 40), which is interesting given that the affected 
individuals in this family demonstrated cerebellopontine atrophy on MRI. 
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Figure 40 – Expression of the Scl25a46 in the rat as determined by Haitina et al. (2006) 382.  On the left a schematic representation of rat brain coronal sections 
used for the expression analysis is shown. The sections are marked with Roman numerals.  On the right, the relative expression of Scl25a46 (normalised against 
genomic DNA) is shown for each region of the brain and other body parts by means of a bar graph.  Note the particularly high expression of this gene in the rat 
hindbrain (marked with a red arrow), a region of the brain demonstrated atrophy on the MRI scans of affected individuals in the index family. 
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VEGFB: 
This gene encodes a member of the PDGF (platelet-derived growth factor)/VEGF 
(vascular endothelial growth factor) family.  The VEGF family members regulate the 
formation of blood vessels and are involved in endothelial cell physiology 394, 395.  This 
member is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and 
NRP-1 (neuropilin-1). 
 
From a neurological point of view, VEGFB stimulates neurogenesis in the adult brain.  
BrdU labeling of immature neurons in the subventricular and subgranular zone is 
reduced in VEGF-B knockout mice and enhanced in VEGFB-treated neuronal cultures 
and in rats given VEGFB via ICV injection 396.  VEGFB is also a survival factor and a 
potent apoptosis inhibitor for neurons.  It is capable of protecting retinal and motor 
neurons from degeneration in vivo 397, 398.  It is also expressed in sensory neurons, but, 
under normal conditions, is not essential for their survival.  However, DRG neurons 
isolated from adult VEGFB knockout mice exhibit increased neuronal stress under 
baseline culture conditions and are also more sensitive to stress stimuli 399.  
 
The variant identified by exome sequencing in this family is a C to G substitution at 
position 286 of the cDNA (ENST00000309422) results in the incorporation of a 
glutamic acid in place of a glutamate at position 96 in the protein product.  It is not a 
novel change, being recorded in dbSNP as rs111555072, but its MAF is sufficiently low 
(0.002) that homozygosity would only be expected to occur in around 1 in a 1,000,000 
births.  The affected base shows mixed conservation scores (PhyloP = 0.919; PhastCons 
= 1).  This portion of the protein has no homologue in the chicken, frog, drosophila, or 
c. elegans, and the amino acid is not conserved in the pufferfish or zebra fish, where a 
threonine is present, or in the duckbill platypus, where a proline is present instead.  It 
is predicted to be damaging by SIFT (0.029), neutral by Provean (-0.304), possibly 
damaging by PolyPhen2 (0.46), and a polymorphism by MutationTaster (0.999). 
 
Publically available organism-wide expression data for VEGFB based on EST tags shows 
that it is widely expressed throughout the body, including the brain, with particular 
enrichment in the tongue (figure 41, left side).  Our own in-house expression data 
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based on Affymetrix Exon Array profiling of ~130 control brains across multiple areas 
demonstrates high levels of expression in all areas of the brain, with the cerebellar being 
two-fold lower than most other areas (figure 41, right side). 
 
	  
Figure 41 - Expression data for the gene VEGFB in man.  The panel on the left shows the 
organism wide gene expression based on publically available EST datasets.  The panel on the 
right shows regional differences in expression across the brain, derived as described in section 
9.2.6, for the 10 CNS regions analysed: putamen (PUTM, n=129), hippocampus (HIPP, 
n=122), temporal cortex (TCTX, n=119), frontal cortex (FCTX, n=127), occipital cortex 
(OCTX, n=129), thalamus (THAL, n=124), cerebellar cortex (CRBL, n=130), substantia nigra 
(SNIG, n=101), intralobular white matter (WHMT, n=131) and medulla (specifically inferior 




CCDC85B, which stands for ‘coiled-coil domain containing 85B’, is also known as 
‘hepatitis delta antigen-interacting protein A’ owing to its homology the hepatitis delta 
viral antigen (HDAg).  The product of this gene appears to function as a transcriptional 
repressor and may inhibit the activity of CTNNB1 in TP53-dependent manner, thus 
regulating cell growth 400.   It has also been implicated in adipocyte differentiation 401. 
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The variant identified by exome sequencing in this family is a G to T substitution at 
position 347 of the cDNA (ENST00000321579) results in the incorporation of a 
phenylalanine in place of a cysteine at position 116 of the protein product.  The 
affected base shows relatively good conservation (PhyloP = 2.392; PhastCons = 1).  The 
affected amino acid, however, is less well preserved:  this portion of the protein has no 
homologue in the chicken or cat, and the affected amino acid is not conserved in 
drosophila, frog, pufferfish, zebra fish or C. elegans, where a tyrosine is present instead.  
It is predicted to be tolerated by SIFT (0.079), neutral by Provean (3.138), possibly 
damaging by PolyPhen2 (0.46), and a disease-causing by MutationTaster (0.999). 
 
	  
Figure 42 - Expression data for the gene CCDC85B in man.  The panel on the left shows the 
organism wide gene expression based on publically available EST datasets.  The panel on the 
right shows regional differences in expression across the brain, derived as described in section 
9.2.6, for the 10 CNS regions analysed: putamen (PUTM, n=129), hippocampus (HIPP, 
n=122), temporal cortex (TCTX, n=119), frontal cortex (FCTX, n=127), occipital cortex 
(OCTX, n=129), thalamus (THAL, n=124), cerebellar cortex (CRBL, n=130), substantia nigra 
(SNIG, n=101), intralobular white matter (WHMT, n=131) and medulla (specifically inferior 
olivary nucleus, MEDU, n=109).  Whiskers extend from the box to 1.5 times the inter-quartile 
range. 
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Publically available systemic expression data for CCDC85B based on EST tags shows 
that it is widely expressed throughout the body, including the brain (figure 42, left 
side).  Our own in-house expression data based on Affymetrix Exon Array profiling of 
~130 control brains across multiple areas demonstrates high levels of expression in all 
areas of the brain, with particularly high expression in the cortex, hippocampus and 
deep grey matter  (figure 42, right side). 
 
RBM14: 
RBM14, which stands for ‘RNA binding motif 14’, encodes a ribonucleoprotein.  
Isoform 1 may function as a nuclear receptor coactivator, enhancing transcription 
through other coactivators such as NCOA6 and CITED1. Isoform 2, functions as a 
transcriptional repressor, modulating transcriptional activities of coactivators, including 
isoform 1, NCOA6 and CITED1. 
 
The variant identified by exome sequencing in this family is a T to G substitution at 
position 1087 of the cDNA (ENST00000310137) results in the incorporation of an 
alanine in place of a serine at position 363 of the protein product.  The mutation is not 
novel.  It is recorded in dbSNP as rs148119991 and has a MAF of 0.0009.  
Homozygosity would thus be expected for approximately 1 in every 5 million births.  
 
The affected base shows relatively neutral conservation scores (PhyloP = 1.25; 
PhastCons = 1).  The affected amino acid, however, is not conserved in several species 
and, perhaps most importantly, multiple sequence alignment demonstrates that this 
amino acid is an alanine (i.e. the same as the mutation found in this family) in our 
closest ancestor, the chimp, as well as the chicken and the puffer fish.  It is predicted to 
be damaging by SIFT (0.018), neutral by Provean (0.370), possibly damaging by 
PolyPhen2 (0.46), and a polymorphism by MutationTaster (0.987). 
 
Publically available organism-wide expression data for RBM14 based on EST tags shows 
that the gene is widely expressed throughout the body, including the brain (figure 43, 
left side).  Our own in-house expression data based on Affymetrix Exon Array profiling 
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of ~130 control brains across multiple areas demonstrates high levels of expression in 
all areas of the brain, particularly the cerebellum (figure 43, right side). 
 
	  
Figure 43 - Expression data for the gene RBM14 in man.  The panel on the left shows the 
organism wide gene expression based on publically available EST datasets.  The panel on the 
right shows regional differences in expression across the brain, derived as described in section 
9.2.6, for the 10 CNS regions analysed: putamen (PUTM, n=129), hippocampus (HIPP, 
n=122), temporal cortex (TCTX, n=119), frontal cortex (FCTX, n=127), occipital cortex 
(OCTX, n=129), thalamus (THAL, n=124), cerebellar cortex (CRBL, n=130), substantia nigra 
(SNIG, n=101), intralobular white matter (WHMT, n=131) and medulla (specifically inferior 
olivary nucleus, MEDU, n=109).  Whiskers extend from the box to 1.5 times the inter-quartile 
range. 
 
9.3.4 Select ion of Candidate Variant for Sequencing 
Based on all available information that we were able to curate, it was not possibly to 
definitively exclude any variant.  However, SLC25A46 stands out as a top hit for several 
reasons, including: 
1) SLC25A46 encodes a mitochondrial solute carrier and thus fits in with our 
initial hypothesis that the disorder seen in this family was likely to result from 
mitochondrial dysfunction, given the occurrence of bilateral visual failure. 
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2) Impaired mitochondrial function would be expected to produce widespread 
neurological dysfunction and this is further supported by the frequent 
occurrence of neurological disease when other members of the SLC25 gene 
family are mutated (see table 29).  Expression profiling suggests high expression 
in the CNS and the rat ortholog is particularly highly expressed in the 
hindbrain, which is, at the very least, interesting in view of the cerebellopontine 
atrophy seen on MRI in this family. 
3) The variant detected in SLC25A46 is novel, as might be expected if it were the 
cause of this highly unusual and complicated phenotype, which combines severe 
myoclonus with visual failure, an axonal motor-sensory peripheral neuropathy 
and cerebellopontine atrophy.  If the condition were caused by one of the non-
novel variants (in VEGFB or RBM14), it is to be expected, based on the MAF of 
the variants and the current population figures for the UK, that there would be 
to be approximately 60 similar cases for VEGFB and 12 for RBM14 in the UK 
alone.  Many of which would be seen at quaternary paediatric institutions like 
Great Ormond Street so that the phenotype might be expected to be more 
recognizable than it was to the neuropaediatricians.  
4) The variant in SLC25A46 was the only variant to be unanimously predicted to 
be damaging by all four in silico prediction programs (notably with near maximal 
scores for the certainty of the prediction). 
5) The affected amino acid is conserved in all species down to phylogenetically 
distant creatures such as C. elegans, suggesting it may play an important role 
within the protein.  This was not true of any other variant. 
6) Finally, the mutation affects the key SOLCAR domain of the protein and 
results in the incorporation of a large, charged, hydrophilic arginine where a 
small, neutral, hydrophobic leucine is normally found.  The difference in 
hydrophobicity is particularly relevant given the mutation is located in the first 
hydrophobic matrix loop and may thus impair its insertion into the membrane. 
 
We therefore decided to take SLC25A46 forward for screening in a cohort of 
individuals with a mitochondrial phenotype.  As an initial first step, we sequenced exon 
4 of SLC25A46 by Sanger methodology in all members of the index family to ensure 
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that it segregated as expected on the basis of the homozygosity mapping.  The results 
(shown in figure 44 below) confirmed that the T to G variant was present in the 
homozygous state only in the two affected individuals and was present in a heterozygous 
state in all other unaffected members of the family. 
 
	  
Figure 44 - Segregation analysis in the index family for the homozygous p.L138R variant in 
SLC25A46.  As expected the variant is only present in the homozygous state in the affected 
individuals.  The unaffected sibling and both parents are heterozygous for this change. 
 
9.3.5 Select ion of Cases for Screening and Sequencing Strategy 
SLC25A46 is encoded by 8 exons.  The alignment of these 8 exons against a schematic 
of the protein structure, showing the two key SOLCAR domains, is shown in figure 45.  
The mutation that we detected in the index family was located in the 4th exon, which 
encodes part of the first SOLCAR domain.  In order to minimise sequencing costs 
while hopefully maximising our chances of finding a second mutation, we decided to 
try and focus our efforts on these SOLCAR domains and on exon 4 in particular.  
Primers were thus designed for exons 2, 3, 4, 5 and 8.  
 
	  
Figure 45 – Schematic representation of the alignment of exons chosen for sequencing against 
protein structure for SLC25A46.  The homozygous variant detected by exome sequencing was 
located in exon 4 of the gene. 
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We selected 288 cases, with the aim of sequencing exon 4 in all 288 and exons 2, 3, 4, 
5 and 8 (which encode the remainder of the two SOLCAR domains) in 192 of these.  
Cases were selected from an in-house library of research samples on the basis that they 
had a clinical presentation compatible with a mitochondrial disorder with onset in the 
first decade of life.  Many of these individuals would have been tested for common 
mitochondrial mutations and deletions, but we were not able to access these results and 
so it is probable that a proportion will have known mutations.  Moreover, we were not 
able to find any individuals with a clinical description that matched this phenotype of 
the index family – in particular no case could be found where the clinical details 
indicated bilateral visual failure in the setting of a more complex neurological disorder.  
We did not select individuals with pure visual failure and no other neurological signs as 
we felt this was too far removed from the severe, complicated phenotype seen in the 
index family.   Nonetheless, we attempted to increase our chances by selecting DNA 
samples if the associated clinical description made any mention of features of the 
clinical presentation, such as myoclonus, cerebellopontine atrophy or a neuropathy.  
All in all, however, this only amounted to a handful of cases and the remainder were 
made up of a mix of disparate presentations compatible with a mitochondrial disorder. 
 
9.3.6 Results  of  Sequencing of  Cohort 
We identified only two missense mutations, both in the heterozygous state.  One, a G 
to T substitution in exon 8 of the gene (c.1137G>T) resulting in the incorporation of 
an aspartate in place of a glutamate at position 379 of the protein, has been previously 
annotated (rs79149180 in dbSNP) with a minor allele frequency of 0.04.  It has been 
observed in the homozygous state in approximately 1 in 200 normal individuals and 
thus is unlikely be disease-causing. 
 
The second mutation was novel.  It was found in exon 4 (c.446G>T) and affected an 
amino acid 9 places downstream of the index family’s mutation, still within the same 
SOLCAR domain.  It results in the incorporation of an isoleucine in place of a serine 
at position 149 of the protein product.  Multiple sequence alignments for this portion 
of the protein were generated from orthologous sequences obtained from Uniprot, 
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FlyBase and WormBase, using ClustalΩ.  As is shown in figure 46, conservation is less 
good at this amino acid position than in the case of the index family’s nearby mutation:  
the zebra fish and C. elegans have asparagine (though this has similar physical properties 
to serine), whilst drosophila has a histidine (which is quite distinct from serine).   
 
	  
Figure 46 - Multiple sequence alignments for the region of SLC25A46 harbouring the novel 
heterozygous p.S149I variant detected by Sanger Sequencing in an individual with a 
mitochondrial phenotype.  The affected base (marked by a red arrown) is conserved in most 
species, but not the zebrafish, drosophila or the nematode worm, C. elegans.  Colours indicate 
physiochemical properties of amino acids (red = small/hydrophobic; blue = acidic; magenta = 
basic; green = hydroxyl/sulfhydrl/amine/glycine). 
 
In silico predictions of pathogenicity are divided down the middle:  the variant is 
predicted to be tolerated by SIFT (0.14), deleterious by Provean (-2.751), benign by 
PolyPhen2 (0.092) and disease-causing by MutationTaster (0.997). 
 
Given the presence of a novel heterozygous mutation in the same exon of the gene as 
our index family, primers were designed for exons 1, 6, and 7 of SLC25A46 in order to 
sequence the remainder of the gene in this individual, looking for a second compound 
	   272	  
heterozygous change.  However, we did not did detect any further potentially causative 
variants. 
 
9.4 Discuss ion 
In the work presented in this chapter, we set out to elucidate the cause of disease in a 
consanguineous kindred exhibiting a complex neurological phenotype, which included 
bilateral visual failure.  On the basis of this particular feature, we hypothesised that the 
causal variant would be likely to be involved in mitochondrial processes as most genetic 
causes of bilateral visual failure known to date have been linked to mitochondrial 
dysfunction.  Using homozygosity mapping and exome sequencing, followed by 
appropriate variant filtration based on the presumed mode of inheritance and disease 
prevalence, we identified 5 possible candidate causal variants.  Of the 5 genes affected, 
only one was involved in mitochondrial function:  SLC25A46, a mitochondrial carrier 
protein of unknown substrate.  The variant in this gene was completely novel, was 
universally predicted to be damaging with near maximal probability scores by all 4 in 
silico prediction programs, was situated in the largest stretch of shared homozygosity, 
and and affected an amino acid that shows absolute conservation across species all the 
way down to the nematode worm, C. elegans.  The substitution causes the insertion of 
arginine, which is the second largest (molecular weight 174.2 Daltons), most highly 
charged (pKa 12.48), and most hydrophilic (hydrophobicity† -4.5) of all the amino 
acids, in the place of leucine, which is relatively small (molecular weight 131.18 
Daltons), neutral, and strongly hydrophobic (hydrophobicity +3.8) leucine.  This 
difference in hydrophobicity, in particular, may be of relevance as the affected amino 
acid sits in a solute carrier domain of the protein –  more precisely, at the very centre of 
the hydrophobic matrix loop that is presumed to loop back and imbed into the 
mitochondrial membrane (see figure 36).  The presence of the charged and strongly 
hydrophilic arginine may, hypothetically, impair the ability of the matrix loop to insert 
into the membrane, disrupting transporter structure and function.  The gene is well 
expressed in the central nervous system and, in the rat at least, is particularly highly 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  †	  Hydrophobicity of amino acids is represented as described in Kyte and Doolittle (1982) 402.  
Positive values indicate hydrophobicity; negative values indicate hydrophilic amino acids.  The 
scale ranges from +4.5 (isoleucine) to -4.5 (arginine). 
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expressed in the hindbrain, an area that showed focal atrophy on MRI scans of affected 
individuals in our family.  Although SLC25A46 has not yet been associated with 
disease, several members of the SLC25 gene family have been and neurological disease 
is a frequent consequence.  Thus, the secondary information collated on this gene and 
the variant detected therein suggest a high level of biological plausibility for causality 
with respect to the disease seen in the index family. 
 
Unfortunately, it has not been possible to move forward from this point for two 
reasons.  Firstly, the disease phenotype is very rare and thus we were unable to find any 
samples in our research database that were labelled as having suffered from similar 
symptoms. In particular, no sample could be found where the clinical description 
explicitly stated that there was bilateral visual failure in the context of a more 
complicated neurological phenotype.  In part, this may have resulted from an issue with 
labelling – most samples with suspected mitochondrial disease are labelled simply as 
‘mitochondrial disease’ without any further elaboration.  In the absence of any samples 
from individuals with a good match for index phenotype, we were forced to select 
samples that were labelled as mitochondrial disease where disease onset had been in 
infancy.  Any sample that mentioned mitochondrial disease as well as neuropathy or 
myoclonus was included.  With such a poorly matched cohort in the context of such a 
rare disease, it is not particularly surprising, therefore, that we did not identify a second 
independent kindred with biallelic mutations in this gene.  Secondly, at the outset of 
this research, the family had made clear that, although they were happy to participate in 
further genetic studies, they did not wish to undergo any further invasive procedures.  
They felt, understandably, that merely knowing the name of the gene responsible for 
the disease in their family was not worth the distress and inconvenience of any further 
invasive procedures since the chance of this knowledge leading to any sort of novel 
treatment in the near future that might directly improve their children’s condition was 
minimal.  This essentially ruled out the possibility of functional studies in patient cell 
lines (derived either from muscle or fibroblasts) that might have otherwise been able to 
demonstrate that mitochondrial dysfunction was indeed the underlying cellular 
phenotype. 
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In summary, the role of mutations in SLC25A46 as the cause of neurological disease in 
this family remains unproven.  The function of the gene and character and position of 
the variant detected therein strongly suggests – to me, at the very least – that it probably 
is the causal gene and, at the time of writing, attempts are being made to assemble a 
cohort for screening that is better matched to the index families phenotype by 
collaborating with the researchers of the neuromuscular unit at the Institute of 
Neurology.  It is my understanding that they may have a cohort of individuals with a 
mitochondrial phenotype characterised by young onset rod-cone dystrophy in whom 
mutational screening of all known genes has been negative. 
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10. Exome Sequencing in General i sed Dystonia with 
Bi lateral  Str iatal  Necros i s  
 
10.1 Introduction 
Bilateral striatal necrosis, characterised by symmetrical degeneration of the caudate 
and/or putamen, can result from a diverse range of conditions, including toxic, 
infectious, metabolic and neurodegenerative disorders 403.  Clinical features reflect the 
intimate involvement of these structures in movement and cognition:  choreoathetosis, 
dystonia, spasticity, dysarthria, dysphagia and cognitive decline are all recognised 
manifestations.  In familial cases, mutations in five genes have so far been linked to this 
condition:  ATP6 404, ND6 405, 406, NDUFV1 407, NUP62 408, SLC25A19 409.  The genes 
ATP6, ND6 and NDUFV1 are all involved in the harnessing of chemical energy by the 
mitochrondrial respiratory chain; SLC25A19 encodes a mitochondrial thiamine 
pyrophosphate carrier; and NUP62 is an essential component of the nuclear pore 
complex, which gates the flow of macromolecules between the nucleus and cytoplasm. 
 
We identified an English kindred in which two of the four siblings were affected by 
familial young onset generalised dystonia.  Previous MRI scans of the brains of both 
affected individuals had demonstrated symmetrical putaminal hyperinstenites 
representative of limited bilateral striatal necrosis.  The remaining two siblings and 
both parents were free of any neurological symptoms, suggesting probable autosomal 
recessive inheritance.  Despite extensive investigation, including sequencing of genes 
known to cause both isolated and complex forms of dystonia, the cause of their disease 
had not been identified.  The family accepted the opportunity to participate in this 
research using exome sequencing and linkage analysis in order to attempt to establish 
the nature of the underlying genetic lesion  
 
10.2 Subjects ,  Materials  and Methods 
10.2.1 Clinical Detai ls  of  the Index Family 
Participants were drawn from a small English kindred.  The genetic pedigree of the core 
family is shown in figure 47.  There was no report of any similar condition either in the 
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extended family.  The family did not report any consanguinity and both parents had 
originated from separate parts of the country. 
 
	  
Figure 47 - Abbreviated genetic pedigree of the index family.  All siblings were in their late 
teens or early twenties and did not have children.  There was no report of any individual with a 
similar neurological disease in the extended family.  The family did not report any 
consanguinity and the parents originated from geographically distant regions of the country. 
 
Individual II:1 was born by normal vaginal delivery after an uneventful pregnancy with 
no history of birth trauma.  Her motor milestones were delayed:  she was only able to 
sit by the age of 2 and was not able to walk until the age of 3 - 4 years.  Her speech was 
also delayed, but initially appeared only mildly affected.  At the age of 7, her speech 
began to deteriorate, becoming progressively difficult to understand, and this was 
followed by progressive deterioration in her walking, with increasing unsteadiness and 
falls.  By the age of 11, she was no longer able to walk independently and required a 
frame.  Spasms of the hands and feet began around the age of 15 and gradually 
worsened.  On examination for this project at the age of 20, visual acuity was 5/12 in 
the right eye and 6/36 in the left.  There was exotropia and hypotropia of the left eye 
along with latent nystagmus and dissociated vertical deviation.  These eye signs were 
not present in her affected sister and were not felt by the neuro-ophthalmologists to be 
related to the dystonic condition but to represent a separate chance occurrence of a 
common and well recognised paediatric ophthalmic syndrome.  Slit lamp examination 
revealed normal retinae.  Speech was markedly dysarthric.  There was generalised 
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dystonia affecting all four limbs, cranial region and trunk, with evidence of scoliosis. 
Choreoathetosis was also evident in the outstretched fingers.  Power was generally 
preserved, with exception of some mild weakness of the first dorsal interossei, abductor 
pollicis brevis and finger extensors bilaterally.  Sensation was normal.  Coordination 
was difficult to assess in the presence of the limb dystonia, but there was probably mild 
appendicular ataxia.  Reflexes were pathologically brisk throughout and the plantars 
were extensor bilaterally.  The gait was dystonic and unsteady.  Cognition appeared 
grossly normal, though formal neuropsychometry had not been undertaken. 
 
She had been extensively investigated as a child by the neuro-paediatricians.  Notably, 
metabolic profiles, including alpha-fetoprotein, lipoprotein A, white cell enzymes and 
very long chain fatty acids, were normal.  Genetic testing for TOR1A, THAP1 and 
PANK2 was negative.  CSF analysis, including oligoclonal bands, pterins and 
monoamine metabolites, was unremarkable.  A DAT-scan revealed a normal pattern of 
tracer uptake.  MRI of the brain, however, demonstrated cerebellar atrophy and 
bilateral pallidal hyperintensities on T2-weighted sequences felt to be consistent with 
limited bilateral striatal necrosis (figure 48). 
 
	  
Figure 48  - MRI of the brain of individual II-1 demonstrates T2 hyperintensity in the region of 
the globus pallidus bilaterally, interpreted by the neuroradiologist to represent limited bilateral 
straital necrosis.  Similar changes were evident on the MRI of her affected sister.  Mild 
cerebellar atrophy (not shown) was also noted.  
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Individual II:3, who was two years younger, was also affected.  The history of her illness 
had followed the same pattern as that of her sister, though the dystonia was slightly 
milder.  Her examination at the age of 18 revealed the same neurological signs and 
deficits, with the exception that there was no exotropia, hypotropia, latent nystagmus, 
or amblyopia.  In addition to the dystonia and choreoathetosis, occasional myoclonic 
jerks were also evident in the arms of this individual.   
   
Individuals II:2, II:4 and both parents were neurologically normal.    
 
DNA was available from all individuals shown on the kindred.  Given the fact that 
both parents were neurologically normal in the context of the occurrence of a young-
onset, relatively severe condition in two of their female children, the most probable 
mode of inheritance was autosomal recessive.  Moreover, in view of the lack of any 
reported consanguinity, it was hypothesised that compound heterozygous mutations 
would be most likely to be responsible for disease in this family  
 
10.2.2 Whole Exome Sequencing 
DNA from both affected siblings and their mother was used to perform whole exome 
sequencing.  Exome sequencing was performed using Illumina’s TruSeq (62Mb) DNA 
Sample Prep Kit and Exome Enrichment Kit as per section 4.15.  Reads were 
subsequently aligned and annotated using the standard approaches set out in sections 
4.16.  Details of the filtering of exome sequencing data are given in the results section 
below.  
 
10.2.3 Genome-Wide Genotyping by DNA Microarray 
Genome-wide genotyping data was obtained for all 4 siblings and for individual I:1 (the 
father) using the OmniExpress platform, which genotypes approximately 500,000 
markers, as per section 4.12.. 
 
10.2.4 Autozygosity Mapping and Linkage Analysis  
Despite the fact that the family did not report any consanguinity, autozygosity mapping, 
performed as per section 4.13, was employed for the sake of completeness.  The extent 
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of homozygosity was quantified and tracts of homozygosity shared only by affected 
individuals were identified that could be further scrutinised for potentially causative 
homozygous variants. 
 
Linkage analysis was performed as per section 4.14.  Both a parametric analysis (using 
an autosomal recessive model with a penetrance of 100% and a pathological allele 
frequency of 0.0001) and a non-parametric analysis were performed to highlight areas 
that might habour a causal variant.  Areas of interest were defined as those with a LOD 
score of greater than 0. 
 
10.2.5 Sequence Analysis  of  Genes Known to be Associated with Bilateral  
Str iatal  Necrosis  
In order to exclude the possibility that disease in this family was due to mutation in a 
gene already known to be associated with hereditary bilateral striatal necrosis, the 
sequence of these genes were scruntinised for possible pathogenic mutations.  In the 
case of the autosomally-located genes, SLC25A19, NUP62 and NDUFV1, the exome 
sequencing data was uploaded to the Integrative Genomics Viewer v2.2 (Broad 
Institute) for inspection.  Each gene was first inspected to ensure all coding exons had 
been covered and subsequently the sequence of each exon in turn was inspected to look 
for variants detected.  In the case, ATP6 and ND6, which are encoded by mitochondrial 
DNA, Sanger sequencing was performed, as per section 4.6 – 4.10, using primers 
previously designed and used by our own diagnostics laboratory. 
 
10.3 Results  
10.3.1 Exome Sequencing 
Exome sequencing produced excellent coverage in all three individuals.  Using the 
CCDS hg19 definition of the exome, the average mean read depth across the entire 
exome was 55 with 93.5% covered by at greater than 2 reads, 81.3% covered at greater 
than 10 reads and 80.4% covered at greater than 20 reads.  This translated to an 
average variant count of 22,250 variants per exome. 
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10.3.2 Autozygosity Mapping  
Autozygosity mapping demonstrated that runs of homozygosity greater than 1Mb in 
length were both rare and small (maximum size < 3Mb), suggesting that recent 
consanguinity was not a feature within this family.  Only three small runs of 
homozygosity that were shared by the two affected siblings and not present in the two 
unaffected siblings were identified (summarized in table 30). 
 
Within these regions, KCND2 (a potassium channel that contributes to repolarization 
in cardiac cells) is the only known gene annotated by Ensembl.  Manual examination of 
the exome data for this gene showed that it had been well covered and no potentially-
causal variants had been detected.  In summary, this analysis suggested that the causal 
variants were more likely to be compound heterozygous changes, as previously 
hypothesized. 
 
Table 30 - Details of the runs of homozygosity found to be shared between both affected 
siblings and not present in any unaffected sibling.  Only one annotated gene was identified 
within these small regions, KCND2.  Biological plausibility for this gene was low and inspection 
of the exome data showed it had been well covered without detection of any potential causal 
variants. 
Chromosome Start  Stop  Size (Kb) Known Genes 
3 95058076 96066172 1008 None 
7 118229822 120273226 2043 KCND2 
23 25798188 27120547 1322 None 
 
 
10.3.3 Linkage Analysis  
Linkage analysis was not expected to produce a truly significant LOD score, but was 
instead used to highlight areas with a greater a priori probability of harboring the causal 
variant.  All peaks of positive linkage shared a common maximal LOD score of 
approximately 0.8 and were thus all treated as areas of potential interest.  The position 
and size of these regions is shown in table 31.   
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Table 31 - Physical characteristics of linkage peaks detected in this family.  Given the small size 
of the family, multiple peaks with a maximal LOD score of 0.8 were identified, which formed 
the primary areas of interest. 
Chromosome Start Position Stop Position Size (Mb) 
1 37185336 91528185 54.34 
2 
 
23050710 31066592 8.02 
62430208 114273105 51.84 
139492011 170146913 30.65 
3 
72354511 111138405 38.78 
191860535 196452238 4.59 
5 
39087074 57411570 18.32 
95882162 101831523 5.95 
6 153588258 167018721 13.43 
8 4219026 13521103 9.30 
9 107552924 108893850 1.34 
10 570172 5593361 5.02 
11 45051827 83282729 38.23 
12 
3255362 8068881 4.81 
46361672 66829726 20.47 
13 27409049 30855014 3.45 
14 24872917 33609861 8.74 
15 37840246 85423958 47.58 
18 2761338 11025325 8.26 
20 
129635 10968733 10.84 
60216060 61008537 0.79 
22 36545780 46931838 10.39 
 
Of note, there is no linkage peak over the chromosomal positions of NUP62 (chr19, 
50,410,082 - 50,432,988) or SLC25A19 (chr17, 73,269,061 – 73,285,591), making it 
distinctly unlikely that these genes were responsible for disease in this family.  NDUFV1 
is, however, covered by a linkage peak on chromosome 11. 
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10.3.4 Exclusion of Genes Known to Cause Bilateral  Str iatal  Necrosis  
Initially, the exome data was manually inspected to look for variants in SLC25A19, 
NDUFV1 and NUP62.  All exons and the intron/exon boundaries of all three genes 
were well covered in the data (> 20 reads minimum; often greater than 50 reads).  No 
potentially causative variants were present (see table 32).  Sanger sequencing of ATP6 
and ND6 failed to reveal any variants in these genes. 
 
Table 32 - Results of sequence analysis of known genes capable of causing bilateral striatal 
necrosis.  SLC25A19, NUP62 and NDUFV1 were analysed via the exome data.  ATP6 and ND6, 
which are encoded by mitochondrial DNA, were sequence using Sanger methodology.  Most 
variants detected were non-coding.  The sole coding variant detected was a common SNP 
present in around 30% of the population, thus essentially ruling it out as a cause of disease in 
this family. 










73285461 C>A None rs2291033 0.11 hom 
73279624 G>C None rs7213318 0.09 het 
73269676 C>T None rs4789164 0.41 hom 
NUP62 
50412417 G>A None rs999583 0.77 hom 
50412217 C>G S283T rs79747934 0.34 hom 
50411742 A>G None rs892028 0.95 hom 
NDUFV1 No variants detected by exome sequencing 
ATP6 No variants detected by Sanger sequencing 
ND6 No variants detected by Sanger sequencing 
 
 
10.3.5 Identif ication of Candidate Causal Variants by Appropriate Fi l tration  
In order to isolate potentially pathogenic variants, we applied a systematic filtering 
procedure to the data, as depicted in figure 49.  We began by selecting only those 
variants that were present in the exome data both affected sibling for analysis. 
Synonymous variants (unless in a splicing region) and variants recorded in dbSNP135 
were initially removed.  We then filtered out any variant present at a global minor allele 
frequency of ≥1% in a range of publically available databases of sequence variation 
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(1000 Genomes, Complete Genomic 69 Database and NHLBI Exome Sequencing 
Project database) as well as those found in 2 or more our own in-house exomes from 
individuals with unrelated diseases (n≈200).   
 
	  
Figure 49 - Schematic representation of the filtration process employed to identify candidate 
causal variants for disease in this family, using all variants detected in the exomes of both 
affected siblings as starting position. 
 
We identified only one gene that harbored potentially causative compound 
heterozygous mutations, NUBPL.  This gene lies in the center of a linkage peak on 
chromosome 14.  Using the longest transcript as a reference (ENST00000281081), the 
first variant is a T to C substitution at position 311 of the cDNA, resulting in the 
incorporation of proline in place of a leucine at position 104 of the protein product.  It 
is predicted to be highly damaging by all four in silico prediction programs (SIFT=0; 
Provean=-6.5; PolyPhen2=1; MutationTaster=0.99).  The affected base is highly 
conserved (PhyloP=3.09; GERP=5.4).  The variant is reported in dbSNP137 with a 
minor allele frequency of 0.001 and has been detected once in the heterozygous state in 
the 11,779 chromosomes sequenced by the NHLBI Exome Sequencing Project.  
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Homozygosity for this variant would thus be expected to occur in approximately 1 in 
4,000,000 births.  It is one amino acid upstream of a previously reported pathogenic 
mutation in this gene (p.D105Y; see section 10.4.2) 410. 
 
The second variant is A to T substitution at position 287 of the cDNA, resulting in the 
incorporation of a valine in the place of an aspartic acid at position 96 of the protein 
product.  It is predicted to be tolerated by SIFT and Provean (though the Provean 
prediction is damaging for some transcripts), ‘possibly damaging’ by PolyPhen2 and 
damaging by MutationTaster (0.99).  The affected base is highly conserved 
(PhyloP=2.228; GERP=5.41) and the variant is not found in any database of human 
variation. 
 
10.3.6 Segregation Analysis  in the Index Family  
Inspection of the mother’s exome data confirmed that she carried only the p.D96V 
mutation and that the two mutations were thus inherited on separate alleles in the 
affected siblings.  Sanger sequencing was undertaken in the entire family for both 
variants, which demonstrated that they segregated with disease in the compound 
heterozygous state (figure 50).  One of the unaffected siblings was heterozygous for the 
p.D96V mutation, while the other possessed two wildtype alleles. 
 
	  
Figure 50 - Results of the segregation analysis for the two mutations in the gene NUBPL in the 
index family.  Disease can be seen to segregate with the mutations in the compound 
heterozygous state.  m1 = p.D96V mutation; m2 = p.L104P mutation; wt = wildtype allele. 
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10.3.7 Attempts to Generate Further Genetic or Functional Evidence That 
Mutations of  NUBPL is the Cause of Disease in this  Family  
Given the identification that the mutations in NUBPL segregated with disease in this 
family, we queried our database of stored research samples for samples donated by 
other individuals with bilateral striatal necrosis in order to attempt to assemble a cohort 
of phenotypically similar individuals in which the NUBPL could be sequenced.  
Unfortunately, no sample could be found that included bilateral striatal necrosis in the 
clinical details.  There are a number of reasons why this might be.  Firstly, bilateral 
striatal necrosis is a very rare condition and only the largest medical institutions are 
likely to have more than one or two cases.  Secondly, bilateral striatal necrosis is 
intimately linked to mitochondrial dysfunction and many individuals develop severe, 
widespread neurological disease.  As a consequence, they often present in infancy and 
undergo investigation in a paediatric institution.  Some do not survive to adulthood 
and those that do may not undergo any further genetic investigation meaning no DNA 
samples are available to us.  Finally, some samples originate from individuals that were 
originally investigated at a time when MRI was used less routinely and neuroimaging 
may have consisted of a CT scan only, meaning that the presence of striatal necrosis 
may be missed. 
 
As it would not be possible to generate further genetic evidence in the form of a second 
segregating family due to the lack of a cohort to screen, we gave thought to the 
possibility of functional studies to demonstrate pathogenicity of the detected 
mutations.  Given that NUBPL encodes a protein that is required for the assembly of 
the respiratory chain NADH dehydrogenase (complex I), the simplest means of doing 
this within an acceptable time frame would have been to obtain patient fibroblasts and 
demonstrate that they showed evidence of complex I deficiency on bioassay.  
Unfortunately, neither of the two affected individuals wished to undergo any further 
invasive procedures, including a skin biopsy, and so it was not possible to pursue this 
means of establishing the pathogenicity of the mutations.  Although it would be 
theoretically possible to engineer cells containing the two mutations by mutatgenesis 
and use these to test the effect of each mutation on complex I function, this is an 
extremely time-consuming process.  Given that this would merely lead to the 
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identification of a new phenotype for a known gene rather than the discovery of a novel 
disease gene, this was not considered worthwhile in terms of the financial and research 
time commitment.  
 
10.4 Discuss ion 
We identified two potentially pathogenic variants in the gene NUBPL that segregated 
with disease in the compound heterozygous state in a family with autosomal recessive 
pallido-pyramidal syndrome and MRI evidence of limited bilateral striatal necrosis and 
cerebellar atrophy.  Our attempts to generate the further evidence that would normally 
be required for publication of this finding failed for two reasons.  Firstly, from a genetic 
point of view, no attempt could be made to find a second independent kindred with 
disease related to bilallelic mutations in this gene as there were no research samples 
available from phenotypically similar individuals for screening.  Secondly, from a 
functional point of view, the hypothesis that fibroblasts from affected individuals 
harboring both mutations would show reduced complex I activity could not be tested as 
neither individual wished to undergo any further invasive procedures. Therefore, for 
the purpose of the following discussion, I have focused instead on a theoretical 
discussion of the a priori plausibility of mutations in NUBPL as a cause of dystonia with 
bilateral striatal necrosis in view of what is already known about the gene and the 
condition in question. 
 
10.4.1 NUBPL is Connected to the Mitochondrial  Respiratory Chain  
NUBPL encodes a protein that is required for the assembly of the respiratory chain 
NADH dehydrogenase (complex I), an oligomeric enzymatic complex located in the 
inner mitochondrial membrane, consisting of 45 subunits and 8 iron-sulfur (Fe/S) 
clusters 411.  The protein encoded by NUBPL is an Fe/S protein that is thought to be 
involved in the transfer of Fe/S to the Fe/S-containing complex I subunits 411.  Its 
knockdown causes improper assembly of the peripheral arm of complex I, reduced 
complex I activity, and abnormal mitochondrial morphology 412.  It is notable that two 
other genes known to cause bilateral striatal necrosis, ND6 and NDUFV1, are also 
components of complex I, whilst ATP6 is a component of complex V, emphasizing the 
importance of mitochondrial bioenergetics in the aetiogenesis of this condition.  
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SLC25A19 encodes a mitochondrial thiamine pyrophosphate carrier and mutations in 
this gene are also likely to result in respiratory chain dysfunction. 
 
10.4.2 NUBPL Has Previously Been Associated with Neurological  Disease  
Mutations in NUBPL have previously been associated with disease resulting from 
complex I deficiency.  To date, 7 patients habouring biallelic mutations in NUBPL have 
been described in the literature 410.  These individuals all exhibited early onset of severe 
neurological disease with a clinical picture dominated by ataxia, dysarthria and variable 
spasticity.  Only 2 of the 7 patients were ever able to walk without support and only 
then at 8 years and 11 years of age, respectively.  None showed evidence of dystonia or 
any other evidence of extrapyramidal involvement.  MRI scans undertaken in these 
individuals showed cerebellar atrophy and cerebellar subcortical white matter signal 
abnormalities in all, along with frequent brainstem signal abnormalities and cerebral 
deep white matter lesions (5 of 7 patients), predominantly affecting the frontal or 
frontoparietal regions.   None showed evidence of basal ganglia abnormalities on MRI. 
 
At first glance, therefore, although there is some overlap clinically (pyramidal 
dysfunction and dysarthria) and neuroradiologically (cerebellar atrophy) between these 
individuals and our family, there are significant differences including most notably the 
presence of generalised dystonia and basal ganglia signal abnormalities and the lack of 
any white matter abnormalities on MRI in our patients. 
 
Let us presume for a moment that the biallelic mutations in NUBPL detected in this 
study are the cause of disease in our family.  What explanations could be advanced to 
account for the difference in phenotype between our own family and that of individuals 
with disease due to mutations in this gene previously described in the literature?  In 
fact, at least three possible explanations exist to account for these differences for these 
differences. 
 
10.4.3 The Current Phenotype Associated with NUBPL Mutations is  a Sel f -
Fulf i l l ing Prophecy Result ing from Systematic Ascertainment Bias  
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After the initial discovery of mutations of NUBPL as a cause of complex I deficiency, 
subsequent patients for mutational screening were selected using MRI pattern 
recognition from a database of more than 3,000 cases using ‘unclassified 
leukoencephalopathy’ as the search criteria 410.  Presumably this was done because it was 
realized that the initial case had a distinctive pattern of MRI abnormalities that closely 
resembled a pattern previously described by Wolf et al. as defining a subset of patients 
with isolated complex I deficiency 413, though this is not explicitly stated.   According to 
subsequent publications that described new cases with NUBPL mutations, inclusion 
criteria for screening used were: 1) extensive cerebellar cortex signal abnormalities; 2) 
signal abnormalities in the corpus callosum; and 3) absence of signal abnormalities in 
the basal ganglia, thalami, and cerebral cortex.  Thus, by definition of criterion 3, no 
individuals with MRI appearances similar to those of our own family would have been 
screened, meaning that even if basal ganglia signal abnormalities exist as part of the 
phenotypic spectrum of NUBPL mutations they could never have been identified by 
these studies. 
 
10.4.4 Functional Data Suggest  the Currently Recognised Phenotype May Be 
the Most Severe End of the Spectrum  
Secondly, all previously reported individuals carry the same putatively causative genetic 
mutation on one allele, that is a branch-point splicing mutation intron 9 (c.815-
27T>C).  Interestingly, this is always found in combination with a missense mutation in 
exon 2 (c.166G>A; p.G56R) on the same allele 410.  Previous functional work involving 
the transgene expression of mutant NUBPL carrying the p.G56R alone showed that this 
missense mutation does not impact substantially on NUBPL mRNA or protein stability, 
protein import in mitochondria, or protein function 414.  Therefore, the c.815-27T>C 
branch-site mutation is thought most likely to be the cause of the complex I deficiency, 
although an additive effect of the missense mutation has not be excluded.  RT-PCR 
further demonstrated that the branch-site mutation resulted in a profound decrease in 
the steady-state level of NUBPL mRNA, quantified as 15% of control levels.  Two 
additional aberrant transcripts were observed, of which one is degraded by nonsense-
mediated decay.  The other aberrant transcript lacked exon 10 and exon 9 was directly 
fused to exon 11, causing a frameshift after glycine 272, with an additional 31 codons 
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until a stop codon is reached.  As a consequence, aspartate 273 is substituted by a 
glutamine followed by 30 random amino acids resulting in an altered C-terminus 
(p.D273QfsX31).  This mutation leads to a decrease in NUBPL protein level 410, 414.  
Finally, the equivalent mutant protein in the yeast Yarrowia lipolytica 
(Ind1p.N271QfsX31) has been shown to be completely non-functional and does not 
support the assembly of complex 1 415.  In about half of the 7 reported cases, this 
pathogenic branch site mutation was inherited with a presumed null allele.  Thus, given 
the above data, at least half of the currently described cases would be expected to have 
almost no functional NUBPL activity whatsoever.  It is quite possible, therefore, that 
the individuals so far reported represent the most severe end of a spectrum of disease 
that mutations in NUBPL may be capable of causing.  Other mutations in this gene, 
such as those that we identified in this study, may be associated with a wider spectrum 
of disease than has so far been recognised, including much milder phenotypes where 
extensive leucoencephalopathy is not a feature. 
 
10.4.5 Phenotypic Heterogeneity i s  Common in Disorders Involving the 
Mitochondria  
Thirdly, diseases in which mitochrondrial dysfunction is key to pathogenesis tend to 
show a much wider spectrum of phenotypes than diseases due to dysfunction in other 
cellular organelles or pathways.  In the case of disease resulting from the mutation of 
genes encoded by mitochrondrial DNA, this is readily explained by mitochondrial 
heteroplasmy within the oocyte leading to a variable load of mutatated mitochrondrial 
DNA in the cells of the progeny.  However, the variability in the severity of disease 
resulting from mitochondrial dysfunction extends beyond this and is also evident when 
the disease gene is an autosomally-encoded mitochondrial gene.  For instance, the gene 
SLC25A19, located on chromosome 17, has been shown to cause bilateral striatal 
necrosis 409.  The affected individuals, who all carried a homozygous p.G125S mutation, 
exhibited onset of lower motor neuron weakness in the first decade of life, leading to 
atrophy and contractures.  On nerve conduction studies an axonal neuropathy was 
evident and MRI of the brain demonstrated bilateral T2 hyperintensities in the 
striatum suggestive of necrosis.  Cognitive abilities were unaffected and no pyramidal, 
extra-pyramidal or cerebellar signs were detected on examination.  However, mutations 
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in SLC25A19 had already been described as causing disease in patients of Amish origin, 
who all harbored a different homozygous mutation of this gene (p.G177A) 416.  These 
individuals universally exhibited a much more severe phenotype with microcephaly, 
onset of weakness by the 20th gestational week, failure to obtain any developmental 
milestones and, finally, death in infancy.  Likewise, mutations in NDUFV1, another 
autosomally-encoded gene associated with bilateral striatal necrosis, are also associated 
with much more severe phenotypes, including diffuse leucoencepahopathy 417 or Leigh 
syndrome with or without myoclonic epilepsy 418, 419.   Thus, knowledge of other 
mitochrondrial disorders suggests that a wide phenotypic spectrum of disease is 
common.  It all probability the severity of the phenotype is determined by the 
functional impact of particular mutations on the mitochrondrial respiratory function, 
which, given their central role in cell survival, can translate into disease phenotypes that 
range from mild to lethal.  Moreover, extensive leucoencephalopathy, as present in all 
currently described cases of NUBPL mutation carriers, is recognised as the more severe 
end of the spectrum of disease resulting from other genes that have also been shown to 
cause limited bilateral striatal necrosis. 
 
10.4.6 Summary  
Although it was not possible in this case to prove by the standards usually required that 
the biallelic mutations in NUBPL were the cause of disease in this family, the lack of 
any other candidate varaints on exome sequencing and the inherent biological 
plausibility of the implicated gene within the framework of what is currently known 
about other genetic causes of bilateral striatal necrosis is persuasive.  Moreover, 
although NUBPL mutations have already been associated with neurological disease that 
is somewhat different and certainly more severe than that seen in our family, I have set 
out several good reasons why this cannot be used to rule out NUBPL as a cause of 
disease in the kindred presented herein.  









Exome Sequencing in Severe, 
Infantile-Onset, Autosomal Recessive 
Choreodystonia 
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11. Exome Sequencing in Severe ,  Infanti le -Onset ,  




Complex neurological phenotypes, including variable degrees of dystonia, have been 
associated with recessive mutations in a number of genes (see table 9 for examples).  
However, many complex phenotypes resist diagnosis and a proportion of these will 
result from mutations in Mendelian disease genes that are not yet known. 
 
We identified a consanguineous Pakistani kindred in which two of the four siblings 
were affected by an undiagnosed, infantile-onset form of severe choreodystonia. The 
phenotype was not recognised as typical of any known genetic disease by the movement 
disorders physicians at the National Hospital for Neurology and Neurosurgery and 
previous mutational screening of genes associated with both isolated and complex 
degenerative dystonic syndromes had all been negative (see section 11.2.1 below). 
 
The family were originally based in Scotland, but had recently moved to London and 
had come under the care of the movement disorders physicians at the National 
Hospital for Neurology and Neurosurgery.  They agreed to participate in our genetic 
research to attempt to elucidate the cause of the disease in their family and signed the 
necessary consent forms.  Unfortunately, shortly after an initial brief meeting with the 
family to obtain samples of blood for genetic analysis and examine the core family, one 
of the affected siblings died quite suddenly and unexpectedly.  
 
At this point, although the family reaffirmed their consent for us to continue with the 
genetic research based on the samples we had already obtained, they asked that they not 
be contacted again until they had had time to come to terms with their loss.  We 
provided them with contact details so that they might re-establish contact when they felt 
ready.  However, at the time of writing, we had not heard from them again and, in line 
with their wishes, we have not made any further attempt at contact ourselves.  We 
subsequently learned that they had returned to Scotland and are thus no longer under 
follow up at the National Hospital.   
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An unfortunate consequence of this unexpected loss of contact was that we were not 
able to establish the full genetic pedigree beyond that of the core family, which had 
been provided at our initial meeting, and no record of this existed in their brief medical 
notes.  However, as we already knew that the parents were first cousins (and had been 
informed the grandparents on one side were also first cousins), we felt confident that 
the likely mode of inheritance was autosomal recessive and that the causal variant 
would thus be homozygous.  Moreover, the family had stated that they were not aware 
of any other affected individual within their extended family and so lack of knowledge 
of the full genetic pedigree was not expected to impact on study design or limit results. 
 
We therefore set about elucidating the cause of disease in this family using a 
combination of whole exome sequencing and autozygosity mapping.  Unlike as had 
been possible for the kindred presented in chapter 9, no assumptions could be made 
regarding the likely cellular function of the causal gene. 
 
11.2 Subjects ,  Materials  and Methods 
11.2.1 Clinical Detai ls  of  the Index Family 
Participants were drawn from a small Pakistani kindred.  The pedigree of the core 
nuclear family is shown in figure 51.  DNA was obtained from all individuals shown in 
the tree except individual II:2 who did not wish to participate in the study as he was 
still living in Scotland.  He was offered the opportunity to provide a DNA sample by 
posted ‘spit kit’ to minimise intrusiveness, but declined. 
 
There were at least two loops of consanguinity within the family, in that the affected 
children’s mother and father were first cousins and one set grandparents were also first 
cousins.  However, for the reasons set out in the section 11.1 above, we were not able 
to establish the structure of the genetic pedigree beyond the core nuclear family.  We 
were, however, told that the family were unaware of any other individual within the 
extended family with neurological disease. 
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Figure 51 – The genetic pedigree of the index family.  At least two consanguineous matings had 
occurred in this family:  the first, shown here, was between individuals I:1 and II:2, who were 
first cousins; the second was between the grandparents on one side of the family, who were also 
first cousins.  Unfortunately, for the reasons set out in section 11.1, we were unable to extend 
the genetic pedigree beyond what is shown here.  The family did, however, inform us that they 
were not aware of any other individual in the extended family with neurological disease of any 
form. 
 
Individuals II:3 and II:4 had both developed neurological signs in their infancy.  They 
showed delayed motor milestones, but did temporarily achieve ambulation and 
remained able to speak at the time of their inclusion in this study.  Their neurological 
illness was dominated by extrapyramidal features, in the form of dystonia with choreic 
elements, but the affected individuals also exhibited signs of cerebellar dysfunction, in 
the form of appendicular ataxia and dysarthria.  At the time of inclusion in this study, 
individuals II-3 and II-4 were aged ?? and ??, respectively, and both required full time 
care and were confined to a wheelchair.  Despite this, there were no pyramidal features 
and cognition was intact on bedside testing, though formal neuropsychometry had not 
been undertaken.  MRI in one of the individuals showed cerebellar atrophy. 
 
Both parents (individuals I-1 and I-2) and both older siblings (II-1 and II-2) were well, 
with no evidence of neurological disease (only the parents and individual II-1 could be 
examined as individual II-2 did not wish to participate). 
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DNA from the affected individuals had previous been screened for mutations in 
TOR1A, PANK2, SCA1, SCA2, SCA3, SCA6 and SCA7 and had tested negative. 
 
11.2.2 Whole Exome Sequencing and Exome Coverage Statist ics 
DNA from both affected siblings was used to perform whole exome sequencing using 
Illumina’s TruSeq (62Mb) DNA sample preparation and exome enrichment kits as per 
section 4.15.  Reads were subsequently aligned and annotated using the standard 
approaches set out in sections 4.16.  Coverage statistics for the exome as a whole were 
obtained using Picard. 
 
11.2.3 Genotyping,  Autozygosity Mapping and Coverage of Homozygous 
Regions 
Genome-wide genotyping data was obtained for all three affected siblings using the 
OmniExpress platform, which utilises approximately 500,000 markers as per section 
4.12  Autozygosity mapping was performed as per section 4.13. 
 
Coverage across regions of shared homozygosity was calculated using BedTools against 
the CCDS definition of the exome and expressed as the percentage of bases target 
covered by at least one read.  Briefly, using Ensembl’s Biomart function, a list of every 
exon of every CCDS gene within each homozygous region was obtained, along with its 
start position, end position and strand.  This information was used to construct a 
simple BED file of the desired targets within the region.  Coverage of these target 
regions was then checked against the BAM file for the exome using BedTools 
‘coveragebed’ function. 
 
11.2.4 Filtration of Variants Detected by Exome Sequencing 
In view of the apparently recessive inheritance pattern and history of consanguinity, we 
initially selected all homozygous variants for consideration.  Subsequently, synonymous 
variants not predicted to affect a canonical splice site (i.e. those not within 10 bases, in 
either direction, of the intron/exon boundary) were discarded.   Given the rarity of the 
disorder present in this family, we further hypothesised that the causal variant was 
unlikely to be found in any database of normal sequence variation.  However, in order 
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to minimize the possibility of incorrectly assigning causality, we filtered out those 
variants that were recorded in the 1000 Genomes, NHLBI or Complete Genomics 69 
datasets at a minor allele frequency of greater than 0.5%.  Given that a variant found at 
even this low frequency would be expected to be occur naturally in the homozygous 
state in around 1 in every 160,000 births, it seemed distinctly unlikely that we would 
risk filtering out the causal variant with this cut-off.  Subsequently, variants that were 
located in a region of shared homozygosity were selected as potentially causal.  No 
filtration was performed on the basis of in silico predictions of pathogenicity or 
conservation scores.   
 
11.2.5 Generation of Nucleotide Multispecies Protein Alignments 
In order to assess conservation of amino acid sequence, Uniprot, FlyBase and 
WormBase were interrogated for orthologous protein sequences.  Actual alignment of 
the sequences obtained in this manner was performed using the freely available web-
based application ClustalΩ. 
 
11.2.6 Generation of Regional Gene Expression Data 
Information on organism wide and brain region specific gene expression was collated as 
per section 4.19. 
 
11.3 Results  	  
11.3.1 Exome Sequencing  
Exome sequencing produced excellent coverage in all three individuals.  Using the 
TruSeq definition of the exome, the average mean read depth across the entire exome 
was 42 with 93.5% of the target covered by at greater than 2 reads, 88.3% covered at 
greater than 10 reads and 80.4% covered at greater than 20 reads.  This translated to an 
average variant count of 22,250 variants per exome. 
 
11.3.2 Autozygosity Mapping 
Autozygosity mapping demonstrated that runs of homozygosity greater than 1Mb were 
relative common in three siblings, with the largest single run of autosomal 
homozygosity stretching for 60Mb, confirming the report of extensive consanguinity 
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within the family.  The runs of homozygosity shared between all both affected siblings 
but not present in the unaffected sibling are summarized in the table 33. 
 
Initially, coverage of the homozygous regions was checked as described in section 
11.2.3.  Subsequently, the number of variants of all types detected in each homozygous 
region was determined along with the number of variants that might be potentially 
causal (i.e. those remaining after filtration as set out in the section 11.2.4 above).  This 
information is also summarized in the table 33. 
 
Table 33 - Summary of homozygous regions shared between both affected individuals but not 
present in their unaffected sibling, showing chromosomal location, size, percentage coverage, 
total variants contained therein and potentially causal variants contained therein. 











3 47598663 49590770 1.99 50 88.9% 28 0 
3 88708334 89097831 0.39 0 - 0 0 
5 3205018 7859434 4.65 12 88.9% 7 0 
5 72601498 73950760 1.35 6 82.3% 1 0 
6 95090000 97751948 2.66 8 97.8% 3 0 
6 163721073 170382923 6.66 28 87.3% 37 0 
7 67165048 72283565 5.12 3 90.5% 0 0 
7 94900975 103672960 8.77 127 88.1% 59 0 
7 118356108 120278563 1.92 1 100% 0 0 
7 137435711 139924127 2.49 19 86.6% 22 0 
8 85152853 86181870 1.03 5 89.9% 0 0 
11 3028140 12286355 9.26 151 90.3% 239 4 
13 35135179 39793979 4.66 22 93.2% 17 0 
13 88799824 89875736 1.08 0 - 0 0 
14 91828769 92095855 0.27 3 96.3% 0 0 
 
As detailed above, all homozygous regions demonstrated coverage of coding bases 
within the range expected for exome sequencing (>80%).  In particular, the largest 
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region of homozygosity on chromosome 11, which haboured the only potentially causal 
variants, was 90% covered.  
 
11.3.3 Overview of Potential ly Causal Variants 
After appropriate filtration as set out in section 11.2.4, four homozygous variants were 
identified that met the criteria for being potentially causative, all located on 
chromosome 11.  These variants are summarized in table 34 and discussed individually 
in the following sections. 
 
Table 34 – Details of potentially causal variants remaining after filtration of exome data, 
including chromosomal location, sequence change, amino acid substitution, zygosity, novelty, 
minor allele frequency (if previously observed) and number of reads covering the variant. 
 
ZNF195: 
ZNF195 encodes a protein belonging to the Krueppel C2H2-type zinc-finger protein 
family.  These family members are transcription factors that are implicated in a variety 
of cellular processes.  No further information is available regarding its specific 
functions. 
 
The variant identified by exome sequencing in this family is a C to T substitution at 
position 497 of the cDNA (ENST00000399602) resulting in the incorporation of a 
valine in place of an alanine at position 166 in the protein product.  The affected base 
Chr Position Gene Change Zygosity Novel? MAF 
Read 
depth 
11 3381741 ZNF195 
c.497C>T 
p.A169V 
Hom Yes - 60 
11 5510682 OR52D1 
C746G>A 
p.G249D 
Hom No 0.001 70 
11 6479001 TRIM3 
c.440G>C 
p.G147A 
Hom Yes - 10 
11 6645261 DCHS1 
c.7646G>A 
p.E2549R 
Hom Yes - 22 
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is poorly conserved (PhyloP = -0.461; PhastCons = 0.406).  In many species, this 
portion of the protein does not have a homologue, the two closest exceptions being the 
Chimpanzee and Rhesus Macaque, both of which also have an alanine at this position.   
The variant is not located in a key domain of the protein according to Uniprot, but 
resides instead in spacer region (amino acids 76 to 243) between an initial KRAB 
domain and the first of 10 zinc fingers.  It is predicted to be tolerated by SIFT (0.245), 
just neutral by Provean (-2.201), probably damaging by PolyPhen2 (0.935), and a 
polymorphism by MutationTaster (0.999). 
 
Publically available organism wide expression data for ZNF195 shows that it is widely 
expressed throughout the body, including the brain (figure 52, left side).  Within the 




Figure 52 - Expression data for the gene ZNF195 in man.  The panel on the left shows the 
organism wide expression data based on publically available EST datasets.  The panel on the 
right shows regional differences in expression across the brain, derived as described in section 
11.2.5, across the 10 CNS regions analysed: putamen (PUTM, n=129), hippocampus (HIPP, 
n=122), temporal cortex (TCTX, n=119), frontal cortex (FCTX, n=127), occipital cortex 
(OCTX, n=129), thalamus (THAL, n=124), cerebellar cortex (CRBL, n=130), substantia nigra 
(SNIG, n=101), intralobular white matter (WHMT, n=131) and medulla (specifically inferior 
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OR52D1 is a class I (that is, phylogenetically derived from aquatic animals) olfactory 
receptor (OR).  Class I ORs were thought to be non-functional genetic relics, but recent 
work involving human OR52D1 has demonstrated that it is, in fact, capable of 
generating currents in response to odorant stimuli, exhibiting a narrow repertoire 
related to that of its orthologous murine OR 420.  ORs are embedded in the plasma 
membrane of the olfactory neurons located in the olfactory epithelium and so do not 
appear a good candidate for mediating widespread neuronal dysfunction.  At the same 
time, however, there is an emerging body of evidence to suggest ORs are expressed in 
other regions of the nervous system beyond the peripheral sense organs, including in 
the neurons of the cerebral cortex and other regions of the adult human brain 421.  It 
has been tentatively suggested that they many act as ‘novel’ chemoreceptors, guiding 
neuronal physiological processes in response to ligands transported by the blood, 
released by neighbouring cells or even by the same cell 422.  Certain “ectopic” ORs 
have been implicated in cell assembly functions in the embryonic period, muscle 
regeneration and regulation of cell adhesion and migration, and sperm chemotaxis 423-
428.  In the CNS, axonal guiding through ORs has also been shown in the olfactory 
system 429-431.  Thus, although a seemingly unlikely cause of neurological disease, 
OR52D1 cannot be dismissed on the basis of its being an olfactory receptor alone. 
 
The variant detected by exome sequencing in this family is a G to A substitution at 
position 746 of the cDNA (ENST00000322641), which leads to the incorporation of 
an aspartic acid in place of a glycine at position 249 of the final protein product.  The 
affected base is particularly well conserved (PhyloP=1.21; PhastCons=0.13).  The variant 
is located in the sixth of seven predicted transmembrane helical domains, which begins 
at amino acid 241 and ends at amino acid 261.  It is recorded in dbSNP (rs147388113) 
and present in 12 out of 12,996 chromosomes sequenced by the NHLBI Exome 
Sequencing Project, making it an unlikely cause of the disease in this family.  It is 
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predicted to be damaging by SIFT (0.004), neutral by Provean (-1.423), possibly 
damaging by PolyPhen2 (0.751), and a polymorphism (0.999) by MutationTaster.  
 
Of note, there is a second independent missense SNP (rs710919) just six bases 
downstream of the variant that we detected that leads to an isoleucine-to-threonine 
substitution at position 251 (i.e. within the same transmembrane domain).  Despite 
being predicted to be more highly damaging by in silico methodology than the variant 
we identified by exome sequencing, this second SNP is common in the general 
population.  It was present on 3,192 of 12,996 chromosomes sequenced by the NHBLI 
Exome Sequencing Project and was observed in the homozygous state in about 7% of 
individuals. 
 
No EST expression data is available for this gene, but our own in house expression data 
shows low-level expression across the brain (not shown). 
 
TRIM3: 
TRIM3 encodes a protein that is a member of the tripartite motif (TRIM) family, also 
called the 'RING-B-box-coiled-coil' (RBCC) subgroup of RING finger proteins. The 
TRIM motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box 
type 2, and a coiled-coil region.  
 
It is intimately involved with neuronal physiology, as is reflected in its original name, 
brain expressed ring finger protein (BERP) 432.  It is similar to a rat protein that is a 
specific partner for the tail domain of myosin V, a class of myosins, which are involved 
in the targeted transport of organelles. The rat protein can also interact with alpha-
actinin-4. Evidence suggests that the human protein may play a role in myosin V-
mediated cargo transport 433.  TRIM3 deficient mice, which are viable, healthy and 
fertile with no gross of histological abnormalities, exhibit reduced synaptic GABAA 
receptor function, which was thought most likely to be due to disrupted kinesin 21B-
dependent  trafficking of the protein 434, 435.  Thus, a mechanism exists by which 
mutation of TRIM3 could be envisioned to lead to aberrant neuronal excitability, 
which has been proposed a mechanism underlying dystonia.  In addition to the above, 
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the has also been linked to nerve growth factor-induced differentiation and neurite 
outgrowth as well as synaptic remodelling, in the latter case as the ubiquitin ligase 
responsible for regulated degradation of key postsynaptic density proteins 436, 437.  A 
recent shotgun proteomics analysis has indicated that TRIM3 is up-regulated in the 
brains of schizophrenic patients 438. 
 
The expression data for TRIM3 is also interesting with respect to the disease phenotype 
seen with in this family.  As shown in figure 53, TRIM3 is highly expressed in the brain 
and shows particularly high levels of expression in the cerebellum.  This is interesting 
for two reasons.  Firstly, the only other significant neurological signs, besides dystonia, 
in the members of this family affected by disease were dysarthria and mild appendicular 
ataxia, suggestive of cerebellar dysfunction and their MRI showed cerebellar atrophy.  
Secondly, evidence from research on one of the best animal models of dystonia, the dt 
rat, suggests that the dystonic phenotype in this animal arises due to cerebellar 
dysfunction and, more precisely, as a result of abnormalities of GABAergic signalling in 
this structure.  The dt rat develops progressively more severe generalized dystonia from 
around postnatal day 14, caused by a deficiency of the neuronally-restricted protein 
caytaxin 439.  Like TRIM3, caytaxin also binds to kinesin light chains to mediate 
intracellular transport of specific cargos 440 and, like TRIM3, it is predominantly 
expressed within the cerebellum 441.  Whilst no differences have been demonstrated in 
cell morphology in the basal ganglia of these rats, Purkinje cells in the vermian and 
paravermian tissues at post natal day 20 at around 5 – 11% smaller in dt rats than in 
their non-mutant littermates 439.  Moreover, levels of the second messenger protein, 
cGMP, are significantly reduced in dt rats and show smaller rises in response to 
harmaline challenge 439.  This suggests a deficit in neurotransmission in the Purkinje 
fibres of this rat, which is probably postsynaptic.  Subsequent work has shown that the 
underlying deficit is increased activity of Purkinje cell GABAergic synapses within the 
dt rat cerebellar nuclei 442-444.  Thus, both TRIM3 and caytaxin have been linked to 
GABAergic activity in the cerebellum and caytaxin deficiency leads to dystonia. 
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Figure 53 - Expression data for the gene TRIM3 in man.  The panel on the left shows the organism wide expression data based on publically available EST 
datasets.  The panel on the right shows regional differences in expression across the brain, derived as described in section 11.2.5, across the 10 CNS regions 
analysed: putamen (PUTM, n=129), hippocampus (HIPP, n=122), temporal cortex (TCTX, n=119), frontal cortex (FCTX, n=127), occipital cortex (OCTX, 
n=129), thalamus (THAL, n=124), cerebellar cortex (CRBL, n=130), substantia nigra (SNIG, n=101), intralobular white matter (WHMT, n=131) and medulla 
(specifically inferior olivary nucleus, MEDU, n=109).  Whiskers extend from the box to 1.5 times the inter-quartile range. 
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The variant detected by exome sequencing in this family is a G to C substitution at 
position 440 of the cDNA (ENST00000345851), which leads to the incorporation of 
an alanine in place of a glycine at position 147 of the final protein product.  The 
affected base has a relatively neutral conservation score (PhyloP=0.398; PhastCons=1).  
The variant is, however, located in the key type 2 B-box domain of the protein, which 
coordinatively binds zinc ions through regularly spaced, ultra-highly conserved histidine 
and cysteine residues and is involved in ubiquitination.  The amino acid affected by 
this mutation sits directly next door to one of these key histidine residues (amino acid 
146).  The B-box domain spans from amino acid 110 to 151.   
 
Despite the critical location of the mutation, it is predicted to be tolerated by SIFT 
(0.903), neutral by Provean (0.307), benign by PolyPhen2 (0), and a polymorphism 
(0.644) by MutationTaster.  At least part of the benign nature of these predictions 
undoubtedly owes to the fact that alanine, like glycine, is a small neutral amino acid 
and thus substitutions of these two amino acids are generally considered less likely to be 
deleterious to the protein.  That said, glycine is a very unique amino acid in that it 
contains a hydrogen at its side chain (rather than a carbon as in the case of all other 
amino acids).  This means that there is much more conformational flexibility in glycine, 
which allows it to reside in parts of proteins structures that are forbidden to all other 
amino acids (such as tight turns in structures).  It can also play a distinct functional role 
by using it sidechain-free backbone to bind phosphates.  In the final analysis, however, 
it is difficult to sustain the argument that TRIM3 function is reliant on the special 
properties of this particular glycine since a glycine is not seen at this position in a 
number of other species, including the chicken (G. Gallus), the tasmanian devil (S. 
Harrisii), the zebra fish (D. Reiro), the pufferfish (T. Rubripes), the nematode worm (C. 
Elegans), whereas the critical neighbouring histidine is conserved in all species (figure 
54) 
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Figure 54 - Multiple species alignment shows only partial conservation of the affected amino 
acid in TRIM3.  Conversely, the neighbouring histidine residue, which is known to be critical 
for TRIM3's function as a ubiquinase, shows absolute conservation in all species.  Colours 
indicate physiochemical properties of amino acids (red = small/hydrophobic; blue = acidic; 
magenta = basic; green = hydroxyl/sulfhydrl/amine/glycine). 	  
DCHS1: 
DCHS1, standing for ‘dachsous 1 (Drosophila)’, is a member of the cadherin 
superfamily.  This family of genes encode calcium-dependent cell-cell adhesion 
molecules.  The particular protein encoded by DCHS1 has a signal peptide, 27 cadherin 
repeat domains and a unique cytoplasmic region.  It is expressed in fibroblasts and 
where it may play a part in wound healing.  More relevant for our purposes, DCHS1 
also forms part of a pathway that regulates planar cell polarity in both Drosophila and 
mice and is involved in genesis of the mouse embryonic cerebral cortex 445, 446.  
Transgenic mice carrying a copy of Dchs1 with a targeted excision of the second exon 
(which prevents its expression by removing the initiator methionine, the signal peptide 
and first 6 cadherin domains) are viable at birth but fail to grow.  They show multiple 
morphological abnormalities, including a widened neural tube, small cystic kidneys, a 
reduced intestinal length, smaller lungs, defects in atrial septation, skeletal 
abnormalities and curly tails 447.  This suggests that DCHS1 is important in the 
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morphogenesis of multiple organs, in mouse at least, and pathogenic mutations in this 
gene might be expected to lead to a phenotype with extra-neurological manifestations. 
 
The variant detected by exome sequencing in this family is a G to A substitution at 
position 7646 of the cDNA (ENST00000299441), which leads to the incorporation of 
an arginine in place of a glutamine at position 2549 of the final protein product.  The 
affected base has a relatively neutral conservation score (PhyloP=0.133; 
PhastCons=0.911).  The variant is located in the 24th cadherin domain, which begins at 
amino acid 2483 and ends at amino acid 2602.  It is predicted to be tolerated by SIFT 
(1), neutral by Provean (0.159), benign by PolyPhen2 (0), and a polymorphism (0.999) 
by MutationTaster. 
 
Publically available systemic expression data for DCHS1 shows that it is widely 
expressed throughout the body, including at relatively high levels in the brain (figure 
55, left side).  Within the brain, it shows a particular emphasis on some areas associated 
with movement disorders, such as the striatum, thalamus and substantia nigra (figure 
55, right side) 
 
11.3.4 Select ion of a Candidate Variant for Further Sequencing 
None of the variants identified in this family are clearly causal.  Those variants with a 
proven role in the brain (DCHS1 and TRIM3) are also, unfortunately, the same variants 
that are predicted to be benign by all in silico programs.  However, after careful 
consideration, it was decided that a priori biological plausibility of neuronal dysfunction 
as a result of disruption of TRIM3 function was sufficiently high to overlook the in 
silico predictions and proceed to a screening of the affected exon in a cohort of 
individuals affected with generalised dystonia in the hope of finding a second family 
with mutations in this gene. 
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Figure 55 - Expression data for the gene DCHS1 in man.  The panel on the left shows the 
organism wide expression data based on publically available EST datasets.  The panel on the 
right shows regional differences in expression across the brain, derived as described in section 
9.2.6, across the 10 CNS regions analysed: putamen (PUTM, n=129), hippocampus (HIPP, 
n=122), temporal cortex (TCTX, n=119), frontal cortex (FCTX, n=127), occipital cortex 
(OCTX, n=129), thalamus (THAL, n=124), cerebellar cortex (CRBL, n=130), substantia nigra 
(SNIG, n=101), intralobular white matter (WHMT, n=131) and medulla (specifically inferior 
olivary nucleus, MEDU, n=109).  Whiskers extend from the box to 1.5 times the inter-quartile 
range. 
 
11.3.5 Screening of  Exon 4 of TRIM3 
Screening of exon 4 of TRIM3 was undertaken using Sanger Sequencing methodology.  
384 DNA samples belonging to individuals diagnosed with dystonia were selected from 
an in-house library of research samples.  As was discussed in chapter 7, no samples were 
available where autosomal recessive inheritance of dystonia was definite.  Therefore,  
samples were selected instead on the basis that the clinical details suggesting either no 
family history or a family history consisting only of affected siblings.  Precise age at 
onset data is not available for most samples, but an attempt was made to ensure young-
onset cases were screened by including those samples that showed a date of receipt 
within 30 years of the donner’s birthdate.  All samples had previously been screened for 
mutations in TOR1A and were negative. 
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No previously unreported, potentially causal mutations were identified in our cohort.  
The only novel change detected was a heterozygous synonymous SNV (c.384G>A) 
which is located 20 bases from the intron/exon boundary and is not predicted to result 
in any splicing changes. 
 
11.4 Discuss ion 
Using a combination of exome sequencing and autozygosity mapping, followed by 
appropriate variant filtration, we set out to establish the genetic cause of disease in a 
consanguineous Pakistani kindred, in which affected individuals exhibited infantile-
onset, severe choreodystonia and cerebellar signs.  We identified 4 potentially causal 
variants.  Of the genes affected, TRIM3 seemed the most biologically plausible as it was 
highly expressed in the brain and, more precisely, in the cerebellum.  Moreover, it has 
functional similarities to the protein mutated in the dt rat model of dystonia, caytaxin, 
in that both interact with memebers of the kinesin family of proteins to mediate 
transport of specific cargos.  Furthermore, experimental evidence has demonstrated 
defects in trafficking of GABAA receptors in TRIM3 knockdown models, whilst 
defective GABAergic transmission in Purkinje fibres is now known to be the 
pathogenic mechanism underlying the dystonic phenotype in dt rats. 
 
On a genetic level, however, the variant detected in this gene is not particularly 
convincing.  Although located next door to a critical, ultra-conserved histidine residue 
that is involved in zinc ion coordination, the glycine to alanine substitute is universally 
predicted to be benign (both are small non-polar amino acids) and interspecies 
conservation is not complete at this position.  In addition, we could find no other 
potentially causal mutations in a cohort of generalised dystonia cases (though this in 
itself is not particularly surprising given the rarity of autosomal recessive dystonia and 
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In summary, at present it is not possible to say with any certainty what the genetic cause 
of the dystonia in this family is.  A number of different possibile explanations exist for 
this.  These are: 
 
1) The causal variant is located in the 10-15% of the CCDS coding bases within the 
homozygous regions that were not covered by exome sequencing.   
2) The genetic cause of this disease is located outside of the CCDS coding region, i.e. 
it is intronic, intragenic or located within a non-coding RNA. 
3) The genetic cause of this disease is an exonic copy number variant that would not 
be expected to be detected by either exome sequencing or by use of genome wide 
SNP data. 
4) Either ZNF195, OR52D1 or DCHS1 is in fact the cause of the disease and we have 
pursued the incorrect variant. 
5) TRIM3 is the cause of the disease, but we have not found a second mutation as 
phenotypic matching in the screening cohort was suboptimal or the disease is 
simply too rare to expect to find a second case in a cohort of this size. 
 
With respect to explanations 1 and 2, whole genome sequencing may hold out hope 
that these problems could be overcome in the near future.  However, even with ‘whole 
genome’ sequencing there are likely to be areas that remain uncovered due to the 
physical features of the DNA, such as repetitiveness and GC content.  Moreover, whole 
genome sequencing comes with it own set of problems, in particular the current lack of 
any large-scale databases of whole-genome variation in normal individuals (particularly 
those of non-white ethnicity) and the absence of any currently validated means of 
predicting the likely pathogenicity of non-coding variants. 
 
With respect to explanation 5, although we attempted to maximize our chances of 
screening autosomal recessive cases by selecting samples from younger individuals with 
either no family history or only affected siblings, it is inevitable that a proportion of the 
cases screened will, in fact, have been either non-genetic or, if genetic, due either to 
genes associated with autosomal dominant inheritance (because of incorrectly recorded 
family history, de novo mutations, or reduced penetrance, for example). 









An Association Study In 
Neuropathological ly  Proven PD  
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To date, several large-scale genome-wide association studies (GWAS) have been 
completed for Parkinson’s disease (PD), culminating in a recently published meta-
analysis that identified 16 loci surpassing the threshold for genome-wide significance 3, 4, 
58, 448, 449.  Of these 16 loci, some are predictable findings, whilst others offer the new 
insights into the pathogenesis of the disease.  For example, from a neuropathological 
perspective, the discovery that variants in SNCA act as a risk factor for PD is consistent 
with the deposition of aggregated α-synuclein in the PD brain.  However, the detection 
of variation in MAPT as a risk factor in PD was unexpected, as the relevance of tau 
aggregation in PD remains unclear. 
 
Predictably, a number of tauopathies are associated with common or rare variants in 
MAPT, including corticobasal degeneration, frontotemporal dementia with 
parkinsonism linked to chromosome 17, and progressive supranuclear palsy (PSP) 450.  
In fact, variation in MAPT is the strongest genetic risk factor for PSP.  The association 
with this condition is driven by a series of polymorphisms in near complete linkage 
disequilibrium, which form an extended haplotype, termed H1, that covers the entire 
gene 451.  Inheritance of two copies of the risk haplotype in this region confers an odds 
ratio for developing PSP of ~4 451.  
 
It is a well known fact that there can be considerable clinical overlap between PD and 
PSP, especially in the earlier stages of the diseases. Even with increased awareness, the 
rate of misdiagnosis of idiopathic PD has been estimated at between 10–25% in 
autopsy studies, and 6–26% in community studies 452, 453.  In one autopsy study of 100 
cases of clinically diagnosed PD, 24 cases were found to be misdiagnosed and 6 of these 
were PSP 452.  It is probable, therefore, that large GWAS, which rely on clinically 
diagnosed PD cases, will contain some individuals with PSP.  Despite the potential for 
clinical confusion, PSP is neuropathologically distinct from idiopathic PD.  PSP is 
classified as a primary tauopathy and is characterised morphologically by deposition of 
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four-repeat tau in neurons as neurofibrillary tangles and in both astrocytes and 
oligodendroglia as tufted astrocytes and coiled bodies, respectively.  The morphological 
characteristics and anatomical distribution of the tau pathology and the biochemical 
composition of the tau lesions are different from those seen in Alzheimer’s disease 454.  
PD, on the other hand, is classified as a synucleinopathy, characterised by abnormal 
fibrillar cytoplasmic inclusions, termed Lewy bodies, of which the principal protein 
component is α-synuclein 455. 
 
Given the strength of the association between MAPT with PSP, it has been suggested 
that the tau signal seen in Parkinson’s disease association studies might be the result of 
unrecognised PSP contamination of the case cohort.   Therefore, in order to answer 
this important question, we performed a focused analysis of our pathologically proven 
PD cases using genotyping data from our own in-house GWAS datasets 3 as well as 
newly genotyped PD brains specifically for this study. 
 
12.2 Subjects ,  Materials  and Methods 
12.2.1 Sourcing of  Tissue Resources 
Cases were selected from two brain banks in London with a confirmed primary 
neuropathological diagnosis of PD.  Neuropathological diagnosis had been made by an 
experienced neuropathologist and was based on accepted morphological criteria 456.  
Cases were excluded who exhibited a family history of Parkinson’s disease consistent 
with Mendelian inheritance of the disease. 
 
12.2.2 Extraction of DNA from Brain Tissue 
DNA from brain tissue was extracted as per section 4.2.3 
 
12.2.3 Genotyping of New Cases 
Newly extracted DNA was genotyped as per section 4.10 using the Immunochip, a 
custom SNP chip supplied by Illumina.  Although absolute numbers of SNPs 
genotyped by the Immunochip is relatively modest (appox. 200,000 SNPs), the strategy 
employed in its design meant that the loci likely to be associated with PD were 
disproportionately well covered.  Genotyping data was viewed in Genome Studio for 
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initial quality control and, subsequently, PLINK files generated using a publically 
available plug-in.   
 
12.2.4 Select ion of Previously Genotyped Cases 
In total, 469 DNA samples from the UK included in the original GWAS discovery and 
replication phases were thought to be derived from neuropathologically proven PD 
cases.  During this work, however, it became apparent that tissue had often been sent 
on the basis of clinical diagnosis alone and, unfortunately, no effort had been made to 
check the neuropathologically diagnosis was in fact iPD. 
 
We therefore undertook a manual review of the clinical history and neuropathological 
diagnosis for all of these cases.  Inclusion criteria were a neuropathological diagnosis 
consistent with iPD and an age at onset of greater than 40 years of age.  Exclusion 
criteria were an alternative primary neuropathogical diagnosis, a family history of PD 
consistent with Mendelian inheritance of the disease, or an age at onset of less than 40 
years of age. 
 
In total 46 were excluded because they did not meet the above criteria.  This included 
12 cases of PSP.  423 remained for inclusion in the analysis.  As above, genotyping data 
was viewed in Genome Studio for initial quality control and, subsequently, PLINK files 
generated using a publically available plug-in. 
 
12.2.5 Generation and Quality Control  of  Control  Genotyping Data 
Genotyping data for 5,200 control individuals from the UK had been obtained using 
the Quad 660 SNP chip for the discovery phase of the GWAS.  For the subsequent 
replication stage of the study, 4,537 control individuals from the UK were genotyped 
using the Immunochip custom SNP chip.  Unfortunately, it was known that there was 
likely to be some overlap between the two populations, which might artificially inflate 
the results of any meta-analysis.  As a first step, therefore, we sought to remove definite 
duplicates from the control population and individuals who are likely to be siblings. 
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Treating both datasets separately initially, PLINK files were generated from the raw 
genotyping data using Genome Studio.  For each dataset, SNPs were eliminated that 
showed a genotyping rate of less than 90% across the dataset or were not in Hardy-
Weinberg equilibrium.  Next, for each dataset in turn, individuals with a genotyping 
failure rate of greater than 10% were also removed.  Finally, both datasets were merged 
and SNPs were eliminated with a genotyping rate of less than 90% across the entirety of 
newly merged dataset (which essentially had the effect of leaving only high quality SNPs 
that were common to both genotyping platforms for consideration).  In the end, 
genotyping information was available for all 9737 individuals across 20,485 markers. 
 
Pairwise identity by descent (IBD) was calculated for this merged dataset using PLINK.  
Each pairwise comparison results in a measure (PI-HAT), ranging from 0 to 1, that 
represents the proportion of the genome that is likely to be identical by descent.  In 
order to accurately estimate IBD, it is desirable to consider greater than 100,000 
independent SNPs, with higher numbers leading to increasing accuracy.  Under these 
optimal conditions, a PI-HAT close to 1 represents a duplicated sample, a PI-HAT of 
around 0.5 represents a sibling, parent or child, a PI-HAT of around 0.25 represents a 
cousin.  However, for the purposes this study, we were limited to the 20,485 markers 
shared between both platforms.  It was recognised that this would lead to a some 
inflation in the value of PI-HAT due to the reduction in the number of independent 
markers which PLINK would be able to consider.  We therefore chose an arbitrary cut-
off point of a PI-HAT of greater than 0.3, which we felt would capture all duplicate 
samples, all 1st degree relatives and most if not all 1st cousins.  In practice, this identified 
2608 pairs of samples that were likely to be related at this level and one member of 
each pair was eliminated from the original unmerged datasets, taking care to remove 
roughly even numbers from each. 
 
12.2.6 Identif ication of Outl iers  and Matching of  Cases to Controls 
Accurate detection of population stratification requires genome-wide genotyping data.  
Since only approximately 20,000 SNPs were shared between the two platforms used for 
genotyping in this study, it was necessary to treat each set of samples separately.  
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Information regarding identity by state was generated using PLINK for both datasets in 
turn for use in the following steps, which were performed on each dataset in turn.   
 
As a first step, aimed at matching the controls as closely as possible to the cases in terms 
of population of origin, clustering was performed on the basis of identity by state (IBS) 
using PLINK in order to sort samples into groups by genetic proximity.  Each group was 
permitted to hold a maximum of 1 case and up to 10 controls.  Groups were then 
reviewed to find those groups than did not contain any case (suggesting that the 
controls contained therein were significantly distinct from the case population) and all 
controls contained within such groups were eliminated.  This resulted in the 
elimination of 1352 controls from the GWAS discovery dataset and 846 controls from 
the GWAS replication dataset. 
 
As a second step, to detect outliers in both cases and controls, each sample in turn was 
paired with its closest neighbour in terms of IBS.  We then determined whether the 
proband's closest neighbour was significantly more distant to the proband than all 
other individuals' nearest neighbour is to them. In other words, from the distribution 
of 'nearest neighbour' scores, one for each individual, we calculated using PLINK a 
sample mean and variance and transformed this measure into a Z score.  Individuals 
with a Z score of -1 in relation to their nearest neighbour (i.e. one standard deviation of 
difference) were eliminated.  The process removed a further 58 individuals for removal 
from the GWAS discovery dataset and a further 130 individuals from the GWAS 
replication dataset. 
 
12.2.7 Select ion of SNPs for Test ing 
The primary analysis focused on a region approximately 500 kilobase (kb) either side of 
MAPT. The single nucleotide polymorphisms (SNPs) tested for association in this 
region were selected on the basis that they had achieved genome-wide significance in 
the UK samples used in the discovery phase of our GWAS meta-analysis and had also 
been genotyped on the custom-built immunochip used for the replication phase. Eight 
SNPs met these requirements (rs393152, rs1635291, rs7215239, rs1237319, 
rs17690703, rs17769552, rs1981997, and rs8070723). None of the SNPs in MAPT 
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chosen by this method are in significant linkage disequilibrium with the SNPs used by 
Vandrocova et al. (2009) in their MAPT haplotype analysis (maximum r2 ≈ 0.2). 
 
In earlier GWAS, the region surrounding α-synuclein (SNCA) has consistently been 
shown to be the locus most strongly associated with PD (International Parkinson’s 
Disease Genomics Consortium et al., 2011; UK Parkinson’s Disease Consortium et al., 
2011; Satake et al., 2009). Thus, in order to verify that this analysis had sufficient 
power to detect previously well-documented associations, we also included the SNPs in 
a second 1 megabase (Mb) region spanning SNCA that met the same requirements as 
above. Two SNPs were available for testing (rs356220 and rs2736990). 
  
12.2.8 Association Analyses and Meta-Analysis  
After implementation of the measure described above, there was genotyping data for 
301 cases and 2455 controls obtained using the Quad 610 SNP chip and 289 cases and  
2301 controls using the Immunochip custom-built SNP chip.  Association between 
genotype at each of the 10 markers indicated above and the subject phenotype 
(case/control) was determined for each dataset independently.  The association analysis 
was performed using PLINK.  Although the minimum minor allele frequency (MAF) 
was set to 5% as is considered best practice, in reality the method of choosing SNPs for 
testing in this study meant that all SNPs would necessarily have a MAF of greater than 
5%.   Subsequently, a meta-analysis of the 2 association analyses was performed using 
the same software.  Fixed and random effects models were used to generate p-values and 
the I2 index was used to quantify heterogeneity between the studies. 
 
12.3 Results  
The primary analysis demonstrated statistically significant association in 8 SNPs 
spanning the MAPT gene (see table 35 and figure 56).  The SNP showing strongest 
association in this study was rs17690703, which had a p-value of 8.9	   x	   10-­‐5 and was 
calculated to confer an odds ratio of 0.76 per minor allele dose. 
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Table 35 - SNPs in a 1Mb region spanning MAPT showing statistically significant association 
with p-values in fixed and random effects models, I2 index, minor allele frequency (MAF) and 















rs393152 41074926 2.0 x 10-4 2.0 x 10-4 0.00 0.24 0.76 
rs1635291 41107696 5.0 x 10-4 5.0 x 10-4 0.00 0.26 0.77 
rs7215239 41123556 3.2 x 10-4 3.2 x 10-4 0.00 0.26 0.76 
rs12373139 41279910 2.1 x 10-4 2.1 x 10-4 0.00 0.24 0.76 
rs17690703 41281077 8.9 x 10-5 8.9 x 10-5 0.00 0.28 0.75 
rs17769552 41283070 9.9 x 10-5 9.9 x 10-5 0.00 0.24 0.74 
rs1981997 41412603 2.7 x 10-4 2.7 x 10-4 0.00 0.24 0.76 
rs8070723 41436901 1.8 x 10-4 1.8 x 10-4 0.00 0.24 0.76 
 
	  
Figure 56 – Physical position of the SNPs tested across the MAPT locus with p-values, 
recombination rate and linkage disequilibrium (LD).  A diamond represents the top hit, which 
is the reference for the LD calculations.   
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The results of the secondary analysis using SNPs spanning SNCA confirms this study’s 
ability to detect the predicted association with this region using only the relatively small 
sub-population of neuropathologically confirmed cases of PD (see table 36 and figure 
57).  rs356220, the SNP showing the strongest association in this study, had a p-value of 
5.4 x 10-4 was calculated to confer an odds ratio of 1.24 per minor allele dose.  
Furthermore, this SNP is in high linkage disequilibrium (r2>0.9) with and shows the 
same direction of effect as the top SNP from the largest meta-analysis published to date 
(rs356219; not included in this study as not common to both genotyping platforms) 
suggesting a consistent pattern of association. 
 
Table 36 - SNPs in a 1Mb region spanning SNCA showing statistically significant association 
with p-values in fixed and random effects models, I2 index, minor allele frequency (MAF) and 











I2 index MAF   Odds ratio per 
minor allele 
dose 
rs356220 90860363 5.4 x 10-4 5.4 x 10-4 0.00 0.36 1.24 
rs2736990 90897564 6.2 x 10-3 6.2 x 10-3 0.00 0.45 1.18 
 
	  
Figure 57 - Physical position of the SNPs tested across the SNCA locus with p-values, 
recombination rate and linkage disequilibrium (LD).  A diamond represents the top hit, which 
is the reference for the LD calculations.   
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12.4 Discuss ion 
Clinical misdiagnosis has the potential to introduce contamination into association 
analysis.  With regard to PD GWAS, PSP contamination is of particular concern as the 
association between PSP and the MAPT locus is particularly strong and studies suggest 
clinical misdiagnosis of PSP as PD is relatively common.  Therefore, in this analysis, we 
relied solely on neuropathological diagnosis as the inclusion criterion for the case 
cohort. 
 
The results confirm that the region surrounding MAPT is associated with idiopathic PD 
in our neuropathologically proven PD cohort and, therefore, that this association does 
not result from contamination with primary tauopathies, such as PSP.  Association at 
the SNCA locus was also seen, confirming the analysis’s power to detect known 
associations even with these moderate sample sizes.  Although the gene most likely to 
be responsible for the association signal remains MAPT itself, this gene is located in a 
block of near complete linkage disequilibrium that extends over a total of nearly 2Mb 
on chromosome 17.  It is conceivable, therefore, that a different gene within this 
haplotype block may in fact be driving the association.   
 
Accepting MAPT as the most likely candidate, the persistence of the association at this 
locus in pathologically proven PD raises the possibility that that dysfunction of tau may 
in fact be pathogenic in PD.  Variants in MAPT may act either to increase expression or 
alter the splicing of tau so as to favour its aggregation.  It is already known that the H1c 
haplotype, which underlies the risk in PSP, results in increased expression of tau, 
particularly of four repeat containing transcripts 457.  Recently, it has also become 
increasingly clear that, in many neurodegenerative diseases, the aggregation of one 
protein may often be associated with or even induce the aggregation of others 458.  On a 
genetic level, studies in clinically defined PD have suggested that genotypes at the 
MAPT and SNCA loci act synergistically to confer susceptibility to PD and that 
variation at MAPT may be particularly associated with cognitive decline 459, 460.  
Certainly, Alzheimer-like tau pathology has long been known to co-exist with the 
morphological changes typical of idiopathic PD, where it may be associated with 
cognitive dysfunction 461.  This has mostly been viewed as a consequence of pathological 
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ageing or co-existent early Alzheimer’s disease, rather than as being an intrinsic part of 
the pathogenic pathway of PD itself.   Co-existent Alzheimer’s disease seems, however, 
unlikely to be able to fully explain the MAPT association in idiopathic PD as a recent 
large GWAS in Alzheimer’s disease failed to demonstrate any association at this locus 
462.  Significant tau pathology has also been noted in some monogenic forms of PD, 
including in some cases resulting from LRRK2 mutation and in some members of the 
Contursi kindred, who carry the A53T SNCA mutation, as well as in α-synuclein 
overexpressing transgenic mice 463, 464.   More recently, it was found that the distribution 
of tauopathy in the brains of individuals with PD was distinct from that observed in 
Alzheimer’s disease, with hyperphosphorylated tau evident in striatum, but not in the 
inferior frontal gyrus despite an increase in α-synuclein in this region 465. 
 
It is likely that more detailed neuropathological studies of tau pathology in the brains of 
individuals with idiopathic and genetic forms of PD will be required to fully dissect out 
its role in the pathogenesis of this condition.   One promising approach may be to look 
for a correlation between the extent of tau pathology in idiopathic PD and the genotype 
at the MAPT locus.  The existence of such a correlation would support the idea of a 
direct effect of these variants on tau aggregation. 
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13. Mutational  Screening of  VPS35 in a UK Parkinson’s  
Disease Cohort  
 
13.1 Introduction 
In 2011, using an whole-exome sequencing approach, two independent groups 
identified a missense mutation in vacuolar protein sorting 35 homolog 
(VPS35 c.1858G>A; p.Asp620Asn) as the probable cause of late-onset PD in a number 
of kindreds.466 Pathogenicity was supported by segregation, evolutionary conservation at 
that base, and software predictions that the variant is likely to be damaging. However, 
no other pathogenic mutations had been identified with certainty in VPS35, and the 
c1858G>A mutation had only ever been found in Caucasian individuals.  Definitive 
evidence that a gene such as VPS35 predisposes to familial Parkinson's disease usually 
requires the identification of other mutations which segregate with Parkinson's disease 
in families, and the observation that VPS35 mutations occur in PD patients in other 
populations.  Moreover, the at the time of publication, it was not known what 
proportion of unexplained familial Parkinsonism VPS35 mutations might account for. 
 
In order to attempt to answer these important questions, we screened our own 
Parkinson's population for variants in this gene, both in order to estimate the frequency 
of the published mutations and in order to search for novel mutations that may be 
disease-causing. 
 
13.2 Subjects ,  Materials  and Methods 
13.2.1 Select ion of Cases of  Mutational Screening 
The study included 160 familial PD cases, 175 young-onset PD cases, and 262 sporadic, 
neuropathologically confirmed PD cases (total number screened, 501). 
Neuropathologically confirmed cases were selected from the Queen Square and 
(Parkinson's disease United Kingdom) brain bank. The study was approved by the East 
Central London Research Ethics Committee 1 and informed consent was obtained as 
per its guidelines. 
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All living patients fulfilled criteria for clinical diagnosis of PD at the time of the study 
with at least 2 of 3 cardinal signs of tremor, rigidity, and bradykinesia, as well as a 
positive response to levodopa therapy. Familial cases were defined as those reporting 1 
or more first degree relatives with PD with a pedigree consistent with autosomal 
dominant inheritance and negative testing for known mutations in SNCA and LRRK2. 
Young-onset PD cases were defined as those who had developed their first signs of the 
disease at age 45 or younger (mean age of onset in young-onset PD was 37 ± 6, range 
14–45 with a male to female ratio of 1.63:1). A family history of PD (first or second 
degree relative) was noted in 31 young-onset PD cases (17.7%). The neuropathological 
diagnosis for brain bank cases was made by an experienced neuropathologist and based 
on accepted morphological criteria (Ince et al., 2008). This group included 166 males 
and 96 females, with an average age at onset of 64 ± 11 years (range, 29–85) and a 
family history recorded in 7.6% of cases. 
 
13.2.2 Mutational Screening 
VPS35 exons 2–12 are located within a region that is duplicated 12 megabases (Mb) 
upstream. Primer pairs were designed specifically to amplify these exons using Gene 
Runner (v.3.0.5, Hastings Software Inc., Hastings, NY, USA) using Ensembl reference 
transcript ENST00000299138.  We amplified all exons and exon-intron boundaries 
using the following PCR reaction mix: 10ng of genomic DNA, 10nM forward primer, 
10nM reverse primer and 10ul of FastStart PCR Master (Roche, IN, USA).  To amplify 
exon 9 and 10, we added 1ul of 5% dimethylsulfoxide (DMSO; American 
Bioanalytical, MA, and USA) to the PCR mix.  Sequencing was accomplished as per 
sections 4.6 – 4.11. 
 
All 17 exons and exon-intron boundaries of VPS35 were sequenced in 96 familial PD 
cases, and exon 15 (in which the c.1858G>A; p.Asp620Asn mutation is found) in an 
additional 64 familial PD cases, 175 young-onset PD cases, and 262 sporadic, 
neuropathologically confirmed PD cases (total number screened, 501). 
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13.2.3 Clinical Characterisation of Individual ’s  Test ing Posit ive of  a VPS35 
Variant  
Clinical details were collated were possible from living family members for those 
affected relatives that were deceased. Where possible affected individuals were clinically 
examined and olfactory testing undertaken using UPSIT.467 
 
13.3 Results  
13.3.1 Results  of  Mutational Screening 
Screening revealed a single case from our familial PD cohort who harbored the 
previously described p.Asp620Asn mutation.  No other nonsynonymous variants were 
detected in any other exon of any sample.  In addition to this, we observed 7 other 
sequence variants, including 2 novel and 5 previously described variants (Table 37 
overleaf 
 
13.3.2 Clinical Characterisation of Kindred with p.Asp620Asn Mutation 
In order to determine whether the p.Asp620Asn mutation segregated with PD in the 
family of the individual from our FPD cohort, we contacted other affected family 
members: a sister, and two cousins, they subsequently were found also to have the 
p.Asp620Asn mutation. The family is of European ancestry, the pedigree (figure 58) is 
consistent with autosomal dominant mode of inheritance and revealed 9 further 
affected individuals across 3 generations, all of whom are deceased. 
 
The index case (IV-7) noticed his first symptoms in 1993 at the age of 40, consisting of 
stiffness in the left arm on waking followed, a few months later, by gradually worsening 
stiffness in the left leg. He was diagnosed as suffering from PD in 1995. At that time, 
examination showed unilateral bradykinesia and reduced arm swing. L-dopa was 
commenced with a good response, although he continued to gradually worsen. He 
began to notice a mild intermittent tremor of the left upper limb 13 years after his 
initial symptoms, followed by the spread of the stiffness to his right upper limb.  
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Table 37 – Details of all variants detected in VPS35 by mutational screening. 	  
Nature	  of	  Variant	   Nucleotide	  change	   Amino	  acid	  change	   Rs	  number	  (if	  
available)	  
Exon	   Number	  of	  case	  
Non-­‐synonymous	   c.1858G>A	   p.Asp620Asn	   Recently	  published	   15	   1	  Synonymous	   c.231T>C	  c.1842T>C	  c.1938C>T	  
p.Leu77Leu	  p.Tyr615Tyr	  p.His646His	  
Rs11550462	  Novel	  Rs16875	  
4	  15	  15	  
1	  1	  1	  UTR	   c.1-­‐34G>A	   	   Rs3743928	   	   1	  Intronic	   c.3+25A>C	  c.1524+42G>C	  c.1648+26G>C	  
	   Novel	  Rs4966616	  Rs2304492	  
1	  12	  14	  
1	  27	  (2	  homo)	  58	  (10	  homo)	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Dyskinesias started after 9 years of L-dopa therapy, but were not severe. He complains 
of difficulty with balance, but has not had any falls. There is no history of mood 
disturbance or other psychiatric features, including visual hallucinations. Cognitively, 
he feels that his concentration has deteriorated somewhat over the years, but he has 
only recently retired from a demanding job. A Mini Mental State Examination (MMSE) 
performed 18 years into the disease revealed a score of 28/30. Olfactory testing was 
undertaken 18 years into the disease, using the 40-item University of Pennsylvania 
Smell Identification Test (UPSIT) 467 and results were interpreted in comparison with 
55 control subjects (27 males and 28 females) and 46 PD patients (30 males and 16 
females) who had been previously tested for a study about olfaction in the UK468. The 
patient correctly identified 29/40 items of the UPSIT, scoring on the 37th percentile of 
55 controls aged between 55 and 65 from the UK, and the 87th percentile of 46 PD 
subjects aged between 55 and 65 from the UK. His sibling (IV-8) developed symptoms 
aged 52 years of age and was formally diagnosed 2 years later. Initial symptoms included 
cramping in the left foot and tripping when walking. Within 6 months she developed a 
unilateral leg tremor. Further symptoms included micrographia, and freezing. 
Dopamine agonists were tried initially but within 3 years she required L-dopa. She has 
not developed any dyskinesias. She does not report any cognitive symptoms and a Mini 
Mental State Examination was 30/30. Olfactory testing was undertaken 11 years into 
the disease as described above with the patient also identifying 29/40 items of the 
UPSIT. Individual IV-5 presented with a stiffness and rigidity of the left leg at the age, 
followed by walking difficulties, bradykinesia, loss of postural reflexes and micrographia 
aged 47. There was no rest tremor. He was diagnosed shortly afterward. He responded 
well to L-dopa, but developed dyskinesias after 10 to 15 years of treatment and has now 
had a deep brain stimulator implanted to good effect. There have been no 
hallucinations or psychiatric complications. The clinical history for individual IV-6, was 
provided by her brother. She developed PD at the age of 41 with noticeable tremor and 
generalized bradykinesia and rigidity. She responded well to L-dopa, developing only 
mild dyskinesias after a reasonable period of treatment. She underwent a pallidotomy at 
around 60 years of age and died at age 66 as a consequence of a nosocomial infection 
after a hip replacement operation.  







Figure 58 – Pedigree of a family showing highly penetrant autosomal dominant inheritance of Parkinson's disease (PD). Age of onset (O:) and age at death (D:) are indicated 
where known for all descendants of I-1 and I-2.  The p.Asp620Asn mutation of VPS35 was confirmed by Sanger sequencing in the 3 living individuals affected by the disease 
who were available for testing. 
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Limited information is available for other affected family members. Individual II-1 
presented with akinetic-rigid parkinsonism in her late fourth decade, family members 
noted that she never developed tremor, but suffered with depression late in the disease 
course. She died aged 66 years. Individuals II-3 and II-5 developed parkinsonism in 
their seventh decade and died in their eighth decade. II-4 developed tremor-
predominant Parkinson's disease aged 35 years and had a slowly progressive disease 
course, dying at the age of 69. Individuals II-9 and II-10 are known to have been 
affected with parkinsonism, but ages of onset are not known. They died in their sixth 
and fourth decade respectively. Individual III-7 developed parkinsonism at age 37. 
Medical records and family members indicate left-sided rigidity, bradykinesia, 
hypomimia, falls, and freezing. Tremor was not recorded. Surgical interventions, 
including pallidotomy (right then left) and thalamotomy, were performed before L-dopa 
was commenced. No dyskinesias developed despite 10 years of treatment and she died 
at age 62. Individual III-9 developed parkinsonism aged 47 years presenting with a 
unilateral rest tremor. Family members report early severe muscular spasms, difficulty 
walking, and falls. Later in the disease, she developed depression and cognitive 
impairment. She died aged 57 years. 
 
13.4 Discuss ion 
Using exome sequencing, two groups independently identified a single c.1858G>A 
mutation in VPS35 as the probable cause of Parkinson's disease in several kindreds. 
Therefore, in this study, we screened our own Parkinson's population for variants in 
this gene, both in order to estimate the frequency of the published mutations and in 
order to search for novel mutations that may be disease-causing. We included PD 
patients with a positive family history, as well as those with early onset and late-onset 
sporadic disease in order to maximize our chances of identifying mutations. 
 
We identified 1 individual with the published putative disease-causing mutation 
(c.1858G>A; p.Asp620Asn). This individual had a family history that was consistent 
with highly penetrant, autosomal dominant Parkinson's disease. Based on clinical 
examination, notes and family reports, the disease in this family appears clinically 
similar to idiopathic PD. Onset was generally unilateral, with slow progression and 
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variable tremor. Cognitive or psychiatric features are not prominent. Response to L-
dopa was generally good and was not associated with early or unusually severe 
dyskinesias. The 2 patients in which olfaction was tested here show mild to moderate 
olfactory dysfunction when compared with controls in the UK, but still performed 
better than the vast majority of PD patients. Olfaction has been demonstrated to be 
unimpaired in homozygous and compound heterozygous carriers of Parkin mutations 
469, 470 but impaired in LRRK2 parkinsonian carriers 471-474, although not to the same 
extent as in sporadic PD. The most notable feature of our kindred is the relatively early 
age at onset. Six individuals developed PD in their third or fourth decades, of which 4 
were younger than the age of 45. 
 
No other potentially disease-causing mutations were found in exon 15 (597 cases 
screened) or in any other exon (96 cases screened). It would seem reasonable to 
conclude, therefore, that the recently published VPS35 c.1858G>A mutation, is not a 
common cause of PD, at least in our cohort of patients. 
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14. Mutational  Screening of  GNAL in a UK Cervical  
Dystonia Cohort  
 
14.1 Introduction 
In 2013, using an whole-exome sequencing approach, mutations in GNAL were 
identified as a novel cause of primary dystonia by one group 171 and confirmed shortly 
afterwards by another 364.  Mutations in this gene appear to cause autosomal dominant, 
primary dystonia with a cervical predilection and evidence of incomplete penetrance 171.   
 
At the time of this work, the frequency of mutations in GNAL as a cause of dystonia 
remains unclear.  In the initial discovery paper by Fuchs et al., researchers reported 
GNAL mutations in 6 out of 39 families screened (~15%), whereas, in the subsequent 
study by Vemula et al., only 3 GNAL mutations were detected in 760 subjects with 
familial or sporadic primary dystonia (<0.5%).  Although the difference in choice of 
cohort to screen makes direct comparison difficult, there was clearly a larger than 
expected difference between the two studies, which made it difficult to judge the true 
frequency of GNAL mutations in primary dystonia.  Yet, this information is clinically 
relevant, as a mutation frequency of ~15% would justify early and widespread genetic 
testing of GNAL in familial dystonia and probably also in younger onset cervical 
dystonia; a frequency of <0.5%, on the other hand, would not. 
 
In order to attempt to answer the question of just how prevalent GNAL mutations 
might be as a cause of familial or, indeed, apparently sporadic cervical dystonia, we 
performed mutational screening of the gene by Sanger sequencing in 192 probands 
with either familial of sporadic cervical dystonia.   
 
14.2 Subjects ,  Materials  and Methods 
14.2.1 Select ion of Cases of  Mutational Screening 
Participants’ DNA was selected from a library of samples donated with prior consent 
for research use on the basis of a clinical description of focal or segmental dystonia that 
included the cervical region.   136 samples belonged to females and 56 to males.  A 
family history, defined as one or more first or second-degree relatives with dystonia, was 
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recorded in 84 cases.  All familial cases had been screened for TOR1A and THAP1 
mutations and were negative.  The study was approved by the East Central London 
Research Ethics Committee 1 and informed consent was obtained as per its guidelines. 
 
14.2.2 Mutational Screening 
Two isoforms of GNAL are expressed in the brain: isoform 1 (ENST00000334049) is 
the longest, whereas isoform 2 (ENST00000423027) is the major isoform.  Primers 
were thus designed to amplify all exons, the exon/intron boundaries and the 5’UTRs 
of both these isoforms.  Sequencing was accomplished as per sections 4.6 – 4.11. 
 
14.2.3 Segregation Analysis  of  Kindreds with GNAL Variants  
Clinical details were collated found to habour GNAL variants. A family history was 
established and the wider family was invited to contact us to provide a history and, 
where possible, attend for examination.  DNA was obtained from all available members 
of the wider kindred – whether affected or unaffected – and the relevant exon of 
GNAL was screened to establish mutational status within the family. 
 
14.3 Results  
14.3.1 Mutational Screening and Segregation Analysis  
We identified only two novel single nucleotide variations in GNAL in three individuals 
in our case cohort.  Neither variant was annotated in dbSNP, 1000 genomes, the 
NHLBI Exome Sequencing Project or cg69 databases.  The first was a missense 
mutation in exon 2 of the gene (cDNA.1053C>T; P149S in ENST00000334049) that 
was detected in one individual with onset of cervical dystonia in the 4th decade.  It was 
predicted to be benign by SIFT and PolyPhen2, but disease-causing by Mutation Taster 
(albeit with a low probability of 0.72).  The individual concerned exhibited early onset 
(3rd decade) cervical dystonia with a similarly affected father, suggesting autosomal 
dominant inheritance.  However, segregation analysis revealed the variant had in fact 
been inherited from his unaffected mother and was also present in his unaffected 
brother (see figure 59A), ruling it out as the cause of the dystonia in this family. 
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The second variant, located in the 5’UTR of isoform 2 (cDNA.199C>T in 
ENST00000423027), was found in two individuals in our cohort.  Both had onset of 
cervical dystonia in the 6th decade of life, but one individual was a sporadic case, whilst 
the other was part of family with multiple affected members (see figure 59B and 59C).  
The variant affected a highly conserved base (PhyloP score = 4.158) and was predicted 
to be disease causing by MutationTaster.  SIFT and PolyPhen2 are unable to offer 
predictions on non-coding variants. 
 
	  
Figure 59 – Genetic pedigrees and results of segregation analysis of kindreds with variants 
detected in GNAL.  Affected individuals are indicated by solid symbols.  None of the detected 
variants segregate with disease, suggesting they are not pathogenic.  m = heterozygous carrier of 
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14.4 Discuss ion 
In conclusion, this work did not identify any mutations in GNAL that could be cause 
of the dystonia in 196 cases drawn from the UK, including 84 familial cases.  Data 
presented herein suggest that GNAL mutations do not represent a common cause of 
dystonia – in the UK population at least – and that the overall frequency of GNAL 
mutations may be closer to the figure obtained by Vemula et al. 364 than the 15% 
initially reported by Fuchs et al. 171.  This study also emphasises the importance of 
segregation studies in establishing the pathogenicity or otherwise of novel variants. 
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15. The Role of  EIF4G1 as a Parkinson’s  Disease Gene 
 
15.1 Introduction 
In September 2011, Chartier-Harlin and colleagues reported that they had determined 
the genetic cause of the Parkinson’s disease in a multi-incident, autosomal dominant 
kindred from Northern France (see figure 60 below) 475.  Using a combination of 
linkage analysis and mutational screening of the coding exons of all 159 genes within 
the region of best linkage, they identified 5 novel variants that were present in 3 
affected family members.  Subsequent segregation analysis in all 10 blood-related, 
affected individuals demonstrated that only one variant (c.3614G>A; p.R1205H) in 
exon 24 of EIF4G1 fully segregated with the disease. 
 
 
Figure 60 - Structure of index family as reported in Chartier-Harlin et al. (2011).  The ages of 
onset for affected individuals are shown in brackets.  An 'M' above the genetic symbol indicates 
that the individual was heterozygous for the EIF4G1 c.3614G>A mutation; ‘wt’ indicates the 
affected individual was homozygous for the normal allele. 
 
Subsequent screening of 4708 individuals with idiopathic PD identified a further 7 
probands who were heterozygous for this variant, though only 3 individuals showed any 
evidence of familial inheritance of disease.  More than one affected individual was 
available for segregation analysis in only 2 these familial and in both cases the affected 
individuals were siblings making the probability of segregation by chance alone high.  
Conversely, the variant was not detected at all in 4050 control subjects. 
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Mutational screening of the full 31 coding exons of the EIF4G1 gene in 225 probands 
with PD and 185 ethnically matched controls identified identified a further four four 
missense variants not observed in controls, that is c.1505C>T; p.Ala502Val, 
c.2056G>T; p.Gly686Cys, c.3490A>C; p.Ser1164Arg, and c.3589C>T; p.Arg1197Trp.  
Subsequent screening of these four variants in a case-control series consisting of 4483 
individuals with idiopathic PD and 3865 age, gender, and ethnically matched control 
subjects identified 2 additional unrelated, affected individuals heterozygotes for the 
p.Ala502Val variant and 2 affected individuals from the same family both carrying the 
p.Gly686Cys variant.  Segregation analysis was not possible in any of these cases and 
the two remaining variants were not observed again in affected or control subjects. 
 
Given that the authors own data suggest an extremely low frequency for these putative 
causal variants within the PD population (0.2% for p.R1205H and 0.06% for p.A502V 
and p.G686C), assignment of pathogenicity can be difficult and the possibility that 
these changes are, in fact, rare but benign variants with no role in the aetiology of PD 
cannot be discounted.   In light of this, we screened 150 familial PD cases from our UK 
familial Parkinson's Disease series, in which we mutations in LRRK2, VPS35 and SNCA 
mutations in order to determine whether we could provide further evidence that this 
gene is indeed a PD-related locus 476, 477.  We also assessed these coding positions in a set 
of African samples (Table 38) from the Human Diversity series – a standard panel of 
African samples, as African samples have the greatest diversity and offer a rapid route to 
the identification of benign polymorphisms	  478,	  479. 
 
15.2 Subjects ,  Materials  and Methods 
15.2.1 Select ion of DNA Samples for Mutational Screening 
The study included DNA samples obtained from 150 familial PD probands.  The study 
was approved by the East Central London Research Ethics Committee 1 and informed 
consent was obtained as per its guidelines. 
 
All living patients fulfilled criteria for clinical diagnosis of PD at the time of the study 
with at least 2 of 3 cardinal signs of tremor, rigidity, and bradykinesia, as well as a 
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positive response to levodopa therapy. Familial cases were defined as those reporting 1 
or more first degree relatives with PD with a pedigree consistent with autosomal 
dominant inheritance and negative testing for known mutations in SNCA and LRRK2. 
 
In addition, DNA was obtained from the Human Diversity Series, a standard panel of 
127 African samples derived from cell lines.  The number of samples per population 
and the geographic origins of the population are shown in the table below: 
 
Table 38 – Characteristics of the DNA samples obtained for various African populations via 
the Human Diversity Series. 
No of Samples Population Geographic Region 
35 Biaka Pygmy Central African Republic 
15 Mbuti Pygmy Democratic Republic of Congo 
12 Bantu N.E. Kenya 
7 San Namibia 
26 Yoruba Nigeria 
24 Mandenka Senegal 
8 Bantu S.E. Pedi South Africa 
 
15.2.2 Mutational Screening of Exons 8 and 22 of EIF4G1 
Primer pairs were designed specifically to amplify these exons of EIF4G1 based on 
transcript NM_182917.3. Sequencing was accomplished as per sections 4.6 – 4.11. 
 
15.2.3 Extraction of NHLBI Exome Sequencing Data 
To obtain a more exhaustive description of the pattern of variability in EIF4G1, we also 
extracted genotype data from the NHLBI exome sequencing project (Exome Variant 
Server, NHLBI Exome Sequencing Project (ESP), Seattle, WA; 
http://evs.gs.washington.edu/EVS/ [accessed January 2011]), which includes exome 
data for 3500 American individuals of European descent and 1850 African Americans. 
Frequencies were computed using VCFTools and annotation of variants was achieved 
by ANNOVAR.  Both pieces of software are freely available online. 
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15.3 Results  
15.3.1 Mutational Screening of Exons 8 and 22 of EIF4G1 
Screening of exons 8 and 22 failed to reveal any mutation previously reported to have 
been associated with PD in our cohort of familial PD.  We identified one coding 
change (c.1456C>T; P486S) in 2 PD patients, but this was recorded in dbSNP 
(rs112545306) and was observed in the NHLBI Exome Sequencing Project dataset at a 
frequency of 0.15% in African Americans. 
 
In the Human Diversity Series panel of African individuals, we identified six non-
synonymous changes in exons 8 and 22 of EIF4G1.  Of these, only one was novel 
(c.1145C>T; P382L), whilst the rest were recorded in dbSNP and mainly seen in 
African populations in the NHLBI Exome Sequencing Project dataset.   In order to 
predict the impact of on protein function of these non-synonymous variants, we 
performed an in-silico analysis using SIFT and PolyPhen.  All varaints, including the 
novel variant, were predicted to be benign.  These results are summarised in table 39 
below: 
 
Table 39 – Characteristics of the variants in EIF4G1 detected in the African Diversity panel by 
Sanger sequencing.  dbSNP accession number, minor allele frequency (MAF), the population of 







MAF Population Predicted 
effect (SIFT) 
c.870G>A p.M290I rs144947145 0.01 San, Bantu SE Tolerated 
c.913C>T p.R305C rs116508885 0.01 Yoruba Tolerated 




c.1145C>T p.P382L NA 0.004 San Tolerated 
c.1429G>A p.E477K rs145228718 0.004 Mandenka Tolerated 
c.3918G>A p.R1216H rs34086109 0.004 Biaka pygmy Tolerated 
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Analysis of the NHLBI datasets demonstrated that the putatively pathogenic A502V 
published by Chartier-Harlin and colleagues was seen in two European-American 
individuals (frequency of 0.02%).  In total, we identified 95 nonsynonymous SNPs 
spread across all 32 exons of the gene.  (NM_182917.3). Of note, 36 of them are 
located in exon 8 or exon 22. 
 
To further investigate coding variability across the EIF4G1 gene we extracted the 
genotypes from the NHLBI dataset and computed the average number of pairwise 
amino acid differences between two randomly selected European-American haplotypes 
from the NHLBI dataset.  This analysis was carried out entirely by Dr Arianna Tucci 
and its results are presented here only for the sake of completeness. 
 
On average two such EIF4G1 sequences diverge by 0.45 aminoacids:  82% of this 
variability (0.37 amino-acid differences) is attributable to exon 8, where the A502V lies; 
whilst 9.8% of this variability is attributable to exon 22 (0.098 amino-acid differences).   
 
15.4 Discuss ion 
Using a combination of linkage analysis and candidate gene sequencing, Chartier et al. 
(2011) recently reported that the p.R1205H mutation in exon 22 of the gene, EIF4G1, 
segregated with disease in a large multi-incident French family showing autosomal 
dominant inheritance of PD 475.  By screening additional patients with clinical or 
pathologically defined PD, they identified 4 less frequent, putatively disease-causing 
mutations, p.A502V, p.G686C, p.S1164R, and p.R1197W, which were absent from 
approximately 4000 controls.  However, segregation analysis was not possible for these 
variants and thus their involvement in disease pathogenesis remains uncertain. 
 
We screened 150 familial PD probands for the two most common mutations 
(p.R1205H and p.A502V) and failed to identify either of these two putative variants.  
Nor did we identify any other coding change that was likely to be pathogenic.  Our 
study of the NHLBI dataset did, however, identify the p.A502V variant in 2 European-
American individuals.  Whilst the nature of the NHLBI dataset means that the 
possibility that these individuals either had or would go on to develop PD cannot be 
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excluded, this finding does cast some doubt on presumed pathogenicity of this variant 
and raise the possibility that it is, in fact, a rare benign polymorphism. 
 
Finally, by computing pairwise amino acid differences for randomly selected European-
American haplotypes from the NHLBI, Dr Tucci was able to show that there appears to 
be more limited selective pressure and a higher sequence variability in the regions of 
the EIF4G1 protein encoded by exons 8 and 22.  This finding is strengthened by the 
relatively high number of missense variants (n=6) identified in these exons in the 
African samples of the Human Diversity series. 
 
In summary, the variants in EIF4G1 identified by Chartier-Harlin et al. are either an 
extremely rare cause of PD in caucasian cohorts or, quite possibly, represent nothing 
more that rare benign polymorphisms in a naturally less conserved portion of the gene. 	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16. Summary and Discuss ion 
 
16.1 Preamble 
In the work presented in this thesis, I sought to apply modern techniques and 
technology to understand the genetic basis of hereditary neurological disease.  The bulk 
of my work focused on the use of whole exome sequencing (WES) as a tool for gene 
discovery in previously ‘unsolved’ kindreds with ostensibly Mendelian inheritance of 
neurological disease.  In the main, the work that I have chosen to present as part of this 
thesis centres around kindreds exhibiting familial forms of dystonia.  This is partly by 
design (dystonia is a condition that has always interested me and one of my primary 
clinical collaborators, who helped in the identification of ‘unsolved’ kindreds, Prof. 
Kailash Bhatia, is a movement disorders specialist with a particular interest in dystonia) 
and partly by chance (for various reasons – some of which I will touch on briefly later – 
it was my work on these unsolved the dystonia kindreds that turned out to be the most 
fruitful, whilst my work on kindreds with various other conditions tended not to 
advance to a stage that might be worthy of inclusion in a thesis). 
 
This period of research has given me an in-depth understanding of the strengths and, 
more importantly perhaps, the challenges, pitfalls and limitations of WES in relation to 
gene discovery.  Initially, I would like to begin by briefly summarising the successes of 
WES with respect to the advances expected from the advent of this technology – as 
previously set out in section 1.6.  This will be presented both from the perspective of 
both my own work and from that of the field of genetic research as a whole. 
 
16.2 WES:  Promise and Reali ty  
16.2.1 New Gene Discovery:   Experience of the Field 
One of the main promises of WES was that its application to previously unsolved 
kindreds would result in the discovery of numerous new causal genes for Mendelian 
disease.  To a large extent, this has been true.  At the time of writing, a PubMed search 
limited to the phrase “whole exome sequencing” alone reveals that a total of 1580 
articles have been published on the technique since 2010, with the yearly totals 
following an roughly exponential growth pattern such that the number of publications 
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in 2014 alone account for nearly two thirds of this total.  At the very least, this is 
evidence that the technique has been rapidly taken up by researchers and has now 
become something of a mainstay in genetic research.  This rapid take up has no doubt 
been influenced by clear evidence of success:  a recently published review article 
estimated that over 150 new genes causing Mendelian disease had be identified by 
means of next-generation sequencing 480.  Whilst this clearly a cause for general 
optimism, my own experience of reading the literature suggests that the distribution of 
gene discoveries between various forms of Mendelian disease has not been even.   
 
The combination of homozygosity mapping and exome sequencing has proved to be 
particular effective in elucidating the cause of Mendelian diseases in consanguineous 
kindreds exhibiting recessive inheritence, even when applied to single, small families.  
Homozygoisty mapping tends to restrict the genomic search space to a far greater extent 
than is possible with linkage analysis, as generally applied to dominant or non-
consanguineous recessive kindreds.  Exome sequencing then functions as essentially 
nothing more than a quick, cheap and efficient means of sequencing the entirety of the 
implicated regions.  To take my own work on the DYT2 kindred as an example, 
homozygosity mapping was able to narrow the genomic search space down from 
>20,000 genes to a mere 285 genes, which exome sequencing demonstrated to contain 
a sum total of 324 variants.  After appropriate filtration, only 2 potentially causal 
variants remained.  Given that the family consisted only of three affected siblings and 
their unaffected parents, the power inherent in the marriages of these two techniques is 
obvious.  In fact, performing a PubMed search on ‘whole exome sequencing’ and 
‘homozygosity mapping’ results in 114 articles, the vast majority of which purport to 
link a particular recessive Mendelian disease with homozygous mutations in a particular 
gene. 
 
The other group of Mendelian disorders that have yielded with relative ease are those 
that might be best categorised as the ‘very rare’.  In using this label, I am thinking of 
disorders where one deals not so much in families, but instead in a small number of 
scattered individuals – as in Kabuki syndrome 84, Freeman-Sheldon syndrome 481, or 
static encephalopathy with neurodegeneration in adulthood 482 (now renamed beta 
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propeller protein associated neurodegeneration, or BPAN for short, in light of the 
discovery of the causal gene).  Many of these ‘very rare’ disorders arise from de novo 
mutations and linkage analysis is thus less useful, particularly if there is unsuspected 
genotypic heterogeneity.  However, by exome sequencing trios (both unaffected parents 
and the affected child), the number of potentially causal variants can be rapidly 
reduced.  Due to the intrinsic error rate of DNA polymerase, each individual carries 
about 70 de novo variants with respect to their parents (see section 1.8).  Most of these 
can be rapidly excluded on the basis that they do not affect protein coding.  It is then a 
relatively simple step to identify potentially causal, de novo variants that are seen in 
many or most affected individuals or, alternatively, to identify genes that are affected by 
multiple different, potentially causal variants in the case cohort as a whole (see section 
1.5.2 for some caveats to this statement).  Phenotypic stratification can (and, indeed, 
has been used to) help guide researchers in identifying such genes where genotypic 
heterogeneity initially obscures the results.  Indeed, this was the approach used to 
identify the first Mendelian disease-gene for Kabuki syndrome in 2010 84.  As a rough 
guide to success, a PubMed search for ‘whole exome sequencing’ and ‘de novo 
mutation’ results in 153 articles, of which approximately half purport to explain various 
very rare Mendelian diseases in terms of de novo mutations in some gene. 
 
The disorders where WES has proved least fruitful are the dominantly inherited 
Mendelian disorders, particularly those with a late onset or where reduced penetrance 
or phenotypic heterogeneity is a factor.  The unexpectedly high level of genetic 
variation encountered in the average healthy exome, including numerous potentially 
and frankly deleterious changes (see section 1.4), means that the exome data alone is 
rarely ever sufficient to pinpoint the likely causal variant, even when multiple affected 
and unaffected individuals in a kindred are sequenced.  Some means of narrowing the 
genomic search space is always required and, for dominant disorders, this usually 
means linkage analysis.  Whilst, as my work on ANO3 shows, the use of exome 
sequencing does mean that there is no longer the requirement to identify a single tight 
region of linkage with a truly significant LOD score, analysis must still result in an area 
or areas of positive linkage that cover a sufficiently small number of potentially causal 
variants to make further progression to segregation analysis and sequencing in 
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independent cohorts a feasible option.  Most of the largest dominant kindreds for 
Mendelian disease have already been ‘solved’, either through positional cloning or by 
virtue of testing positive for a gene already discovered by that means in some other 
family.  Given the tendency to small family size in the Western world, most of the 
remaining unsolved kindreds are small or, at best, moderately sized, usually with a total 
of less than 10 individuals in the three living generations (if one assumes ~2 children 
per generation, on average).  With respect to the disease under study, a later age at 
onset, reduced penetrance and/or phenotypic heterogeneity can have a large impact on 
linkage analysis.  Later age at onset often means that the youngest generation(s) cannot 
be included in any analysis since it is impossible to say whether they are truly unaffected 
or whether they will merely manifest at a later date.  Reduced penetrance can 
dramatically reduce the power of linkage analysis in small families, when a non-
manifesting carrier is included as an unaffected individual, leading to spurious areas of 
positive linkage that swell the list of potentially causal variants to unmanageable levels.  
Phenotypic variation has a similar effect, but can also lead to the labelling of affected 
individuals as unaffected if their phenotype is so mild as to go unnoticed/unreported 
or sufficiently different to be thought to represent an unrelated medical condition. 
 
16.2.2 My Own Experience of New Gene Discovery:   The Good  
Within this thesis, I have presented work that demonstrates a range of outcomes 
resulting from the application of WES to unsolved Mendelian kindreds.  This work has 
resulted in the publication of two new genes for primary isolated dystonia, ANO3 
(DYT24) and HPCA (DYT2).  In addition, the work presented in chapter 9, makes a 
compelling case – to my mind at least – that the homozygous mutations that we 
detected in the gene SLC25A46 are the most likely cause of the complex neurological 




ANO3 was identified in a moderately-sized Caucasian kindred exhibiting autosomal 
dominant inheritance of tremulous craniocervical dystonia.  There is little doubt that 
the structure of the family brought with it some advantages from the point of view of a 
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traditional linkage analysis approach to gene identification:  the index affected 
individual had remarried and transmission of the causal mutation to subsequent 
generations had occurred on both sides of the family resulting in a doubling of the 
family size by Western standards (and, by extension, in the availability of affected 
individuals with greater genetic separation for subsequent exome sequencing).  In the 
end, however, even this fortuitous pattern of inheritance was not sufficient to produce 
a truly significant linkage peak.  Instead, analysis yielded 5 linkage peaks with a LOD 
score of 2.01.  In total, these linkage peaks covered a total of 801 known genes.  
Positional cloning would thus clearly have been a non-starter.  Even a candidate gene 
approach would not have helped.  Based on homology to ANO1 and ANO2, the best 
guess at the time of the work on this family was that ANO3 might function as a Ca2+-
activated chloride channel.   A gene thought to function as an ion channel is unlikely 
to have been prioritised given the state of knowledge at that time of the pathogenesis of 
dystonia at that time.  (Since then, the assumption that ANO3 functions as an ion 
channel has actually been challenged 483 and the best that can be currently be said of its 
true function is simply that it remains unknown at present). 
 
In total, using a targeted NGS approach, we identified five potentially causal mutations 
in this gene in separate individuals with craniocervical dystonia.  In two of these 
individuals, autosomal dominant inheritance was evident within their living family 
members and, in both – admittedly small – kindreds, the mutations in ANO3 showed 
perfect segregation with the disease phenotype.  The phenotype of disease in these 
families matched that of the index family perfectly:  tremulous, slightly jerky 
craniocervical dystonia with its onset in the first five decades of life and with no 
generalisation despite prolonged follow-up. 
 
Like all new genes, the true test of the validity of ANO3 as a new dystonia gene will be 
the identification of further kindreds exhibiting dystonia that segregates with mutations 
in the gene can by independent research groups.  In this regard, ANO3 has one 
particular disadvantage:  its size.  ANO3 is composed of 27 coding exons making 
mutational screening by Sanger Sequencing in any significant number of cases a very 
time consuming and expensive process.   It is likely that screening a gene of this size on 
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any large scale could only be untaken by NGS, most likely by using a targeted approach 
aimed at simultaneously sequencing all reported dystonia genes.  Whilst this approach 
is certainly feasible today and has already been used for mutational screening in other 
disorders, it is yet to be applied in the field of dystonia research, at least in any 




HPCA was identified in a small consanguineous kindred of Sephardic Jewish ancestry 
who exhibited young-onset generalised dystonia with a craniocervical predominance, 
inherited in an ostensibly recessive manner.  In order to identify the gene, a 
combination of homozygoisty mapping and exome sequencing were applied to the 
family.   As stated above, this combination represents a powerful technique in genetic 
discovery since homozygosity mapping requires far fewer individuals DNA to effectively 
narrow the genomic search space and can usually do so to a far greater degree than does 
linkage analysis, unless the kindred is very large.  In the case of this particular family, 
after appropriate filtration, only 2 candidate causal variants were identified within the 
largest tract of homozygosity for further consideration.  In trying to determine which of 
these two variants was most likely to be causal, we were helped considerably by the 
extremely favourable expression pattern of HPCA compared with that of LAPTM5 and 
also by the fact that the homozygous mutation in the index family affected a Ca2+-
coordinating amino acid in the critical EF hand domain 2, causing the substitution a 
positively-charged lysine residue in place of the widetype neutral asparagine.  Binding of 
a positively-charged Ca2+ to this domain is required to operate the mirystoyl switch 
mechanism that results in a conformational change in the protein that causes extrusion 
of the mirystoyl moiety.  The extrusion of this moiety allows the protein to translocate 
to the plasma membrane and bind with downstream interactors.  The nature and 
position of the mutation that we detected thus suggested a plausible mechanism for 
pathogenicity.  The finding of a further kindred with compound heterozygous 
mutations in this gene was perhaps lucky given the apparent rarity of autosomal 
recessive isolated dystonia and the relatively low level of natural sequence variation in 
publically available databases.   Despite this, one might reasonably hope that 
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identification of further independent kindreds by other research groups will be 
considerably easier than for ANO3.  The gene is only very small – consisting of just 3 
coding exons – and will thus be easy to screen in large cohorts using even conventional 
methodologies.  Furthermore, whilst the autosomal recessive isolated dystonia probably 
is very rare in populations where consanguineous marriages are infrequent, such as that 
of most of Europe and the USA, it probably exists at a significantly higher frequency 
elsewhere and may thus turn out to be more common globally than expected. 
 
Finally, in chapter 9, I presented my work on a small consanguineous kindred 
exhibiting recessive inheritance of a complex neurological phenotype consisting of 
bilateral visual failure, severe action myoclonus, and a peripheral motorsensory axonal 
polyneuropathy.  Bilateral visual failure, particularly in the context of clinical evidence 
to suggest widespread peripheral and central neurological dysfunction, is highly 
suggestive of mitochondrial dysfunction.  With this in mind, the novel, homozygous 
mutation in the gene SLC25A46, which encodes a mitochondrial carrier protein highly 
expressed in the nervous system, naturally presented itself as a top candidate on the 
basis of its inherent biological plausibility.   Moreover, the affected amino acid forms 
part of the key solute carrier domain of the gene’s protein product.  Unsurprisingly 
perhaps, it is thus highly conserved and its substitution was universally predicted to be 
deleterious by all in silico prediction methods used.  Indeed, it is my belief that this is 
the causative mutation in this family.  As of yet, however, I do not yet have enough 
evidence to publish.  Ideally, I would have liked to find a second independent 
individual or kindred with a similar phenotype who possessed biallelic mutations in 
this gene.  Unfortunately, the phenotype is quite unusual and we were unable to 
identify any cases that matched the clinical description at our institution. 
 
Recently, two possible means of advancing with work on this kindred have come to 
light.  Contrary to the information that I was first given, the family now recall that 
there is, in fact, a cousin who also had a child who died in infancy of a severe 
neurological disease.  I am currently trying to obtain a clinical description of the child’s 
symptoms and signs, but it is not unreasonable to hypothesise that their illness may 
represent a more severe presentation of the same genetic lesion.  We have established 
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that DNA from this child is held in storage at Great Ormond Street hospital and have 
been provide with consent from the family to obtain a sample for genetic testing.  If the 
homozygous mutation in SLC25A46 can be demonstrated in the DNA of the child and, 
with luck, the other remaining candidates shown to be absent, this would probably be 
sufficient evidence to go ahead and publish on the basis of a single family.  (This 
scenario is feasible because, apart from SLC25A46, no other candidate variant is 
located in the same stretch of homozygosity on chromosome 5.  In particular, if the 
decreased child did not share the share the tract of homozygosity on chromosome 11, 
this would immediately eliminate 3 of the 4 other candidate variants) 
 
From the point of view of assembling a phenotypically similar cohort, I have recently 
learned that the Neuromuscular department may keep a list of the samples from patient 
with a mitochrondrial phenotype that includes visual failure secondary to rod-cone 
dystrophy in whom no mutation has been identified.  I am current attempting to make 
contact with the relevant parties to obtain DNA from these individuals for testing. 
 
16.2.3 My Own Experience of New Gene Discovery:   The Bad  
Within this category, I include my work on kindreds that progressed to an advanced  
phase but failed to reveal any variant for which a reasonable argument for pathogenicity 
could be maintained.  The two examples of such kindreds that I have included in my 
thesis are presented in chapters 6 and 11.  
 
In chapter 6, I presented my work on a large kindred exhibiting ostensibly autosomal 
dominant inheritance of late-onset tremulous cervical dystonia.  Initially, producing a 
workable list of candidate variants in this family was hampered by the fact that the late-
onset of the disorder meant that the affectation status of only a single generation could 
accurately be determined.  This precluded any meaningful linkage analysis and thus 
afforded no opportunity to narrow the genomic search space.  Concessions thus had to 
be made from the very outset, including, most notably, filtering the exome data to leave 
only novel variants shared between all three affected members for further 
consideration.  This was followed by a decision about which of the candidate variants 
to test for segregation in the family based on a compiled character profile.  Although I 
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tried to be as unbiased and as scientific in going about this as possible, the process 
necessarily entailed some degree subjectivity.  In the end, none of the variants chosen 
for segregation analysis could be shown to fully segregate with disease in the family, 
bringing work to a grinding halt.  Nonetheless, it is notable that the variant that I had 
chosen as my top candidate – the p.Y605C variant in CACNA2D3 – came closest of all 
to fully segregating with disease, raising the possibility that the single mismatch 
observed was due to a phenocopy within the family.  Indeed, the possibility of 
phenocopies had been suggested to me at the outset by my supervisor as he felt that the 
family appeared slightly ‘over-dominant’.  As stated in the conclusion of chapter 6, the 
passage of time will probably be the most helpful factor in solving this family as 
accurate knowledge of the affectation status of the second generation will permit 
linkage analysis and increase the power of segregation analysis.  Unfortunately, given 
the average age at onset of symptoms in affected individuals was in the 7th decade, 
another 20 or 30 years will probably required to pass before this becomes a reality! 
 
In chapter 11, I presented my work on a small, consanguineous Pakistani kindred 
exhibiting infantile onset, autosomal recessive choreodystonia.  Four potentially causal 
candidate homozygous variants remained in this family after appropriate filtration, of 
which that detected in the gene TRIM3 seemed the most plausible based on its postion 
with in a key functional domain of the protein and what is currently known about the 
genes function and expression pattern.  Unfortunately, the nature of the variant itself 
was far less convincing – consisting of a glycine-to-alanine substitution that was 
universally predicted to be tolerated – and no further potentially causal mutations 
could be found in a small independent cohort of young onset dystonia (though, 
admittedly, the phenotype of individuals included in this cohort was not a particularly 
good match for that of the affected individuals in the index family).  It is difficult to see 
how work could be advanced further on this family beyond further mutational 
screening of all candidate causal genes in a phenotypically well matched cohort of 
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16.2.4 My Own Experience of New Gene Discovery:   The Just Plain Ugly 
The kindreds presented herein are only a selection of those on which I worked during 
my time at the Institute of Neurology.   They represent those in which the work 
advanced to a stage where the list of variants could be sufficiently narrowed so as not 
allow some vaguely scientific means of progressing towards a list of one or more top 
candidates.  There were, however, several further kindreds where work stopped short of 
this point.  By and large, the problem was either one of too many or, alternatively, too 
few variants.   
 
In some kindreds, difficulties in accurate phenotyping (dystonia), small family size that 
precluded any form of linkage (dystonia, ataxia), or lack of any similar cases for 
screening at our institute (familial temporal lobe epilepsy) meant that the list of variants 
was so unwieldy that my attempts to identify top candidates was in reality nothing more 
than hopeful guesswork.  It is possible that, with time or the development and 
application of other ancillary clinical techniques, some of these families will yield:  
small families, if followed up, will eventually become large enough to permit some form 
of linkage, whilst re-phenotying of some kindreds using surrogate markers of carrier 
status, such as temporal discrimination testing in dystonia, may prove a workable 
strategy in the future. 
 
In some kindreds, on the other hand, the problem was one of two few variants.  By way 
of example, I worked on two families where the mode of inheritance (x-linked 
parkinsonism with psychiatric features) or a previously-published, seemingly-robust 
linkage interval (geniospasm) had tempted me into thinking that finding the candidate 
variant might a relatively easy affair.  It turned out not to be the case:  no shared 
potentially pathogenic variants could be found in the anticipated regions.  There are a 
number of possible explanations for this.  Firstly, the limitations placed on the genomic 
search space could have been incorrect.  The clinical manifestations of geniospasm are 
relatively subtle and there is a tendency for them to remit as the patient ages so that, in 
some cases, family members’ reports that they were affected at birth were used to assign 
affectation status, despite the fact this could no longer by verified by clinical 
examination.  There was thus a very real risk of incorrectly assigning affected status, 
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leading to incorrect linkage and a search that is doomed to fail from the beginning.  In 
the case of the kindred exhibiting hereditary parkinsonism with psychiatric features, the 
inheritance pattern that best fitted the pattern of disease in the family was x-linked 
recessive (with no affected females and no male with affected children) but the family 
was relatively small and it is possible (albeit less likely) that disease could have been 
inherited in a autosomal dominant pattern with reduced penetrance.  Whilst 
affectation status in this family could certainly much more easily be assigned with 
relative certainty, it remained too small for any useful genome-wide linkage analysis and 
so that, if autosomal dominant inheritance with reduced penetrance was assumed, the 
list of potentially causal variants once again became unmanageably large.  On the 
assumption that the mode of inheritance is truly x-linked and the causal variant on X 
has merely been missed by exome sequencing, DNA from this family has been sent for 
whole genome sequencing and search for it has now been taken up by one of my 
research colleagues, Dr Niccolo Mencacci.  I await the results of his analysis with 
interest. 
 
16.3 Expanding the Phenotype:   My Own Experience 
In section 1.6.2, I stated that one of the spin-offs of widespread use of exome 
sequencing had been increased awareness of genetic pleiotropy and gave a few examples 
genes in which mutations are now recognised to cause a much wider phenotypic 
spectrum of disease than previously thought.  For my own part, the research presented 
herein has led to the identification of two new phenotypes for known Mendelian 
disease genes, one already published and one in the process of publication. 
 
Firstly, in chapter 8, I was able to demonstrate that compound heterozygous mutations 
in ATM were responsible for a variant form of ataxia telangiectasia (AT) in a small 
muslim Indian kindred.  The phenotype that the affected individuals exhibited was 
characterised by dopa-responsive cervical dystonia and ocular telangiectasia without any 
associated ataxia.  Although variant presentations of AT are well documented, dopa-
responsive dystonia had never previously been reported as a possible manifestation of 
mutations in this gene, meaning AT had never been considered as a possible 
differential diagnosis in this family.  Indeed, the mild ocular telangiectasia was only 
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noted once the genetic diagnosis became apparent.  This discovery adds AT to the list 
of diagnostic considerations in undiagnosed dopa-responsive dystonia  (particularly if 
cervical) and this is important since, despite the lack of typical features, individuals with 
variant presentations of AT still appear to be at the same elevated risk of malignancy 
and medical investigations involving radiation must be avoided. 
 
Secondly, in chapter 10, I have presented compelling evidence to suggest biallelic 
mutations in the gene NUBPL – previously only associated with a very severe disease 
characterised radiologically by widespread leucodystrophy – can also result in a much 
milder phenotype, characterised instead by young-onset dystonia and bilateral striatal 
necrosis.  As part of my argument, I suggest that by and large the previously-published, 
ostensibly ‘characteristic’ phenotype of NUBPL-related disease has resulted from 
systematic ascertainment bias in the selection of cases for mutational screening.  This 
work therefore highlights the danger inherent in such an approach in an age when 
phenotypic pleiotropy is being increasingly recognised to play an important role in 
genetic disease.  Although this presents a challenge to clinicians who must decide which 
genes to test based on the phenotype of the patient, it is to be hoped that a shift from 
reliance on traditional sequencing methodologies to next-generation targeted or even 
whole exome sequencing in genetic diagnosis will compensate for this increased 
complexity. 
 
16.4 Brief  Summary of  Other Aspects  of  My Research 
In addition my use of exome sequencing to attempt to discover new Mendelian disease 
genes, I also used more traditional sequencing methods to confirm the validity and 
assess the prevalence of Mendelian disease genes published by others, namely VPS35, 
GNAL and EIF4G1.  In addition, in a brief break away from the world of Mendelian 
genetics, I performed a small association study in neuropathologically proven PD.  
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16.4.1 VPS35 is  a Rare Cause of Famil ial  Parkinson’s Disease 
As with all genes identified by NGS, including those I have proposed herein, it is 
important that replication studies are performed in order to confirm the result in other 
populations; to determine whether the mutations reported in the index study are truly 
pathogenic; to assess the prevalence of mutations in that gene as a cause of disease; and 
to assess whether there are any phenotypic clues to the underlying genetic cause that 
may be of use to clinicians. 
 
Mutations is the gene VPS35 were reported to cause autosomal dominant Parkinson’s 
disease (PD) by two groups simultaneously in 2011 466, 484. In collaboration with a fellow 
researcher, I subsequently performed mutational screening of the gene in a large UK 
Parkinsons Disease.  We identified one large kindred split between the UK and 
Australia that harboured the already published p.Asp620Asn mutation, further 
confirming the validity of VPS35 as a Mendelian disease gene for Parkinson’s disease.  
The phenotype of the kindred was essentially indistinguishable from that of late-onset 
idiopathic Parkinson’s disease 
 
16.4.2 GNAL is  not a Common Cause of  Primary Iso lated 
Dystonia 
Mutations is the gene GNAL were reported to cause autosomal dominant primary 
isolated dystonia in early 2013 334 and confirmed by a second group shortly thereafter .  
The phenotype was said to consist of cervical predominant dystonia with generalisation 
in about 10%.  The initial discovery paper suggested a somewhat incredible prevalence 
of approximately 15%, with the authors claiming to have detected mutations in 6 of 
only 39 families screened.  If verified, this claim would have significant implications for 
genetic testing, since cervical dystonia is common and testing for GNAL mutations 
would have seemed mandatory in anybody with a family history or a younger age at 
onset.  I set about screening 196 individuals with familial and sporadic cervical onset or 
predominant dystonia.  I detected no pathogenic mutations in this cohort and argued 
that GNAL was very unlikely to be a common cause of cervical dystonia, in the UK 
population at least 485.  Subsequent screening studies in other populations have 
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supported this assertion, suggesting the true prevalence is likely to be closer to 0.5 – 1% 
486. 
 
16.4.3 The Link Between EIF4G1 and PD is Tenuous  
Mutations in EIF4G1 were published as a cause of autosomal dominant PD in 
September 2011 475.  In collaboration with two other research colleagues at our 
institution, I performed mutational screening of the gene in a cohort 150 UK familial 
PD cases.  We did not find any pathogenic mutations in this cohort.  In addition, we 
demonstrated that the one of the proposed pathogenic variants from the original study 
(p.Ala502Val) was in fact present in the datasets of the NHLBI Exome Sequencing 
Project, casting significant doubt on its pathogenicity.  Subsequent studies of a much 
larger scale have confirmed that EIF4G1 is not a high risk PD gene and that the 
originally published p.Arg1205His mutation is not significantly associated with 
increased risk of PD, in the Icelandic population at least 487. 
 
16.4.4 MAPT is  Associated with Neuropathological ly -Proven 
Parkinson’s  Disease  
Association studies in Parkinson’s disease have demonstrated multiple genetic loci that 
influence risk in the idiopathic form of the disorder.  Prior to my work, however, all 
previous studies had been carried out using samples from clinically diagnosed cases.  As 
I point out in chapter 12, however, the error rate for clinical diagnosis of idiopathic 
Parkinson’s disease is in the range of 10 – 25% 452.  Given that at least one of the 
common clinical mimics, progressive supranuclear palsy (PSP), is not a synucleinopathy 
at all but a tauopathy instead and that the relevance of tau aggregation in Parkinson’s 
disease was uncertain, we set about answering the question of whether the previously 
reported association in MAPT might be due to contamination of the case group by 
individual’s with PSP who had been misdiagnosed as having idiopathic Parkinson’s 
disease  My work showed that the association signal in MAPT remained even when the 
case cohort was defined purely by neuropathological means and simultaneously 
confirmed the association with the well known SNCA locus.  This suggests tau 
aggregation has a role to play in the pathogenesis of idiopathic PD. 
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16.5 Future Direct ions in Next Generation Sequencing 
By way of conclusion, I would like to briefly consider the developments that are likely 
in genetic research into the causes of human disease in the near future, as familiarity 
with NGS techniques increases and cost continues to fall.  The rewards in terms of the 
advancement of scientific understanding promise to be significant.  At the same time, 
however, as I highlight in the following sections, trail-blazing pioneers are likely to face 
considerable challenges along the way. 
 
16.5.1 The Argument for  Whole Genome Sequencing 
The widespread application of whole exome sequencing to the genetics of Mendelian 
disease has resulted in a rapid acceleration of the pace of discovery.  More than 85% of 
known disease-causing mutations occur in the protein coding regions of the genome 
(i.e. exons) 20.  Sequencing of this part of the genome thus provides knowledge about 
genetic variation in a region that should be highly enriched for variants with 
consequence for human health, making the identification of clinically meaningful 
results more efficient.  However, the exome represents only about 1% of the entire 
genome and it should be recognised that to say that 85% of known disease-causing 
mutations occur in protein-coding regions of the genome is not equivalent to saying 
that the 85% of disease-causing mutations will be found to affect protein-coding DNA 
sequences.  I think it would be incredibly short-sighted to believe that the remaining 
99% of the human genome will not, in the future, be shown to be important in the 
causality of more than the currently estimated 15% of human disease.  (It should be 
noted also that much of the current estimate of the 15% contribution of non-coding 
regions to Mendelian disease is taken up my non-coding variants affecting canonical 
splice sites immediately adjacent to exon/intron boundaries, which can, in any case, be 
captured by current exome sequencing techniques).   Perhaps the most notable recent 
example of the identification of non-coding genetic variation as a cause of Mendelian 
disease is encapsulated by the discovery of a intronic expansion in the gene C9orf72 as 
a relatively common cause of both familial amyotrophic lateral sclerosis and 
frontotemporal dementia.  This discovery signposts the possibility that that non-coding 
variation may turn out to have a much more important role – numerically speaking – in 
human disease than has been anticipated to date.  In fact, it is currently thought that 
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the the C9orf72 mutation is the single most common genetic cause of ALS and FTD, 
accounting for up to 50% of familial cases in and over 25% of sporadic cases in some 
European populations 80, 81. 
 
Whole genome sequencing is technically feasible today and would thus seem to be the 
logical successor to whole exome sequencing in research aimed at discovery of new 
causes of Mendalian disease.  Certainly, it would offer a number of theoretical 
advantages over whole exome sequencing.   Most obviously, it would allow for a 
complete assessment of the genetic variation in relation to Mendalian disease.  In 
theory at least, disease resulting from non-coding variants could be identified by 
demonstrating segregation in much the same manner as is currently done in 
experiments utilising whole exome data.  Moreover, whole genome sequencing would 
allow for the assessment of the contribution of exonic copy number variants and large-
scale deletions in a manner that is currently only truly possible by the use of ancillary 
genetic techniques, such as multiplex ligation dependent probe amplification or 
fluorescent in-situ probe hybridisation, respectively. 
 
16.5.2 Super Size Me:  Giant Haystacks of  Whole Genome Data 
Despite the possible benefits, the idea that whole-genome sequencing data could really 
be used in the same manner that whole-exome data is used today is currently somewhat 
far-fetched.  Some have likened identifying the causal variant amidst the background of 
natural human variation in an exome to finding a needle in a haystack.  However, the 
average human exome typically includes a mere ~22,000 variants;  in comparison, the 
average human genome contains around 4 million variants, of which about 3.5 million 
are single nucleotide variants 488.  The haystack just got a whole lot bigger!  Two major 
problems arise from working with the entire human genome:  the first relates to a 
relative lack of annotation; the second to the difficulty in prioritising candidate 
variants. 
 
16.5.3 Whole Genome Data: The Pressing Need for a Better Map 
The challenge of interpretation of non-coding sequencing data is made significantly 
harder by an imperfect knowledge of the full range of mechanisms of regulatory control 
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and the incomplete annotation of even those that are recognised.  Currently recognised 
regulatory mechanisms that have been associated with human disease are diverse and 
include:  splice sites (both canonical and weakly specified) 489-491; sequences regulating 
translation, stability and localisation (5’ and 3’UTRs) 492, 493; trans-regulatory RNAs (i.e. 
long non-coding RNA) 494, 495; promotor sequences 496-498; enhancer sequences 499; and 
synonymous mutations within coding sequences 500.  Several large-scale projects are 
currently underway to enhance the annotation of the non-coding genome, which will 
be a necessary first step in permitting systematic interpretation of variants in these 
regions. 
 
16.5.4 Whole Genome Data: The Problem of Variant Fi l tration 
To date, almost all successful disease gene discovery studies using exome sequencing 
have relied on a form of variant filtration designed to whittle down the relatively 
modest number of variants detected by such studies to a small list of one or more 
potentially causal variants.  This filtration process relies on knowledge of which variants 
are observed in the normal healthy population, which positions have been conserved 
through evolution by purifying selection and, occasionally, on the ability of tried and 
tested in silico prediction programs to give an indication of the likelihood that a variant 
will have a functional consequences on human physiology.  Unfortunately, at present, 
this knowledge base simply does not exist for the entire human genome.  
 
Firstly, the number of human genomes to be sequenced in their entirety for which data 
has been made publically available remains relatively modest.  The 1000 Genomes 
Project probably represents the greatest resource at present.  By definition, however, 
this can only hope to document human genetic variation down to a MAF of 0.1%, 
which, in reality, only encompasses relatively common variations (the definition of a 
polymorphism is a variant occurring at a frequency of 0.5% or greater).  Moreover, the 
number number of populations currently sampled is limited.   Given that a significant 
proportion of variants detected by exome sequencing are rare or, even, effectively 
private to particular sub-population or even individuals, there is no reason to suspect 
that a similar situation will not prevail in the case of whole-genome data.  In fact, there 
is good reason to believe that a greater toleration of genetic drift in non-coding regions 
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would mean that the extent of rare or semi-private variation in small sub-populations 
would be far greater in non-coding regions than is seen in protein-coding regions. 
 
Secondly, the use of evolutionary conservation as a guide to the likely deleteriousness of 
an observed variant relies on genomic sequencing data being made available for a 
significant number of other species.  Naturally, genomic sequencing in other species 
tends to lag behind that of humans (with the exception of well-studied creatures, such 
as the worm and fly, that possess smaller, more easily sequenced genomes).  Moreover, 
natural variation between species is far greater in non-coding regions than in coding 
regions, making identification of orthologous DNA sequences and multispecies 
alignment much harder.  Taken together, these facts make estimation of the true degree 
of evolutionary conservation more difficult and more prone to error on a genomic 
level. 
 
Finally, since both the degree of evolutionary conservation at the site of a variant and 
its appearance in databases of normal sequence variation, in combination with the 
physicochemical properties of the observed amino acid substitutions, are some of the 
main considerations taken in account by algoritms making in silico predictions of 
pathogenicity, most of the currently available prediction programs are currently unable 
to provide any predictions for non-coding substitutions.  Even in the case of those that 
can (such as MutationTaster), the accuracy of their predictions is far from certain.  As a 
consequence, there is currently no real tried and tested method of predicting the 
functional consequence of any given non-coding variant on human physiology.  Whilst 
the imperfections of the predictions SIFT and PolyPhen are well documented (and are 
briefly summarised in sections 2.7.4 – 2.7.7), they do, at the very least, provide a helpful 
guide as to the likely functional consequence of a given protein-coding variant, which 
will not be available to researchers picking over non-coding data.  Analytical restriction 
of in silico predictions of pathogenicity to coding mutations would seem, therefore, to 
be untenable in the long term. 
 
One final practical consideration that needs to be taken into account is the sheer 
volumes of data generated by whole genome sequencing.  This will produce significant 
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challenges in terms of data storage and bioinformatics analysis for laboratories working 
with whole genome data on any sort of scale.  For individual researchers, it is notable 
that the storage space required for a raw sequence data file from a single whole genome 
currently exceeds the capacity of most desktop computers.  This means that systems will 
have to be developed that allow remote, seamless access to sequencing data stored on 
enormous central servers.  
 
16.5.3 Association Studies Using Rare Variants 
Although genome wide association studies (GWAS) have successfully revealed 
numerous susceptibility genes for common neurologic diseases, the odds ratios 
associated with these risk alleles are relatively low and, even taken together, account for 
only a small part of the estimated heritability of the condition being examined.  This 
state of affairs has led to the hypothesis that a significant proportion of this missing 
heritability may be accounted for by rare variants of moderate to large effect size, 
affecting both coding and non-coding regulatory sequences. Chip-based GWAS, 
however, can only detect common genetic variation as rare variants are poorly targeted 
by design.  The advent of next-generation sequencing, on the other hand, and the rapid 
precipitous fall in its cost have paved the way for the detection of rare, disease-
associated variants via exome or even whole genome sequencing, in theory at least.   
Although association studies based on whole genome data would allow an assessment 
of the contribution of nearly all forms of genetic variation to human disease, it is 
unlikely that any such studies will be attempted any time soon.  The cost remains 
prohibitive when one considers the number of individuals that must be sequenced to 
perform an adequately powered association study and, as mentioned earlier, handling, 
storage and interpretation of such vast quantities of data would be problematic.  Whilst 
association studies based on exome sequencing data can only ever allow an assessment 
of the contribution of rare coding variants to disease risk, they are far more attractive 
from a financial and technical view point and I suspect it will not be long before they 
begin to appear in the publication record.  That said, even for the use of exome data in 
this manner, there remain considerable challenges that will have to be tackled before 
such studies might stand a chance of success. 
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One of the most significant challenges will be obtaining adequate power to detect the 
effects of such rare variants.  In general, the power of association tests between single 
variants and a disease trait decreases as the minor allele frequency of the variant does.  
A large effect size can compensate for this to some degree, but only if it is very large.  
Thus, rare variant association studies are likely to require enormous sample sizes, 
especially it there is to be any hope of detecting those rare variants with only moderate 
effect sizes.  This will significantly increase the cost of such studies and will mandate 
large, international cooperative efforts to achieve the necessary sample sizes. 
 
A second equally challenging problem is that of defining the level of association that 
will be considered significant.  The typical chip-based GWAS significance threshold is 
set at 5×10-8, the result of a statistical correction that is based on the assumption that 
approximately one million independent tests are being conducted simultaneously.   
Whilst significant linkage would mean that tests conducted on rare variants are not 
really completely independent, it is, nonetheless, likely that there will be far more rare 
variants than there are common variants genotyped by DNA array in present-day 
GWAS.  This would mean a required threshold of significance for rare variant 
association studies that is even more stringent than that currently employed in chip-
based GWAS.  Such a stringent threshold may be unattainable in a single variant 
analysis, unless the sample sizes are truly enormous.  One solution to this problem may 
be to analyse multiple rare variants within a given region together, with the most 
convenient division being a gene.  The most advanced application of these methods to 
date can take into account both risk and protective variants within the same region, 
aggregating the individual association signals into a single combined association score 76, 
501.  
 
A final problem arises from the fact that many rare variants are of recent origin in 
human evolutionary terms and, as a result of a rapid human demographic explosion, 
are often confined to particular subpopulations (see section 1.4) 502.   This makes rare 
variant studies more susceptible to inter-population differences in allele frequency and 
false positive associations can more easily result from subtle underlying population 
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substructure 503.  Whilst robust methods have been developed to correct for population 
stratification in GWAS, they are currently lacking for rare variant association studies. 
 
In summary, although the use of NGS data in association studies is now feasible and 
intrinsically attractive, there remain considerable challenges to its implementation and 
many prerequisite methodologies remain in their infancy.  
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